These are representative sample records from Science.gov related to your search topic.
For comprehensive and current results, perform a real-time search at Science.gov.
1

Document Concurrence System  

NASA Technical Reports Server (NTRS)

The Document Concurrence System is a combination of software modules for routing users expressions of concurrence with documents. This system enables determination of the current status of concurrences and eliminates the need for the prior practice of manually delivering paper documents to all persons whose approvals were required. This system runs on a server, and participants gain access via personal computers equipped with Web-browser and electronic-mail software. A user can begin a concurrence routing process by logging onto an administration module, naming the approvers and stating the sequence for routing among them, and attaching documents. The server then sends a message to the first person on the list. Upon concurrence by the first person, the system sends a message to the second person, and so forth. A person on the list indicates approval, places the documents on hold, or indicates disapproval, via a Web-based module. When the last person on the list has concurred, a message is sent to the initiator, who can then finalize the process through the administration module. A background process running on the server identifies concurrence processes that are overdue and sends reminders to the appropriate persons.

Muhsin, Mansour; Walters, Ian

2004-01-01

2

Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer.  

PubMed

The purpose of this retrospective study is to investigate the impact of concurrent chemotherapy on definitive radiotherapy for the International Federation of Gynecology and Obstetrics (FIGO) IIIb cervical cancer. Between 2000 and 2009, 131 women with FIGO IIIb cervical cancer were treated by definitive radiotherapy (i.e. whole pelvic external beam radiotherapy for 40-60 Gy in 20-30 fractions with or without center shielding and concomitant high-dose rate intracavitary brachytherapy with 192-iridium remote after loading system for 6 Gy to point A of the Manchester method). The concurrent chemotherapy regimen was cisplatin (40 mg/m(2)/week). After a median follow-up period of 44.0 months (range 4.2-114.9 months) and 62.1 months for live patients, the five-year overall survival (OS), loco-regional control (LRC) and distant metastasis-free survival (DMFS) rates were 52.4, 80.1 and 59.9%, respectively. Univariate and multivariate analyses revealed that lack of concurrent chemotherapy was the most significant factor leading to poor prognosis for OS (HR = 2.53; 95% CI 1.44-4.47; P = 0.001) and DMFS (HR = 2.53; 95% CI 1.39-4.61; P = 0.002), but not for LRC (HR = 1.57; 95% CI 0.64-3.88; P = 0.322). The cumulative incidence rates of late rectal complications after definitive radiotherapy were not significantly different with or without concurrent chemotherapy (any grade at five years 23.9 vs 21.7%; P = 0.669). In conclusion, concurrent chemotherapy is valuable in definitive radiotherapy for Japanese women with FIGO IIIb cervical cancer. PMID:22843624

Kuroda, Yuuki; Murakami, Naoya; Morota, Madoka; Sekii, Shuhei; Takahashi, Kana; Inaba, Koji; Mayahara, Hiroshi; Ito, Yoshinori; Yoshimura, Ryo-Ichi; Sumi, Minako; Kagami, Yoshikazu; Katsumata, Noriyuki; Kasamatsu, Takahiro; Itami, Jun

2012-07-01

3

Effect of concurrent chemotherapy and radiotherapy on breast cosmesis: a study of patients' perceptions  

Microsoft Academic Search

The effect of concurrent chemotherapy and radiotherapy on breast cosmesis in the conservative treatment of breast cancer is controversial. The aim of this study was to investigate the effect on cosmesis of adding concurrent chemotherapy to conservative surgery and radiotherapy in the treatment of stage I or II carcinoma of the breast. Eligible patients were invited to complete a questionnaire

N. J. Warner; A. M. Rangan; A. O. Langlands; J. Boyages

1998-01-01

4

Performance prediction of concurrent systems  

NASA Technical Reports Server (NTRS)

Concurrent systems are computers that use multiple processors to solve a single problem. A means to predict the application performance on these systems is a useful tool in many areas of concurrent system research. A computationally efficient and accurate method to predict performance for a class of parallel computations on concurrent systems is described. A parallel computation is modeled as a task system with precedence relationships expressed as a series parallel directed acyclic graph. Resources in concurrent systems are modeled as service centers in queueing network models. Using these two models as inputs, the method outputs predictions of both the time to complete the computation and the concurrent system utilization. The algorithm used is based on the approximate Mean Value Analysis in queueing network modeling with extensions to model concurrency in the computation. The new algorithm was validated against both detailed simulation and actual execution on a commercial multiprocessor.

Mak, Victor W. K.

1987-01-01

5

Reirradiation of recurrent breast cancer with and without concurrent chemotherapy  

PubMed Central

Background Treatment options for loco-regional recurrent breast cancer after previous irradiation are limited. The efficacy of chemotherapy might be hampered because of impaired tissue perfusion in preirradiated tissue. Thus, mastectomy or local excision and reconstructive surgery are the preferred treatments. However, in recent years evidence accumulates that a second breast conserving approach with reirradiation as part of the treatment might be feasible and safe and, furthermore, reirradiation might be an option for palliation. Here we report on the experience of a single community centre in reirradiation of recurrent breast cancer. Methods The report is based on 29 patients treated with reirradiation. All data were prospectively collected. The median age was 63 years (range 35 to 82 yrs). The interval between initial diagnosis and diagnosis before start of reirradiation was 11.6 months to 295.5 months. The mean total dose (initial dose and reirradiation dose) was 106.2 Gy (range 80.4 to 126 Gy) and the mean BED3 Gy 168,5 Gy (range 130,6 to 201,6). The mean interval between initial radiotherapy and reirradiation was 92.9 months (range 8.7 to 290.1). Inoperable or incompletely resected patients were offered concurrent chemotherapy with either 5-FU or capecitabine. All patients received 3D-conformal radiotherapy with 1.6 to 2.5 Gy/fraction five times weekly. The treatment volume comprised all visible lesions or lesions detectable on CT/MRI/FDG-PET/CT or the tumour bed or recurrent tumour. Results The local progression-free survival of all patients at one and two years was 81% and 63%. Patients who had no surgery of the recurrence (16/29) had local progression-free survival at one and two years of 72% and 25% with a median progression-free survival time of 17 months. Partial remission and good symptom relief was achieved in 56% (9/16) or complete response of symptoms and/or tumour in 44% (7/16). Patients who had no distant metastases and had at least an R1-resection had a local progression-free survival of 90% after 2 years. The disease-free survival after 2 years was 43% and the median disease-free survival time was 24 months. In four patients a second breast conserving operation was performed and the cosmetic results in all four patients are good to excellent. Acute side effects were mild to moderate with no grade 3 or 4 toxicity. Accordingly, no grade 3 or 4 late effects were observed so far. No grade 3 or 4 plexopathy was observed. Conclusion In this heterogeneous group of patients reirradiation of locoregional recurrences of breast cancer showed low to moderate acute toxicity. In our experience, local control rates are high and palliation is good. PMID:18801165

Wurschmidt, Florian; Dahle, Jorg; Petersen, Cordula; Wenzel, Claudia; Kretschmer, Matthias; Bastian, Christoph

2008-01-01

6

Proton Beam Therapy and concurrent chemotherapy for esophageal cancer  

PubMed Central

Purpose/Objective Proton beam therapy (PBT) is a promising modality for the management of thoracic malignancies. We report our preliminary experience of treating esophageal cancer patients with concurrent chemotherapy (CChT) and PBT at MD Anderson Cancer Center. Materials/Methods This is an analysis of 62 esophageal cancer patients enrolled on a prospective study evaluating normal tissue toxicity from CChT/PBT from 2006 to 2010. Patients were treated with Passive Scattering PBT with 2 or 3 field beam arrangement using 180–250 MV protons. We used the method of Kaplan and Meier to assess time to event outcomes and compared the distributions between groups using the log-rank test. Results The median follow-up time was 20.1 months for survivors. The median age was 68 years (range 38–86). Most were males (82%), had adenocarcinomas (76%) and had stage II-III disease (84%). The median radiation dose was 50.4 Gray-Equivalence (Gy(RBE)) (range 36–57.6). The most common grade 2–3 acute toxicities from CChT/PBT were esophagitis (46.8%), fatigue (43.6%), nausea (33.9%), anorexia (30.1%), and radiation dermatitis (16.1%). There were two cases of grade 2 and 3 radiation pneumonitis and two grade 5 toxicities. A total of 29 patients (46.8%) received preoperative CChT/PBT with one postoperative death. The pathologic complete response (pCR) rate for the surgical cohort was 28%, and the pCR and near CR rate (0–1% residual cells) was 50%. While there were significantly fewer local-regional recurrences in the preoperative group (3/29) as compared to the definitive CChT/PBT group (16/33) (log-rank test p=0.005), there were no differences in DM free interval or OS between the two groups. Conclusions This is the first report of patients treated with PBT/CChT for esophageal cancer. Our data suggest that this modality is associated with a few severe toxicities but the pathologic response and clinical outcomes are encouraging. Prospective comparison with more traditional approach is warranted. PMID:22417808

Lin, Steven H.; Komaki, Ritsuko; Liao, Zhongxing; Wei, Caimiao; Myles, Bevan; Guo, Xiaomao; Palmer, Matthew; Mohan, Radhe; Swisher, Stephen G.; Hofstetter, Wayne L.; Ajani, Jaffer A.; Cox, James D.

2014-01-01

7

Reirradiation of recurrent breast cancer with and without concurrent chemotherapy  

Microsoft Academic Search

BACKGROUND: Treatment options for loco-regional recurrent breast cancer after previous irradiation are limited. The efficacy of chemotherapy might be hampered because of impaired tissue perfusion in preirradiated tissue. Thus, mastectomy or local excision and reconstructive surgery are the preferred treatments. However, in recent years evidence accumulates that a second breast conserving approach with reirradiation as part of the treatment might

Florian Würschmidt; Jörg Dahle; Cordula Petersen; Claudia Wenzel; Matthias Kretschmer; Christoph Bastian

2008-01-01

8

Concurrent chemotherapy and radiation for advanced cervical cancer  

Microsoft Academic Search

While surgery remains the primary mode of treat- ment for most patients with early stage cervical cancer, efforts to improve survival among women with advanced stage di- sease have turned to the combination of radiation and chemo- therapy. To date, studies investigating the use of neoadjuvant chemotherapy prior to radiation have been disappointing; although tumor volume has been noted to

MARC J. KLEINBERG; J. MICHAEL STRAUGHN JR.; RONALD D. ALVAREZ

9

Concurrent ultrasonic weld evaluation system  

DOEpatents

A system for concurrent, non-destructive evaluation of partially completed welds for use in conjunction with an automated welder. The system utilizes real time, automated ultrasonic inspection of a welding operation as the welds are being made by providing a transducer which follows a short distance behind the welding head. Reflected ultrasonic signals are analyzed utilizing computer based digital pattern recognition techniques to discriminate between good and flawed welds on a pass by pass basis. The system also distinguishes between types of weld flaws.

Hood, Donald W. (Idaho Falls, ID); Johnson, John A. (Idaho Falls, ID); Smartt, Herschel B. (Idaho Falls, ID)

1987-01-01

10

Concurrent ultrasonic weld evaluation system  

DOEpatents

A system for concurrent, non-destructive evaluation of partially completed welds for use in conjunction with an automated welder is disclosed. The system utilizes real time, automated ultrasonic inspection of a welding operation as the welds are being made by providing a transducer which follows a short distance behind the welding head. Reflected ultrasonic signals are analyzed utilizing computer based digital pattern recognition techniques to discriminate between good and flawed welds on a pass by pass basis. The system also distinguishes between types of weld flaws. 5 figs.

Hood, D.W.; Johnson, J.A.; Smartt, H.B.

1987-12-15

11

Concurrent ultrasonic weld evaluation system  

DOEpatents

A system for concurrent, non-destructive evaluation of partially completed welds for use in conjunction with an automated welder. The system utilizes real time, automated ultrasonic inspection of a welding operation as the welds are being made by providing a transducer which follows a short distance behind the welding head. Reflected ultrasonic signals are analyzed utilizing computer based digital pattern recognition techniques to discriminate between good and flawed welds on a pass by pass basis. The system also distinguishes between types of weld flaws.

Hood, D.W.; Johnson, J.A.; Smartt, H.B.

1985-09-04

12

Administration of Concurrent Vaginal Brachytherapy During Chemotherapy for Treatment of Endometrial Cancer  

SciTech Connect

Purpose: To evaluate the tolerability and toxicity of administering vaginal brachytherapy (VB) concurrently during chemotherapy compared with the sequential approach for patients with endometrial cancer. Methods and Materials: A retrospective analysis of 372 surgically staged patients with endometrial cancer American Joint Committee on Cancer 2009 stages I to IV treated with adjuvant postoperative radiation therapy (RT) at our institution from 2001 to 2012 was conducted. All patients received VB + external beam RT (EBRT) + 6 cycles of adjuvant carboplatin- and paclitaxel-based chemotherapy. The VB mean dose was 15.08 Gy (range, 15-20 Gy), with 3 to 4 weekly applications, and the EBRT mean dose was 45 Gy delivered with 3-dimensional or intensity modulated RT techniques. Hematologic, gastrointestinal (GI), and genitourinary (GU) toxicities were assessed by Common Toxicity Criteria (CTC) and compared between sequential and concurrent chemotherapy and VB schedules. Results: Among patients who received RT and adjuvant chemotherapy, 180 of 372 patients (48%) received RT sandwiched between cycles 3 and 4 of chemotherapy. A separate group of 192 patients (52%) were treated with VB during the first 3 cycles of chemotherapy, with a weekly application on nonchemotherapy days, and received the EBRT portion in a sandwiched fashion. Patients treated with VB during chemotherapy had a decreased overall treatment time by 4 weeks (P<.001; 95% confidence interval: 3.99-4.02) and sustained no difference in CTC-graded acute hematologic, GI, or GU toxicities in comparison with the patients treated with VB and chemotherapy in a sequential manner (P>.05). CTC grade 3 or 4 hematologic, GI, and GU toxicities were zero. Conclusions: VB during chemotherapy is well tolerated, decreases overall treatment time, and does not render more toxicity than the sequential regimen.

Nagar, Himanshu; Boothe, Dustin; Parikh, Amar; Yondorf, Menachem; Parashar, Bhupesh [Department of Radiation Oncology, Weill Cornell Medical College of Cornell University, New York, New York (United States); Gupta, Divya; Holcomb, Kevin; Caputo, Thomas [Division of Gynecological Oncology, Department of Obstetrics and Gynecology, Weill Cornell Medical College of Cornell University, New York, New York (United States); Chao, K. S. Clifford; Nori, Dattatreyudu [Department of Radiation Oncology, Weill Cornell Medical College of Cornell University, New York, New York (United States); Wernicke, A. Gabriella, E-mail: gaw9006@med.cornell.edu [Department of Radiation Oncology, Weill Cornell Medical College of Cornell University, New York, New York (United States)

2013-11-15

13

Concurrency Control and Recovery in Database Systems  

Microsoft Academic Search

This book is an introduction to the design and implementation of concurrency control and recovery mechanisms for transaction management in centralized and distributed database systems. Concurrency control and recovery have become increasingly important as businesses rely more and more heavily on their on-line data processing activities. For high performance, the system must maximize concurrency by multiprogramming transactions. But this can

Philip A. Bernstein; Vassos Hadzilacos; Nathan Goodman

1987-01-01

14

A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma.  

PubMed

The aim of this randomized study was to compare the efficacy of induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus induction chemotherapy plus radiotherapy (IC+RT) for patients with locoregionally advanced nasopharyngeal carcinoma. From August 2002 to April 2005, 408 patients were randomly divided into two groups: an IC+CCRT group and an IC+RT group. Patients in both groups received the same induction chemotherapy: two cycles of floxuridine (FuDR)+carboplatin (FuDR, 750 mg/m(2), d1-5; carboplatin, area under the curve [AUC]=6). The patients received radiotherapy 1 week after they finished the induction chemotherapy. The patients in the IC+CCRT group also received carboplatin (AUC=6) on days 7, 28, and 49 of radiotherapy. Eight patients did not meet the inclusion criteria, and the remaining 400 cases were analyzed. Grade III or IV toxicity was found in 28.4% of the patients in the IC+CCRT group and 13.1% of those in the IC+RT group (P<.001). Five-year overall survival rates were 70.3% and 71.7% (P=0.734) in the IC+CCRT and IC+RT groups, respectively. No significant differences in failure-free survival, locoregional control, and distant control were found between the two groups. Compared with the IC+RT program, the IC+CCRT program used in the present study did not improve the overall survival and failure-free survival in patients with locoregionally advanced nasopharyngeal carcinoma. Using carboplatin in the concurrent chemoradiotherapy was not suitable for nasopharyngeal carcinoma. PMID:22591726

Huang, Pei-Yu; Cao, Ka-Jia; Guo, Xiang; Mo, Hao-Yuan; Guo, Ling; Xiang, Yan-Qun; Deng, Man-Quan; Qiu, Fang; Cao, Su-Mei; Guo, Ying; Zhang, Li; Li, Ning-Wei; Sun, Rui; Chen, Qiu-Yan; Luo, Dong-Hua; Hua, Yi-Jun; Mai, Hai-Qiang; Hong, Ming-Huang

2012-10-01

15

Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer  

Microsoft Academic Search

BACKGROUND: Despite broad advances in multimodal treatment of locally advanced breast cancer (LABC), 30 to 40% of patients develop loco-regional relapse. The aim of this study was to analyze in a retrospective manner the effectiveness of concurrent chemo-radiotherapy (CCRTh) after neoadjuvant chemotherapy (NCT) in patients with LABC. METHODS: One hundred twelve patients with LABC (stage IIB-IIIB) were treated with NCT

Alberto Alvarado-Miranda; Oscar Arrieta; Carlos Gamboa-Vignolle; David Saavedra-Perez; Rafael Morales-Barrera; Enrique Bargallo-Rocha; Juan Zinser-Sierra; Victor Perez-Sanchez; Teresa Ramirez-Ugalde; Fernando Lara-Medina

2009-01-01

16

Concurrent use of chemotherapy or novel agents in combination with radiation in breast cancer  

Microsoft Academic Search

Treating breast cancer patients concurrently with chemotherapy and radiation is a potentially attractive approach. The goal\\u000a is to develop strategies that enhance the effects of each modality while minimizing toxicity. Most data evaluating the role\\u000a of simultaneous therapy have been generated from small phase 1 and 2 trials. As few prospective, randomized controlled trials\\u000a have been performed in this area,

Kevin Kalinsky; Alice Ho; Christopher A. Barker; Andrew Seidman

2009-01-01

17

Acute Esophagus Toxicity in Lung Cancer Patients After Intensity Modulated Radiation Therapy and Concurrent Chemotherapy  

SciTech Connect

Purpose: The purpose of this study was to investigate the dose-effect relation between acute esophageal toxicity (AET) and the dose-volume parameters of the esophagus after intensity modulated radiation therapy (IMRT) and concurrent chemotherapy for patients with non-small cell lung cancer (NSCLC). Patients and Methods: One hundred thirty-nine patients with inoperable NSCLC treated with IMRT and concurrent chemotherapy were prospectively analyzed. The fractionation scheme was 66 Gy in 24 fractions. All patients received concurrently a daily dose of cisplatin (6 mg/m Superscript-Two ). Maximum AET was scored according to Common Toxicity Criteria 3.0. Dose-volume parameters V5 to V70, D{sub mean} and D{sub max} of the esophagus were calculated. A logistic regression analysis was performed to analyze the dose-effect relation between these parameters and grade {>=}2 and grade {>=}3 AET. The outcome was compared with the clinically used esophagus V35 prediction model for grade {>=}2 after radical 3-dimensional conformal radiation therapy (3DCRT) treatment. Results: In our patient group, 9% did not experience AET, and 31% experienced grade 1 AET, 38% grade 2 AET, and 22% grade 3 AET. The incidence of grade 2 and grade 3 AET was not different from that in patients treated with CCRT using 3DCRT. The V50 turned out to be the most significant dosimetric predictor for grade {>=}3 AET (P=.012). The derived V50 model was shown to predict grade {>=}2 AET significantly better than the clinical V35 model (P<.001). Conclusions: For NSCLC patients treated with IMRT and concurrent chemotherapy, the V50 was identified as most accurate predictor of grade {>=}3 AET. There was no difference in the incidence of grade {>=}2 AET between 3DCRT and IMRT in patients treated with concurrent chemoradiation therapy.

Kwint, Margriet [Department of Radiation Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands)] [Department of Radiation Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands); Uyterlinde, Wilma [Department of Thoracic Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands)] [Department of Thoracic Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands); Nijkamp, Jasper; Chen, Chun; Bois, Josien de; Sonke, Jan-Jakob [Department of Radiation Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands)] [Department of Radiation Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands); Heuvel, Michel van den [Department of Thoracic Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands)] [Department of Thoracic Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands); Knegjens, Joost; Herk, Marcel van [Department of Radiation Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands)] [Department of Radiation Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands); Belderbos, Jose, E-mail: j.belderbos@nki.nl [Department of Radiation Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands)] [Department of Radiation Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands)

2012-10-01

18

Automated Concurrent Blackboard System Generation in C++  

NASA Technical Reports Server (NTRS)

In his 1992 Ph.D. thesis, "Design and Analysis Techniques for Concurrent Blackboard Systems", John McManus defined several performance metrics for concurrent blackboard systems and developed a suite of tools for creating and analyzing such systems. These tools allow a user to analyze a concurrent blackboard system design and predict the performance of the system before any code is written. The design can be modified until simulated performance is satisfactory. Then, the code generator can be invoked to generate automatically all of the code required for the concurrent blackboard system except for the code implementing the functionality of each knowledge source. We have completed the port of the source code generator and a simulator for a concurrent blackboard system. The source code generator generates the necessary C++ source code to implement the concurrent blackboard system using Parallel Virtual Machine (PVM) running on a heterogeneous network of UNIX(trademark) workstations. The concurrent blackboard simulator uses the blackboard specification file to predict the performance of the concurrent blackboard design. The only part of the source code for the concurrent blackboard system that the user must supply is the code implementing the functionality of the knowledge sources.

Kaplan, J. A.; McManus, J. W.; Bynum, W. L.

1999-01-01

19

Efficient deadlock detection for concurrent systems  

Microsoft Academic Search

Concurrent systems are prone to deadlocks that arise from competing access to shared resources and syn- chronization between the components. At the same time, concurrency leads to a dramatic increase of the possible state space due to interleavings of computations, which makes standard verification techniques often infeasible. Previous work has shown that approximating the state space of component based systems

Saddek Bensalem; Andreas Griesmayer; Axel Legay; Thanh-Hung Nguyen; Doron Peled

2011-01-01

20

Intensity-Modulated Radiotherapy With Concurrent Chemotherapy for Previously Irradiated, Recurrent Head and Neck Cancer  

SciTech Connect

Purpose: Primary treatment fails in >70% of locally advanced head and neck cancer patients. Salvage therapy has a 30-40% response rate, but few long-term survivors. Intensity-modulated radiotherapy (IMRT) has recently emerged as a new modality for salvage therapy. This retrospective study evaluated our experience using every-other-week IMRT with concurrent chemotherapy. Methods and Materials: Between 2001 and 2006, 41 patients underwent IMRT as repeat RT with concurrent chemotherapy. All but 6 patients received 60 Gy at 2 Gy/fraction. RT was delivered on an alternating week schedule. Results: With a median follow-up time of 14 months, the overall response rate was 75.6%, with a complete response and partial response rate of 58.5% and 17.1%, respectively. The Kaplan-Meier estimate of overall survival, disease-free survival, and progression-free survival at 24 months was 48.7%, 48.1%, and 38%, respectively. Patients who underwent surgery as a part of their salvage therapy had a mean estimated survival of 30.9 months compared with 22.8 months for patients who received only chemoradiotherapy (p = 0.126). Grade 3 or 4 acute toxicities occurred in 31.7% of patients, but all had resolved within 2 months of therapy completion. No deaths occurred during treatment, except for 1 patient, who died shortly after discontinuing treatment early because of previously undiagnosed metastatic disease; 6 patients had long-term complications. Conclusions: Concurrent chemotherapy with repeat radiotherapy with IMRT given every other week appears to be both well tolerated and feasible in patients treated with previous radiotherapy for recurrent head and neck cancer. IMRT represents a reasonable modality for reducing treatment-related toxicities in a repeat RT setting.

Biagioli, Matthew C. [Department of Radiation Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL (United States)], E-mail: MCBiagioli@yahoo.com; Harvey, Mark [Department of Radiation Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL (United States); Roman, Eloy; Raez, Luis E. [Department of Medicine, Division of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL (United States); Wolfson, Aaron H. [Department of Radiation Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL (United States); Mutyala, Subhakar [Department of Radiation Oncology, Albert Einstein Medical Center, New York, NY (United States); Han, Hyo S. [Department of Medicine, Division of Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL (United States); Markoe, Arnold [Department of Radiation Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL (United States)

2007-11-15

21

Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors.  

PubMed

The aim of this study was to evaluate the survival of 395 previously untreated cervical cancer patients with at least one high risk factor following concurrent chemoradiation and to assess the toxicities. Two different chemotherapy regimens were used for concurrent chemoradiation. In the patients with squamous cell carcinoma, 100 mg/m2 of cisplatin was infused intravenously, followed immediately by five consecutive daily administrations of 5-fluorouracil, 1,000 mg/m2/day, each infused intravenously over 24 hr. As for the patients with adenocarcinoma, 70 mg/m2 of cisplatin, 250 mg/m2 of cytoxan and 45 mg/m2 of adriamycin were administered intravenously on days 1, 2, and 3, respectively. The 5-year survival rate was 54.4% with stage III and IV, 62.6% with lymph node metastasis on computed tomogram or MRI, 77.9% with stage I-II disease with lesion size > or =4 cm, and 50.3% with small cell carcinoma or adenocarcinoma. Side effects from concurrent chemoradiation such as nausea, vomiting, and alopecia were present in all 395 cases. Anemia, leukopenia, thrombocytopenia, hepatotoxicity, and nephrotoxicity were observed to varying degrees, but there was no toxic death. This study suggests that cisplatin-based concurrent chemoradiation in treating cervical cancer patients with high risk factors is effective and relatively well tolerated, with acceptable toxicity. PMID:10983693

Park, T K; Kim, S N; Kim, S W; Kim, G E; Suh, C O

2000-08-01

22

Concurrency Compliant Embedded System Modeling Methodology  

Microsoft Academic Search

To meet time-to-market demands, it is crucial that improvement be made to the system design efficiency. By utilizing a reusable design methodology, it is possible to meet project management requirements. Component integrations may often fail due to concurrency concerns. These concurrency problems mainly occur when components access share resources simultaneously and communicate with each other. If these problems are not

Sifat Islam; Ravi Shankar; Ankur Agarwal; Andrew Katan; Cyril-Daniel Iskander

2008-01-01

23

Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Locoregionally Advanced Laryngeal and Hypopharyngeal Cancers  

SciTech Connect

Purpose: To perform a retrospective review of laryngeal/hypopharyngeal carcinomas treated with concurrent chemotherapy and intensity-modulated radiotherapy (IMRT). Methods and Materials: Between January 2002 and June 2005, 20 laryngeal and 11 hypopharyngeal carcinoma patients underwent IMRT with concurrent platinum-based chemotherapy; most patients had Stage IV disease. The prescription of the planning target volume for gross, high-risk, and low-risk subclinical disease was 70, 59.4, and 54 Gy, respectively. Acute/late toxicities were retrospectively scored using the Common Toxicity Criteria scale. The 2-year local progression-free, regional progression-free, laryngectomy-free, distant metastasis-free, and overall survival rates were calculated using the Kaplan-Meier method. Results: The median follow-up of the living patients was 26 months (range, 17-58 months). The 2-year local progression-free, regional progression-free, laryngectomy-free, distant metastasis-free, and overall survival rate was 86%, 94%, 89%, 92%, and 63%, respectively. Grade 2 mucositis or higher occurred in 48% of patients, and all experienced Grade 2 or higher pharyngitis during treatment. Xerostomia continued to decrease over time from the end of RT, with none complaining of Grade 2 toxicity at this analysis. The 2-year post-treatment percutaneous endoscopic gastrostomy-dependency rate for those with hypopharyngeal and laryngeal tumors was 31% and 15%, respectively. The most severe late complications were laryngeal necrosis, necrotizing fascitis, and a carotid rupture resulting in death 3 weeks after salvage laryngectomy. Conclusion: These preliminary results have shown that IMRT achieved encouraging locoregional control of locoregionally advanced laryngeal and hypopharyngeal carcinomas. Xerostomia improved over time. Pharyngoesophageal stricture with percutaneous endoscopic gastrostomy dependency remains a problem, particularly for patients with hypopharyngeal carcinoma and, to a lesser extent, those with laryngeal cancer. Strategies using IMRT to limit the dose delivered to the esophagus/inferior constrictor musculature without compromising target coverage might be useful to further minimize this late complication.

Lee, Nancy Y. [Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)], E-mail: leen2@mskcc.org; O'Meara, William; Chan, Kelvin [Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Della-Bianca, Cesar; Mechalakos, James G. [Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Zhung, Joanne; Wolden, Suzanne L.; Narayana, Ashwatha [Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Kraus, Dennis; Shah, Jatin P. [Department of Surgery, Division of Head and Neck Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY (United States); Pfister, David G. [Department of Medicine, Division of Head and Neck Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)

2007-10-01

24

Radiotherapy With or Without Concurrent Chemotherapy for Lymph Node Recurrence After Radical Surgery of Thoracic Esophageal Squamous Cell Carcinoma  

Microsoft Academic Search

Purpose: To retrospectively compare the outcomes of patients with lymph node recurrence after radical surgery of esophageal cancer, when given radiotherapy with or without concurrent chemotherapy. Methods and Materials: Between January 1996 and December 2005, the data from 73 patients with lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma were retrospectively reviewed. The patients were separated

Jin-Cheng Lu; Cheng Kong; Hua Tao

2010-01-01

25

Concurrent cerebellar and cervical intramedullary tuberculoma: Paradoxical response on antitubercular chemotherapy and need for surgery  

PubMed Central

Spinal intramedullary tuberculoma (SIT) is a rare manifestation of neurotuberculosis. Concurrent SIT and intracranial tuberculoma are further unusual. Most of these tuberculomas respond completely to medical therapy, and surgical excision is seldom required. In this report, we describe a 17-year-old boy who developed cervical intramedullary tuberculoma at C3-C6 level with a concurrent lesion involving the right cerebellar hemisphere while on treatment for tubercular meningitis. This patient had paradoxical increase in size of the cervical lesion even though the cerebellar lesion showed regression in size. In this article, we discuss the paradoxical response to anti-tubercular therapy in central nervous system tuberculosis, possible causes of nonresolution of tuberculoma on medical therapy and evaluate the role of surgery in these cases. PMID:25250077

Das, Kuntal Kanti; Jaiswal, Sushila; Shukla, Mukesh; Srivastava, Arun Kumar; Behari, Sanjay; Kumar, Raj

2014-01-01

26

Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer  

PubMed Central

AIM: To evaluate the dosimetry, efficacy and toxicity of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy for patients with locally advanced cervical and upper thoracic esophageal cancer. METHODS: A retrospective study was performed on 7 patients who were definitively treated with IMRT and concurrent chemotherapy. Patients who did not receive IMRT radiation and concurrent chemotherapy were not included in this analysis. IMRT plans were evaluated to assess the tumor coverage and normal tissue avoidance. Treatment response was evaluated and toxicities were assessed. RESULTS: Five- to nine-beam IMRT were used to deliver a total dose of 59.4-66 Gy (median: 64.8 Gy) to the primary tumor with 6-MV photons. The minimum dose received by the planning tumor volume (PTV) of the gross tumor volume boost was 91.2%-98.2% of the prescription dose (standard deviation [SD]: 3.7%-5.7%). The minimum dose received by the PTV of the clinical tumor volume was 93.8%-104.8% (SD: 4.3%-11.1%) of the prescribed dose. With a median follow-up of 15 mo (range: 3-21 mo), all 6 evaluable patients achieved complete response. Of them, 2 developed local recurrences and 2 had distant metastases, 3 survived with no evidence of disease. After treatment, 2 patients developed esophageal stricture requiring frequent dilation and 1 patient developed tracheal-esophageal fistula. CONCLUSION: Concurrent IMRT and chemotherapy resulted in an excellent early response in patients with locally advanced cervical and upper thoracic esophageal cancer. However, local and distant recurrence and toxicity remain to be a problem. Innovative approaches are needed to improve the outcome. PMID:17006988

Wang, Shu-Lian; Liao, Zhongxing; Liu, Helen; Ajani, Jaffer; Swisher, Stephen; Cox, James D; Komaki, Ritsuko

2006-01-01

27

Salivary Gland Tumors Treated With Adjuvant Intensity-Modulated Radiotherapy With or Without Concurrent Chemotherapy  

SciTech Connect

Purpose: To analyze the recent single-institution experience of patients with salivary gland tumors who had undergone adjuvant intensity-modulated radiotherapy (IMRT), with or without concurrent chemotherapy. Patients and Methods: We performed a retrospective analysis of 35 salivary gland carcinoma patients treated primarily at the Dana-Farber Cancer Institute between 2005 and 2010 with surgery and adjuvant IMRT. The primary endpoints were local control, progression-free survival, and overall survival. The secondary endpoints were acute and chronic toxicity. The median follow-up was 2.3 years (interquartile range, 1.2-2.8) among the surviving patients. Results: The histologic types included adenoid cystic carcinoma in 15 (43%), mucoepidermoid carcinoma in 6 (17%), adenocarcinoma in 3 (9%), acinic cell carcinoma in 3 (9%), and other in 8 (23%). The primary sites were the parotid gland in 17 (49%), submandibular glands in 6 (17%), tongue in 4 (11%), palate in 4 (11%), and other in 4 (11%). The median radiation dose was 66 Gy, and 22 patients (63%) received CRT. The most common chemotherapy regimen was carboplatin and paclitaxel (n = 14, 64%). A trend was seen for patients undergoing CRT to have more adverse prognostic factors, including Stage T3-T4 disease (CRT, n = 12, 55% vs. n = 4, 31%, p = .29), nodal positivity (CRT, n = 8, 36% vs. n = 1, 8%, p = .10), and positive margins (n = 13, 59% vs. n = 5, 38%, p = .30). One patient who had undergone CRT developed an in-field recurrence, resulting in an overall actuarial 3-year local control rate of 92%. Five patients (14%) developed distant metastases (1 who had undergone IMRT only and 4 who had undergone CRT). Acute Grade 3 mucositis, esophagitis, and dermatitis occurred in 8%, 8%, and 8% (1 each) of IMRT patients and in 18%, 5%, and 14% (4, 1, and 3 patients) of the CRT group, respectively. No acute Grade 4 toxicity occurred. The most common late toxicity was Grade 1 xerostomia (n = 8, 23%). Conclusions: Treatment of salivary gland malignancies with postoperative IMRT was well tolerated with a high rate of local control. Chemoradiotherapy resulted in excellent local control in a subgroup of patients with adverse prognostic factors and might be warranted in select patients.

Schoenfeld, Jonathan D., E-mail: jdschoenfeld@partners.org [Department of Radiation Oncology, Harvard Radiation Oncology Program, Boston, MA (United States); Sher, David J. [Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States); Norris, Charles M. [Department of Surgery, Division of Otolaryngology, Brigham and Women's Hospital, Boston, MA (United States); Haddad, Robert I.; Posner, Marshall R. [Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (United States); Department of Medicine, Brigham and Women's Hospital, Boston, MA (United States); Balboni, Tracy A.; Tishler, Roy B. [Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States)

2012-01-01

28

Concurrent Radiotherapy and Gemcitabine for Unresectable Pancreatic Adenocarcinoma: Impact of Adjuvant Chemotherapy on Survival  

SciTech Connect

Purpose: To retrospectively analyze results of concurrent chemoradiotherapy (CCRT) using gemcitabine (GEM) for unresectable pancreatic adenocarcinoma. Methods and Materials: Records of 108 patients treated with concurrent external beam radiotherapy (EBRT) and GEM were reviewed. The median dose of EBRT in all 108 patients was 50.4 Gy (range, 3.6-60.8 Gy), usually administered in conventional fractionations (1.8-2 Gy/day). During radiotherapy, most patients received GEM at a dosage of 250 to 350 mg/m{sup 2} intravenously weekly for approximately 6 weeks. After CCRT, 59 patients (54.6%) were treated with adjuvant chemotherapy (AC), mainly with GEM. The median follow-up for all 108 patients was 11.0 months (range, 0.4-37.9 months). Results: Initial responses after CCRT for 85 patients were partial response: 26 patients, no change: 51 patients and progressive disease: 8 patients. Local progression was observed in 35 patients (32.4%), and the 2-year local control (LC) rate in all patients was 41.9%. Patients treated with total doses of 50 Gy or more had significantly more favorable LC rates (2-year LC rate, 42.9%) than patients treated with total doses of less than 50 Gy (2-year LC rate, 29.6%). Regional lymph node recurrence was found in only 1 patient, and none of the 57 patients with clinical N0 disease had regional lymph node recurrence. The 2-year overall survival (OS) rate and the median survival time in all patients were 23.5% and 11.6 months, respectively. Patients treated with AC had significantly more favorable OS rates (2-year OS, 31.8%) than those treated without AC (2-year OS, 12.4%; p < 0.0001). On multivariate analysis, AC use and clinical T stage were significant prognostic factors for OS. Conclusions: CCRT using GEM yields a relatively favorable LC rate for unresectable pancreatic adenocarcinoma, and CCRT with AC conferred a survival benefit compared to CCRT without AC.

Ogawa, Kazuhiko, E-mail: kogawa@med.u-ryukyu.ac.jp [Department of Radiology, University of the Ryukyus, Okinawa (Japan); Ito, Yoshinori [Department of Radiation Oncology, National Cancer Center, Tokyo (Japan); Hirokawa, Naoki [Department of Radiology, Sapporo Medical University, Sapporo (Japan); Shibuya, Keiko [Department of Radiation Oncology and Image-Applied Therapy, Kyoto University, Kyoto (Japan); Kokubo, Masaki [Department of Radiation Oncology, Institute of Biomedical Research and Innovation Hospital, Kobe (Japan); Ogo, Etsuyo [Department of Radiation Oncology, Kurume University, Kurume (Japan); Shibuya, Hitoshi [Department of Radiology, Tokyo Medical and Dental University, Tokyo (Japan); Saito, Tsutomu [Department of Radiation Oncology, Nihon University Itabashi Hospital, Tokyo (Japan); Onishi, Hiroshi [Department of Radiology, Yamanashi University, Yamanashi (Japan); Karasawa, Katsuyuki [Department of Radiation Oncology, Tokyo Metropolitan Komagome Hospital, Tokyo (Japan); Nemoto, Kenji [Department of Radiation Oncology, Yamagata University, Yamagata (Japan); Nishimura, Yasumasa [Department of Radiation Oncology, Kinki University School of Medicine, Osaka (Japan)

2012-06-01

29

ACTORS: A Model of Concurrent Computation in Distributed Systems  

E-print Network

A foundational model of concurrency is developed in this thesis. We examine issues in the design of parallel systems and show why the actor model is suitable for exploiting large-scale parallelism. Concurrency in actors ...

Agha, Gul Abdulnabi

1985-06-01

30

Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer  

SciTech Connect

Purpose: To evaluate a multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer. Methods and Materials: Patients with stages T2-4aN0M0 bladder cancer suitable for cystectomy underwent radical transurethral resection and induction chemotherapy, followed by concurrent chemoradiotherapy (CCRT). Patients with a Karnofsky performance status (KPS) <80 or age {>=}70 years underwent Protocol A: induction chemotherapy with three cycles of the cisplatin and 5-fluorouracil (CF) regimen, and CCRT with six doses of weekly cisplatin and 64.8 Gy radiotherapy given with the shrinking-field technique. Patients with KPS {>=}80 and age <70 years underwent Protocol B: induction chemotherapy with three cycles of weekly paclitaxel plus the CF regimen, and CCRT with six doses of weekly paclitaxel and cisplatin plus 64.8 Gy radiotherapy. Interval cystoscopy was employed after induction chemotherapy and when radiotherapy reached 43.2 Gy. Patients without a complete response (CR) were referred for salvage cystectomy. Results: Among 30 patients (median, 66 years) enrolled, 17 and 13 patients underwent Protocol A and B, respectively. After induction chemotherapy, 23 patients achieved CR. Five (17%) of 7 patients without CR underwent salvage cystectomy. Overall, 28 patients (93%) completed the protocol treatment. Of 22 patients who completed CCRT, 1 had recurrence with carcinoma in situ and 3 had distant metastases. After a median follow-up of 47 months, overall and progression-free survival rate for all patients were 77% and 54% at 3 years, respectively. Of 19 surviving patients, 15 (79%) retained functioning bladders. Conclusions: Our protocols may be alternatives to cystectomy for selected patients who wish to preserve the bladder.

Lin, C.-C. [Department of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan (China); Department of Urology, National Taiwan University College of Medicine, Taipei, Taiwan (China); Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (China); Hsu, C.-H. [Department of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan (China); Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (China); Cheng, Jason C. [Department of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan (China); Huang, C.-Y. [Department of Urology, National Taiwan University College of Medicine, Taipei, Taiwan (China); Tsai, Y.-C. [Department of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan (China); Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (China); Hsu, F.-M. [Department of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan (China); Huang, K.-H. [Department of Urology, National Taiwan University College of Medicine, Taipei, Taiwan (China); Cheng, A.-L. [Department of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan (China); Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan (China); Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (China); Pu, Y.-S. [Department of Urology, National Taiwan University College of Medicine, Taipei, Taiwan (China)], E-mail: yspu@ntu.edu.tw

2009-10-01

31

A Matched-Case Comparison to Explore the Role of Consolidation Chemotherapy After Concurrent Chemoradiation in Cervical Cancer  

SciTech Connect

Purpose: The aim of this study was to compare the efficacy and toxicity of consolidation chemotherapy after concurrent chemoradiation (CCRT) and CCRT alone in patients with locally advanced cervical carcinoma. Methods and Materials: Using medical records from January 2001 to December 2007, 39 patients treated with consolidation chemotherapy after CCRT (Group 1) were matched to 39 patients treated with CCRT alone (Group 2). Consolidation chemotherapy consisted of three additional cycles of chemotherapy with cisplatin 60 mg/m{sup 2} (Day 1) and 5-fluorouracil 1,000 mg/m{sup 2} per day (Days 1-5) given every 3 weeks. The primary endpoint was overall survival. Results: During a median follow-up period of 35 months (range, 8-96 months), 10 (25.6%) and 16 (41.0%) patients showed disease progression in Groups 1 and 2, respectively. Distant recurrence with or without locoregional/lymphogenous recurrence occurred more frequently in Group 2 than in Group 1 (23.1% vs. 7.7%, p = 0.06). By contreast, there was no difference in locoregional or lymphogenous recurrence between the two groups. The rate of overall survival was higher in Group 1 than in Group 2 (92.7% vs. 69.9%, p = 0.042), whereas the difference in progression-free survival between the groups was not statistically significant (70.1% vs. 55.1%, p = 0.079). Although the difference was not statistically significant, neutropenia was more common in Group 1 than in Group 2 (10.9% vs. 4.7%, p = 0.07). Conclusions: Consolidation chemotherapy after CCRT may improve survival and reduce distant recurrence without additional toxicity compared to CCRT alone in patients with locally advanced cervical carcinoma.

Choi, Chel Hun; Lee, Yoo-Young; Kim, Min Kyu; Kim, Tae-Joong; Lee, Jeong-Won [Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Nam, Hee Rim; Huh, Seung Jae [Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Lee, Je-Ho; Bae, Duk-Soo [Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Kim, Byoung-Gie, E-mail: bksong.kim@samsung.com [Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of)

2011-12-01

32

A Deductive Database Support to the Specification of Concurrent Systems  

Microsoft Academic Search

We present an approach to the specification of concurrent systems, by means of a deductive database management system. The approach is based on the synthesis of logic formulas: starting from a temporal logic formula, that represents the requirements of a system, a general model for such formula, is derived. From this model, all the concurrent systems satisfying the formula can

Patrizia Asirelli; Stefania Gnesi; Maria Cristina Rossi

1996-01-01

33

Concurrency Control in Distributed Database Systems  

Microsoft Academic Search

In this paper we survey, consolidate, and present the state of the art in distributed database concurrency control. The heart of our analysts is a decomposition of the concurrency control problem into two major subproblems: read-write and write-write synchronization. We describe a series of synchromzation techniques for solving each subproblem and show how to combine these techniques into algorithms for

Philip A. Bernstein; Nathan Goodman

1981-01-01

34

S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer  

PubMed Central

AIM: To investigate the feasibility and efficacy of the combination of S-1 with gemcitabine followed by oral S-1 with concurrent radiotherapy (intensity modulated radiotherapy, IMRT) and maintenance therapy with S-1 for locally advanced pancreatic cancer. METHODS: Subjects selected in the study were patients who had unresectable and locally advanced pancreatic cancer without distant metastases, adequate organ and marrow functions, an Eastern Cooperative Oncology Group performance status of 0-1 and no prior anticancer therapy. Initially the subjects received two cycles of chemotherapy, oral administration of S-1 40 mg/m2 twice daily from day 1 to day 14 of a 21-d cycle, with 30-min intravenous infusions of gemcitabine 1000 mg/m2 on day 1 and day 8. Two weeks after the completion of chemotherapy, S-1 was administered orally with concurrent IMRT. Oral S-1 was administered at a dose of 80 mg/m2 per day twice daily from day 1 to day 14 and from day 22 to day 35. Radiation was concurrently delivered at a dose of 50.4 Gy (1.8 Gy/d, 5 times per week, 28 fractions). One month after the completion of chemotherapy and radiotherapy, S-1 was administered orally at a dose of 80 mg/m2 per day twice daily for 14 d, followed by a 14-d rest period. This cycle was repeated as maintenance therapy, until unacceptable toxicity occurred or the disease worsened. Thirty-two patients were involved in this study. The median follow-up was 15.6 mo (range: 8.6-32.3 mo). RESULTS: Thirty-two patients completed the scheduled course of chemotherapy, while 30 patients (93.8%) received chemoradiotherapy with two patients ceasing to continue with radiotherapy. The major toxic effects were nausea and leukopenia. There was no grade 4 toxicity or treatment-related death. According to the Response Evaluation Criteria in Solid Tumors criteria, the objective tumor response was partial response in 17 (53.1%) patients, stable disease in 9 (28.1%), and progressive disease in 6 (18.8%). The median overall survival and median progression-free survival were 15.2 mo and 9.3 mo, respectively. The survival rates at 1 year and 2 years were 75% and 34.4%, respectively. CONCLUSION: The combination of S-1 with gemcitabine followed by oral S-1 with IMRT and maintenance therapy with S-1 alone in patients with locally advanced pancreatic cancer may be considered a well-tolerated, promising treatment regimen. PMID:25320537

Ke, Qing-Hua; Zhou, Shi-Qiong; Yang, Ji-Yuan; Du, Wei; Liang, Gai; Lei, Yong; Luo, Fei

2014-01-01

35

System level concurrency control for distributed database systems  

Microsoft Academic Search

A distributed database system is one in which the database is spread among several sites and application programs “move” from site to site to access and update the data they need. The concurrency control is that portion of the system that responds to the read and write requests of the application programs. Its job is to maintain the global consistency

Daniel J. Rosenkrantz; Richard Edwin Stearns; Philip M. Lewis II

1978-01-01

36

Risk factors for acute esophagitis in non–small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy  

Microsoft Academic Search

Purpose: To determine the risk factors for acute esophagitis (AE) in non-small-cell lung cancer (NSCLC) patients treated with concurrent chemotherapy (CCT) and three-dimensional conformal radiotherapy (3D-CRT). Methods and Materials: Clinical data were retrospectively analyzed for 215 NSCLC patients treated with CCT and 3D-CRT during 2000-2003, 127 of whom also had induction chemotherapy (ICT). Carboplatin and paclitaxel were the most commonly

Xiong Wei; H. Helen. Liu; Susan L. Tucker; Zhongxing Liao; Chaosu Hu; Radhe Mohan; James D. Cox; Ritsuko Komaki

2006-01-01

37

Chemotherapy  

MedlinePLUS

( Quimioterapia ) Chemotherapy (say: kee-moe-THER-ah-pee) is the use of medicines to treat cancer. Cancer is a ... throughout the body making the person very sick. Chemotherapy medicines stop the growth of cancer cells. As ...

38

Concurrent engineering of an infrared telescope system  

NASA Astrophysics Data System (ADS)

A concurrent engineering approach to the design and analysis of a space-borne Electro-Optical (EO) sensor is presented. A detailed design of an infrared telescope payload is developed by an interdisciplinary team of mechanical, structural, thermal, and optical engineers using a Simulation Driven Engineering (SDE) software environment. The telescope payload design is also integrated with a conceptual level design of the space segment of a mission that incorporates the payload. The flow of the concurrent design process is described, and design outputs are provided.

Geis, Jason; Lang, Jeffrey; Peterson, Leslie; Roybal, Francisco; Tanzillo, Jennifer; Thomas, David; Warren, David

2011-10-01

39

Radiotherapy With or Without Concurrent Chemotherapy for Lymph Node Recurrence After Radical Surgery of Thoracic Esophageal Squamous Cell Carcinoma  

SciTech Connect

Purpose: To retrospectively compare the outcomes of patients with lymph node recurrence after radical surgery of esophageal cancer, when given radiotherapy with or without concurrent chemotherapy. Methods and Materials: Between January 1996 and December 2005, the data from 73 patients with lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma were retrospectively reviewed. The patients were separated into two groups: radiochemotherapy (RC, 31 patients) and radiotherapy alone (RA, 42 patients). Patients in the RC group received at least two cycles of 5-fluorouracil/cisplatin chemotherapy concurrently with radiotherapy. Results: The median duration of follow-up was 11 months (range, 2-48). The overall survival rate for all patients was 46.7% and 4.7% at 1 and 3 years, respectively. The median overall survival time was 9 months (95% confidence interval, 6.96-11.04) and 17 months (95% confidence interval, 13.61-20.39) for RA and RC groups, respectively. The survival rate at 1 and 3 years was 62.5% and 10.5% in the RC group and 33.8% and 0% in the RA group (p = .0049, log-rank test; hazard ratio for death, 0.52; 95% confidence interval, 0.30-0.92). Acute toxicities were more frequent in the RC group than in the RA group. No significant differences were found in the late toxicity profiles between the two groups. Conclusion: The results of the present retrospective analysis suggest that RC should be considered an effective and well-tolerated treatment of patients with thoracic esophageal squamous cell carcinoma and postoperative lymph node recurrence.

Lu Jincheng, E-mail: lujincheng@msn.co [Department of Radiotherapy, Jiangsu Cancer Hospital, Nanjing (China); Kong Cheng; Tao Hua [Department of Radiotherapy, Jiangsu Cancer Hospital, Nanjing (China)

2010-11-01

40

Concurrent Cycle Collection in Reference Counted Systems  

Microsoft Academic Search

Automatic storage reclamation via reference counting has important advantages, but has always suffered from a major weakness due to its inability to reclaim cyclic data structures. We describe a novel cycle collection algorithm that is both concurrent — it is capable of collecting garbage even in the presence of simultaneous mutation — and localized — it never needs to perform

David F. Bacon; V. T. Rajan

2001-01-01

41

Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer  

PubMed Central

Purpose To evaluate the treatment outcome of salvage concurrent radio-chemotherapy for patients with loco-recurrent esophageal cancer after surgery. Methods 50 patients with loco-recurrent squamous-cell cancer after curative esophagectomy were retrospectively analyzed. Patients were treated with radiotherapy (median 60?Gy) combined with chemotherapy consisting of either 5-fluorouracil (5-FU) plus cisplatin (DDP) (R-FP group) or paclitaxel plus DDP (R-TP group). Results The median follow-up period was 16.0?months. The 1-year and 3-year survival rates were 56% and 14%, respectively. The median progression-free survival (PFS) and overall survival (OS) time was 9.8 and 13.3?months respectively. There was no statistical significance of the PFS of the two groups. The OS (median 16.3?months) in the R-TP group was superior to that in the R-FP group (median: 9.8?months) (p?=?0.012). Among the patients who had received ?60?Gy irradiation dose, the median PFS (10.6?months) and OS (16.3?months) were significantly superior to the PFS (8.7?months) and OS (11.3?months) among those patients did not (all p?chemotherapy was an effective salvage treatment. Younger age, treatment with the TP regimen and an irradiation dose ?60?Gy might improve the patients’ treatment outcome. PMID:22713587

2012-01-01

42

The Concurrency Workbench: A Semantics Based Tool for the Verification of Concurrent Systems \\Lambda  

E-print Network

primarily to validate (as opposed to verify) existing real­world systems. In order to achieve proven a valuable aid in teaching and research. 1 Introduction This paper describes the Concurrency, are particularly suitable for automated analysis because their finitary nature ensures the existence of decision

Parrow, Joachim

43

Radiobiological compensation: A case study of uterine cervix cancer with concurrent chemotherapy  

SciTech Connect

The case of a patient diagnosed with uterine cervix cancer is presented as an example of the clinical application of the radiobiological compensation method implemented at Centro Estatal de Cancerologia de Durango. Radiotherapy treatment was initially modified to compensate for the chemotherapy component and, as medical complications arose during treatment delivery resulting in an 18 days gap, new compensation followed. All physical and radiobiological assumptions to calculate the Biologically Effective Dose in the external beam and brachytherapy parts of the treatment are presented. Good local control of the tumor was achieved, the theoretical tolerance limits for the organs at risk were not surpassed and the patient manifested no extensive morbidity.

Herrera, Higmar; Yanez, Elvia; Lopez, Jesus [Centro Estatal de Cancerologia de Durango, Victoria de Durango, Durango (Mexico); ISSSTE General Hospital Dr. Santiago Ramon y Cajal, Victoria de Durango, Durango (Mexico)

2012-10-23

44

Radiobiological compensation: A case study of uterine cervix cancer with concurrent chemotherapy  

NASA Astrophysics Data System (ADS)

The case of a patient diagnosed with uterine cervix cancer is presented as an example of the clinical application of the radiobiological compensation method implemented at Centro Estatal de Cancerología de Durango. Radiotherapy treatment was initially modified to compensate for the chemotherapy component and, as medical complications arose during treatment delivery resulting in an 18 days gap, new compensation followed. All physical and radiobiological assumptions to calculate the Biologically Effective Dose in the external beam and brachytherapy parts of the treatment are presented. Good local control of the tumor was achieved, the theoretical tolerance limits for the organs at risk were not surpassed and the patient manifested no extensive morbidity.

Herrera, Higmar; Yañez, Elvia; López, Jesús

2012-10-01

45

Computational simulation for concurrent engineering of aerospace propulsion systems  

NASA Technical Reports Server (NTRS)

Results are summarized for an investigation to assess the infrastructure available and the technology readiness in order to develop computational simulation methods/software for concurrent engineering. These results demonstrate that development of computational simulation methods for concurrent engineering is timely. Extensive infrastructure, in terms of multi-discipline simulation, component-specific simulation, system simulators, fabrication process simulation, and simulation of uncertainties--fundamental to develop such methods, is available. An approach is recommended which can be used to develop computational simulation methods for concurrent engineering of propulsion systems and systems in general. Benefits and issues needing early attention in the development are outlined.

Chamis, C. C.; Singhal, S. N.

1993-01-01

46

A Phase II Study of Radiotherapy and Concurrent Paclitaxel Chemotherapy in Breast-Conserving Treatment for Node-Positive Breast Cancer  

SciTech Connect

Purpose: Administering adjuvant chemotherapy before breast radiotherapy decreases the risk of systemic recurrence, but delays in radiotherapy could yield higher local failure. We assessed the feasibility and efficacy of placing radiotherapy earlier in the breast-conserving treatment course for lymph node-positive breast cancer. Methods and Materials: Between June 2000 and December 2004, 44 women with node-positive Stage II and III breast cancer were entered into this trial. Breast-conserving surgery and 4 cycles of doxorubicin (60 mg/m{sup 2})/cyclophosphamide (600 mg/m{sup 2}) were followed by 4 cycles of paclitaxel (175 mg/m{sup 2}) delivered every 3 weeks. Radiotherapy was concurrent with the first 2 cycles of paclitaxel. The breast received 39.6 Gy in 22 fractions with a tumor bed boost of 14 Gy in 7 fractions. Regional lymphatics were included when indicated. Functional lung volume was assessed by use of the diffusing capacity for carbon monoxide as a proxy. Breast cosmesis was evaluated with the Harvard criteria. Results: The 5-year actuarial rate of disease-free survival is 88%, and overall survival is 93%. There have been no local failures. Median follow-up is 75 months. No cases of radiation pneumonitis developed. There was no significant change in the diffusing capacity for carbon monoxide either immediately after radiotherapy (p = 0.51) or with extended follow-up (p = 0.63). Volume of irradiated breast tissue correlated with acute cosmesis, and acute Grade 3 skin toxicity developed in 2 patients. Late cosmesis was not adversely affected. Conclusions: Concurrent paclitaxel chemotherapy and radiotherapy after breast-conserving surgery shortened total treatment time, provided excellent local control, and was well tolerated.

Chen, William C. [Department of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH (United States); Kim, Janice [Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA (United States); Kim, Edward [Department of Radiation Oncology, Ohio State University Medical Center, Columbus, OH (United States); Silverman, Paula [Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH (United States); Overmoyer, Beth [Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (United States); Cooper, Brenda W. [Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH (United States); Anthony, Sue [Department of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH (United States); Shenk, Robert; Leeming, Rosemary [Department of Surgery, University Hospitals Case Medical Center, Cleveland, OH (United States); Hanks, Shelli H. [Arizona Institute of Urology, Tucson, AZ (United States); Lyons, Janice A., E-mail: janice.lyons@uhhospitals.org [Department of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH (United States)

2012-01-01

47

Probabilistic simulation of concurrent engineering of propulsion systems  

NASA Technical Reports Server (NTRS)

Technology readiness and the available infrastructure is assessed for timely computational simulation of concurrent engineering for propulsion systems. Results for initial coupled multidisciplinary, fabrication-process, and system simulators are presented including uncertainties inherent in various facets of engineering processes. An approach is outlined for computationally formalizing the concurrent engineering process from cradle-to-grave via discipline dedicated workstations linked with a common database.

Chamis, C. C.; Singhal, S. N.

1993-01-01

48

Concurrency control in heterogeneous distributed database systems  

E-print Network

concurrency compared to the solution proposed in [14] and in [13] since global transactions can be executed in parallel if they do not conflict with one another either directly or indi- rectly contrary to the solution in [14] and are not aborted like.../write operations on the global data iteu& supported by the HDDBS. Each transaction con- sists of a. BEGIN operation aud an arbitrary number of READ/WRITE operations, followed by either a COMMIT or an ABORT operation. '2. Global Data iManager (GDM): interfaces...

Rahman, Md. Rezaur

2012-06-07

49

A Concurrent Distributed System for Aircraft Tactical Decision Generation  

NASA Technical Reports Server (NTRS)

A research program investigating the use of artificial intelligence (AI) techniques to aid in the development of a Tactical Decision Generator (TDG) for Within Visual Range (WVR) air combat engagements is discussed. The application of AI programming and problem solving methods in the development and implementation of a concurrent version of the Computerized Logic For Air-to-Air Warfare Simulations (CLAWS) program, a second generation TDG, is presented. Concurrent computing environments and programming approaches are discussed and the design and performance of a prototype concurrent TDG system are presented.

McManus, John W.

1990-01-01

50

Predictors of Acute Esophagitis in Lung Cancer Patients Treated With Concurrent Three-Dimensional Conformal Radiotherapy and Chemotherapy  

SciTech Connect

Purpose: To evaluate the risk factors for acute esophagitis (AET) in lung cancer patients treated with concurrent 3D-CRT and chemotherapy. Methods and Materials: Data from 100 patients treated with concurrent chemoradiotherapy with a mean dose of 62.05 {+-} 4.64 Gy were prospectively evaluated. Esophageal toxicity was graded according to criteria of the Radiation Therapy Oncology Group. The following dosimetric parameters were analyzed: length and volume of esophagus in treatment field, percentage of esophagus volume treated to {>=}10, {>=}20, {>=}30, {>=}35, {>=}40, {>=}45, {>=}50, {>=}55, and {>=}60 Gy, and the maximum (D{sub max}) and mean doses (D{sub mean}) delivered to the esophagus. Also, we developed an esophagitis index (EI) to account the esophagitis grades over treatment time. Results: A total of 59 patients developed AET (Grade 1, 26 patients; Grade 2, 29 patients; and Grade 3, 4 patients). V50 was associated with AET duration (p = 0.017), AET Grade 1 duration (p = 0.016), maximum analgesia (p = 0.019), esophagitis index score (p = 0.024), and AET Grade {>=}1 (p = 0.058). If V50 is <30% there is a 47.3% risk of AET Grade {>=}1, which increases to 73.3% if V50 is {>=}30% (p = 0.008). The predictive abilities of models (sensitivity and specificity) were calculated by receiver operating characteristic curves. Conclusions: According to the receiver operating characteristic curve analysis, the 30% of esophageal volume receiving {>=}50 Gy was the most statistically significant factor associated with AET Grade {>=}1 and maximum analgesia (A{sub max}). There was an association with AET Grade {>=}2 but it did not achieve statistical significance (p = 0.076)

Rodriguez, Nuria [Department of Radiation Oncology, Hospital de la Esperanza, IMAS, Barcelona (Spain); Department of Medicine, Universitat Autonoma de Barcelona, Barcelona (Spain)], E-mail: nrodriguez@imas.imim.es; Algara, Manuel [Department of Radiation Oncology, Hospital de la Esperanza, IMAS, Barcelona (Spain); Universitat Pompeu Fabra, Barcelona (Spain); Foro, Palmira [Department of Radiation Oncology, Hospital de la Esperanza, IMAS, Barcelona (Spain); Lacruz, Marti [Department of Radiation Oncology, Hospital de la Esperanza, IMAS, Barcelona (Spain); Universitat Pompeu Fabra, Barcelona (Spain); Reig, Anna; Membrive, Ismael; Lozano, Joan; Lopez, Jose Luis [Department of Radiation Oncology, Hospital de la Esperanza, IMAS, Barcelona (Spain); Quera, Jaime [Department of Radiation Oncology, Hospital de la Esperanza, IMAS, Barcelona (Spain); Universitat Pompeu Fabra, Barcelona (Spain); Fernandez-Velilla, Enric; Sanz, Xavier [Department of Radiation Oncology, Hospital de la Esperanza, IMAS, Barcelona (Spain)

2009-03-01

51

Early Clinical Outcome With Concurrent Chemotherapy and Extended-Field, Intensity-Modulated Radiotherapy for Cervical Cancer  

SciTech Connect

Purpose: To assess the early clinical outcomes with concurrent cisplatin and extended-field intensity-modulated radiotherapy (EF-IMRT) for carcinoma of the cervix. Methods and Materials: Thirty-six patients with Stage IB2-IVA cervical cancer treated with EF-IMRT were evaluated. The pelvic lymph nodes were involved in 19 patients, and of these 19 patients, 10 also had para-aortic nodal disease. The treatment volume included the cervix, uterus, parametria, presacral space, upper vagina, and pelvic, common iliac, and para-aortic nodes to the superior border of L1. Patients were assessed for acute toxicities according to the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3.0. All late toxicities were scored with the Radiation Therapy Oncology Group late toxicity score. Results: All patients completed the prescribed course of EF-IMRT. All but 2 patients received brachytherapy. Median length of treatment was 53 days. The median follow-up was 18 months. Acute Grade {>=}3 gastrointestinal, genitourinary, and myelotoxicity were seen in 1, 1, and 10 patients, respectively. Thirty-four patients had complete response to treatment. Of these 34 patients, 11 developed recurrences. The first site of recurrence was in-field in 2 patients (pelvis in 1, pelvis and para-aortic in 1) and distant in 9 patients. The 2-year actuarial locoregional control, disease-free survival, overall survival, and Grade {>=}3 toxicity rates for the entire cohort were 80%, 51%, 65%, and 10%, respectively. Conclusion: Extended-field IMRT with concurrent chemotherapy was tolerated well, with acceptable acute and early late toxicities. The locoregional control rate was good, with distant metastases being the predominant mode of failure. We are continuing to accrue a larger number of patients and longer follow-up data to further extend our initial observations with this approach.

Beriwal, Sushil [Department of Radiation Oncology, Pittsburgh, PA (United States)]. E-mail: beriwals@upmc.edu; Gan, Gregory N. [University of Pittsburgh School of Medicine, Pittsburgh, PA (United States); Heron, Dwight E. [Department of Radiation Oncology, Pittsburgh, PA (United States); Selvaraj, Raj N. [Department of Radiation Oncology, Pittsburgh, PA (United States); Kim, Hayeon [Department of Radiation Oncology, Pittsburgh, PA (United States); Lalonde, Ron [D3 Advanced Radiation Planning, Pittsburgh, PA (United States); Kelley, Joseph L. [Division of Gynecologic Oncology, Department of Gynecology, University of Pittsburgh Cancer Institute, Pittsburgh, PA (United States); Edwards, Robert P. [Division of Gynecologic Oncology, Department of Gynecology, University of Pittsburgh Cancer Institute, Pittsburgh, PA (United States)

2007-05-01

52

Metrics for Quality and Concurrency in Object-Based Systems  

Microsoft Academic Search

This paper defines metrics for object-based systems. A hierarchical, abstract representation of object-based software is presented, and is used to define programming-language-independent metrics formulas. Novel techniques are given for measuring information hiding, cohesion, encapsulation, coupling, “object-orientedness,” maintainability, and potential concurrency among and within objects. The metrics are useful for guiding design optimization. Additionally, the concurrency metrics are useful for guiding

Lonnie R. Welch; Mrinalini Lankala; William H. Farr; Dieter K. Hammer

1996-01-01

53

Treatment of Stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: Impact of chemotherapy schemes  

SciTech Connect

Purpose: The aim of this study was to evaluate the impact of different chemotherapy regimens in patients with advanced nasopharyngeal carcinoma (NPC) treated by induction-concurrent chemoradiotherapy. Methods and Materials: Between 1998 and 2003, 75 Stage IV(A-B) NPC patients were treated with 3 cycles of induction chemotherapy with cisplatin plus 5-fluorouracil (PF) (n = 41) or cisplatin plus gemcitabine (PG) (n = 34), followed by accelerated radiotherapy in concurrence with 2 cycles of cisplatin. In 18 (24%) patients, cisplatin was completely replaced by carboplatin in both concurrent cycles, mainly because of borderline renal functions. Results: The median follow-up was 3.6 years. The 3-year locoregional failure-free survival, progression-free survival, and overall survival of the whole group were 80%, 68%, and 80% respectively. No significant difference was found between patients treated with either induction regimens. However, patients with only carboplatin in the 2 concurrent cycles had significantly inferior 3-year locoregional failure-free survival (56% vs. 86%, p = 0.014), progression-free survival (39% vs. 72%, p = 0.001), and overall survival (61% vs. 87%, p = 0.046) when compared with the rest of the group. In multivariate analysis, the complete replacement of cisplatin by carboplatin during concurrent chemoradiotherapy was still an independent adverse factor in locoregional failure-free survival (hazard ratio, 3.662; 95% CI, 1.145-11.765; p = 0.029) and progression-free survival (hazard ratio, 3.390; 95% CI, 1.443-7.937; p = 0.005). Conclusions: The more convenient PG regimen is as effective as the PF regimen as induction chemotherapy for patients with advanced NPC. Replacing cisplatin with carboplatin in the concurrent phase carries a poor prognosis.

Yau, T.K. [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China)]. E-mail: tkokyau@gmail.com; Lee, Anne [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China); Wong, Dominique [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China); Pang, Ellie S.Y. [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China); Ng, W.T. [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China); Yeung, Rebecca [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China); Soong, Inda S. [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China)

2006-11-15

54

Chemotherapy  

MedlinePLUS

... A needle is inserted into the fluid-filled space surrounding the spinal cord and the chemo drugs are injected into the spinal fluid. Continue Combination Therapy Chemotherapy can be used alone to treat cancer ...

55

Chemotherapy  

MedlinePLUS

Donate Donate One Time Monthly Event Tribute For brain tumor information and support Call: 800-886-ABTA (2282) ... Donate Now Menu Treatment & Care Continuum of Care Brain Tumor Treatments Steroids Surgery Chemotherapy Radiation Stereotactic Radiosurgery Proton ...

56

Effect of Concurrent High-Dose Cisplatin Chemotherapy and Conformal Radiotherapy on Cervical Esophageal Cancer Survival  

SciTech Connect

Purpose: To determine whether a change in treatment policy to conformal, elective nodal radiotherapy and concurrent high-dose cisplatin improved survival for cervical esophageal cancer patients. Methods and Materials: All cervical esophageal cancer patients treated between 1997 and 2005 were restaged (1983 American Joint Committee on Cancer criteria). Patients treated before 2001 (previous cohort [PC]) were compared with those treated from 2001 onward (recent cohort [RC]). The PC institutional chemoradiotherapy protocol was 54 Gy in 20 fractions within 4 weeks, with 5-fluorouracil (1,000 mg/m{sup 2}) on Days 1-4 and either mitomycin C (10 mg/m{sup 2}) or cisplatin (75 mg/m{sup 2}) on Day 1. The RC institutional chemoradiotherapy protocol was conformal radiotherapy, 70 Gy in 35 fractions within 7 weeks, to the primary tumor and elective nodes, with high-dose cisplatin (100 mg/m{sup 2}) on Days 1, 22, and 43. Results: The median follow-up was 3.1 years (PC, 8.1 and RC, 2.3). Of 71 patients (25 women and 46 men), 21 of 29 in the PC and 29 of 42 in the RC were treated curatively (curative subgroup, n = 50). Between the two groups, no differences in overall survival or locoregional relapse-free survival were seen. The overall survival rate at 2 and 5 years was 35% (range, 24-47%) and 21% (range, 12-32%) in the whole group and 46% (range 32-60%) and 28% (range, 15-42%) in the curative group, respectively. In the curative group, no statistically significant prognostic factors were found. Trends toward better locoregional relapse-free survival were seen in women (2-year rate, 73% vs. for men, 36%; p = 0.08) and in patients aged >64 years (2-year rate, 68% vs. age {<=}64 years, 34%; p = 0.10). Conclusion: No survival improvement could be demonstrated after changing the treatment policy to high-dose cisplatin-based, conventionally fractionated conformal chemoradiotherapy. Female gender and older age might predict for better outcomes.

Huang Shaohui [Radiation Medicine Program, Princess Margaret Hospital, Toronto, ON (Canada); Lockwood, Gina [Department of Biostatistics, Princess Margaret Hospital, Toronto, ON (Canada); Brierley, James; Cummings, Bernard; Kim, John; Wong, Rebecca; Bayley, Andrew [Radiation Medicine Program, Princess Margaret Hospital, Toronto, ON (Canada); Department of Radiation Oncology, University of Toronto, Toronto, ON (Canada); Ringash, Jolie [Radiation Medicine Program, Princess Margaret Hospital, Toronto, ON (Canada); Department of Radiation Oncology, University of Toronto, Toronto, ON (Canada)], E-mail: Jolie.Ringash@rmp.uhn.on.ca

2008-07-01

57

The engineering of concurrent simulations of complex systems  

Microsoft Academic Search

Concurrent process-oriented programming is a natural medium for simulating complex systems, particularly systems where many simple components interact in an environ- ment (which may itself be complex). There is little guidance for engineering complex systems simulation. In the context of simulation work to support immunological research, we explore relevant approaches to modelling, and draw on concepts from dependable and high-integrity

Fiona A. C. Polack; Paul S. Andrews; Adam T. Sampson

2009-01-01

58

Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort  

PubMed Central

Purposes First, to evaluate outcome, the benefit of concurrent chemotherapy and prognostic factors in a cohort of sixty-four high-grade glioma patients who underwent a second course of radiation therapy at progression. Second, to validate a new prognostic score for overall survival after reirradiation of progressive gliomas with an independent patient cohort. Patients and methods All patients underwent fractionated reirradiation with a median physical dose of 36 Gy. Median planned target volume was 110.4 ml. Thirty-six patients received concurrent chemotherapy consisting in 24/36 cases (67%) of carboplatin and etoposide and in 12/36 cases (33%) of temozolomide. We used the Kaplan Meier method, log rank test and proportional hazards regression analysis for statistical assessment. Results Median overall survival from the start of reirradiation was 7.7?±?0.7 months. Overall survival rates at 6 and 12 months were 60?±?6% and 24?±?6%, respectively. Despite relatively large target volumes we did not observe any major acute toxicity. Concurrent chemotherapy did not appear to improve outcome. In contrast, female gender, young age, WHO grade III histology, favorable Karnofsky performance score and complete resection of the tumor prior to reirradiation were identified as positive prognostic factors for overall survival. We finally validated a recent suggestion for a prognostic score with our independent but small patient cohort. Our preliminary findings suggest that its ability to discriminate between different prognostic groups is limited. Conclusions Outcome of our patients was comparable to previous studies. Even in case of large target volumes reirradiation seems to be feasible without observing major toxicity. The benefit of concurrent chemotherapy is still elusive. A reassessment of the prognostic score, tested in this study, using a larger patient cohort is needed. PMID:23822643

2013-01-01

59

Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern  

PubMed Central

Background To assess the therapeutic outcome and failure pattern of three-dimensional conformal radiotherapy (3D-CRT)-based concurrent chemoradiotherapy (CCRT) for recurrence of esophageal squamous cell carcinoma (SCC) after radical surgery. Methods Treatment outcome and failure pattern were retrospectively evaluated in 83 patients with localized cervical and thoracic recurrences after radical surgery for thoracic esophageal SCC. All patients were treated with 3DCRT-based CCRT (median radiation dose 60 Gy), in which 39 received concurrent cisplatin plus 5-fluorouracil (PF), and 44 received concurrent docetaxel plus cisplatin (TP). Treatment response was evaluated at 1–3 months after CCRT. Results With a median follow-up of 34 months (range, 2–116 months), the 3-year overall survival (OS) of all the patients was 51.8% and the median OS time was 43.0 months. The overall tumor response rate was 75.9% (63/83), with a complete remission (CR) rate of 44.6% (37/83). In univariate analysis, tumor response after CCRT (p?=?0.000), recurrence site (p?=?0.028) and concurrent chemotherapy (p?=?0.090) showed a trend favoring better OS. Multivariate analysis revealed that tumor response after CCRT (p?=?0.000) and concurrent chemotherapy (p?=?0.010) were independent predictors of OS. Forty-seven patients had progressive diseases after CCRT, 27 had local failure (27/47, 57.4%), 18 had distant metastasis (18/47, 38.3%) and 2 had both local and distant failures (2/47, 4.3%). Conclusions 3DCRT-based CCRT is effective in postoperatively recurrent esophageal SCC. Patients that obtained complete remission after CCRT appeared to achieve long-term OS and might benefit from concurrent TP regimen. Local and distant failures remained high and prospective studies are needed to validate these factors. PMID:24139225

2013-01-01

60

Whole Brain Radiotherapy Plus Concurrent Chemotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Meta-Analysis  

PubMed Central

Objective The aim of the present meta-analysis is to evaluate the response rate, median survival time (MST) and toxicity in patients with brain metastases (BM) originating from non-small cell lung cancer (NSCLC) and who were treated using either whole brain radiotherapy (WBRT) plus concurrent chemotherapy or WBRT alone. Methods PubMed, EMBASE, Web of Science, The Cochrane Library, clinical trials and current controlled trials were searched to identify any relevant publications. After screening the literature and undertaking quality assessment and data extraction, the meta-analysis was performed using Stata11.0 software. Results In total, six randomized controlled trials (RCT) involving 910 participants were included in the meta-analysis. The results of the analysis indicate that WBRT plus concurrent chemotherapy was more effective at improving response rate (RR?=?2.06, 95% CI [1.13, 3.77]; P?=?0.019) than WBRT alone. However, WBRT plus concurrent chemotherapy did not improve median survival time (MST) (HR?=?1.09, 95%CI [0.94, 1.26]; P?=?0.233) or time of neurological progression (CNS-TTP) (HR?=?0.93, 95%CI [0.75, 1.16]; P?=?0.543), and increased adverse events (Grade?3) (RR?=?2.59, 95% CI [1.88, 3.58]; P?=?0.000). There were no significant differences in Grade 3–5 neurological or hematological toxicity between two patient groups (RR?=?1.08, 95%CI [0.23, 5.1]; P?=?0.92). Conclusion The combination of chemotherapy plus WBRT in patients with BM originating from NSCLC may increase treatment response rates of brain metastases with limited toxicity. Although the therapy schedule did not prolong MST or CNS-TTP, further assessment is warranted. PMID:25347291

Qin, Hong; Pan, Feng; Li, Jianjun; Zhang, Xiaoli; Liang, Houjie; Ruan, Zhihua

2014-01-01

61

Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study.  

PubMed

We carried out a prospective phase II study of patients with limited stage small cell lung cancer (LS-SCLC) assigned to receive stereotactic body radiotherapy (SBRT) concurrently with cisplatin-based chemotherapeutic regimen with OS and PFS as the primary study endpoints. Patients with pathologically proven LS-SCLC received 4-6 cycles of cisplatin 75 mg/(m(2)/day) given intravenously on day 1 and etoposide 80 mg/(m(2)/day) given intravenously on days 1-5, both at 3 weekly intervals. SBRT at a dose of 4,000-4,500 cGy in ten fractions was given concurrently with chemotherapy starting on day 1. The Kaplan-Meier curve and life tables were used to describe survival data. Adverse events were evaluated according to the common terminology criteria for adverse events version of the radiation therapy oncology group (RTOG). Twenty-nine patients were included and followed up for a median duration of 19 (range 10-85) months. The median OS was 27 (95 % CI 20.2-33.8) months. The median PFS was 12 (95 % CI 4.2-19.8) months. No grade 4 adverse events were observed. Grade 3 adverse events occurred in only 5 (13.8 %, 5/29) patients. Neutropenia of any grade was observed in 6 (15 %, 6/29) patients, with grade 3 neutropenia only seen in one (3.4 %, 1/29) patient. The combination of chemotherapy and early concurrent SBRT could be a safe and effective treatment for LS-SCLC patients. Our study confirmed that SBRT with concurrent chemotherapy is another new treatment option for LS-SCLC patients. PMID:25416052

Li, Chongyi; Xiong, Yanli; Zhou, Zejun; Peng, Yu; Huang, Huan; Xu, Mingfang; Kang, Houyi; Peng, Bo; Wang, Dong; Yang, Xueqin

2014-12-01

62

Efficient Checking of Link-reversal-based Concurrent Systems  

E-print Network

are limited to single token-based concurrent systems. The basic idea Supported by projects P21694 and P20529-robin schedule by a more relaxed fairness assumption in which in each infinite run, each process receives of the Austrian Science Fund (FWF). Supported in part by the Austrian National Research Network S11403-N23 (Ri

63

ACTORS: A model of concurrent computation in distributed systems  

Microsoft Academic Search

The transition from sequential to parallel computation is an area of critical concern in today's computer technology, particularly in architecture, programming languages, systems, and artificial intelligence. This book addresses issues in concurrency, and by producing both a syntactic definition and a denotational model of Hewitt's actor paradigm - a model of computation specifically aimed at constructing and analyzing distributed large-scale

G. Agha

1986-01-01

64

Concurrent Chemoradiotherapy With Paclitaxel and Nedaplatin Followed by Consolidation Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Uterine Cervix: Preliminary Results of a Phase II Study  

SciTech Connect

Purpose: To evaluate the efficacy and toxicities of concurrent chemoradiotherapy (CCRT) and consolidation chemotherapy in patients with locally advanced squamous cell cervical carcinoma. Methods and Materials: Patients with LASCC (FIGO Stage IIB-IIIB) were treated with pelvic external beam radiotherapy (45 Gy for Stage IIB and 50 Gy for Stage III) and high-dose-rate intracavitary brachytherapy (50 Gy for Stage IIB and 35 Gy for Stage III). The cumulative dose at point A was 50 Gy for Stage IIB and 65 Gy for Stage III. Concurrent chemotherapy with paclitaxel (35 mg/m{sup 2}) and nedaplatin (20 mg/m{sup 2}) was given every week for 6 weeks. Consolidation chemotherapy with paclitaxel (135 mg/m{sup 2}) and nedaplatin (60 mg/m{sup 2}) was administered every 3 weeks for 4 cycles. Results: All patients completed CCRT, and 28 of 34 patients completed consolidation chemotherapy. The complete response rate was 88% (95% CI, 73-96%). The most common Grade 3 or higher toxicities were leukopenia/neutropenia (10.9% of the cycles). During a median follow up of 23 months (range, 14-30 months), 5 patients had locoregional failure and 1 patient had distant metastasis. The estimated 2-year progression-free survival and overall survival were 82% (95% CI, 68-95%) and 93% (95% CI, 83-100%), respectively. Grade 3 late complications occurred in 3 patients (9%). Conclusions: CCRT with paclitaxel and nedaplatin followed by consolidation chemotherapy is well tolerated and effective in patients with locally advanced squamous cell cervical carcinoma. Further randomized trials of comparing this regimen with the standard treatment are worth while.

Zhang Meiqin, E-mail: pianozmq@hotmail.co [Department of Gynecologic Oncology, Cancer Hospital, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai (China); Liu Suping; Wang, Xiang-E. [Department of Gynecologic Oncology, Cancer Hospital, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai (China)

2010-11-01

65

The evolution of the PVM concurrent computing system  

SciTech Connect

Concurrent and distributed computing, using portable software systems or environments on general purpose networked computing platforms, has recently gained widespread attention. Many such systems have been developed, and several are in production use. This paper describes the evolution of the PVM system, a software infrastructure for concurrent computing in networked environments. PVM has evolved over the past years; it is currently in use at several hundred institutions worldwide for applications ranging from scientific supercomputing to high performance computations in medicine, discrete mathematics, and databases, and for learning parallel programming. We describe the historical evolution of the PVM system, outline the programming model and supported features, present results gained from its use, list representative applications from a variety of disciplines that PVM has been used for, and comment on future trends and ongoing research projects.

Giest, G.A. [Oak Ridge National Lab., TN (United States); Sunderam, V.S. [Emory Univ., Atlanta, GA (United States). Dept. of Mathematics and Computer Science

1993-07-01

66

Concurrent algorithms for a mobile robot vision system  

SciTech Connect

The application of computer vision to mobile robots has generally been hampered by insufficient on-board computing power. The advent of VLSI-based general purpose concurrent multiprocessor systems promises to give mobile robots an increasing amount of on-board computing capability, and to allow computation intensive data analysis to be performed without high-bandwidth communication with a remote system. This paper describes the integration of robot vision algorithms on a 3-dimensional hypercube system on-board a mobile robot developed at Oak Ridge National Laboratory. The vision system is interfaced to navigation and robot control software, enabling the robot to maneuver in a laboratory environment, to find a known object of interest and to recognize the object's status based on visual sensing. We first present the robot system architecture and the principles followed in the vision system implementation. We then provide some benchmark timings for low-level image processing routines, describe a concurrent algorithm with load balancing for the Hough transform, a new algorithm for binary component labeling, and an algorithm for the concurrent extraction of region features from labeled images. This system analyzes a scene in less than 5 seconds and has proven to be a valuable experimental tool for research in mobile autonomous robots. 9 refs., 1 fig., 3 tabs.

Jones, J.P.; Mann, R.C.

1988-01-01

67

Concurrent algorithms for a mobile robot vision system  

Microsoft Academic Search

The application of computer vision to mobile robots has generally been hampered by insufficient on-board computing power. The advent of VLSI-based general purpose concurrent multiprocessor systems promises to give mobile robots an increasing amount of on-board computing capability, and to allow computation intensive data analysis to be performed without high-bandwidth communication with a remote system. This paper describes the integration

J. P. Jones; R. C. Mann

1988-01-01

68

Randomized Clinical Trial of Weekly vs. Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Locally Advanced Cervical Cancer  

SciTech Connect

Purpose: To compare compliance, toxicity, and outcome of weekly and triweekly cisplatin administration concurrent with radiotherapy in locally advanced cervical cancer. Methods and Materials: In this open-label, randomized trial, 104 patients with histologically proven Stage IIB-IVA cervical cancer were randomly assigned by a computer-generated procedure to weekly (weekly cisplatin 40 mg/m{sup 2}, six cycles) and triweekly (cisplatin 75 mg/m{sup 2} every 3 weeks, three cycles) chemotherapy arms during concurrent radiotherapy. The difference of compliance and the toxicity profiles between the two arms were investigated, and the overall survival rate was analyzed after 5 years. Results: All patients tolerated both treatments very well, with a high completion rate of scheduled chemotherapy cycles. There was no statistically significant difference in compliance between the two arms (86.3% in the weekly arm, 92.5% in the triweekly arm, p > 0.05). Grade 3-4 neutropenia was more frequent in the weekly arm (39.2%) than in the triweekly arm (22.6%) (p = 0.03). The overall 5-year survival rate was significantly higher in the triweekly arm (88.7%) than in the weekly arm (66.5%) (hazard ratio 0.375; 95% confidence interval 0.154-0.914; p = 0.03). Conclusions: Triweekly cisplatin 75-mg/m{sup 2} chemotherapy concurrent with radiotherapy is more effective and feasible than the conventional weekly cisplatin 40-mg/m{sup 2} regimen and may be a strong candidate for the optimal cisplatin dose and dosing schedule in the treatment of locally advanced cervical cancer.

Ryu, Sang-Young, E-mail: ryu@kcch.re.kr [Department of Obstetrics and Gynecology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul (Korea, Republic of); Lee, Won-Moo; Kim, Kidong [Department of Obstetrics and Gynecology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul (Korea, Republic of); Park, Sang-Il [Department of Gynecologic Oncology, Dongnam Institute of Radiological and Medical Sciences, Busan (Korea, Republic of); Kim, Beob-Jong; Kim, Moon-Hong; Choi, Seok-Cheol [Department of Obstetrics and Gynecology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul (Korea, Republic of); Cho, Chul-Koo [Department of Radiation Oncology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul (Korea, Republic of); Nam, Byung-Ho [Cancer Biostatistics Branch, Research Institute and Hospital, National Cancer Center, Goyang (Korea, Republic of); Lee, Eui-Don [Department of Gynecologic Oncology, Dongnam Institute of Radiological and Medical Sciences, Busan (Korea, Republic of)

2011-11-15

69

Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.  

PubMed

We conducted a phase II trial of concurrent chemoradiotherapy (CCRT) followed by 2 cycles of L-asparaginase-containing chemotherapy for patients who were newly diagnosed with stages IE and IIE nasal extranodal NK/T cell lymphoma (ENKTL). CCRT consisted of 40-44 Gy of radiotherapy with weekly administration of 30 mg/m(2) of cisplatin for 4 weeks. Two cycles of VIDL (etoposide (100 mg/m(2)), ifosfamide (1,200 mg/m(2)), and dexamethasone (40 mg) from days 1 to 3, and L-asparaginase (4,000 IU/m(2)) every other day from days 8 to 20) were administered sequentially. CCRT yielded a 90 % overall response rate without significant side effects in 30 patients, including 20 patients with complete response (CR); however, two patients showed distant disease progression. After CCRT, VIDL chemotherapy showed an 87 % final CR rate (26/30). Although grade III or IV hematologic toxicity was frequent during VIDL chemotherapy, no treatment-related mortality was observed, and L-asparaginase-associated toxicity was manageable. With a median follow-up of 44 months, 11 patients showed local (n?=?4) and distant (n?=?7) relapse or progression. The estimated 5-year progression-free and overall survival rates were 73 and 60 %, respectively. In conclusion, CCRT followed by L-asparaginase-containing chemotherapy is a feasible treatment for newly diagnosed stages IE/IIE nasal ENKTL. PMID:24947798

Kim, Seok Jin; Yang, Deok-Hwan; Kim, Jin Seok; Kwak, Jae-Yong; Eom, Hyeon-Seok; Hong, Dae Sik; Won, Jong Ho; Lee, Jae Hoon; Yoon, Dok Hyun; Cho, Jaeho; Nam, Taek-Keun; Lee, Sang-Wook; Ahn, Yong Chan; Suh, Cheolwon; Kim, Won Seog

2014-11-01

70

Involved-Field Radiotherapy versus Elective Nodal Irradiation in Combination with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study  

PubMed Central

This prospective randomized study is to evaluate the locoregional failure and its impact on survival by comparing involved field radiotherapy (IFRT) with elective nodal irradiation (ENI) in combination with concurrent chemotherapy for locally advanced non-small cell lung cancer. It appears that higher dose could be delivered in IFRT arm than that in ENI arm, and IFRT did not increase the risk of initially uninvolved or isolated nodal failures. Both a tendency of improved locoregional progression-free survival and a significant increased overall survival rate are in favor of IFRT arm in this study. PMID:23762840

Chen, Ming; Bao, Yong; Ma, Hong-Lian; Wang, Jin; Wang, Yan; Peng, Fang; Zhou, Qi-Chao; Xie, Cong-Hua

2013-01-01

71

A concurrent distributed system for aircraft tactical decision generation  

NASA Technical Reports Server (NTRS)

A research program investigating the use of AI techniques to aid in the development of a tactical decision generator (TDG) for within visual range (WVR) air combat engagements is discussed. The application of AI programming and problem-solving methods in the development and implementation of a concurrent version of the computerized logic for air-to-air warfare simulations (CLAWS) program, a second-generation TDG, is presented. Concurrent computing environments and programming approaches are discussed, and the design and performance of prototype concurrent TDG system (Cube CLAWS) are presented. It is concluded that the Cube CLAWS has provided a useful testbed to evaluate the development of a distributed blackboard system. The project has shown that the complexity of developing specialized software on a distributed, message-passing architecture such as the Hypercube is not overwhelming, and that reasonable speedups and processor efficiency can be achieved by a distributed blackboard system. The project has also highlighted some of the costs of using a distributed approach to designing a blackboard system.

Mcmanus, John W.

1990-01-01

72

Transurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy (concomitant boost), with or without concurrent cisplatin, for patients with invasive bladder cancer - clinical outcome  

PubMed Central

Aim of the study To evaluate the toxicity, clinical effectiveness and survival rate of transurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy (concomitant boost), with or without concurrent cisplatin in patients with muscle invasive bladder cancer. Material and methods Between March 2004 and December 2009, 35 patients with histologically proven invasive carcinoma of the bladder (T2-4a, N0-1, M0), who were fit for combined radiochemotherapy and refused radical surgery or were medically or surgically inoperable, were selected for the bladder-sparing protocol. Results In this study, twenty-five patients (25/35; 72%) received two cycles of neoadjuvant chemotherapy, and ten of them (10/35; 28%) only one, because of treatment-related toxicity. In twenty-one patients (21/35; 60%) chemotherapy consisting of gemcitabine with cisplatin and in fourteen patients (14/35; 40%) gemcitabine with carboplatin were applied. Only 13 patients (13/35; 37%) received combined irradiation with cisplatin. All patients completed their planned course of radiation therapy. Complete response (CR) occurred in 26/35 (74%) patients, partial response (PR) in 2/35(6%), and stable disease (SD) in 7/35 (20%). The overall actuarial survival rates at 3 and 5 years were 75% and 66%, respectively. Disease-specific actuarial survival rates at 3 and 5 years were 81% and 71%, respectively. Conclusions Conservative treatment of patients with muscle-invasive bladder cancer by transurethral resection, neoadjuvant chemotherapy, and accelerated hyperfractionated radiotherapy with concomitant boost, with or without concurrent cisplatin, provides a high probability of local and distal response with acceptable toxicity in properly selected patients. PMID:24596519

Jakubowicz, Jerzy; Skora, Tomasz; Pudelek, Katarzyna

2013-01-01

73

Dynamic Multi-Rigid-Body Systems with Concurrent Distributed Contacts  

Microsoft Academic Search

. Consider a system of bodies with multiple concurrent contacts. The multi-rigid-bodycontact problem is to predict the accelerations of the bodies and the normal and friction loadsacting at the contacts. This paper presents theoretical results for the multi-rigid-body contactproblem under the assumptions that one or more contacts occur over locally planar, finite regionsand friction forces are consistent with the maximum

Jong-shi Pang; Jeffrey C. Trinkle

2001-01-01

74

Modeling Biological Systems in Stochastic Concurrent Constraint Programming  

Microsoft Academic Search

Abstract We present an application of stochastic Concurrent Constraint Programming (sCCP) for modeling biological systems. We provide a library of sCCP processes that can be used to describe straightforwardly biological networks. In the mean- while, we show that sCCP proves to be a general and extensible framework, allowing to describe a wide class of dynamical behaviours and kinetic laws.

Luca Bortolussi; Alberto Policriti

2008-01-01

75

Systemic autoimmune disease and concurrent nematode infection in a dog.  

PubMed

Systemic lupus erythematosus was diagnosed in a dog with concurrent nematode infection. The clinical signs of disease were unusually severe and included multiple neurologic deficits, polyarthritis, and weight loss. The dog was thrombocytopenic, and serotest results included positive lupus erythematosus test, positive rheumatoid factor test, positive antinuclear antibody test, hypergammaglobulinemia, and high platelet-associated IgG concentration. After treatment of hookworm, whipworm, and heartworm infections concurrently with corticosteroid and empiric treatment, the dog's condition improved. However, 10 days later, cyclophosphamide administration was necessary for continued immunosuppression. The dog was euthanatized because of progressive deterioration and development of canine coronavirus diarrhea. Serotest data generated from the dog's serum obtained at the time of referral suggested that autoantibodies and circulating immune complexes may have included IgE isotypes. PMID:2551867

McVey, D S; Rudd, R; Toshach, K; Moore, W E; Keeton, K S

1989-10-01

76

Concurrent Hyperfractionated Radiation Therapy and Chemotherapy in Locally Advanced (Stage III) Non-Small-Cell Lung Cancer: Single Institution Experience With 600 Patients  

SciTech Connect

Purpose: Our institutional experience with the use of hyperfractionated radiation therapy (RT) alone or concurrently with chemotherapy (RT-CHT) in Stage III non-small-cell lung cancer was reviewed. Methods and Materials: Three phase III and two phase II studies included a total of 600 patients. Hyperfractionated RT alone was given to 127 patients, and hyperfractionated RT-CHT was given to 473 patients. RT doses were 64.8 Gy and 69.6 Gy (using 1.2 Gy twice daily) and 67.6 Gy (using 1.3 Gy twice daily). CHT consisted of concurrent administration of carboplatin and etoposide to 409 patients and concurrent administration of carboplatin and paclitaxel to 64 patients. Results: The median survival times were 19 months, 21 months, and 12 months for all, RT-CHT, and RT-only patients, respectively. The survival difference between the RT-CHT and RT group was significant (p < 0.0001). Four-year rates of local progression-free survival (LPFS) and distant metastasis-free survival (DMFS) were 29% and 35%, respectively, for the entire group. The RT-CHT group had significantly better LPFS rates than the RT group (31% for the RT-CHT group vs. 16% for the RT group; p = 0.0015) but not DMFS rates (36% for the RT-CHT group vs. 36% for the RT group, p = 0.0571). Acute high-grade esophagitis, pneumonitis, and hematological toxicities were seen most frequently and in 11%, 9%, and 12% of patients, respectively. Late high-grade esophageal and bronchopulmonary toxicity were each seen in 6% of patients. Conclusions: Compared to the majority of existing phase II and III studies, this study reconfirmed the excellent results achieved with concurrent RT-CHT, including low toxicity. Concurrent RT-CHT results in survival benefit primarily by increasing LPFS, not DMFS.

Jeremic, Branislav, E-mail: nebareje@gmail.com [Department of Oncology, University Hospital, Kragujevac (Serbia); Milicic, Biljana; Milisavljevic, Slobodan [Department of Oncology, University Hospital, Kragujevac (Serbia)

2012-03-01

77

Effectiveness of integration of system-level optimization in concurrent engineering for rocket design  

E-print Network

Integrated concurrent engineering is a method for rapid conceptual design. Previous study has suggested that integration of system-level optimization techniques into integrated concurrent engineering can benefit the design ...

Bairstow, Brian Kenichi

2006-01-01

78

Radiotherapy concurrently with weekly cisplatin, followed by adjuvant chemotherapy, for N2-3 nasopharyngeal cancer: a multicenter trial of the Forum for Nuclear Cooperation in Asia  

PubMed Central

The purpose of this study was to evaluate the efficacy and toxicity of radiotherapy concurrently with weekly cisplatin, followed by adjuvant chemotherapy, for the treatment of N2–3 nasopharyngeal cancer (NPC) in Asian countries, especially regions of South and Southeast Asian countries where NPC is endemic. Between 2005 and 2009, 121 patients with NPC (T1–4 N2–3 M0) were registered from Vietnam, Malaysia, Indonesia, Thailand, The Philippines, China and Bangladesh. Patients were treated with 2D radiotherapy concurrently with weekly cisplatin (30 mg/m 2), followed by adjuvant chemotherapy, consisting of cisplatin (80 mg/m2 on Day 1) and fluorouracil (800 mg/m2 on Days 1–5) for 3 cycles. Of the 121 patients, 56 patients (46%) required interruption of RT. The reasons for interruption of RT were acute non-hematological toxicities such as mucositis, pain and dermatitis in 35 patients, hematological toxicities in 11 patients, machine break-down in 3 patients, poor general condition in 2 patients, and others in 8 patients. Of the patients, 93% completed at least 4 cycles of weekly cisplatin during radiotherapy, and 82% completed at least 2 cycles of adjuvant chemotherapy. With a median follow-up time of 46 months for the surviving 77 patients, the 3-year locoregional control, distant metastasis-free survival and overall survival rates were 89%, 74% and 66%, respectively. No treatment-related deaths occurred. Grade 3–4 toxicities of mucositis, nausea/vomiting and leukopenia were observed in 34%, 4% and 4% of the patients, respectively. In conclusion, further improvement in survival and locoregional control is necessary, although our regimen showed acceptable toxicities. PMID:23192700

Ohno, Tatsuya; Thinh, Dang Huy Quoc; Kato, Shingo; Devi, C.R. Beena; Tung, Ngo Thanh; Thephamongkhol, Kullathorn; Calaguas, Miriam Joy C.; Zhou, Juying; Chansilpa, Yaowalak; Supriana, Nana; Erawati, Dyah; Banu, Parvin Akhter; Koo, Cho Chul; Kobayashi, Kunihiko; Nakano, Takashi; Tsujii, Hirohiko

2013-01-01

79

Factors Associated With Severe Acute Esophagitis From Hyperfractionated Radiotherapy With Concurrent Chemotherapy for Limited-Stage Small-Cell Lung Cancer  

SciTech Connect

Purpose: To describe incidence and identify factors associated with development of severe acute esophagitis during hyperfractionated radiotherapy with concurrent chemotherapy (BID-CRT) in patients with limited-stage small-cell lung cancer (SCLC). Methods and Materials: Retrospective cohort analysis of patient-, tumor-, and treatment-related variables was performed to identify factors associated with Radiation Therapy Oncology Group (RTOG) Grade 3 acute esophagitis. Twice-daily chemoradiotherapy (BID-CRT) involved 45 Gy at 1.5 Gy per fraction, treated twice daily with concurrent platinum-based chemotherapy. Logistic regression analyses were used to identify factors associated with esophagitis. Results: Between June 1999 and June 2007, 48 patients underwent curative intent BID-CRT for SCLC and were included in the analysis. Median radiotherapy dose was 45 Gy (range, 42-51 Gy) delivered with a median 4 cycles of chemotherapy (range, 2-6). RTOG Grade 3 acute esophagitis developed in 11 patients. No patient developed Grade 4 or 5 esophagitis. Simple logistic regression analyses demonstrated a highly significant association between Grade 3 acute esophagitis and mean esophageal dose (p = 0.002) as well as relative volume dosimetric area under curve (RV-AUC; p = 0.004). Using multiple regression analysis, RV-AUC was identified as the only factor associated with Grade 3 esophagitis (p = 0.004). The most strongly associated dosimetric volume was the V15 (Grade 3 esophagitis rates of 15% vs. 64% for V15 <60% versus {>=}60%, respectively). Conclusions: RV-AUC is the factor most associated with development of Grade 3 acute esophagitis in limited stage SCLC patients receiving BID-CRT.

Watkins, John M. [Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina (United States); Wahlquist, Amy E. M.S. [Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston, South Carolina (United States); Shirai, Keisuke [Department of Medicine, Division of Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina (United States); Garrett-Mayer, Elizabeth [Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina (United States); Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston, South Carolina (United States); Aguero, Eric G.; Fortney, John A. [Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina (United States); Sherman, Carol A. [Department of Medicine, Division of Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina (United States); Sharma, Anand K. [Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina (United States)], E-mail: sharmaak@musc.edu

2009-07-15

80

A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer  

PubMed Central

The Radiation Therapy Oncology Group reported a maximum tolerated dose of 74 Gy for patients with non-small cell lung cancer (NSCLC); however, it was unclear whether this dose could be safely administered to Asian patients due to differences in their physique compared to Western patients. We therefore conducted a modified Phase I trial to determine whether 70 Gy could be safely delivered to Chinese patients with NSCLC undergoing 3D-conformal radiation therapy (3D-CRT) with concurrent chemotherapy. Previously untreated NSCLC patients received 3D-CRT (2 Gy/day, 5 fractions per week). Three dose levels were examined: 62, 66 and 70 Gy. Two cycles of concurrent chemotherapy (vinorelbine and carboplatin) were started on the first day of radiation therapy. Dose-limiting toxicity (DLT) was defined as severe or life-threatening side effects that altered the continued implementation of chemoradiotherapy. Among the 19 patients recruited in this study, most of the haematologic and non-haematologic toxicities were mild to moderate and clinically manageable. Only one patient, in the 70 Gy cohort, experienced a DLT of Grade 3 radiation-induced pneumonia. The overall response rate was 77.8% (14/18). The median progression-free survival (PFS) was 12 months, and the 1-year PFS was 37.6%. Our results support both the feasibility of incorporating 3D-CRT with concurrent vinorelbine and carboplatin and a dose escalation to 70 Gy for Chinese patients with NSCLC, based on the acceptable toxicity and encouraging overall response and survival rates. A further evaluation of this regimen in a prospective Phase II trial is ongoing. PMID:22988282

Lin, Qiang; Liu, Yue'e; Wang, Na; Huang, Yuehua; Ge, Xiaohui; Ren, Xiaocang; Chen, Xueji; Hu, Jing; Guo, Zhijun; Zhao, Yannan; Asaumi, Junichi

2013-01-01

81

Dynamic systems-engineering process - The application of concurrent engineering  

NASA Technical Reports Server (NTRS)

A system engineering methodology is described which enables users, particulary NASA and DOD, to accommodate changing needs; incorporate emerging technologies; identify, quantify, and manage system risks; manage evolving functional requirements; track the changing environment; and reduce system life-cycle costs. The approach is a concurrent, dynamic one which starts by constructing a performance model defining the required system functions and the interrelationships. A detailed probabilistic risk assessment of the system elements and their interrelationships is performed, and quantitative analysis of the reliability and maintainability of an engineering system allows its different technical and process failure modes to be identified and their probabilities to be computed. Decision makers can choose technical solutions that maximize an objective function and minimize the probability of failure under resource constraints.

Wiskerchen, Michael J.; Pittman, R. Bruce

1989-01-01

82

FEASIBILITY AND DOSE DISCOVERY ANALYSIS OF ZOLEDRONIC ACID WITH CONCURRENT CHEMOTHERAPY IN THE TREATMENT OF NEWLY DIAGNOSED METASTATIC OSTEOSARCOMA: A REPORT FROM THE CHILDEREN'S ONCOLOGY GROUP  

PubMed Central

Aim Patients with metastatic osteosarcoma (OS) have a poor outcome with conventional therapies. Zoledronic acid (ZA) is a third-generation bisphosphonate that reduces skeletal-related events in many adult cancers, and preclinical data suggests a possible benefit in OS. This study assessed the maximum tolerated dose (MTD) and feasibility of ZA when combined with chemotherapy in patients with metastatic OS. Patients and Methods Patients with a histologic diagnosis of OS were eligible if they were <40 years of age, had initially metastatic disease, and met organ function requirements. Treatment combined surgery and a conventional chemotherapy regimen. ZA was given concurrent with chemotherapy for a total 8 doses over 36 weeks. Three dose levels of ZA were tested: 1.2 mg/m2 [max 2 mg], 2.3 mg/m2 [max 4 mg] and 3.5 mg/m2 [max 6 mg]. The MTD was determined during induction. Six patients were to be treated at each dose level, with an additional 6 patients treated at the MTD to help assess post-induction feasibility. Results Twenty-four patients (median age 13.5 years [range, 7-22]; 16 females) were treated. Five patients experienced dose limiting toxicities (DLTs) during induction, including 3 patients treated with 3.5 mg/m2. DLTs included hypophosphatemia, hypokalemia, hyponatremia, mucositis, limb pain and limb edema. There were no reports of excessive renal toxicity or osteonecrosis of the jaw. The MTD was defined as 2.3 mg/m2 (max 4 mg). Conclusions ZA can be safely combined with conventional chemotherapy with the MTD of 2.3 mg/m2 (max 4 mg) for patients with metastatic osteosarcoma. PMID:23664013

Goldsby, Robert E.; Fan, Timothy M.; Villaluna, Doojduen; Wagner, Lars M.; Isakoff, Michael S.; Meyer, James; Randall, R. Lor; Lee, Sharon; Kim, Grace; Bernstein, Mark; Gorlick, Richard; Krailo, Mark; Marina, Neyssa

2013-01-01

83

Hypofractionated Accelerated Radiotherapy With Concurrent Chemotherapy For Locally Advanced Squamous Cell Carcinoma of the Head and Neck  

SciTech Connect

Purpose: To investigate the tumor control rates in locally advanced head-and-neck cancer using accelerated hypofractionated radiotherapy with chemotherapy. Methods and Materials: The data from patients with squamous cell cancer of the larynx, oropharynx, oral cavity, and hypopharynx (International Union Against Cancer Stage II-IV), who received accelerated hypofractionated radiotherapy with chemotherapy between January 1, 1998, and April 1, 2005, were retrospectively analyzed. Two different chemotherapy schedules were used, carboplatin and methotrexate, both single agents administered on an outpatient basis. The endpoints were overall survival, local control, and disease-free survival. Results: A total of 81 patients were analyzed. The 2-year overall survival rate was 71.6% (95% confidence interval [CI], 61.5-81.8%). The 2-year disease-free survival rate was 68.6% (95% CI, 58.4-78.8%). The 2-year local control rate was 75.4% (95% CI, 65.6-85.1%). When excluding patients with Stage II oral cavity, larynx, and hypopharynx tumors, 68 patients remained. For these patients, the 2-year overall survival, local control, and disease-free survival rate was 67.6% (95% CI, 56.0-79.2%), 72.0% (95% CI, 61.0-83.0%), and 64.1% (95% CI, 52.6-75.7%), respectively. Conclusion: Accelerated hypofractionated radiotherapy and synchronous chemotherapy can achieve high tumor control rates while being resource sparing and should be the subject of prospective evaluation.

Sanghera, Paul [Cancer Centre, Queen Elizabeth Hospital, Birmingham (United Kingdom); McConkey, Chris [Clinical Trials Unit, University of Warwick, Coventry (United Kingdom); Ho, Kean-Fatt [Cancer Centre, Queen Elizabeth Hospital, Birmingham (United Kingdom); Glaholm, John [Cancer Centre, Queen Elizabeth Hospital, Birmingham (United Kingdom); Hartley, Andrew [Cancer Centre, Queen Elizabeth Hospital, Birmingham (United Kingdom)]. E-mail: andrew.hartley@uhb.nhs.uk

2007-04-01

84

Ocular toxicity of systemic anticancer chemotherapy  

PubMed Central

The increased use of chemotherapeutic agents has resulted in longer cancer patient survival. Consequently the ophthalmologist is seeing more patients with adverse ocular side effects secondary to these antineoplastic agents. Ocular toxicity induced by cancer chemotherapy includes a broad spectrum of disorders, reflecting the unique anatomical, physiological and biochemical features of the eye. Understanding the ocular side effects will assist the ophthalmologist and oncologist to recognize them early and intervene before blindness occurs. Anticipation of various treatment-related toxicities may also provide the opportunity for pharmacists to develop intervention strategies that could minimize or eliminate an expected side effect. The ophthalmologist should examine patients on anticancer therapy at baseline and three monthly thereafter. The various ocular side effects of anticancer chemotherapeutic agents, tamoxifen, and interferon on the adnexia, anterior segment, posterior segment and neuro-ophthalmic structures were reviewed.

Omoti, Afekhide Ernest; Omoti, Caroline Edijana

85

High-dose Extended-Field Irradiation and High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Cervical Cancer With Positive Para-Aortic Lymph Nodes  

SciTech Connect

Purpose: To determine the efficacy and toxicity of extended-field radiotherapy (RT) with concurrent platinum-based chemotherapy in patients with uterine cervical carcinoma and positive para-aortic nodes. Methods and Materials: We retrospectively reviewed the results for 33 women with Stage IB-IVB cervical cancer. Each patient had received 59.4 Gy, including a three-dimensional conformal boost to the para-aortic lymph nodes and 41.4-50.4 Gy of external beam radiotherapy to the pelvis. Each patient also underwent six or seven applications of high-dose-rate brachytherapy (median, 5 Gy to point A at each session). Results: The median follow-up period of surviving patients was 39 months. The most common acute toxicity was hematologic, observed in 23 women. Severe acute and late gastrointestinal toxicity was observed in 3 and 4 patients, respectively. More than three-quarters of patients showed a complete response, encompassing the primary mass, metastatic pelvic, and para-aortic lymph nodes. Of the 33 women, 15 had no evidence of disease, 6 had persistent disease, 4 developed in-field failures, and 6 developed distant failures. The 5-year overall and disease-free survival rate was 47% and 42%, respectively. Conclusion: Concurrent chemoradiotherapy with extended-field radiotherapy is feasible in women with uterine cervical carcinoma and positive para-aortic lymph nodes, with acceptable late morbidity and a high survival rate, although it was accompanied by substantial acute toxicity.

Kim, Young Seok; Kim, Jong Hoon; Ahn, Seung Do; Lee, Sang-wook; Shin, Seong Soo [Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of); Nam, Joo-Hyun; Kim, Young-Tak; Kim, Yong-Man; Kim, Jong-Hyeok [Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of); Choi, Eun Kyung [Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of)], E-mail: ekchoi@amc.seoul.kr

2009-08-01

86

Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma  

SciTech Connect

Purpose: To compare the benefit achieved by concurrent chemoradiotherapy (CRT) and/or accelerated fractionation (AF) vs. radiotherapy (RT) alone with conventional fractionation (CF) for patients with T3-4N0-1M0 nasopharyngeal carcinoma (NPC). Methods and Materials: All patients were irradiated with the same RT technique to {>=}66 Gy at 2 Gy per fraction, conventional five fractions/week in the CF and CF+C (chemotherapy) arms, and accelerated six fractions/week in the AF and AF+C arms. The CF+C and AF+C patients were given the Intergroup 0099 regimen (concurrent cisplatin plus adjuvant cisplatin and 5-fluorouracil). Results: Between 1999 and April 2004, 189 patients were randomly assigned; the trial was terminated early because of slow accrual. The median follow-up was 2.9 years. When compared with the CF arm, significant improvement in failure-free survival (FFS) was achieved by the AF+C arm (94% vs. 70% at 3 years, p = 0.008), but both the AF arm and the CF+C arm were insignificant (p {>=} 0.38). Multivariate analyses showed that CRT was a significant factor: hazard ratio (HR) = 0.52 (0.28-0.97), AF per se was insignificant: HR = 0.68 (0.37-1.25); the interaction of CRT by AF was strongly significant (p = 0.006). Both CRT arms had significant increase in acute toxicities (p < 0.005), and the AF+C arm also incurred borderline increase in late toxicities (34% vs. 14% at 3 years, p = 0.05). Conclusions: Preliminary results suggest that concurrent chemoradiotherapy with accelerated fractionation could significantly improve tumor control when compared with conventional RT alone; further confirmation of therapeutic ratio is warranted.

Lee, Anne W.M. [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China)]. E-mail: awmlee@ha.org.hk; Tung, Stewart Y. [Tuen Mun Hospital, Hong Kong (China); Chan, Anthony T.C. [Prince of Wales Hospital, Hong Kong (China); Chappell, Rick [Department of Biostatistics, University of Wisconsin Medical School, Madison, WI (United States); Fu, Y.-T. [Queen Elizabeth Hospital, Hong Kong (China); Lu, Tai-Xiang [Cancer Center, Sun Yat Sen University, Guangzhou (China); Tan, Terence [National Cancer Center, Singapore (Japan); Chua, Daniel T.T. [Queen Mary Hospital, Hong Kong (China); O'Sullivan, Brian [Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario (Canada); Xu, Shirley L. [Center for Clinical Trials, Chinese University of Hong Kong, Hong Kong (China); Pang, Ellie S.Y. [Center for Epidemiology and Biostatistics, Chinese University of Hong Kong, Hong Kong (China); Sze, W.-M. [Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong (China); Leung, T.-W. [Tuen Mun Hospital, Hong Kong (China); Kwan, W.-H. [Prince of Wales Hospital, Hong Kong (China); Chan, Paddy [Queen Elizabeth Hospital, Hong Kong (China); Liu, X.-F. [Cancer Center, Sun Yat Sen University, Guangzhou (China); Tan, E.-H. [National Cancer Center, Singapore (Japan); Sham, Jonathan [Queen Mary Hospital, Hong Kong (China); Siu, Lillian [Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario (Canada); Lau, W.-H. [Queen Elizabeth Hospital, Hong Kong (China)

2006-09-01

87

Research on Application of Concurrent Circumstance in Development of Military Equipment Logistics Information System  

Microsoft Academic Search

By analyzing the characteristics about development of military equipment logistics information system, concurrent circumstance was applied to development of military equipment logistics information system and a development method of military equipment logistics information system under concurrent development circumstance was put forward. By establishing of system integrated development groups and design of information exchange platform, the development method was discussed.

Shuai Pei; Tie-Ning Wang; Chun-Liang Chen; Hong-Shui Liu

2008-01-01

88

Systemic chemotherapy in inoperable or metastatic bladder cancer  

Microsoft Academic Search

Urothelial cancer is a common malignancy. The management of patients with recurrent disease after cystectomy or initially metastatic or unresectable disease represents a therapeutic challenge. Systemic chemotherapy prolongs survival but long-term survival remains infrequent. During recent years there has been improvement due to the use of novel chemotherapeutic agents, mainly gemcitabine and the taxanes. The long- considered-standard MVAC has been

A. Bamias; I. Tiliakos; D. Karali; M. A. Dimopoulos

2006-01-01

89

Metastatic intratesticular alveolar rhabdomyosarcoma discovered after induction of systemic chemotherapy.  

PubMed

Alveolar rhabdomyosarcoma is an aggressive cancer that can metastasize to a variety of organs. We present what we believe to be the first reported case of metastatic intratesticular rhabdomyosarcoma in a patient presenting with testicular pain shortly after the induction of systemic chemotherapy. The published data regarding this unusual condition are reviewed. PMID:17482950

Cannon, Glenn M; Polsky, Ethan G; Bellinger, Mark F

2007-05-01

90

Bortezomib and Chemotherapy for Systemic Light-Chain Amyloidosis  

Cancer.gov

In this trial, patients with previously untreated systemic light-chain amyloidosis will be randomly assigned to receive melphalan and dexamethasone with or without bortezomib. Doctors will assess the overall hematologic response rates to these chemotherapy regimens, as well as organ responses.

91

Postoperative Radiation Therapy With or Without Concurrent Chemotherapy for Node-Positive Thoracic Esophageal Squamous Cell Carcinoma  

SciTech Connect

Purpose: To retrospectively compare the efficacy of radiation therapy (RT) and chemotherapy plus RT (CRT) for the postoperative treatment of node-positive thoracic esophageal squamous cell carcinoma (TESCC) and to determine the incidence and severity of toxic reactions. Methods and Materials: We retrospectively reviewed data from 304 patients who had undergone esophagectomy with 3-field lymph node dissection for TESCC and were determined by postoperative pathology to have lymph node metastasis without distant hematogenous metastasis. Of these patients, 164 underwent postoperative chemotherapy (cisplatin 80 mg/m{sup 2}, average days 1-3, plus paclitaxel 135 mg/m{sup 2}, day 1; 21-day cycle) plus RT (50 Gy), and 140 underwent postoperative RT alone. Results: The 5-year overall survival rates for the CRT and RT groups were 47.4% and 38.6%, respectively (P=.030). The distant metastasis rate, the mixed (regional lymph node and distant) metastasis rate, and the overall recurrence rate were significantly lower in the CRT group than in the RT group (P<.05). However, mild and severe early toxic reactions, including neutropenia, radiation esophagitis, and gastrointestinal reaction, were significantly more common in the CRT group than in the RT group (P<.05). No significant differences in incidence of late toxic reactions were found between the 2 groups. Conclusions: Our results show that in node-positive TESCC patients, postoperative CRT is significantly more effective than RT alone at increasing the overall survival and decreasing the rates of distant metastasis, mixed metastasis, and overall recurrence. Severe early toxic reactions were more common with CRT than with RT alone, but patients could tolerate CRT.

Chen, Junqiang; Pan, Jianji [Department of Radiation Oncology, Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou (China)] [Department of Radiation Oncology, Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou (China); Liu, Jian, E-mail: liujianfj@yahoo.com.cn [Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fuzhou (China)] [Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fuzhou (China); Li, Jiancheng [Department of Radiation Oncology, Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou (China)] [Department of Radiation Oncology, Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou (China); Zhu, Kunshou [Department of Surgery, Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou (China)] [Department of Surgery, Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou (China); Zheng, Xiongwei [Department of Pathology, Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou (China)] [Department of Pathology, Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou (China); Chen, Mingqiang [Department of Radiation Oncology, Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou (China)] [Department of Radiation Oncology, Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou (China); Chen, Ming [School of Graduate, Fujian University of Traditional Chinese Medicine, Fuzhou (China)] [School of Graduate, Fujian University of Traditional Chinese Medicine, Fuzhou (China); Liao, Zhongxing [Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States)] [Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States)

2013-07-15

92

Dose Escalation of Total Marrow Irradiation With Concurrent Chemotherapy in Patients With Advanced Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation  

SciTech Connect

Purpose: We have demonstrated that toxicities are acceptable with total marrow irradiation (TMI) at 16 Gy without chemotherapy or TMI at 12 Gy and the reduced intensity regimen of fludarabine/melphalan in patients undergoing hematopoietic cell transplantation (HCT). This article reports results of a study of TMI combined with higher intensity chemotherapy regimens in 2 phase I trials in patients with advanced acute myelogenous leukemia or acute lymphoblastic leukemia (AML/ALL) who would do poorly on standard intent-to-cure HCT regimens. Methods and Materials: Trial 1 consisted of TMI on Days -10 to -6, etoposide (VP16) on Day -5 (60 mg/kg), and cyclophosphamide (CY) on Day -3 (100 mg/kg). TMI dose was 12 (n=3 patients), 13.5 (n=3 patients), and 15 (n=6 patients) Gy at 1.5 Gy twice daily. Trial 2 consisted of busulfan (BU) on Days -12 to -8 (800 {mu}M min), TMI on Days -8 to -4, and VP16 on Day -3 (30 mg/kg). TMI dose was 12 (n=18) and 13.5 (n=2) Gy at 1.5 Gy twice daily. Results: Trial 1 had 12 patients with a median age of 33 years. Six patients had induction failures (IF), and 6 had first relapses (1RL), 9 with leukemia blast involvement of bone marrow ranging from 10%-98%, 5 with circulating blasts (24%-85%), and 2 with chloromas. No dose-limiting toxicities were observed. Eleven patients achieved complete remission at Day 30. With a median follow-up of 14.75 months, 5 patients remained in complete remission from 13.5-37.7 months. Trial 2 had 20 patients with a median age of 41 years. Thirteen patients had IF, and 5 had 1RL, 2 in second relapse, 19 with marrow blasts (3%-100%) and 13 with peripheral blasts (6%-63%). Grade 4 dose-limiting toxicities were seen at 13.5 Gy (stomatitis and hepatotoxicity). Stomatitis was the most frequent toxicity in both trials. Conclusions: TMI dose escalation to 15 Gy is possible when combined with CY/VP16 and is associated with acceptable toxicities and encouraging outcomes. TMI dose escalation is not possible with BU/VP16 due to dose-limiting toxicities. Future efforts will focus on whether further dose escalation with CY/VP16 is safe, with the goal of improving disease control in this high-risk population.

Wong, Jeffrey Y.C., E-mail: jwong@coh.org [Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California (United States); Forman, Stephen; Somlo, George [Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California (United States)] [Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California (United States); Rosenthal, Joseph [Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California (United States) [Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California (United States); Department of Pediatrics, City of Hope National Medical Center, Duarte, California (United States); Liu An; Schultheiss, Timothy; Radany, Eric [Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California (United States)] [Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California (United States); Palmer, Joycelynne [Department of Biostatistics, City of Hope National Medical Center, Duarte, California (United States)] [Department of Biostatistics, City of Hope National Medical Center, Duarte, California (United States); Stein, Anthony [Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California (United States)] [Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California (United States)

2013-01-01

93

Computer Aided Methods Supporting Concurrent Engineering when designing Mechatronic Systems Controlled by a PLC  

Microsoft Academic Search

A successful concurrent start of the interdisciplinary design team is crucial when designing mechatronic systems in order to ensure consistent data throughout the development process and establish rapid development. The aim of this work is to enable a concurrent conceptual design and to initiate the domain-specific embodiment design when developing mechatronic systems controlled by a PLC. The work results in

Jens BATHELT

94

Automatic verification of finite state concurrent system using temporal logic specifications: a practical approach  

Microsoft Academic Search

We give an efficient procedure for verifying that a finite state concurrent system meets a specification expressed in a (propositional) branching-time temporal logic. Our algorithm has complexity linear in both the size of the specification and the size of the global transition graph for the concurrent system. We also show how the logic and our algorithm can be modified to

Edmund M. Clarke; E. Allen Emerson; A. Prasad Sistla

1983-01-01

95

An Exercise in Concurrency: a CSP Process as a Condition\\/ event System  

Microsoft Academic Search

We provide full CSP with a truly concurrent and distributed operational semantics based on C\\/E Systems: given a CSP process Pr, a contact-free C\\/E System is derived the case graph of which is understood as the operational semantics of Pr. Thus concurrency and causal dependencies among the actions a process can perform are explicitly described.

Pierpaolo Deganot; Roberto Gorrieri; Sergio Marchetti

1987-01-01

96

Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy  

SciTech Connect

Purpose: To determine the risk factors for acute esophagitis (AE) in non-small-cell lung cancer (NSCLC) patients treated with concurrent chemotherapy (CCT) and three-dimensional conformal radiotherapy (3D-CRT). Methods and Materials: Clinical data were retrospectively analyzed for 215 NSCLC patients treated with CCT and 3D-CRT during 2000-2003, 127 of whom also had induction chemotherapy (ICT). Carboplatin and paclitaxel were the most commonly used agents for both ICT and CCT. The median prescription dose of radiotherapy was 63.5 Gy in 35 fractions. AE was graded during each treatment week and 1-month follow-up visits. The factors related to clinical and disease characteristics, CCT and 3D-CRT treatments, and treatment planning were reviewed and analyzed for their association with Grade {>=}3 AE using univariate and multivariate logistic tests. Results: The rate of any grade AE was 93.0% and of Grade {>=}3 was 20.5%. Univariate analyses showed that none of the clinical factors was significantly associated with Grade {>=}3 AE. However, the mean radiation dose to the esophagus, the absolute esophageal volume treated above 15 Gy (aV15) through aV45 Gy, and the relative esophagus volume treated above 10 Gy (rV10) through rV45 Gy were significant risk factors for Grade {>=}3 AE. Only rV20 was retained as the single risk factor in multivariate analyses. Conclusions: The risk of AE in the NSCLC patients treated with CCT and 3D-CRT was primarily determined by dosimetric factors. These factors should be carefully considered during treatment planning to minimize the incidence of AE.

Wei Xiong [Department of Radiation Physics, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States); Liu, H. Helen [Department of Radiation Physics, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States)]. E-mail: hliu@mdanderson.org; Tucker, Susan L. [Department of Biostatistics and Applied Mathematics, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States); Liao Zhongxing [Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States); Hu Chaosu [Cancer Hospital, Fudan University, Shanghai (China); Mohan, Radhe [Department of Radiation Physics, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States); Cox, James D. [Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States); Komaki, Ritsuko [Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States)

2006-09-01

97

Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer  

PubMed Central

Indoleamine 2,3-dioxygenase (IDO) has recently been proposed to account for tumor-induced immunosuppression by influencing the conversion of tryptophan (Trp) into kynurenine (Kyn). The objective of our study was to correlate IDO activity with disease outcome in non-small cell lung cancer (NSCLC) patients treated with multimodal combination therapy. In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. The mean plasma Kyn/Trp ratio was used as a surrogate indicator of IDO activity. The 33 participants were distributed as follows: 15 females, 18 males; median age = 62; median overall survival (OS) = 22.4 (95% CI 19.3–25.1) months; median progression-free survival (PFS) = 11.5 (95% CI 6.7–16.3) months. The mean Kyn/Trp ratio at baseline (4.5 ± 2.8) was higher than that of healthy controls (2.9 ± 1.9, p = 0.03) and increased after induction therapy (5.2 ± 3.2, p = 0.08) and chemoradiation (5.8 ± 3.9, p = 0.01). The post-treatment Kyn/Trp ratio and radiologic responses were not significantly associated at any time point. No significant correlation was found between baseline Kyn/Trp ratios and OS (HR = 1.1, 95% CI 0.45–2.5) or PFS (HR = 0.74, 95% CI 0.30–1.82). A post-induction chemotherapy increase in IDO activity portended worse OS (HR = 0.43, 95% CI 0.19–0.95, p = 0.037) and PFS (HR = 0.47, 95% CI 0.22–1.0, p = 0.055). This observed increase in IDO transcription may be a means for tumors to evade immunosurveillance. PMID:23802083

Creelan, Ben C.; Antonia, Scott; Bepler, Gerold; Garrett, Timothy J.; Simon, George R.; Soliman, Hatem H.

2013-01-01

98

Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Anal Cancer Patients Treated With Concurrent Chemotherapy and Intensity-Modulated Radiotherapy  

SciTech Connect

Purpose: To test the hypothesis that the volume of pelvic bone marrow (PBM) receiving 10 and 20 Gy or more (PBM-V{sub 10} and PBM-V{sub 20}) is associated with acute hematologic toxicity (HT) in anal cancer patients treated with concurrent chemoradiotherapy. Methods and Materials: We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy. The median radiation dose to gross tumor and regional lymph nodes was 50.4 and 45 Gy, respectively. Pelvic bone marrow was defined as the region extending from the iliac crests to the ischial tuberosities, including the os coxae, lumbosacral spine, and proximal femora. Endpoints included the white blood cell count (WBC), absolute neutrophil count (ANC), hemoglobin, and platelet count nadirs. Regression models with multiple independent predictors were used to test associations between dosimetric parameters and HT. Results: Twenty patients (42%) had Stage T3-4 disease; 15 patients (31%) were node positive. Overall, 27 (56%), 24 (50%), 4 (8%), and 13 (27%) experienced acute Grade 3-4 leukopenia, neutropenia, anemia, and thrombocytopenia, respectively. On multiple regression analysis, increased PBM-V{sub 5}, V{sub 10}, V{sub 15}, and V{sub 20} were significantly associated with decreased WBC and ANC nadirs, as were female gender, decreased body mass index, and increased lumbosacral bone marrow V{sub 10}, V{sub 15}, and V{sub 20} (p < 0.05 for each association). Lymph node positivity was significantly associated with a decreased WBC nadir on multiple regression analysis (p < 0.05). Conclusion: This analysis supports the hypothesis that increased low-dose radiation to PBM is associated with acute HT during chemoradiotherapy for anal cancer. Techniques to limit bone marrow irradiation may reduce HT in anal cancer patients.

Mell, Loren K. [Department of Radiation and Cellular Oncology, University of Chicago and University of Illinois at Chicago, Chicago, IL (United States)], E-mail: lmell@radonc.uchicago.edu; Schomas, David A. [Department of Radiation Oncology, Mayo Clinic, Rochester, MN (United States); Salama, Joseph K. [Department of Radiation and Cellular Oncology, University of Chicago and University of Illinois at Chicago, Chicago, IL (United States); The Cancer Research Center, University of Chicago, Chicago, IL (United States); Devisetty, Kiran; Aydogan, Bulent [Department of Radiation and Cellular Oncology, University of Chicago and University of Illinois at Chicago, Chicago, IL (United States); Miller, Robert C. [Department of Radiation Oncology, Mayo Clinic, Rochester, MN (United States); Jani, Ashesh B. [Department of Radiation Oncology, Emory University, Atlanta, GA (United States); Kindler, Hedy L. [Section of Hematology/Oncology, University of Chicago, Chicago, IL (United States); Mundt, Arno J. [Department of Radiation Oncology, University of California San Diego, La Jolla, CA (United States); Roeske, John C.; Chmura, Steven J. [Department of Radiation and Cellular Oncology, University of Chicago and University of Illinois at Chicago, Chicago, IL (United States)

2008-04-01

99

Design and Analysis Tools for Concurrent Blackboard Systems  

NASA Technical Reports Server (NTRS)

A blackboard system consists of a set of knowledge sources, a blackboard data structure, and a control strategy used to activate the knowledge sources. The blackboard model of problem solving is best described by Dr. H. Penny Nii of the Stanford University AI Laboratory: "A Blackboard System can be viewed as a collection of intelligent agents who are gathered around a blackboard, looking at pieces of information written on it, thinking about the current state of the solution, and writing their conclusions on the blackboard as they generate them. " The blackboard is a centralized global data structure, often partitioned in a hierarchical manner, used to represent the problem domain. The blackboard is also used to allow inter-knowledge source communication and acts as a shared memory visible to all of the knowledge sources. A knowledge source is a highly specialized, highly independent process that takes inputs from the blackboard data structure, performs a computation, and places the results of the computation in the blackboard data structure. This design allows for an opportunistic control strategy. The opportunistic problem-solving technique allows a knowledge source to contribute towards the solution of the current problem without knowing which of the other knowledge sources will use the information. The use of opportunistic problem-solving allows the data transfers on the blackboard to determine which processes are active at a given time. Designing and developing blackboard systems is a difficult process. The designer is trying to balance several conflicting goals and achieve a high degree of concurrent knowledge source execution while maintaining both knowledge and semantic consistency on the blackboard. Blackboard systems have not attained their apparent potential because there are no established tools or methods to guide in their construction or analyze their performance.

McManus, John W.

1991-01-01

100

Modifying Immune System Response to Cancer Chemotherapy Could Lead to New Treatment Approaches  

Cancer.gov

Researchers at NCI have discovered a mechanism by which cancer patients' immune systems respond to chemotherapy. They conclude that this response can potentially be modified to improve the effectiveness of antitumor vaccines that are given once chemotherapy is completed.

101

Effectiveness of Integration of System-Level Optimization in Concurrent Engineering for Rocket Design  

E-print Network

Effectiveness of Integration of System-Level Optimization in Concurrent Engineering for Rocket in Concurrent Engineering for Rocket Design by Brian Kenichi Bairstow Submitted to the Department of Aeronautics these results further study was carried out. A two-stage liquid rocket software model was created to serve

de Weck, Olivier L.

102

Deadlock avoidance in flexible manufacturing systems with concurrently competing process flows  

Microsoft Academic Search

The concurrent flow of multiple jobs through a FMS can lead to deadlock conditions due to competition for limited resources in the system. The authors develop a Petri net (PN) model of concurrent job flow and dynamic resource allocation in an FMS and define deadlock in terms of transition enabling in the PN model. The problem of deadlock avoidance is

Z. A. Banaszak; B. H. Krogh

1990-01-01

103

Synthesis of Concurrent Systems with Many Similar PAUL C. ATTIE  

E-print Network

University and E. ALLEN EMERSON The University of Texas at Austin Methods for synthesizing concurrent satisfiability have been proposed by Emerson and Clarke and by Manna and Wolper. An important advantage#ce of Scientific Research, Air Force Materiel Command, USAF, under grant number F49620�96�1�0221. E.A. Emerson

Emerson, E. Allen

104

Fixturing System in an Information Model Based Concurrent Engineering Environment  

Microsoft Academic Search

A distinguishing aspect of concurrent engineering is the intensive informa ion interchange between areas that are involved with the product life cycles. Shared information structures to integ ate different software applications have become necessary to support effectively the interchange o informa ion. While much work done in product model and manufactu ing model, there is a need to make them

Nilo T. Bugtai

2007-01-01

105

Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer  

SciTech Connect

Purpose: For locoregionally advanced inoperable non-small-cell lung cancer (NSCLC), concurrent chemoradiotherapy has become a standard therapy. We conducted a Phase II trial to examine the efficacy and toxicity of adding gemcitabine and vinorelbine induction chemotherapy to concurrent chemoradiotherapy with oral etoposide and cisplatin. Methods and Materials: Eligibility included inoperable clinical Stage III NSCLC without pleural effusion, ECOG performance status 0-1, and weight loss {<=}5%. Induction chemotherapy consisted of three cycles of gemcitabine 1,000 mg/m{sup 2} and vinorelbine 30 mg/m{sup 2}, each given i.v. on Days 1 and 8, every 3 weeks. During once-daily thoracic radiotherapy (1.8 Gy/day, total 63 Gy), two cycles of oral etoposide (100 mg on Days 1-5 and 8-12) plus cisplatin (50 mg/m{sup 2} on Days 1 and 8) were given concurrently 4 weeks apart. Results: Between April 2002 and November 2003, 42 patients were enrolled and 40 were included in response and toxicity evaluation. The median age was 59 years and 13 patients had IIIA and 27 had IIIB; 24 had squamous ca, 12 had adenocarcinoma, and 4 had others. Objective tumor responses were obtained in 29 patients (72.5%), including 18 (45.0%) after induction chemotherapy. After a median follow-up of 23.8 months, the median survival time and progression-free survival was 23.2 months and 10.9 months, respectively, with 2-year survival rate of 43.9%. For the patients with supraclavicular nodal involvement, the median survival time was 11.8 months with 2-year survival rate of 16.7%, whereas the corresponding figures were 27.8 months and 52.0%, respectively, for those without supraclavicular nodal involvement. Toxicity of induction chemotherapy was mild and well tolerated. However, concurrent chemoradiotherapy was associated with G3/4 hematologic toxicity in 75.7%, G3 esophagitis in 24.2%, and two treatment-related deaths. There were nonlife-threatening late toxicities in additional 6 patients. Conclusions: Induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with etoposide and cisplatin showed very promising survival in patients with Stage III NSCLC, especially in those without supraclavicular nodal involvement, which warrants further evaluation.

Lee, Dae Ho [Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of); Han, Ji-Youn [Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of); Cho, Kwan Ho [Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of); Pyo, Hong Ryull [Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of); Kim, Hyae Young [Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of); Yoon, Sung Jin B.S. [Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of); Lee, Jin Soo [Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of)]. E-mail: jslee@ncc.re.kr

2005-11-15

106

A Semi-blind Frequency-Domain Concurrent Equalizer for OFDM Systems  

Microsoft Academic Search

This paper proposes a semi-blind algorithm for frequency-domain (post-FFT) soft-decision concurrent equalization in OFDM systems. The objective is to improve system performance by increasing data throughput or decreasing power requirements, when compared with pilot based conventional channel estimation techniques. The constant modulus algorithm and the soft decision-directed technique were concurrently employed to adjust the coefficients of a post-FFT equalizer bank.

Estevan M. Lopes; Fabbryccio A. C. M. Cardoso; Dalton S. Arantes

2009-01-01

107

Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer.  

PubMed

The aim of the study was to evaluate the efficacy and safety of intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy as induction therapy in clinical stage III unresectable non-small cell lung cancer (NSCLC). Between January 2011 and July 2014, 48 patients, stage III, performance status 0-1, with unresectable clinical stage IIIA or IIIB NSCLC suitable for definitive radiation treatment, were included in the study. Patients with T3N1M0 and T4 (ipsilateral lung nodules) N0-1M0 were not included. Patients were given 3 cycles of chemotherapy every 3 weeks. Carboplatin (AUC5 by i.v. on day 1) and gemcitabine (i.v. 1,000 mg/m(2) on days 1 and 8) were administered. Paclitaxel liposome was injected at 1-3 mg/ml concentration into the tumor lesion by computed tomography-guided percutaneous fine-needle intratumoral injection and proven malignant lymph nodes according to pretreatment histological/cytological results by endobronchial ultrasound drug delivery with a needle on day 1 and day 8. Toxicity was assessed on days 8 and 22 in each cycle. Overall response rate (ORR) evaluation was performed at the end of cycle 3. Out of the 48 enrolled patients, 28 were males and 20 females, 19 patients had stage IIIA and 29 stage IIIB NSCLC. Thirty-six partial responses and two complete responses were observed, for an ORR of 81 %. The most frequent G3-G4 toxicity included neutropenia (in 15 % of cases), hypertransaminasemia (6 %), and diarrhea (4 %). A median PFS of 16.5 months (95 % CI 13.7-19.2) and median OS of 23.2 months (95 % CI 20.0-26.3) were observed. Eleven stage IIIA patients underwent surgery, for a resection rate of 58 %. Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy demonstrated a considerable disease response and resection rate, with acceptable toxicity. PMID:25429832

Lu, Bei; Sun, Lixin; Yan, Xi; Ai, Zhenzhong; Xu, Jinzhi

2015-01-01

108

Monitoring Dosimetric Impact of Weight Loss With Kilovoltage (KV) Cone Beam CT (CBCT) During Parotid-Sparing IMRT and Concurrent Chemotherapy  

SciTech Connect

Purpose: Parotid-sparing head-and-neck intensity-modulated radiotherapy (IMRT) can reduce long-term xerostomia. However, patients frequently experience weight loss and tumor shrinkage during treatment. We evaluate the use of kilovoltage (kV) cone beam computed tomography (CBCT) for dose monitoring and examine if the dosimetric impact of such changes on the parotid and critical neural structures warrants replanning during treatment. Methods and materials: Ten patients with locally advanced oropharyngeal cancer were treated with contralateral parotid-sparing IMRT concurrently with platinum-based chemotherapy. Mean doses of 65 Gy and 54 Gy were delivered to clinical target volume (CTV)1 and CTV2, respectively, in 30 daily fractions. CBCT was prospectively acquired weekly. Each CBCT was coregistered with the planned isocenter. The spinal cord, brainstem, parotids, larynx, and oral cavity were outlined on each CBCT. Dose distributions were recalculated on the CBCT after correcting the gray scale to provide accurate Hounsfield calibration, using the original IMRT plan configuration. Results: Planned contralateral parotid mean doses were not significantly different to those delivered during treatment (p > 0.1). Ipsilateral and contralateral parotids showed a mean reduction in volume of 29.7% and 28.4%, respectively. There was no significant difference between planned and delivered maximum dose to the brainstem (p = 0.6) or spinal cord (p = 0.2), mean dose to larynx (p = 0.5) and oral cavity (p = 0.8). End-of-treatment mean weight loss was 7.5 kg (8.8% of baseline weight). Despite a {>=}10% weight loss in 5 patients, there was no significant dosimetric change affecting the contralateral parotid and neural structures. Conclusions: Although patient weight loss and parotid volume shrinkage was observed, overall, there was no significant excess dose to the organs at risk. No replanning was felt necessary for this patient cohort, but a larger patient sample will be investigated to further confirm these results. Nevertheless, kilovoltage CBCT is a valuable tool for patient setup verification and monitoring of dosimetric variation during radiotherapy.

Ho, Kean Fatt, E-mail: hokeanfatt@hotmail.com [Academic Radiation Oncology, The Christie NHS Foundation Trust, Manchester (United Kingdom); Marchant, Tom; Moore, Chris; Webster, Gareth; Rowbottom, Carl [North Western Medical Physics, The Christie NHS Foundation Trust, Manchester (United Kingdom); Penington, Hazel [Wade Radiotherapy Research Centre, The Christie NHS Foundation Trust, Manchester (United Kingdom); Lee, Lip; Yap, Beng; Sykes, Andrew; Slevin, Nick [Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester (United Kingdom)

2012-03-01

109

3F6 -Software Engineering and Design Concurrent Systems I  

E-print Network

· Second Life Operating System · Linux or Windows · Mobile phone Real time system · Process control system · Engine management system Applications · Microsoft Office Embedded system · Dishwasher · Video recorder Networks Distributed Systems/ Database Systems Operating Systems Real-time Systems Programs Communication

Young, Steve

110

Accumulation-based concurrent fault detection for linear digital state variable systems  

Microsoft Academic Search

An algorithmic fault detection scheme for linear digital state variable systems is proposed. The proposed scheme eliminates the necessity of observing the internal states of the system for concurrent fault detection by utilizing an accumulation-based approach. Observation merely of the inputs and the outputs results in significantly reduced area overhead and no performance penalty. Experimental re- sults verify that 100%

Ismet Bayraktaroglu; Alex Orailoglu

2000-01-01

111

Concurrent Online Testing for Many Core Systems-on-Chips  

E-print Network

provide sufficient reliability and availability to systems with this redundancy. COLT manages the process of testing a subset of processing cores while the rest of the system remains operational. This can be considered a temporary, graceful degradation...

Lee, Jason Daniel

2012-02-14

112

Pulmonary Toxicity in Stage III Non-Small Cell Lung Cancer Patients Treated With High-Dose (74 Gy) 3-Dimensional Conformal Thoracic Radiotherapy and Concurrent Chemotherapy Following Induction Chemotherapy: A Secondary Analysis of Cancer and Leukemia Group B (CALGB) Trial 30105  

SciTech Connect

Purpose: Cancer and Leukemia Group B (CALGB) 30105 tested two different concurrent chemoradiotherapy platforms with high-dose (74 Gy) three-dimensional conformal radiotherapy (3D-CRT) after two cycles of induction chemotherapy for Stage IIIA/IIIB non-small cell lung cancer (NSCLC) patients to determine if either could achieve a primary endpoint of >18-month median survival. Final results of 30105 demonstrated that induction carboplatin and gemcitabine and concurrent gemcitabine 3D-CRT was not feasible because of treatment-related toxicity. However, induction and concurrent carboplatin/paclitaxel with 74 Gy 3D-CRT had a median survival of 24 months, and is the basis for the experimental arm in CALGB 30610/RTOG 0617/N0628. We conducted a secondary analysis of all patients to determine predictors of treatment-related pulmonary toxicity. Methods and Materials: Patient, tumor, and treatment-related variables were analyzed to determine their relation with treatment-related pulmonary toxicity. Results: Older age, higher N stage, larger planning target volume (PTV)1, smaller total lung volume/PTV1 ratio, larger V20, and larger mean lung dose were associated with increasing pulmonary toxicity on univariate analysis. Multivariate analysis confirmed that V20 and nodal stage as well as treatment with concurrent gemcitabine were associated with treatment-related toxicity. A high-risk group comprising patients with N3 disease and V20 >38% was associated with 80% of Grades 3-5 pulmonary toxicity cases. Conclusions: Elevated V20 and N3 disease status are important predictors of treatment related pulmonary toxicity in patients treated with high-dose 3D-CRT and concurrent chemotherapy. Further studies may use these metrics in considering patients for these treatments.

Salama, Joseph K., E-mail: joseph.salama@duke.edu [Duke University Medical Center, Durham, NC (United States); Stinchcombe, Thomas E. [University of North Carolina at Chapel Hill, Chapel Hill, NC (United States); Gu Lin; Wang Xiaofei [CALGB Statistical Center, Duke University Medical Center, Durham, NC (United States); Morano, Karen [Quality Assurance Review Center, Lincoln, RI (United States); Bogart, Jeffrey A. [State University of New York Upstate Medical University, Syracuse, NY (United States); Crawford, Jeffrey C. [Duke University Medical Center, Durham, NC (United States); Socinski, Mark A. [University of North Carolina at Chapel Hill, Chapel Hill, NC (United States); Blackstock, A. William [Wake Forest University School of Medicine, Winston-Salem, NC (United States); Vokes, Everett E. [University of Chicago, Chicago, IL (United States)

2011-11-15

113

A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer  

PubMed Central

Objectives: The aim of this study was to evaluate the efficacy and tolerability of the combination of cisplatin–gemcitabine with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC). Methods: This was a phase II, multicenter, open-label, single-arm trial in treatment-naïve patients with stage IIIA and IIIB LA-NSCLC. After three induction cycles with gemcitabine 1250 mg/m2 plus cisplatin 80 mg/m2, two concurrent chemoradiotherapy cycles with gemcitabine 300 mg/m2, cisplatin 80 mg/m2, and radiotherapy (63 Gy) were administered. The primary endpoint was response rate after induction chemotherapy followed by concurrent chemoradiotherapy. Secondary endpoints included time to progressive disease (TtPD), overall survival (OS), and safety. Results: Overall, 49 patients (median age 63.4 years; 73.5% male; Karnofsky performance status scores of 80, 85, 90, and 100 [16.3%, 2.0%, 49.0%, and 32.7%, respectively]; disease stage IIIA or IIIB 28.6% and 71.4%, respectively) were enrolled and treated. Response rate was 38.8% (95% confidence interval [CI] 25.2–53.8%). Median TtPD was 11.4 months (95% CI 9.4–12.9). Median OS was 21.8 months (95% CI 17.5–26.0), with 1- and 2-year survival rates of 70.8% and 43.7%, respectively. Overall, six patients discontinued from study treatment due to adverse events (AEs), of which two were serious AEs. The most relevant grade 3/4 AEs were neutropenia and thrombocytopenia in induction chemotherapy and chemoradiotherapy, and grade 3 events related to radiation in acute chemoradiotherapy, e.g. dysphagia, radiation pneumonitis, and radiation esophagitis. Conclusions: Induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine (300 mg/m2) and cisplatin was associated with acceptable toxicity. The observed median OS time was 21.8 months. Response evaluation was difficult as in many cases it was not possible to differentiate tumor progression from local radiofibrosis. PMID:23634194

Lambrechts, Marc; Kraaij, Kees; Soldatenkova, Victoria; Chouaki, Nadia; Colinet, Benoit

2013-01-01

114

Interpreting concurrence in terms of covariances in a generalized spin star system  

E-print Network

The quantum dynamics of M pairwise coupled spin 1/2 is analyzed and the time evolution of the entanglement get established within a prefixed couple of spins is studied. A conceptual and quantitative link between the concurrence function and measurable quantities is brought to light providing a physical interpretation for the concurrence itself as well as a way to measure it. A generalized spin star system is exactly investigated showing that the entanglement accompanying its rich dynamics is traceable back to the covariance of appropriate commuting observables of the two spins.

F. Palumbo; A. Napoli; A. Messina

2006-06-20

115

A Modular Approach for Reusing Formalisms in Verification Tools of Concurrent Systems  

E-print Network

used for verifying complex concurrent systems, mod- elled using various formalisms. However on standard XML technologies; their use provides the capability of rapidly and automatically obtaining tools for represent- ing and validating models. It thus enables fast iterations in developing and testing complex

André, �tienne

116

Exposure, infection, systemic cytokine levels and antibody responses in young children concurrently exposed to  

E-print Network

Exposure, infection, systemic cytokine levels and antibody responses in young children concurrently% of the children showed immunological evidence of exposure to schistosome parasites and 13% showed immunological and exposure. Overall the results show that (1) significantly more children are exposed to schistosome

Mutapi, Francisca

117

Model-based Testing for Concurrent Systems: Unfolding-based Test Selection  

E-print Network

suite to the im- plementation, its execution; and decision of the success or the failure of the test]. This relation has become a standard, and it is used as a basis in several testing theories for extended stateModel-based Testing for Concurrent Systems: Unfolding-based Test Selection Hern´an Ponce de Le

Paris-Sud XI, Université de

118

DCCA: a versatile paradigm for the description and development of concurrent communicating systems  

Microsoft Academic Search

Few methodologies exist that facilitate the formal specification and prototyping of distributed systems. In this paper, we describe certain features of the Dynamic Coordinated Concurrent Activities (DCCA) model. Any DCCA specification consists of a set of of largely independent processes, each of which, how- ever, needs to coordinate with several of its Upeers\\

Sudhir Aggarwal; Sandeep Mitra; Sanjay S. Jagdale

1995-01-01

119

Concurrent and Discriminant Validity of the Gordon Diagnostic System: A Preliminary Study.  

ERIC Educational Resources Information Center

Investigated discriminant and concurrent validity of Gordon Diagnostic System (GDS) in 29 boys categorized into "normals" or "attention deficit hyperactivity disordered" (ADHD) based on teacher ratings. Results failed to demonstrate discriminant validity of any GDS score regardless of behavior rating used. Vigilance Correct and Vigilance Omission…

Wherry, Jeffrey N.; And Others

1993-01-01

120

A Functional Programming Approach to the Specification and Verification of Concurrent Systems  

Microsoft Academic Search

Networks of communicating processes can be viewed as networks of stream transformers and programmed in a lazy functional language. Thus the correctness of concurrent systems can be reduced to the correctness of functional programs. In this paper such correctness is proved formally in theµ-calculus extended with recursion equations for functional programs. Theµ-calculus is chosen since it allows the definition of

Peter Dybjer; Herbert P. Sander

1989-01-01

121

AN ALGORITHM TO SUPPORT CODE-SKELETON GENERATION FOR CONCURRENT SYSTEMS*  

E-print Network

AN ALGORITHM TO SUPPORT CODE-SKELETON GENERATION FOR CONCURRENT SYSTEMS* Maria Heloisa Penedo for automatic generation of code skeletons. better code skeletons is possible than with either alone or without these models; and we describe an algorithm to generate code skeletons from these models and the mapping between

Berry, Daniel M.

122

A Phase I/II Radiation Dose Escalation Study With Concurrent Chemotherapy for Patients With Inoperable Stages I to III Non-Small-Cell Lung Cancer: Phase I Results of RTOG 0117  

SciTech Connect

Purpose: In preparation for a Phase III comparison of high-dose versus standard-dose radiation therapy, this Phase I/II study was initiated to establish the maximum tolerated dose of radiation therapy in the setting of concurrent chemotherapy, using three-dimensional conformal radiation therapy for non-small-cell lung cancer. Methods and Materials: Eligibility included patients with histologically proven, unresectable Stages I to III non-small-cell lung cancer. Concurrent chemotherapy consisted of paclitaxel, 50 mg/m{sup 2}, and carboplatin, AUC of 2, given weekly. The radiation dose was to be sequentially intensified by increasing the daily fraction size, starting from 75.25 Gy/35 fractions. Results: The Phase I portion of this study accrued 17 patients from 10 institutions and was closed in January 2004. After the initial 8 patients were accrued to cohort 1, the trial closed temporarily on September 26, 2002, due to reported toxicity. Two acute treatment-related dose-limiting toxicities (DLTs) were reported at the time: a case of grade 5 and grade 3 radiation pneumonitis. The protocol, therefore, was revised to de-escalate the radiation therapy dose (74 Gy/37 fractions). Patients in cohort 1 continued to develop toxicity, with 6/8 (75%) patients eventually developing grade >=3 events. Cohort 2 accrued 9 patients. There was one DLT, a grade 3 esophagitis, in cohort 2 in the first 5 patients (1/5 patients) and no DLTs for the next 2 patients (0/2 patients). Conclusions: The maximum tolerated dose was determined to be 74 Gy/37 fractions (2.0 Gy per fraction) using three-dimensional conformal radiation therapy with concurrent paclitaxel and carboplatin therapy. This dose level in the Phase II portion has been well tolerated, with low rates of acute and late lung toxicities.

Bradley, Jeffrey D., E-mail: jbradley@wustl.ed [Washington University School of Medicine, St. Louis, Missouri (United States); Moughan, Jennifer [RTOG Statistical Headquarters, Philadelphia, Pennsylvania (United States); Graham, Mary V. [Phelps County Medical Center, Rolla, Missouri (United States); Byhardt, Roger [Medical College of Wisconsin, Milwaukee, Wisconsin (United States); Govindan, Ramaswamy [Washington University School of Medicine, St. Louis, Missouri (United States); Fowler, Jack [University of Wisconsin, Madison, Wisconsin (United States); Purdy, James A. [University of California at Davis, Davis, California (United States); Michalski, Jeff M. [Washington University School of Medicine, St. Louis, Missouri (United States); Gore, Elizabeth [Medical College of Wisconsin, Milwaukee, Wisconsin (United States); Choy, Hak [University of Texas Southwestern, Dallas, Texas (United States)

2010-06-01

123

Concurrent three-dimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single-institution study  

PubMed Central

Aim The aim of this study was to evaluate the effects of radiotherapy plus concurrent weekly cisplatin chemotherapy on the postoperative recurrence of mediastinal lymph node metastases in esophageal cancer patients. Methods Ninety-eight patients were randomly enrolled to receive either three-dimensional conformal radiotherapy alone (group A) or concurrent chemoradiotherapy (group B). A radiation dose of 62–70 Gy/31–35 fractions was delivered to the recurrent tumor. Furthermore, the patients in group B simultaneously received weekly doses of cisplatin (30 mg/m2), and the survival outcomes and toxic effects were compared. Results The response rate of group B (91.8%) was significantly greater than that of group A (73.5%) (?2?=?5.765, P?=?0.016). The 1- and 3-year survival rates of group B (85.7% and 46.9%, respectively) were also greater than those of group A (69.4% and 28.6%, respectively). However, there were no significant differences in the 5-year survival rates. The numbers of patients who died of distant metastases in groups A and B were 13 (26.5%) and 5 (10.2%), respectively (?2?=?4.356, P?=?0.036). Acute radiation-related esophagitis and granulocytopenia in group B was frequent. However, intergroup differences in terms of late toxicity were not significant. Conclusions Three-dimensional conformal radiotherapy (3DCRT) is a practical and feasible technique to treat the recurrence of mediastinal lymph node metastases of postoperative esophageal cancer. In addition, concurrent chemotherapy can increase local tumor control, decrease the distant metastasis rate, and increase the long-term survival rate. PMID:24438695

2014-01-01

124

Intelligent quality function deployment system in concurrent engineering environment  

NASA Astrophysics Data System (ADS)

This paper describes work being undertaken in the development of an intelligent distributed quality function deployment (IDQFD) system, which supports product design team to transfer and deployment the `Voice of Customer' through `House of Quality' into the various stages of product planning, engineering and manufacturing. The requirement modeling of products, the optimization in QFD are indicated. The framework of the system, including QFD tools and platform for distributed collaborative work in QFD, is described. The strategy and methods for the collaboration processing in QFD process are presented. It shows promise for application in practice.

Lin, Zhihang; Che, Ada

1998-10-01

125

A concurrent scheduling model of distributed train control system  

Microsoft Academic Search

A!JstTtId- Distributed railway interlocking System (DRIS) and the process logics of the interlocking devices in DRIS are proposed in our previous research. In DRIS, the signal, track unit and switch point have their own control logic. When a train requests a route, the devices which are related to the requested route will cooperate to complete the route reservation for the

Xinhong Hei; Weigang Ma; Jinli Gao; Guo Xie

2011-01-01

126

Concurrent Validity of the Jastak Assessment System with Teachers' Ratings.  

ERIC Educational Resources Information Center

Cluster analysis of IQ and achievement test scores using the Jastak Assessment System, an approach purporting to derive behavioral descriptors of personality domains, was performed for 24 learning disabled and mildly retarded 7-to 17-year-olds. Disagreements between teacher and JAS ratings ranged from 37 percent - 71 percent for the clusters.…

McLoughlin, Caven S.; Book, Robert M.

1982-01-01

127

Modeling of concurrent engineering processes for integrated systems development  

Microsoft Academic Search

For the reengineering of development processes and for its continuous improvement, the development process has to be modeled and documented. A process map is the basis for the way how a system will be or has been designed. The standard methods and tools for process modeling are mostly used for business process modeling and redesign. Due to the special nature

Ernst Fricke; Herbert Negele; Lutz Schrepfer; Alfred Dick; Bernd Gebhard; Nicole Hartlein

1998-01-01

128

Association of Clinical and Dosimetric Factors with Postoperative Pulmonary Complications in Esophageal Cancer Patients Receiving Intensity-Modulated Radiation Therapy and Concurrent Chemotherapy Followed by Thoracic Esophagectomy  

Microsoft Academic Search

Background  To investigate the association between clinical\\/dosimetric factors and postoperative pulmonary complications (PPC) in esophageal\\u000a cancer patients undergoing neoadjuvant chemotherapy and intensity-modulated radiation therapy (IMRT) followed by thoracic\\u000a esophagectomy.\\u000a \\u000a \\u000a \\u000a Methods  The data from 52 patients receiving combined modality treatment were analyzed. Chemotherapy was taxane-based in 43 and 5-fluorouracil-based\\u000a in 9 patients. IMRT (40–45 Gy, median 40 Gy, at 1.8–2 Gy per fraction) was given using

Feng-Ming Hsu; Yung-Chie Lee; Jang-Ming Lee; Chih-Hung Hsu; Chia-Chi Lin; Yu-Chieh Tsai; Jian-Kuen Wu; Jason Chia-Hsien Cheng

2009-01-01

129

Local hyperthermia and systemic chemotherapy for treatment of recurrent melanoma.  

PubMed

Thirty-two patients with recurrent (skin) or metastatic (skin, node, or both) melanoma have been treated with a hyperthermia-cisplatin regimen. The hyperthermic treatment was carried out for 60 minutes at 43 degrees C with the MHS-SMA and the Sapic SVO3 ALENIA devices once a week. When the tumor temperature reached 42 degrees C, cisplatin was administered at a dosage of 50 mg/m2 given by intravenous bolus infusion. The treatment was repeated four times and the tumor response evaluated 4 weeks after the last treatment. Significant systemic or local toxicity was not seen. In terms of results, there were 9 patients with complete responses (28.1%), 13 with partial responses (40.6%), 8 with no change (25.0%), and two with disease progression (6.3%). The objective response rate was 68.7%. The response duration for those with complete responses ranged from 4 to 49 months (median 20 months). The median time to progression for patients with partial responses and those with no change was 6 and 5 months, respectively, with ranges of 1-7 and 1-10 months, respectively. The 4-year actuarial survival rates were 47.6% and 20.3% for the complete and incomplete responders, respectively. These results can be considered satisfactory, taking into account that most patients were pretreated with radiotherapy, chemotherapy or both, confirming the therapeutic potential of the hyperthermia and cisplatin regimen. PMID:7638988

Di Filippo, F; Carlini, S; Garinei, R; Perri, P; Anzà, M; Ferranti, F; Saracca, E; Schiratti, M; Cavaliere, F; Cavaliere, R

1995-01-01

130

Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors  

PubMed Central

Systemic chemotherapy has been relatively ineffective in the treatment of malignant brain tumors even though systemic chemotherapy drugs are small molecules that can readily extravasate across the porous blood-brain tumor barrier of malignant brain tumor microvasculature. Small molecule systemic chemotherapy drugs maintain peak blood concentrations for only minutes, and therefore, do not accumulate to therapeutic concentrations within individual brain tumor cells. The physiologic upper limit of pore size in the blood-brain tumor barrier of malignant brain tumor microvasculature is approximately 12 nanometers. Spherical nanoparticles ranging between 7 nm and 10 nm in diameter maintain peak blood concentrations for several hours and are sufficiently smaller than the 12 nm physiologic upper limit of pore size in the blood-brain tumor barrier to accumulate to therapeutic concentrations within individual brain tumor cells. Therefore, nanoparticles bearing chemotherapy that are within the 7 to 10 nm size range can be used to deliver therapeutic concentrations of small molecule chemotherapy drugs across the blood-brain tumor barrier into individual brain tumor cells. The initial therapeutic efficacy of the Gd-G5-doxorubicin dendrimer, an imageable nanoparticle bearing chemotherapy within the 7 to 10 nm size range, has been demonstrated in the orthotopic RG-2 rodent malignant glioma model. Herein I discuss this novel strategy to improve the effectiveness of systemic chemotherapy for the treatment of malignant brain tumors and the therapeutic implications thereof. PMID:19723323

Sarin, Hemant

2009-01-01

131

Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial  

PubMed Central

Background Accelerated hypofractionated radiotherapy can shorten total treatment time and overcome the accelerated repopulation of tumour cells during radiotherapy. This therapeutic approach has demonstrated good efficacy in the treatment of locally advanced non-small-cell lung cancer (NSCLC). However, the optimal fractionation scheme remains uncertain. The purpose of this phase I trial was to explore the maximum tolerated dose (MTD) of accelerated hypofractionated three-dimensional conformal radiotherapy (3-DCRT) (at 3 Gy/fraction) administered in combination with concurrent vinorelbine (NVB) and carboplatin (CBP) chemotherapy for unresectable stage III NSCLC. Methods Previously untreated cases of unresectable stage III NSCLC received accelerated hypofractionated 3-DCRT, delivered at 3 Gy per fraction, once daily, with five fractions per week. The starting dose was 66 Gy and an increment of 3 Gy was utilized. Higher doses continued to be tested in patient groups until the emergence of dose-limiting toxicity (DLT). The MTD was regarded as the dose that was one step below the dose at which DLT occurred. Patients received at least one cycle of a concurrent two-drug chemotherapy regimen of NVB and CBP. Results A total of 13 patients were enrolled and progressed through three dose escalation groups: 66 Gy, 69 Gy, and 72 Gy. No treatment-related deaths occurred. The major adverse events included radiation oesophagitis, radiation pneumonitis, and neutropenia. Nausea, fatigue, and anorexia were commonly observed, although the magnitude of these events was typically relatively minor. Among the entire group, four instances of DLT were observed, including two cases of grade 3 radiation oesophagitis, one case of grade 3 radiation pneumonitis, and one case of grade 4 neutropenia. All of these cases of DLT occurred in the 72 Gy group. Therefore, 72 Gy was designated as the DLT dose level, and the lower dose of 69 Gy was regarded as the MTD. Conclusions For unresectable stage III NSCLC 69 Gy (at 3 Gy/fraction) was the MTD of accelerated hypofractionated 3-DCRT administered in combination with concurrent NVB and CBP chemotherapy. The toxicity of this chemoradiotherapy regimen could be tolerated. A phase II trial is recommended to further evaluate the efficacy and safety of this regimen. PMID:23957889

2013-01-01

132

Penn researchers repair immune system in leukemia patients following chemotherapy:  

Cancer.gov

A new treatment using leukemia patients’ own infection-fighting cells appears to protect them from infections and cancer recurrence following treatment with fludarabine-based chemotherapy, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

133

Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy  

PubMed Central

Background To evaluate the efficacy of three-dimensional radiotherapy for non-small cell lung cancer (NSCLC) patients with bone metastases. Methods Clinical data for 95 NSCLC patients with bone metastases were collected and prognostic factors were analyzed. All patients received radiation to their thoracic primary tumor and ?2 cycles of chemotherapy. Results Of these 95 patients, 47 patients had only bone metastases and 48 had both bone metastases and other organ metastases. Univariate analysis showed that factors that statistically significantly contributed to patients having longer overall survival (OS) included receiving a radiation dose to the primary tumor ?63 Gy, responding to treatment and receiving ?4 cycles of chemotherapy (p?=?0.001, p?=?0.037 and p?=?0.009, respectively). A radiation dose to the primary tumor ?63 Gy remained significant for patients with bone metastases only as well as those with bone and other organ metastases when they were analyzed separately (p?=?0.045 and p?=?0.012, respectively). For patients with bone metastases only, those with T1-2 tumors had longer OS than those with T3-4 (p?=?0.048); and patients who received ?4 cycles chemotherapy compared with those who received <4 cycles had similar OS (p?=?0.385). On multivariate analysis, only a radiation dose ?63 Gy (p?=?0.028) and having only bone metastases (p?=?0.006) were independent prognostic factors for better OS. Conclusions A radiation dose to the primary tumor ?63 Gy and having only bone metastases were associated with better OS in NSCLC patients with bone metastases. For patients with bone metastases only, besides radiation dose, T status was also correlated with OS, whereas the number of chemotherapy cycles was not. Therefore, aggressive thoracic radiation may play an important role in improving OS. PMID:24962716

2014-01-01

134

The Authentication System for Multi-modal Behavior Biometrics Using Concurrent Pareto Learning SOM  

Microsoft Academic Search

\\u000a We have proposed the integration of behavior biometrics using Supervised Pareto learning SOM to improve the accuracy of authentication.\\u000a For small systems such as mobile devices, this method may be heavy, because of the memory usage or computational power. In\\u000a this paper, we propose the application of Concurrent Pareto learning SOM, which uses a small map for each user. The

Hiroshi Dozono; Shinsuke Ito; Masanori Nakakuni

135

[The system design of an intraperitoneal perfusion machine for hyperthermic chemotherapy based on single chip microcomputer].  

PubMed

A new kind of method for intraperitoneal hyperthermic chemotherapy has been proved to be very effective for the therapy of gastrointestinal cancer. In this article is reported an intraperitoneal perfusion machine which is designed for instituting the treatment. The liquor of the chemotherapy drug is infused into the abdomen after being heated by heating system; the liquor flows out of the abdomen is abandoned. The temperature of heating and the velocity of flow are controlled by MCU, thus the temperature of the liquor of the chemotherapy drug in the abdomen can be adjusted to the most favarable temperature. PMID:16013264

Zhang, Zhiyong; Yang, Xuandong; Li, Kaiyang

2005-06-01

136

Design and Analysis Techniques for Concurrent Blackboard Systems. Ph.D. Thesis  

NASA Technical Reports Server (NTRS)

Blackboard systems are a natural progression of knowledge-based systems into a more powerful problem solving technique. They provide a way for several highly specialized knowledge sources to cooperate to solve large, complex problems. Blackboard systems incorporate the concepts developed by rule-based and expert systems programmers and include the ability to add conventionally coded knowledge sources. The small and specialized knowledge sources are easier to develop and test, and can be hosted on hardware specifically suited to the task that they are solving. The Formal Model for Blackboard Systems was developed to provide a consistent method for describing a blackboard system. A set of blackboard system design tools has been developed and validated for implementing systems that are expressed using the Formal Model. The tools are used to test and refine a proposed blackboard system design before the design is implemented. My research has shown that the level of independence and specialization of the knowledge sources directly affects the performance of blackboard systems. Using the design, simulation, and analysis tools, I developed a concurrent object-oriented blackboard system that is faster, more efficient, and more powerful than existing systems. The use of the design and analysis tools provided the highly specialized and independent knowledge sources required for my concurrent blackboard system to achieve its design goals.

Mcmanus, John William

1992-01-01

137

Concurrent Chemoradiotherapy Followed by Consolidation Chemotherapy With Bi-Weekly Docetaxel and Carboplatin for Stage III Unresectable, Non-Small-Cell Lung Cancer: Clinical Application of a Protocol Used in a Previous Phase II Study  

SciTech Connect

Purpose: To assess the clinical applicability of a protocol evaluated in a previously reported phase II study of concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin in patients with stage III, unresectable, non-small-cell lung cancer (NSCLC). Methods and Materials: Between January 2000 and March 2006, 116 previously untreated patients with histologically proven, stage III NSCLC were treated with concurrent chemoradiotherapy. Radiation therapy was administered in 2-Gy daily fractions to a total dose of 60 Gy in combination with docetaxel, 30 mg/m{sup 2}, and carboplatin at an area under the curve value of 3 every 2 weeks during and after radiation therapy. Results: The median survival time for the entire group was 25.5 months. The actuarial 2-year and 5-year overall survival rates were 53% and 31%, respectively. The 3-year cause-specific survival rate was 60% in patients with stage IIIA disease, whereas it was 35% in patients with stage IIIB disease (p = 0.007). The actuarial 2-year and 5-year local control rates were 62% and 55%, respectively. Acute hematologic toxicities of Grade {>=}3 severity were observed in 20.7% of patients, while radiation pneumonitis and esophagitis of Grade {>=}3 severity were observed in 2.6% and 1.7% of patients, respectively. Conclusions: The feasibility of the protocol used in the previous phase II study was reconfirmed in this series, and excellent treatment results were achieved.

Saitoh, Jun-Ichi, E-mail: junsaito@sannet.ne.jp [Division of Radiation Oncology, Saitama Cancer Center, Saitama (Japan); Saito, Yoshihiro; Kazumoto, Tomoko; Kudo, Shigehiro; Yoshida, Daisaku; Ichikawa, Akihiro [Division of Radiation Oncology, Saitama Cancer Center, Saitama (Japan); Sakai, Hiroshi; Kurimoto, Futoshi [Division of Respiratory Disease, Saitama Cancer Center, Saitama (Japan); Kato, Shingo [Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba (Japan); Shibuya, Kei [Department of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma (Japan)

2012-04-01

138

Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study  

PubMed Central

Background The objective of this study was to evaluate the radiation dose and response in terms of local-regional progression-free survival (LRPFS) and overall survival (OS) of patients with stage IV non-small cell lung cancer (NSCLC) undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy. Methods In all, we enrolled 201 patients with stage IV NSCLC in this study and analyzed OS in 159 patients and LRPFS in 120. Results The 1-, 2-, 3-, and 5-year OS rates were 46.2%, 19.5%, 11.7%, and 5.8%, respectively, the median survival time being 12 months. The median survival times in differential treatment response of primary tumors were 19 of complete response, 13 of partial response, 8 of stable disease, and 6 months of progressive disease, respectively (P?=?0.000). The 1-, 2-, 3-, and 5-year LRPFS rates of patients undergoing four to five cycles with doses ?63 Gy and <63 Gy were 77.4% and 32.6%, 36.2% and 21.7%, 27.2% and 0, and 15.9% and 0, respectively (P?=?0.002). According to multivariate analyses, four to five cycles of chemotherapy, gross tumor volume <175.00 cm3 and post-treatment Karnofsky Performance Status score stable or increased by at least 10 units were independent prognostic factors for better OS (P?=?0.035, P?=?0.008, and P?=?0.000, respectively). Radiation dose to the primary tumor ?63 Gy resulted in better OS (P?=?0.057) and LRPFS (P?=?0.051), both findings being of borderline significance. Conclusions Treatment of IV NSCLC with joint administration of four to five cycles of chemotherapy and three-dimensional radiotherapy may prolong survival, particularly in patients receiving ?63 Gy radiotherapy, with gross tumor volume <175.00 cm3 and post-treatment Karnofsky Performance Status score not lower than pretreatment values. PMID:25001175

2014-01-01

139

Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12  

SciTech Connect

Purpose: The purpose of RTOG 97-12 was to determine the maximum tolerated dose (MTD) of thoracic radiation therapy (RT) with concurrent chemotherapy for patients with limited-stage small-cell lung cancer. Patients and Methods: Sixty-four patients received four cycles of cisplatin (60 mg/m{sup 2} i.v.) and etoposide (120 mg/m{sup 2} i.v. Days 1-3) (PE), with concurrent thoracic RT starting on Day 1. Thoracic RT was given during the first two cycles with 1.8 Gy/fraction daily to the clinical target volume, followed by thoracic RT to the gross tumor volume b.i.d. for the last 3, 5, 7, 9, or 11 treatment days (total dose 50.4, 54.0, 57.6, 61.2, or 64.8 Gy, respectively). The MTD was based on the dose that produced Grades 3-4 nonhematologic toxicity (mainly esophagitis and pneumonitis) in greater than 50% of patients. Results: After the first 8 patients were enrolled in Arm 1, administration of etoposide was changed from 120 mg/m{sup 2} i.v. on Days 2 and 3 of each cycle to 240 mg/m{sup 2} p.o. for patient convenience as outpatients. Total thoracic RT doses from 50.4 Gy to 61.2 Gy over 5 weeks given with PE were well tolerated. Three of the first 5 patients in the 64.8 Gy arm developed Grade 3 acute esophagitis; the MTD was determined to be 61.2 Gy. Fifty-four (87%) of the 62 evaluable patients achieved a complete (68%) or partial (19%) tumor response. The 18-month survival was 25% for patients receiving 50.4 Gy and 82% for those receiving 61.2 Gy. Conclusions: The MTD for this accelerated thoracic RT regimen with concurrent PE was 61.2 Gy over 5 weeks.

Komaki, Ritsuko [Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX (United States)]. E-mail: rkomaki@mdanderson.org; Swann, R. Suzanne [Radiation Therapy Oncology Group, Philadelphia, PA (United States); Ettinger, David S. [Kimmel Comp Cancer Center at Johns Hopkins, Baltimore, MD (United States); Glisson, Bonnie S. [Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX (United States); Sandler, Alan B. [Vanderbilt University Medical Center, Nashville, TN (United States); Movsas, Benjamin [Fox Chase Cancer Center, Philadelphia, PA (United States); Suh, John [Cleveland Clinic Foundation, Cleveland, OH (United States); Byhardt, Roger W. [Medical College of Wisconsin, Milwaukee, WI (United States)

2005-06-01

140

Feasibility and Efficacy of Induction Docetaxel, Cisplatin, and 5-Fluorouracil Chemotherapy Combined With Cisplatin Concurrent Chemoradiotherapy for Nonmetastatic Stage IV Head-and-Neck Squamous Cell Carcinomas  

SciTech Connect

Purpose: To report the experience of treating selected fit patients with locally advanced head-and-neck squamous cell carcinoma with three cycles of induction TPF (docetaxel 75 mg/m{sup 2}, cisplatin 75 mg/m{sup 2}, 5-fluorouracil 750 mg/m{sup 2}, Days 2-5) followed by concurrent three-weekly bolus cisplatin 100 mg/m{sup 2} chemoradiotherapy. Methods and Materials: Between March 2006 and February 2010, 66 patients with nonmetastatic Stage IV head-and-neck squamous cell carcinoma were treated in a single institution with three cycles of induction TPF, followed by radical radiotherapy with concurrent cisplatin 100 mg/m{sup 2}. Results: Median age was 54 years (range, 33-69 years). Median follow-up was 21 months (range, 4-55 months). During TPF, Grade 3 toxicity occurred in 18 patients (27%), dose modifications in 10 (15%), delays in 3 (5%), and unplanned admissions in 6 (9%); a clinical tumor response was documented in 60 patients (91%). Median time from the final cycle of TPF to commencing radiotherapy was 22 days. Sixty-two patients (94%) received radical radiotherapy, and all completed treatment with no delays {>=}3 days. One, two, and three cycles of concurrent cisplatin were delivered to 18 patients (29%), 38 patients (61%), and 3 patients (5%), respectively. Ninety-two percent of patients received enteral feeding; median weight loss during treatment was 7%. Forty-two patients (68%) had unplanned admissions with no on-treatment deaths. Three unrelated deaths occurred after treatment. At 1 year after treatment, 21% of patients without disease progression remained gastrostomy dependent. Of 58 assessable patients, 50 (86%) achieved a complete response after treatment. One- and 2-year progression-free survival, cause-specific survival, and overall survival were 88%, 92%, and 86% and 80%, 85%, and 80%, respectively. Conclusion: The combination of induction TPF with concurrent cisplatin chemoradiotherapy in patients with locally advanced head and neck squamous cell carcinoma is tolerable, with encouraging efficacy.

Prestwich, Robin J., E-mail: Robin.Prestwich@leedsth.nhs.uk [Department of Clinical Oncology, St. James's Institute of Oncology, Leeds (United Kingdom); Oeksuez, Didem Colpan; Dyker, Karen; Coyle, Catherine; Sen, Mehmet [Department of Clinical Oncology, St. James's Institute of Oncology, Leeds (United Kingdom)

2011-11-15

141

Concurrent Mission and Systems Design at NASA Glenn Research Center: The Origins of the COMPASS Team  

NASA Technical Reports Server (NTRS)

Established at the NASA Glenn Research Center (GRC) in 2006 to meet the need for rapid mission analysis and multi-disciplinary systems design for in-space and human missions, the Collaborative Modeling for Parametric Assessment of Space Systems (COMPASS) team is a multidisciplinary, concurrent engineering group whose primary purpose is to perform integrated systems analysis, but it is also capable of designing any system that involves one or more of the disciplines present in the team. The authors were involved in the development of the COMPASS team and its design process, and are continuously making refinements and enhancements. The team was unofficially started in the early 2000s as part of the distributed team known as Team JIMO (Jupiter Icy Moons Orbiter) in support of the multi-center collaborative JIMO spacecraft design during Project Prometheus. This paper documents the origins of a concurrent mission and systems design team at GRC and how it evolved into the COMPASS team, including defining the process, gathering the team and tools, building the facility, and performing studies.

McGuire, Melissa L.; Oleson, Steven R.; Sarver-Verhey, Timothy R.

2012-01-01

142

Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.  

PubMed

This study analyzed outcomes of systemic chemotherapy for advanced neuroendocrine carcinoma (NEC) of the digestive system. Clinical data from 258 patients with unresectable or recurrent NEC of the gastrointestinal tract (GI) or hepato-biliary-pancreatic system (HBP), who received chemotherapy, were collected from 23 Japanese institutions and analyzed retrospectively. Patients had primary sites in the esophagus (n = 85), stomach (n = 70), small bowel (n = 6), colorectum (n = 31), hepato-biliary system (n = 31) and pancreas (n = 31). Median overall survival (OS) was 13.4 months the esophagus, 13.3 months for the stomach, 29.7 months for the small bowel, 7.6 months for the colorectum, 7.9 months for the hepato-biliary system and 8.5 months for the pancreas. Irinotecan plus cisplatin (IP) and etoposide plus cisplatin (EP) were most commonly selected for GI-NEC and HBP-NEC. For patients treated with IP/EP (n = 160/46), the response rate was 50/28% and median OS was 13.0/7.3 months. Multivariate analysis among patients treated with IP or EP showed that the primary site (GI vs HBP; hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.35-0.97) and baseline serum lactate dehydrogenase levels (not elevated vs elevated; HR 0.65, 95% CI 0.46-0.94) were independent prognostic factors for OS, while the efficacy of IP was slightly better than for EP (HR 0.80, 95% CI 0.48-1.33; P = 0.389). IP and EP are the most common treatment regimens for NEC of the digestive system. HBP primary sites and elevated lactate dehydrogenase levels are unfavorable prognostic factors for survival. A randomized controlled trial is required to establish the appropriate chemotherapy regimen for advanced NEC of the digestive system. This study was registered at UMIN as trial number 000005176. PMID:24975505

Yamaguchi, Tomohiro; Machida, Nozomu; Morizane, Chigusa; Kasuga, Akiyoshi; Takahashi, Hideaki; Sudo, Kentaro; Nishina, Tomohiro; Tobimatsu, Kazutoshi; Ishido, Kenji; Furuse, Junji; Boku, Narikazu; Okusaka, Takuji

2014-09-01

143

Stable Adaptive Work-Stealing for Concurrent Many-Core Runtime Systems  

NASA Astrophysics Data System (ADS)

The proliferation of many-core architectures has led to the explosive development of parallel applications using programming models, such as OpenMP, TBB, and Cilk/Cilk++. With increasing number of cores, however, it becomes even harder to efficiently schedule parallel applications on these resources since current many-core runtime systems still lack effective mechanisms to support collaborative scheduling of these applications. In this paper, we study feedback-driven adaptive scheduling based on work stealing, which provides an efficient solution for concurrently executing a set of applications on many-core systems. To dynamically estimate the number of cores desired by each application, a stable feedback-driven adaptive algorithm, called SAWS, is proposed using active workers and the length of active deques, which well captures the runtime characteristics of the applications. Furthermore, a prototype system is built by extending the Cilk runtime system, and the experimental results, which are obtained on a Sun Fire server, show that SAWS has more advantages for scheduling concurrent parallel applications. Specifically, compared with existing algorithms A-Steal and WS-EQUI, SAWS improves the performances by up to 12.43% and 21.32% with respect to mean response time respectively, and 25.78% and 46.98% with respect to processor utilization, respectively.

Cao, Yangjie; Sun, Hongyang; Qian, Depei; Wu, Weiguo

144

Proposal for direct measurement of concurrence via visibility in a cavity QED system  

E-print Network

Proposal for direct measurement of concurrence via visibility in a cavity QED system Sang Min Lee,1 Se-Wan Ji,1 Hai-Woong Lee,1 and M. Suhail Zubairy2,3 1Department of Physics, Korea Advanced Institute of Science and Technology, Daejeon 305...-701, Korea 2Department of Physics and Institute for Quantum Studies, Texas A&M University, College Station, Texas 77843-4242, USA 3Texas A&M University at Qatar, Education City, P.O. Box 23874, Doha, Qatar #1;Received 24 January 2008; published 22 April...

Lee, Sang Min; Ji, Se-Wan; Lee, Hai-Woong; Zubairy, M. Suhail

2008-01-01

145

Evaluating Algorithm Animation for Concurrent Systems: A Comprehension-Based Approach  

Microsoft Academic Search

For over 15 years visualization tools have attempted to present the complexity of concurrent programs in easily digestible formats. For example, visualization tools, that display an execution-based animation of concurrent algorithms, have been used extensively in educational contexts to illustrate the behavior of concurrent algorithms to students. However, there is little documented evidence that such tools significantly improve the users'

Connor Hughes; Jim Buckley

2004-01-01

146

Radiation Therapy with Concurrent Chemotherapy for Locally Advanced Cervical Carcinoma: Outcome Analysis with Emphasis on the Impact of Treatment Duration on Outcome  

PubMed Central

Objective. To assess the effectiveness and toxicity of carboplatin concurrent with pelvic external beam radiation and low-dose rate brachytherapy and to assess the impact that adherence to the treatment plan has on outcomes. Methods. Retrospective chart review of 56 patients treated from January 2001 to December 2010. Results. Median follow-up was 68 months. Optimal dose of radiation (ORT) was defined as a minimal cervical dose exceeding 70?Gy, point A dose of 80–90?Gy, and duration not exceeding 56 days. Only 50% received ORT. In multivariable analyses we only found ORT to be statistically significant predictor for progression-free survival (PFS) and overall survival (OS) (HR [95% CI] for non-ORT vs. ORT: 2.4 [1.2, 5.1], P = 0.014 for PFS and 2.2 [1.1, 4.6], P = 0.035 for OS). The 5-year PFS in patients who received ORT was better than that in patients who received non-ORT, 56% vs. 22% (95% CI: [36%, 72%] vs. [9%, 39%]). Patients who received ORT had a better 5-year OS as well (59% vs. 33%; 95% CI: [38%, 75%] vs. [16%, 51%]). Conclusion. Patients with locally advanced cervical cancer treated with weakly carboplatin or cisplatin, teletherapy, and low dose-dose rate brachytherapy have poorer outcomes when treatment duration is prolonged.

Diaz, Juan; Micaily, Bizhan; Ferriss, J. Stuart

2014-01-01

147

Effects of Neoadjuvant Intraperitoneal/Systemic Chemotherapy (Bidirectional Chemotherapy) for the Treatment of Patients with Peritoneal Metastasis from Gastric Cancer  

PubMed Central

Novel multidisciplinary treatment combined with neoadjuvant intraperitoneal-systemic chemotherapy protocol (NIPS) and peritonectomy was developed. Ninety-six patients were enrolled. Peritoneal wash cytology was performed before and after NIPS through a port system. Patients were treated with 60?mg/m2 of oral S-1 for 21 days, followed by a 1-week rest. On days 1, 8, and 15, 30?mg/m2 of Taxotere and 30?mg/m2 of cisplatin with 500?mL of saline were introduced through the port. NIPS is done 2 cycles before surgery. Three weeks after NIPS, 82 patients were eligible to intend cytoreductive surgery (CRS) by gastrectomy + D2 dissection + periotnectomy to achieve complete cytoreduction. Sixty-eight patients showed positice cytology before NIPS, and the positive cytology results became negative in 47 (69%) patients after NIPS. Complete pathologic response on PC after NIPS was experienced in 30 (36.8%) patients. Stage migration was experienced in 12 patients (14.6%). Complete cytoreduction was achieved in 58 patients (70.7%). By the multivariate analysis, complete cytoreduction and pathologic response became a significantly good survival. However the high morbidity and mortality, stringent patient selection is important. The best indications of the therapy are patients with good pathologic response and PCI ? 6, which are supposed to be removed completely by peritonectomy. PMID:22900159

Yonemura, Yutaka; Elnemr, Ayman; Endou, Yoshio; Ishibashi, Haruaki; Mizumoto, Akiyoshi; Miura, Masahiro; Li, Yan

2012-01-01

148

Concurrent Training.  

E-print Network

??Das Kombinieren von Kraft- und Ausdauertraining bezeichnet man als concurrent Training. Die vorliegende Literaturanalyse beschäftigt sich mit den unterschiedlichen Studiendesigns und Studienergebnissen, die seit der… (more)

Bellante, Andreas

2014-01-01

149

Development of figurative language skills following central nervous system-directed chemotherapy delivered in early childhood.  

PubMed

Central nervous system (CNS)-directed chemotherapy is delivered for the treatment of childhood acute lymphoblastic leukaemia (ALL). Figurative language deficits have been described in children following CNS-directed chemotherapy; however, comprehensive analysis of figurative interpretation errors, potentially providing clinical utility to assist with intervention planning, has never been performed. The present study aimed to compare the figurative language skills of seven children treated with CNS-directed chemotherapy for ALL before the age of 6 years (mean age at diagnosis 3 years 10 months) and a matched control group of children, using the Test of Language Competence-Expanded Edition (TLC-E) Figurative Language sub-test. It was hypothesised that the children treated with CNS-directed chemotherapy would demonstrate a decreased performance in and an alternative method of interpreting figurative language. The results suggest no negative effects of CNS-directed chemotherapy on figurative language. There were no statistically significant differences between groups for TLC-E Figurative Language sub-test composite scores and picture component errors, nor were there clinically significant differences observed from descriptive comparisons of individual case data and error analysis. As these skills continue to emerge beyond childhood, the need to monitor skill development in ALL survivors beyond childhood is highlighted. PMID:23607904

Dowling, Emma K; Lewis, Fiona M; Murdoch, Bruce E

2014-04-01

150

Phase II Study of Accelerated High-Dose Radiotherapy With Concurrent Chemotherapy for Patients With Limited Small-Cell Lung Cancer: Radiation Therapy Oncology Group Protocol 0239  

SciTech Connect

Purpose: To investigate whether high-dose thoracic radiation given twice daily during cisplatin-etoposide chemotherapy for limited small-cell lung cancer (LSCLC) improves survival, acute esophagitis, and local control rates relative to findings from Intergroup trial 0096 (47%, 27%, and 64%). Patients and Methods: Patients were accrued over a 3-year period from 22 US and Canadian institutions. Patients with LSCLC and good performance status were given thoracic radiation to 61.2 Gy over 5 weeks (daily 1.8-Gy fractions on days 1-22, then twice-daily 1.8-Gy fractions on days 23-33). Cisplatin (60 mg/m{sup 2} IV) was given on day 1 and etoposide (120 mg/m{sup 2} IV) on days 1-3 and days 22-24, followed by 2 cycles of cisplatin plus etoposide alone. Patients who achieved complete response were offered prophylactic cranial irradiation. Endpoints included overall and progression-free survival; severe esophagitis (Common Toxicity Criteria v 2.0) and treatment-related fatalities; response (Response Evaluation Criteria in Solid Tumors); and local control. Results: Seventy-two patients were accrued from June 2003 through May 2006; 71 were evaluable (median age 63 years; 52% female; 58% Zubrod 0). Median survival time was 19 months; at 2 years, the overall survival rate was 36.6% (95% confidence interval [CI] 25.6%-47.7%), and progression-free survival 19.7% (95% CI 11.4%-29.6%). Thirteen patients (18%) experienced severe acute esophagitis, and 2 (3%) died of treatment-related causes; 41% achieved complete response, 39% partial response, 10% stable disease, and 6% progressive disease. The local control rate was 73%. Forty-three patients (61%) received prophylactic cranial irradiation. Conclusions: The overall survival rate did not reach the projected goal; however, rates of esophagitis were lower, and local control higher, than projected. This treatment strategy is now one of three arms of a prospective trial of chemoradiation for LSCLC (Radiation Therapy Oncology Group 0538/Cancer and Leukemia Group B 30610).

Komaki, Ritsuko, E-mail: rkomaki@mdanderson.org [Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Paulus, Rebecca [Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania (United States); Ettinger, David S. [Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland (United States); Videtic, Gregory M.M. [Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio (United States); Bradley, Jeffrey D. [Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri (United States); Glisson, Bonnie S. [Department of Thoracic/Head and Neck Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Langer, Corey J. [Thoracic Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania (United States); Sause, William T. [Radiation Center, LDS Hospital, Salt Lake City, Utah (United States); Curran, Walter J. [Department of Radiation Oncology, Jefferson Medical College, Philadelphia, Pennsylvania (United States); Choy, Hak [Department of Radiation Oncology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (United States)

2012-07-15

151

Multidisciplinary treatment including systemic chemotherapy for a malignant phyllodes tumour of the prostate  

PubMed Central

A 22-year-old man was referred to our hospital with macroscopic hematuria and consistent anal pain. Magnetic resonance imaging revealed an enlarged prostate tumour invading the bladder and rectum. A biopsy revealed an unclassified spindle cell sarcoma. Subsequently, radical cystoprostatectomy and resection of the rectum were performed. A histopathological examination revealed a prostatic malignant phyllodes tumour with a negative surgical margin. However, a local recurrence was identified 2 months after surgery. Induction therapy included 4 cycles of systemic chemotherapy comprising etoposide with ifosfamide and cisplatin. Although a partial response was observed at the local site, lung metastasis developed. Second-line chemotherapy with ifosfamide and doxorubicin with radiotherapy to the pelvis was administered and led to complete regression; however, its efficacy was transient. Although additional chemotherapy was administered, the patient eventually died due to the rapidly growing, recurrent tumour. PMID:24839496

Murakami, Yasukiyo; Tabata, Ken-ichi; Sugita, Atsushi; Mochizuki, Kohei; Maeyama, Ryota; Okazaki, Miyoko; Nishi, Morihiro; Matsumoto, Kazumasa; Fujita, Tetsuo; Satoh, Takefumi; Jiang, Shi-Xu; Saegusa, Makoto; Iwamura, Masatsugu

2014-01-01

152

Multidisciplinary treatment including systemic chemotherapy for a malignant phyllodes tumour of the prostate.  

PubMed

A 22-year-old man was referred to our hospital with macroscopic hematuria and consistent anal pain. Magnetic resonance imaging revealed an enlarged prostate tumour invading the bladder and rectum. A biopsy revealed an unclassified spindle cell sarcoma. Subsequently, radical cystoprostatectomy and resection of the rectum were performed. A histopathological examination revealed a prostatic malignant phyllodes tumour with a negative surgical margin. However, a local recurrence was identified 2 months after surgery. Induction therapy included 4 cycles of systemic chemotherapy comprising etoposide with ifosfamide and cisplatin. Although a partial response was observed at the local site, lung metastasis developed. Second-line chemotherapy with ifosfamide and doxorubicin with radiotherapy to the pelvis was administered and led to complete regression; however, its efficacy was transient. Although additional chemotherapy was administered, the patient eventually died due to the rapidly growing, recurrent tumour. PMID:24839496

Murakami, Yasukiyo; Tabata, Ken-Ichi; Sugita, Atsushi; Mochizuki, Kohei; Maeyama, Ryota; Okazaki, Miyoko; Nishi, Morihiro; Matsumoto, Kazumasa; Fujita, Tetsuo; Satoh, Takefumi; Jiang, Shi-Xu; Saegusa, Makoto; Iwamura, Masatsugu

2014-03-01

153

Post-game analysis: An initial experiment for heuristic-based resource management in concurrent systems  

NASA Technical Reports Server (NTRS)

In concurrent systems, a major responsibility of the resource management system is to decide how the application program is to be mapped onto the multi-processor. Instead of using abstract program and machine models, a generate-and-test framework known as 'post-game analysis' that is based on data gathered during program execution is proposed. Each iteration consists of (1) (a simulation of) an execution of the program; (2) analysis of the data gathered; and (3) the proposal of a new mapping that would have a smaller execution time. These heuristics are applied to predict execution time changes in response to small perturbations applied to the current mapping. An initial experiment was carried out using simple strategies on 'pipeline-like' applications. The results obtained from four simple strategies demonstrated that for this kind of application, even simple strategies can produce acceptable speed-up with a small number of iterations.

Yan, Jerry C.

1987-01-01

154

System front-end design for concurrent acquisition of electroencephalograms and EIT data  

NASA Astrophysics Data System (ADS)

There is recently considerable interest in medical imaging to combine recording of bioelectrical signals with imaging procedures. For example, electroencephalograms (EEGs) recorded during functional magnetic resonance imaging are increasingly being used for neurological and behavioural research. Concurrent acquisition of EEGs and electrical impedance tomography (EIT) data have been suggested as a non invasive technique that could help localize the area of the brain responsible for seizures in epileptic patients awaiting resective surgery. Despite reasonably distinct spectra, EEGs and EIT signals are difficult to record simultaneously because of their very different amplitudes. In this paper, we describe the front-end of a 24-channel system designed to acquire both signals from the same set of scalp electrodes using time-division multiplexing. We have developped a 10-layer 20×15 cm printed circuit board of the front-end and are currently performing circuit characterization tests. System performance parameters and in vivo images will be presented at the conference.

Guardo, R.; Jehanne-Lacasse, J.; Moumbe, A. P.; Gagnon, H.

2010-04-01

155

Cryosurgical modeling: effects of cryotherapy and chemotherapy on the viability of two model cell systems  

Microsoft Academic Search

Cryotherapy and chemotherapy are widely but separately used in the treatment and control of cancer. The authors examined the effect of combining the two therapies in an in vitro cell system. The combination provided a greater loss in cell viability than in either treatment alone

D. M. Clarke; R. G. Van Buskirk; J. G. Baust

1999-01-01

156

Complementary therapies for side effects of chemotherapy and radiotherapy in the upper gastrointestinal system  

Microsoft Academic Search

IntroductionChemotherapy and radiotherapy remain the mainstay of treatment for patients with advanced malignant disease that is incurable by local surgery. However, effective use of these therapies is limited by toxic effects. Serious side effects in the upper GI system include mucositis, xerostomia, nausea and vomiting. Standard care for these side effects is suboptimal. Recent studies suggest complementary and alternative medicine

Elad Schiff; Eran Ben-Arye

2011-01-01

157

Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.  

PubMed

While concurrent chemoradiotherapy is a standard treatment for good-performance patients with non-small cell lung cancer, acute esophagitis is a frequent toxicity. The incidence of severe acute esophagitis > or = grade 3 in patients treated with standard (once-daily) radiation therapy alone is 1.3%, increasing to 14% to 25% with the addition of concurrent chemotherapy, and 24% to 34% for the combination of hyperfractionated (twice-daily) radiation therapy plus concomitant chemotherapy. Although esophagitis is almost never a cause of mortality, it results in significant morbidity and may force treatment breaks, which are associated with inferior outcome in non-small cell lung cancer. Substantial investigative efforts to prevent or ameliorate esophagitis have been conducted. We describe herein the rationale/study design for a multi-institutional, phase II randomized study to evaluate either daily subcutaneous or intravenous bolus infusions of amifostine in patients with non-small cell lung cancer who receive standard fractionated thoracic radiation therapy concurrently with weekly paclitaxel and carboplatin chemotherapy. PMID:15726523

Werner-Wasik, Maria; Langer, Corey; Movsas, Benjamin

2004-12-01

158

Improving the Hadoop map\\/reduce framework to support concurrent appends through the BlobSeer BLOB management system  

Microsoft Academic Search

Hadoop is a reference software framework supporting the Map\\/Reduce programming model. It relies on the Hadoop Distributed File System (HDFS) as its primary storage system. Although HDFS does not offer support for concurrently appending data to existing files, we argue that Map\\/Reduce applications as well as other classes of applications can benefit from such a functionality. We provide support for

Diana Moise; Gabriel Antoniu; Luc Bougé

2010-01-01

159

Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer  

Microsoft Academic Search

BACKGROUND: Drug resistance in breast cancer is a major obstacle to successful chemotherapy. In this study we used cDNA microarray technology to examine gene expression profiles obtained from fine needle aspiration (FNA) of primary breast tumors before and after systemic chemotherapy. Our goal was to determine the feasibility of obtaining representative expression array profiles from limited amounts of tissue and

Christos Sotiriou; Trevor J Powles; Mitch Dowsett; Amir A Jazaeri; Andrew L Feldman; Laura Assersohn; Chandramouli Gadisetti; Steven K Libutti; Edison T Liu

2002-01-01

160

Long-term Follow-up of the RTOG 9501/Intergroup Phase III Trial: Postoperative Concurrent Radiation Therapy and Chemotherapy in High-Risk Squamous Cell Carcinoma of the Head and Neck  

SciTech Connect

Purpose: Previous analysis of this Intergroup trial demonstrated that with a median follow-up among surviving patients of 45.9 months, the concurrent postoperative administration of cisplatin and radiation therapy improved local-regional control and disease-free survival of patients who had high-risk resectable head-and-neck carcinomas. With a minimum of 10 years of follow-up potentially now available for all patients, these results are updated here to examine long-term outcomes. Methods and Materials: A total of 410 analyzable patients who had high-risk resected head-and-neck cancers were prospectively randomized to receive either radiation therapy (RT: 60 Gy in 6 weeks) or identical RT plus cisplatin, 100 mg/m{sup 2}i.v. on days 1, 22, and 43 (RT + CT). Results: At 10 years, the local-regional failure rates were 28.8% vs 22.3% (P=.10), disease-free survival was 19.1% vs 20.1% (P=.25), and overall survival was 27.0% vs 29.1% (P=.31) for patients treated by RT vs RT + CT, respectively. In the unplanned subset analysis limited to patients who had microscopically involved resection margins and/or extracapsular spread of disease, local-regional failure occurred in 33.1% vs 21.0% (P=.02), disease-free survival was 12.3% vs 18.4% (P=.05), and overall survival was 19.6% vs 27.1% (P=.07), respectively. Conclusion: At a median follow-up of 9.4 years for surviving patients, no significant differences in outcome were observed in the analysis of all randomized eligible patients. However, analysis of the subgroup of patients who had either microscopically involved resection margins and/or extracapsular spread of disease showed improved local-regional control and disease-free survival with concurrent administration of chemotherapy. The remaining subgroup of patients who were enrolled only because they had tumor in 2 or more lymph nodes did not benefit from the addition of CT to RT.

Cooper, Jay S., E-mail: jcooper@maimonidesmed.org [Maimonides Cancer Center, New York, New York (United States); Zhang Qiang; Pajak, Thomas F. [Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania (United States)] [Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania (United States); Forastiere, Arlene A. [Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland (United States)] [Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland (United States); Jacobs, John [Barbara Ann Karmanos Comprehensive Cancer Center, Wayne State University, Detroit, Michigan (United States)] [Barbara Ann Karmanos Comprehensive Cancer Center, Wayne State University, Detroit, Michigan (United States); Saxman, Scott B. [Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland (United States)] [Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland (United States); Kish, Julie A. [H. Lee Moffitt Cancer Center, Tampa, Florida (United States)] [H. Lee Moffitt Cancer Center, Tampa, Florida (United States); Kim, Harold E. [Wayne State University Medical Center, Detroit, Michigan (United States)] [Wayne State University Medical Center, Detroit, Michigan (United States); Cmelak, Anthony J. [Vanderbilt Cancer Center, Nashville, Tennessee (United States)] [Vanderbilt Cancer Center, Nashville, Tennessee (United States); Rotman, Marvin [SUNY Health Center at Brooklyn, Brooklyn, New York (United States)] [SUNY Health Center at Brooklyn, Brooklyn, New York (United States); Lustig, Robert [Hospital of University of Pennsylvania, Philadelphia, Pennsylvania (United States)] [Hospital of University of Pennsylvania, Philadelphia, Pennsylvania (United States); Ensley, John F. [Barbara Ann Karmanos Comprehensive Cancer Center, Wayne State University, Detroit, Michigan (United States)] [Barbara Ann Karmanos Comprehensive Cancer Center, Wayne State University, Detroit, Michigan (United States); Thorstad, Wade [Washington University, St. Louis, Missouri (United States)] [Washington University, St. Louis, Missouri (United States); Schultz, Christopher J. [Medical College of Wisconsin, Milwaukee, Wisconsin (United States)] [Medical College of Wisconsin, Milwaukee, Wisconsin (United States); Yom, Sue S. [University of California, San Francisco, California (United States)] [University of California, San Francisco, California (United States); Ang, K. Kian [University of Texas MD Anderson Cancer Center, Houston, Texas (United States)] [University of Texas MD Anderson Cancer Center, Houston, Texas (United States)

2012-12-01

161

Phase I Study of Concurrent High-Dose Three-Dimensional Conformal Radiotherapy With Chemotherapy Using Cisplatin and Vinorelbine for Unresectable Stage III Non-Small-Cell Lung Cancer  

SciTech Connect

Purpose: To determine the maximum tolerated dose in concurrent three-dimensional conformal radiotherapy (3D-CRT) with chemotherapy for unresectable Stage III non-small-cell lung cancer (NSCLC). Patients and Methods: Eligible patients with unresectable Stage III NSCLC, age {>=}20 years, performance status 0-1, percent of volume of normal lung receiving 20 GY or more (V{sub 20}) {<=}30% received three to four cycles of cisplatin (80 mg/m{sup 2} Day 1) and vinorelbine (20 mg/m{sup 2} Days 1 and 8) repeated every 4 weeks. The doses of 3D-CRT were 66 Gy, 72 Gy, and 78 Gy at dose levels 1 to 3, respectively. Results: Of the 17, 16, and 24 patients assessed for eligibility, 13 (76%), 12 (75%), and 6 (25%) were enrolled at dose levels 1 to 3, respectively. The main reasons for exclusion were V{sub 20} >30% (n = 10) and overdose to the esophagus (n = 8) and brachial plexus (n = 2). There were 26 men and 5 women, with a median age of 60 years (range, 41-75). The full planned dose of radiotherapy could be administered to all the patients. Grade 3-4 neutropenia and febrile neutropenia were noted in 24 (77%) and 5 (16%) of the 31 patients, respectively. Grade 4 infection, Grade 3 esophagitis, and Grade 3 pulmonary toxicity were noted in 1 patient, 2 patients, and 1 patient, respectively. The dose-limiting toxicity was noted in 17% of the patients at each dose level. The median survival and 3-year and 4-year survival rates were 41.9 months, 72.3%, and 49.2%, respectively. Conclusions: 72 Gy was the maximum dose that could be achieved in most patients, given the predetermined normal tissue constraints.

Sekine, Ikuo, E-mail: isekine@ncc.go.jp [Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo (Japan); Sumi, Minako; Ito, Yoshinori [Division of Radiation Oncology, National Cancer Center Hospital, Tokyo (Japan); Horinouchi, Hidehito; Nokihara, Hiroshi; Yamamoto, Noboru; Kunitoh, Hideo; Ohe, Yuichiro; Kubota, Kaoru; Tamura, Tomohide [Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo (Japan)

2012-02-01

162

Phase II Trial of Combined Modality Therapy With Concurrent Topotecan Plus Radiotherapy Followed by Consolidation Chemotherapy for Unresectable Stage III and Selected Stage IV Non-Small-Lung Cancer  

SciTech Connect

Purpose: The optimal combination of chemotherapy and radiotherapy (RT) and the role of consolidation chemotherapy in patients with locally advanced non-small-cell lung cancer (NSCLC) are unknown. Topotecan is active against NSCLC, can safely be combined with RT at effective systemic doses, and can be given by continuous infusion, making it an attractive study agent against locally advanced NSCLC. Methods and Materials: In this pilot study, 20 patients were treated with infusion topotecan 0.4 mg/m{sup 2}/d with three-dimensional conformal RT to 63 Gy both delivered Monday through Friday for 7 weeks. Patients without progression underwent consolidation chemotherapy with etoposide and a platinum agent for one cycle followed by two cycles of docetaxel. The study endpoints were treatment response, time to progression, survival, and toxicity. Results: Of the 20 patients, 19 completed induction chemoradiotherapy and 13 completed consolidation. Of the 20 patients, 18 had a partial response and 1 had stable disease after induction chemoradiotherapy. The 3-year overall survival rate was 32% (median, 18 months). The local and distant progression-free survival rate was 30% (median, 21 months) and 58% (median, not reached), respectively. Three patients developed central nervous system metastases, 1 within 228 days, 1 within 252 days, and 1 within 588 days. Three patients had pulmonary emboli. Therapy was well tolerated with 1 of 20 developing Grade 4 lymphopenia. Grade 3 hematologic toxicity was seen in 17 of 20 patients but was not clinically significant. Other Grade 3 toxicities included esophagitis in 3, esophageal stricture in 2, fatigue in 8, and weight loss in 1. Grade 3 pneumonitis occurred in 6 of 20 patients. Conclusion: Continuous infusion topotecan with RT was well tolerated and active in the treatment of poor-risk patients with unresectable Stage III NSCLC.

Seung, Steven K. [Oregon Clinic, Portland, OR (United States); Department of Radiation Oncology, Earle A. Chiles Research Institute, Portland, OR (United States)], E-mail: steven.seung@providence.org; Ross, Helen J. [Mayo Clinic, Scottsdale, AZ (United States)

2009-03-01

163

Direct Diffusion of cfVDiamminedichloroplatinum(II) in Intraperitoneal Rat Tumors after Intraperitonal Chemotherapy: A Comparison with Systemic Chemotherapy1  

Microsoft Academic Search

Chemotherapy i.p. is increasingly being tested as a treatment modality for cancer limited to the peritoneal cavity. We have developed a rat tumor model in which penetration and distribution of m-diamminedichloropla- tinum(II) into intraperitoneal tumors have been studied. The platinum concentration in intraperitoneal tumor nodules, measured by two tech niques, flame-lossatomic absorption spectroscopy and proton-induced X- ray emission, was always

Gerrit Los; Peter H. A. Mutsaers; Wim J. F. van der Vijgh; Glenn S. Baldew; Peter W. de Graaf; J. Gordon MeVie

164

Algorithms incorporating concurrency and caching  

E-print Network

This thesis describes provably good algorithms for modern large-scale computer systems, including today's multicores. Designing efficient algorithms for these systems involves overcoming many challenges, including concurrency ...

Fineman, Jeremy T

2009-01-01

165

Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for Successful Systemic Oncolytic Virotherapy  

PubMed Central

We have previously reported that a burst of vascular endothelial growth factor (VEGF) signaling to tumor-associated endothelium induces a proviral state, during which systemically delivered oncolytic reovirus can replicate in endothelium, thereby inducing immune-mediated vascular collapse and significant antitumor therapy. Using chimeric receptors, we show here that induction of the proviral state proceeds through VEGFR2, but not VEGFR1, signaling in endothelial cells. In contrast, innate immune activation by reovirus-exposed endothelial cells was predominantly through VEGFR1. By screening conventional chemotherapies for their ability to induce similar effects in combination with reovirus both in vitro and in vivo, we observed that the proviral state could also be induced in endothelial cells exposed to VEGF during rebound from paclitaxel-mediated inhibition of VEGF signaling. We translated these in vitro findings in vivo by careful scheduling of paclitaxel chemotherapy with systemic virotherapy, neither of which alone had therapeutic effects against B16 tumors. Systemic availability of reovirus during endothelial cell recovery from paclitaxel treatment allowed for endothelial replication of the virus, immune-mediated therapy, and tumor cures. Therefore, careful scheduling of combination viro- and chemotherapies, which preclinical testing suggests are individually ineffective against tumor cells, can lead to rational new clinical protocols for systemic treatments with oncolytic viruses. PMID:21792179

Kottke, Timothy; Chester, John; Ilett, Elizabeth; Thompson, Jill; Diaz, Rosa; Coffey, Matt; Selby, Peter; Nuovo, Gerard; Pulido, Jose; Mukhopadhyay, Debabrata; Pandha, Hardev; Harrington, Kevin; Melcher, Alan; Vile, Richard

2011-01-01

166

Acute Myeloid Leukemia: Nanomedicine drug delivery system could improve chemotherapy  

E-print Network

by their cardiotoxicity and the development of drug-resistance of tumors. In addition, the efficiency of anthracyclines the pharmacological properties of anthracyclines, a novel nanomedicine drug delivery system has been developed reputation for innovative research, interdisciplinarity and successful training. Its 4 faculties (Engineering

Pfeifer, Holger

167

Integration of system-level optimization with concurrent engineering using parametric subsystem modeling  

E-print Network

The introduction of concurrent design practices to the aerospace industry has greatly increased the efficiency and productivity of engineers during design sessions. Teams that are well-versed in such practices such as JPL's ...

Schuman, Todd, 1979-

2004-01-01

168

Curative-intent stereotactic body radiation therapy for residual breast cancer liver metastasis after systemic chemotherapy.  

PubMed

Liver metastases from breast cancer are generally treated with systemic therapy such as chemotherapy or hormonotherapy. However, local treatment options such as resection, radiofrequency ablation (RFA), and radiotherapy can also be considered to treat oligometastases. We report the case of a 45-year-old female treated with stereotactic body radiotherapy (SBRT) after chemotherapy against a solitary liver metastasis from primary breast cancer. A liver metastasis with diameter of 35 mm developed 3.5 years after surgery for primary breast cancer in 2004. Fourteen courses of triweekly docetaxel treatments considerably decreased the metastatic lesion, but there still remained a tiny lesion radiographically. Chemotherapy was stopped because of the side-effects of docetaxel, and then SBRT was selected for additional treatment, aiming at complete cure of metastasis. X-ray irradiation (52.8 Gy/4 fractions) was applied to the remaining metastatic lesion, and magnetic resonance imaging (MRI) showed no evidence of residual tumor 4 months after irradiation. Neither regrowth nor recurrences have been found until now, 24 months after SBRT. SBRT for oligometastases of breast cancer may be one of the possible curative-intent options, being less invasive than surgical resection or RFA. PMID:21728002

Kagara, Naofumi; Nakano, Yoshiaki; Watanabe, Ami; Inatome, Junichi; Nakamura, Hidetoshi; Kim, Chiwan; Danno, Katsuki; Taniguchi, Hirokazu; Kanoh, Toshiyuki; Kimura, Yutaka; Ohnishi, Tadashi; Tono, Takeshi; Monden, Takushi; Imaoka, Shingi; Kagawa, Kazufumi

2014-11-01

169

Chemotherapy Effects  

MedlinePLUS

... our Understanding Chemotherapy guide that discusses chemotherapy side effects. Home Care for the Cancer Patient: Chemotherapy This section of our Home Care guide provides a brief overview of chemotherapy and managing some of its side effects. Chemo Brain The mental cloudiness some people notice ...

170

Concurrency A Dialogue on Concurrency  

E-print Network

is it with you and peaches? Professor: Ever read T.S. Eliot? The Love Song of J. Alfred Prufrock, "Do I dare starting to impress. In fact, you just told us everything we need to know about concurrency! Well done to eat a peach", and all that fun stuff? Student: Oh yes! In English class in high school. Great stuff! I

Arpaci-Dusseau, Remzi

171

A Concurrency and Time Centered Framework for Certification of Autonomous Space Systems  

E-print Network

are data structures that are designed to provide the flexibility and usability of the popular ISO C++ STL containers, while at the same time they are hand-crafted to guarantee domain-specific policies, such as conformance to a given concurrency model...

Dechev, Damian

2010-07-14

172

Synthesis of Concurrent Systems for an Atomic Read / Atomic Write Model of Computation  

E-print Network

. Allen EMERSON z Department of Computer Sciences The University of Texas at Austin emerson of a decision procedure for testing temporal satisfiability have been proposed by Emerson and Clarke [EC82. The synthesis method of Emerson and Clarke [EC82] produces concurrent pro­ grams for the shared memory model

Emerson, E. Allen

173

Benchmarking an interdisciplinary concurrent design methodology for electronic\\/mechanical systems  

Microsoft Academic Search

The paper describes the evolution of an Interdisciplinary Concurrent Design Methodology (ICDM) and the metrics used to compare four generations of wearable computer artifacts produced by the methodology at each stage of ICDM's growth. The product cycle is defined, its phases, and the design informa- tion representation for each phase. Six generic axes of design activity are defined, and the

Asim Smailagic; Daniel P. Siewiorek; Drew Anderson; Chris Kasaback; Thomas L. Martin; John Stivoric

1995-01-01

174

Behavioral Approach System (BAS) Sensitivity and Bipolar Spectrum Disorders: A Retrospective and Concurrent Behavioral High-Risk Design  

Microsoft Academic Search

In this article, we tested the vulnerability hypothesis of the behavioral approach system (BAS) hypersensitivity model of\\u000a bipolar disorders. We examined whether self-reported BAS sensitivity predicts lifetime bipolar spectrum diagnoses as well\\u000a as symptoms and personality characteristics associated with bipolar disorder using a retrospective and concurrent behavioral\\u000a high-risk design. Participants with high (HBAS; n=28) or moderate (MBAS; n=24) BAS sensitivity

Lauren B. Alloy; Lyn Y. Abramson; Patricia D. Walshaw; Alex Cogswell; Jeannette M. Smith; Amy M. Neeren; Megan E. Hughes; Brian M. Iacoviello; Rachel K. Gerstein; Jessica Keyser; Snezana Urosevic; Robin Nusslock

2006-01-01

175

Concurrent validity and intrasession reliability of the IDEEA accelerometry system for the quantification of spatiotemporal gait parameters.  

PubMed

The aim of this pilot study was to evaluate concurrent validity and intrasession reliability of the IDEEA (Minisun, Fresno, CA) accelerometry system (and associated software) with force plate measurements for spatiotemporal gait variables recorded during normal walking. Ten healthy individuals were asked to walk at a self-selected comfortable speed, over five multicomponent force plates embedded into the walkway floor. For each trial, spatiotemporal gait parameters (single support time, cadence, speed, step and stride length) obtained by the force plates were compared to those recorded by IDEEA. Concurrent (criterion-related) validity between the two systems was analysed with intraclass correlation (ICC) (2,1). Intrasession reliability was quantified by using coefficient of variations (CV) and ICC. For the ensemble of the parameters, ICC (2,1) ranged between 0.998 (cadence) and 0.784 (step length right) (p<0.001-0.01). However, speed, step length and stride length were significantly lower for IDEEA (~7%; p<0.001) compared to force plate data. Intrasession reliability of IDEEA was excellent, with CV lower than 5.7 and ICC higher than 0.961. The present accelerometry system demonstrated strong concurrent validity for the assessment of spatiotemporal gait parameters. However, spatial variables (stride and step length) and walking speed were significantly underestimated compared with analyses using force plates. PMID:17336070

Maffiuletti, Nicola A; Gorelick, Mark; Kramers-de Quervain, Ines; Bizzini, Mario; Munzinger, Jeannette Petrich; Tomasetti, Samuele; Stacoff, Alex

2008-01-01

176

Dynamic programming methods for concurrent design and dynamic allocation of vehicles embedded in a system-of-systems  

NASA Astrophysics Data System (ADS)

Recent developments indicate a changing perspective on how systems or vehicles should be designed. Such transition comes from the way decision makers in defense related agencies address complex problems. Complex problems are now often posed in terms of the capabilities desired, rather than in terms of requirements for a single systems. As a result, the way to provide a set of capabilities is through a collection of several individual, independent systems. This collection of individual independent systems is often referred to as a "System of Systems'' (SoS). Because of the independent nature of the constituent systems in an SoS, approaches to design an SoS, and more specifically, approaches to design a new system as a member of an SoS, will likely be different than the traditional design approaches for complex, monolithic (meaning the constituent parts have no ability for independent operation) systems. Because a system of system evolves over time, this simultaneous system design and resource allocation problem should be investigated in a dynamic context. Such dynamic optimization problems are similar to conventional control problems. However, this research considers problems which not only seek optimizing policies but also seek the proper system or vehicle to operate under these policies. This thesis presents a framework and a set of analytical tools to solve a class of SoS problems that involves the simultaneous design of a new system and allocation of the new system along with existing systems. Such a class of problems belongs to the problems of concurrent design and control of a new systems with solutions consisting of both optimal system design and optimal control strategy. Rigorous mathematical arguments show that the proposed framework solves the concurrent design and control problems. Many results exist for dynamic optimization problems of linear systems. In contrary, results on optimal nonlinear dynamic optimization problems are rare. The proposed framework is equipped with the set of analytical tools to solve several cases of nonlinear optimal control problems: continuous- and discrete-time nonlinear problems with applications on both optimal regulation and tracking. These tools are useful when mathematical descriptions of dynamic systems are available. In the absence of such a mathematical model, it is often necessary to derive a solution based on computer simulation. For this case, a set of parameterized decision may constitute a solution. This thesis presents a method to adjust these parameters based on the principle of stochastic approximation simultaneous perturbation using continuous measurements. The set of tools developed here mostly employs the methods of exact dynamic programming. However, due to the complexity of SoS problems, this research also develops suboptimal solution approaches, collectively recognized as approximate dynamic programming solutions, for large scale problems. The thesis presents, explores, and solves problems from an airline industry, in which a new aircraft is to be designed and allocated along with an existing fleet of aircraft. Because the life cycle of an aircraft is on the order of 10 to 20 years, this problem is to be addressed dynamically so that the new aircraft design is the best design for the fleet over a given time horizon.

Nusawardhana

177

The effects of concurrent task interference on category learning: Evidence for multiple category learning systems  

Microsoft Academic Search

Participants learned simple and complex category structures under typical single-task conditions and when performing a simultaneous\\u000a numerical Stroop task. In the simple categorization tasks, each set of contrasting categories was separated by a unidimensional\\u000a explicit rule, whereas the complex tasks required integrating information from three stimulus dimensions and resulted in implicit\\u000a rules that were difficult to verbalize. The concurrent Stroop

Elliott M. Waldron; F. Gregory Ashby

2001-01-01

178

Concurrent, Overlapping Development and the Dynamic System Analysis of a Software Project  

Microsoft Academic Search

In recent years concurrent, overlapping development activities of engineering tasks have proved to be a cost-effective and time-efficient way to build products geared toward meeting the demands of a competitive and quality-conscious market. In this study, we examine the structure and dynamics of a software project in information technology industrial research and development that has this methodology as its foundation.

Jaideep Ghosh

2010-01-01

179

Cancer Chemotherapy  

MedlinePLUS

... cells grow and die in a controlled way. Cancer cells keep forming without control. Chemotherapy is drug ... Your course of therapy will depend on the cancer type, the chemotherapy drugs used, the treatment goal ...

180

Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer.  

PubMed

Adjuvant treatment for early breast cancer is an evolving field. Since the advent of the initial cyclophosphamide, methotrexate and 5-fluorouracil (CMF) regimens, which reduced risk for recurrence and death, anthracyclines and subsequently taxanes were added to the cytotoxic armamentarium for use sequentially or in combination in the adjuvant setting. The efficacy and toxicity of each chemotherapy regimen must be viewed within the context of host co-morbidities and the specific biologic phenotype of the tumor. In the era of mammographic screening, small, node-negative breast cancer is the most frequent presentation of the disease. Patient selection for adjuvant chemotherapy has become a key issue. Traditional prognostic factors continue to be of value in determining the risk for relapse, but new and sophisticated genomic tools (such as Oncotype Dx and Mammaprint) are now available and may improve our ability to select patients. For those patients who do require adjuvant chemotherapy, the 'one size fits all' paradigm should never again feature in the treatment of early breast cancer, following the important insights yielded by biomarker research to identify those who will benefit the most from a particular drug. In this review we focus on some of the current controversies and potential future steps in adjuvant chemotherapy for treatment of early breast cancer. PMID:19344489

López-Tarruella, Sara; Martín, Miguel

2009-01-01

181

Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas  

PubMed Central

The prognosis of patients with central nervous system relapse of aggressive lymphoma is very poor with no therapy established so far. In a prospective multicenter phase II study, we evaluated a potentially curative chemotherapy-only regimen in these patients. Adult immunocompetent patients 65 years of age or under received induction chemotherapy with MTX/IFO/DEP (methotrexate 4 g/m2 intravenously (i.v.) Day 1, ifosfamide 2 g/m2 i.v. Days 3– 5 and liposomal cytarabine 50 mg intrathecally (i.th) Day 6) and AraC/TT/DEP (cytarabine 3g/m2 i.v. Days 1–2, thiotepa 40 mg/m2 i.v. Day 2 and i.th. liposomal cytarabine 50 mg i.th. Day 3) followed by high-dose chemotherapy with carmustine 400 mg/m2 i.v. Day ?5, thiotepa 2×5 mg/kg i.v. Days ?4 to ?3 and etoposide 150 mg/m2 i.v. Days ?5 to ?3, and autologous stem cell transplantation Day 0 (HD-ASCT). Thirty eligible patients (median age 58 years) were enrolled. After HD-ASCT (n=24), there was a complete remission in 15 (63%), partial remission in 2 (8%) and progressive disease in 7 (29%) patients. Myelotoxicity was the most adverse event with CTC grade 3/4 infections in 12% of MTX/IFO/DEP courses, 21% of AraC/TT/DEP courses and 46% of HD-ASCT courses. The 2-year time to treatment failure was 49%±19 for all patients and 58%±22 for patients completing HD-ASCT. The protocol assessed proved feasible and highly active with long-lasting remissions in a large proportion of patients. (ClinicalTrials.govIdentifier NCT01148173) PMID:23242601

Korfel, Agnieszka; Elter, Thomas; Thiel, Eckhard; Hänel, Matthias; Möhle, Robert; Schroers, Roland; Reiser, Marcel; Dreyling, Martin; Eucker, Jan; Scholz, Christian; Metzner, Bernd; Röth, Alexander; Birkmann, Josef; Schlegel, Uwe; Martus, Peter; Illerhaus, Gerard; Fischer, Lars

2013-01-01

182

Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas.  

PubMed

The prognosis of patients with central nervous system relapse of aggressive lymphoma is very poor with no therapy established so far. In a prospective multicenter phase II study, we evaluated a potentially curative chemotherapy-only regimen in these patients. Adult immunocompetent patients 65 years of age or under received induction chemotherapy with MTX/IFO/DEP (methotrexate 4 g/m(2) intravenously (i.v.) Day 1, ifosfamide 2 g/m(2) i.v. Days 3- 5 and liposomal cytarabine 50 mg intrathecally (i.th) Day 6) and AraC/TT/DEP (cytarabine 3g/m(2) i.v. Days 1-2, thiotepa 40 mg/m(2) i.v. Day 2 and i.th. liposomal cytarabine 50 mg i.th. Day 3) followed by high-dose chemotherapy with carmustine 400 mg/m(2) i.v. Day -5, thiotepa 2×5 mg/kg i.v. Days -4 to -3 and etoposide 150 mg/m(2) i.v. Days -5 to -3, and autologous stem cell transplantation Day 0 (HD-ASCT). Thirty eligible patients (median age 58 years) were enrolled. After HD-ASCT (n=24), there was a complete remission in 15 (63%), partial remission in 2 (8%) and progressive disease in 7 (29%) patients. Myelotoxicity was the most adverse event with CTC grade 3/4 infections in 12% of MTX/IFO/DEP courses, 21% of AraC/TT/DEP courses and 46% of HD-ASCT courses. The 2-year time to treatment failure was 49%±19 for all patients and 58%±22 for patients completing HD-ASCT. The protocol assessed proved feasible and highly active with long-lasting remissions in a large proportion of patients. (ClinicalTrials.govIdentifier NCT01148173). PMID:23242601

Korfel, Agnieszka; Elter, Thomas; Thiel, Eckhard; Hänel, Matthias; Möhle, Robert; Schroers, Roland; Reiser, Marcel; Dreyling, Martin; Eucker, Jan; Scholz, Christian; Metzner, Bernd; Röth, Alexander; Birkmann, Josef; Schlegel, Uwe; Martus, Peter; Illerhaus, Gerard; Fischer, Lars

2013-03-01

183

Sensors 2000! Program: Advanced Biosensor and Measurement Systems Technologies for Spaceflight Research and Concurrent, Earth-Based Applications  

NASA Technical Reports Server (NTRS)

Sensors 2000! (S2K!) is a specialized, integrated projects team organized to provide focused, directed, advanced biosensor and bioinstrumentation systems technology support to NASA's spaceflight and ground-based research and development programs. Specific technology thrusts include telemetry-based sensor systems, chemical/ biological sensors, medical and physiological sensors, miniaturized instrumentation architectures, and data and signal processing systems. A concurrent objective is to promote the mutual use, application, and transition of developed technology by collaborating in academic-commercial-govemment leveraging, joint research, technology utilization and commercialization, and strategic partnering alliances. Sensors 2000! is organized around three primary program elements: Technology and Product Development, Technology infusion and Applications, and Collaborative Activities. Technology and Product Development involves development and demonstration of biosensor and biotelemetry systems for application to NASA Space Life Sciences Programs; production of fully certified spaceflight hardware and payload elements; and sensor/measurement systems development for NASA research and development activities. Technology Infusion and Applications provides technology and program agent support to identify available and applicable technologies from multiple sources for insertion into NASA's strategic enterprises and initiatives. Collaborative Activities involve leveraging of NASA technologies with those of other government agencies, academia, and industry to concurrently provide technology solutions and products of mutual benefit to participating members.

Hines, J.

1999-01-01

184

The Concurrency Column  

Microsoft Academic Search

Process calculi like ACP, CCS, CSP and various flavours of the ?-calculus are popular specification formalisms for concurrent, distribu ted and possibly mo- bile systems. The semantic theory of process calculi has been the subject of extensive investigation for about twenty five years now, and several robust, general principles and results applying to a variety of different formalisms have been

Luca Aceto

185

The PVM (Parallel Virtual Machine) system: Supercomputer level concurrent computation on a network of IBM RS/6000 power stations  

SciTech Connect

The PVM (Parallel Virtual Machine) system enables supercomputer level concurrent computations to be performed on interconnected networks of heterogeneous computer systems. Specifically, a network of 13 IBM RS/6000 powerstations has been successfully used to execute production quality runs of superconductor modeling codes at more than 250 Mflops. This work demonstrates the effectiveness of cooperative concurrent processing for high performance applications, and shows that supercomputer level computations may be attained at a fraction of the cost on distributed computing platforms. This paper describes the PVM programming environment and user facilities, as they apply to hardware platforms comprising a network of IBM RS/6000 powerstations. The salient design features of PVM will be discussed; including heterogeneity, scalability, multilanguage support, provisions for fault tolerance, the use of multiprocessors and scalar machines, an interactive graphical front end, and support for profiling, tracing, and visual analysis. The PVM system has been used extensively, and a range of production quality concurrent applications have been successfully executed using PVM on a variety of networked platforms. The paper will mention representative examples, and discuss two in detail. The first is a material sciences problem that was originally developed on a Cray 2. This application code calculates the electronic structure of metallic alloys from first principles and is based on the KKR-CPA algorithm. The second is a molecular dynamics simulation for calculating materials properties. Performance results for both applicants on networks of RS/6000 powerstations will be presented, and accompanied by discussions of the other advantages of PVM and its potential as a complement or alternative to conventional supercomputers.

Sunderam, V.S. (Emory Univ., Atlanta, GA (USA). Dept. of Mathematics and Computer Science); Geist, G.A. (Oak Ridge National Lab., TN (USA))

1991-01-01

186

Sustained Intraperitoneal Chemotherapy via an Injectable Depot Delivery System for the Treatment of Ovarian Cancer.  

E-print Network

??Ovarian cancer has the highest mortality rate of all gynecological malignancies, due to inadequate treatment strategies and poor early diagnosis. Intraperitoneal (IP) chemotherapy administered on… (more)

Zahedi, Payam

2012-01-01

187

CONCURRENT CHEMORADIATION FOR ESOPHAGEAL CARCINOMA: PRELIMINARY RESULTS  

Microsoft Academic Search

Despite all advances, treatment of esophageal carcinoma is still unsatisfactory. Currently the standard non-surgical treatment of esophageal cancer is concurrent chemotherapy and radiotherapy (chemoradiation), with results comparable to best surgical series. A few years ago, we started a chemoradiation protocol for the cancer of esophagus as a curative treatment, of which we present the preliminary results here. Files of all

P. Haddad; F. Amouzgar-Hashemi

188

Concurrent manipulation of binary search trees  

Microsoft Academic Search

The concurrent manipulation of a binary search tree is considered in this paper. The systems presented can support any number of concurrent processes which perform searching, insertion, deletion, and rotation (reorganization) on the tree, but allow any process to lock only a constant number of nodes at any time. Also, in the systems, searches are essentially never blocked. The concurrency

H. T. Kung; Philip L. Lehman

1980-01-01

189

Frequency-domain fluorescence lifetime optrode system design and instrumentation without a concurrent reference light-emitting diode.  

PubMed

We report the design, development, and implementation of an improved instrumentation approach for frequency-domain fluorescence lifetime (FDFL) optrodic sensing without a concurrent reference LED. FDFL traditionally uses a reference LED, at approximately the same wavelength as the sensor fluorophore emission, to measure phase shifts associated with changes in the fluorescence lifetime of fluorophore. For this work we used an oxygen optrode to design, develop, and test the reference-LED-free FDFL approach. Electronics and optics were optimized, and key system parameters, such as inherent system phase shifts, were determined to insure best performance. In our tests with the oxygen optrode, we observed that several key performance characteristics were improved by the implementation of the reference-LED-free instrumentation platform. This system can potentially be adapted to other analyte-selective fluorophores, which will enable scientists and researchers to expand the application of optrodic sensors as basic research tools in biology, medicine, and agriculture. PMID:19823237

Chatni, Mohammad Rameez; Li, Gang; Porterfield, David Marshall

2009-10-10

190

Complications Encountered with a Transfemorally Placed Port-Catheter System for Hepatic Artery Chemotherapy Infusion  

SciTech Connect

A port-catheter system was implanted via femoral artery access for hepatic artery chemotherapy infusion. Implantation was attempted in 90 patients and was successful in 88. Blood flow redistribution was performed using embolization coils. In the first ten patients a soft heparin-coated infusion catheter was used. For the following 78 patients we used a stiffer catheter coated with fluorine-acryl-styrene-urethane-silicone (FASUS) copolymer. The catheter was connected to a port implanted subcutaneously below the level of the inguinal ligament. Complications during the procedure and after placement were observed in 7 of 90 patients and 24 of 88 patients, respectively. These included catheter obstruction (11%), dislocation of the catheter tip (10%), drug toxicity (5.7%), and catheter infection (3.4%). In 6 of 10 patients with catheter obstruction, recanalization of the port system was achieved. In 7 of 9 patients with dislocation of the indwelling catheter tip, replacement of the port system was successful. Our complications appear to be comparable with those encountered with the subclavian/brachial approach when the new catheter coating is used. Notable is the avoidance of cerebral infarcts.

Kuroiwa, Toshiro; Honda, Hiroshi; Yoshimitsu, Kengo; Irie, Hiroyuki; Aibe, Hitoshi; Tajima, Tsuyoshi; Shinozaki, Kenji; Masuda, Kouji [Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 (Japan)

2001-03-15

191

Chemotherapy in penile cancer.  

PubMed

Penile cancer is an aggressive disease and after systemic progression it is virtually incurable. While this squamous cell cancer responds to chemotherapy, successful treatment of lymphatic metastases can only be achieved with aggressive surgical treatment in combination with chemotherapy. However, because penile carcinoma is relatively rare there is a paucity of clinical data on the chemotherapy for this aggressive disease. Recent advances have included the establishment of less toxic regimens incorporating taxanes, while cisplatinum remains central to all regimens. Multi-institutional studies are urgently needed to advance the multimodal care for patients with penile cancer. PMID:22654965

Hakenberg, Oliver W; Protzel, Chris

2012-06-01

192

Chemotherapy in penile cancer  

PubMed Central

Penile cancer is an aggressive disease and after systemic progression it is virtually incurable. While this squamous cell cancer responds to chemotherapy, successful treatment of lymphatic metastases can only be achieved with aggressive surgical treatment in combination with chemotherapy. However, because penile carcinoma is relatively rare there is a paucity of clinical data on the chemotherapy for this aggressive disease. Recent advances have included the establishment of less toxic regimens incorporating taxanes, while cisplatinum remains central to all regimens. Multi-institutional studies are urgently needed to advance the multimodal care for patients with penile cancer. PMID:22654965

Protzel, Chris

2012-01-01

193

A novel nanoscale delivery system for spatio-temporal delivery of combination chemotherapy  

E-print Network

In the continuing search for effective treatments for cancer, the emerging model is the combination of traditional chemotherapy with anti-angiogenesis agents that inhibit blood vessel growth. However, the implementation ...

Eavarone, David A. (David Alan)

2009-01-01

194

Adjuvant Chemotherapy in Primary Breast Cancer  

Microsoft Academic Search

Adjuvant systemic chemotherapy reduces the risk of relapse by about 25%. In hormone receptor-negative tumors, adjuvant chemotherapy is considered standard, independent of age or lymph node status. In hormone receptor- positive disease, an indication for adjuvant chemotherapy is given in patients at increased risk of relapse. Endocrine therapy should then be administered sequentially after chemotherapy. Anthracyclines are considered standard adjuvant

Nadia Harbeck; Gunter von Minckwitz

2006-01-01

195

Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study  

Microsoft Academic Search

Brain gray matter alterations have been reported in cross-sectional magnetic resonance imaging (MRI) studies of breast cancer\\u000a patients after cancer treatment. Here we report the first prospective MRI study of women undergoing treatment for breast cancer,\\u000a with or without chemotherapy, as well as healthy controls. We hypothesized that chemotherapy-associated changes in gray matter\\u000a density would be detectable 1 month after treatment,

Brenna C. McDonaldSusan; Susan K. Conroy; Tim A. Ahles; John D. West; Andrew J. Saykin

2010-01-01

196

Functional Assessment of a Skin Care System in Patients on Chemotherapy  

Microsoft Academic Search

Background\\/Purpose: Cancer patients undergoing chemotherapy frequently experience skin problems such as xerosis. The aim of this study was to verify whether a concomitant treatment with an acidic washing and an acidic emollient (both pH 5.5) can significantly improve the quality of the skin in such patients. Methods: 30 adult patients on chemotherapy experiencing dry and sensitive skin were included in

J. W. Fluhr; M. Miteva; G. Primavera; M. Ziemer; P. Elsner; E. Berardesca

2007-01-01

197

Concurrent engineering  

NASA Technical Reports Server (NTRS)

The following subject areas are covered: issues (liquid rocket propulsion - current development approach, current certification process, and costs of engineering changes); state of the art (DICE information management system, key government participants, project development strategy, quality management, and numerical propulsion system simulation); needs identified; and proposed program.

Chamis, C. C.; Leger, L.; Hunter, D.; Jones, C.; Sprague, R.; Berke, L.; Newell, J.; Singhal, S.

1991-01-01

198

The Concurrency Control Mechanism of SDD1: A System for Distributed Databases (The Fully Redundant Case)  

Microsoft Academic Search

SDD-1, A System for Distributed Databases, is a distributed database system being developed by Computer Corporation of America (CCA), Cambridge, MA. SDD-1 permits data to be stored redundantly at several database sites in order to enhance the reliability and responsiveness of the system and to facilitate upward scaling of system capacity. This paper describes the method used by SDD-1 for

Philip A. Bernstein; James B. Rothnie Jr.; Nathan Goodman; Christos H. Papadimitriou

1978-01-01

199

Surviving Chemotherapy  

NSDL National Science Digital Library

Lecture outlinne, with embedded notes, to serve as a starting point for in-class discussion, student research and presentation. Lecture provides a review of cancer, chemotherapy, risk factors for cancer, and correlations between all and nutrition.

Dr. Margaret A McMichael (Baton Rouge Community College Biological Sciences)

2008-08-15

200

Concurrent Validity and Test-retest Reliability of the OPTOGait Photoelectric Cell System for the Assessment of Spatio-temporal Parameters of the Gait of Young Adults  

PubMed Central

[Purpose] The purpose of this study was to investigate the concurrent validity and test-retest reliability of the recently introduced OPTOGait Photoelectric Cell System for the assessment of spatio-temporal parameters of gait. [Subjects] Twenty healthy young adults (mean age = 27.35, SD = 7.4) were asked to walk 3 times on walkway at a comfortable speed. [Methods] Concurrent validity was assessed by comparing data obtained using the OPTOGait and GAITRite systems, and reliability was assessed by comparing data from the first and third OPTOGait sessions. [Results] Concurrent validity, as identified by intra-class correlation coefficients (ICC (2, 1) = 0.929–0.998), coefficients of variation (CVME = 0.32–11.30%), and 95% limits of agreement, showed high levels of correlation. In addition, the test-retest reliability of the OPTOGait Photoelectric Cell System was demonstrated as showing a high level of correlation with all spatio-temporal parameters by intra-class correlation coefficients (ICC (3, 1) = 0.785–0.952), coefficients of variation (CVME = 1.66–4.06%), 95% limits of agreement, standard error of measurement (SEM = 2.17–5.96%), and minimum detectable change (MDC95% = 6.01–16.52%). [Conclusion] The OPTOGait Photoelectric Cell System has strong concurrent validity along with relative and absolute test-retest reliabilities. This portable system with easy-to-use features can be used for clinical assessments or research purposes as an objective means of assessing gait. PMID:24567681

Lee, Myung Mo; Song, Chang Ho; Lee, Kyoung Jin; Jung, Sang Woo; Shin, Doo Chul; Shin, Seung Ho

2014-01-01

201

Concurrent Computing  

NSDL National Science Digital Library

* a preliminary introduction to essential networking concepts, * parallel computing and types of parallel computers, * basics of message-passing parallel computing,* embarrassingly parallel computations,* partitioning and divide-and-conquer strategies,* pipelined computations, * synchronous computations,* programming with shared memory, pthreads,* parallel sorting algorithms,* numerical algorithms,* searching and optimization,* distributed computing using grids,* networks for high-performance cluster computing, and * parallel I/O and parallel file systems.

Apon, Amy

202

Tornado: Maximizing Locality and Concurrency in a Shared Memory Multiprocessor Operating System  

Microsoft Academic Search

We describe the design and implementation of Tornado, a new operating system designed from the ground up specifically for today's shared memory multiprocessors. The need for im- proved locality in the operating system is growing as multipro- cessor hardware evolves, increasing the costs for cache misses and sharing, and adding complications due to NUMAness. Tor- nado is optimized so that

Benjamin Gamsa; Orran Krieger; Jonathan Appavoo; Michael Stumm

1999-01-01

203

Considerations for Monitoring Highly Concurrent Systems Ruth Mizzi Christian Colombo Adrian Francalanza Gordon Pace  

E-print Network

to the properties they embody. 1. INTRODUCTION The extensive use of software systems in everyday operations requires parallel resources would lie idle waiting for sequential monitor feedback. To address this (and other to runtime monitor real-life sys- tems [3], monitoring properties over parts of the system which run

Francalanza, Adrian

204

A Concurrent Implementation of the Cascade-Correlation Algorithm, Using the Time Warp Operating System  

NASA Technical Reports Server (NTRS)

This paper discusses the method in which the Cascade-Correlation algorithm was parallelized in such a way that it could be run using the Time Warp Operating System (TWOS). TWOS is a special purpose operating system designed to run parellel discrete event simulations with maximum efficiency on parallel or distributed computers.

Springer, P.

1993-01-01

205

Clinical Analysis for Brain Tumor-Related Epilepsy during Chemotherapy for Systemic Cancer with Single Brain Metastasis  

PubMed Central

Purpose The purpose of this prospective observational study was to determine the incidence, patterns, and predisposing factors for brain tumor-related epilepsy (BTRE) during chemotherapy for systemic cancer with single brain metastasis (BM). Materials and Methods Between February 2006 and June 2010, 103 patients who underwent chemotherapy for systemic cancer with single BM were enrolled. We compared the clinical factors of patients and BM between patients with and without BTRE. We determined the number of patients with BTRE attacks, and seizure-free survival according to the following comparative groups: presence vs. absence of a history of BTRE; high-risk vs. low-risk groups; and presence vs. absence of disease-progression of BM. Results Ninety-three of 103 patients (90.3%) remained seizure-free during chemotherapy. The seizure-free rates were 88.9% and 91.0% among patients with or without a history of BTRE, respectively (p=0.694), 87.8% and 92.6% among high- and low-risk patients (p=0.427), respectively, and 62.5% and 98.7% among patients with or without disease-progression of BM (p=0.001), retrospectively. Based on multivariate analysis, the significance of abnormal findings on electroencephalogram (EEG) (p=0.017), and the absence of disease-progression of BM (p=0.001) had an association with seizure-free survival. Conclusion The significance of abnormal findings on EEG, and disease-progression of BM play important roles in the development of BTRE during chemotherapy for systemic cancer with BM. PMID:22022293

Lee, Eun Hee; Lee, Kyoung Soo

2011-01-01

206

Symbolically Modeling Concurrent MCAPI Executions  

NASA Technical Reports Server (NTRS)

Improper use of Inter-Process Communication (IPC) within concurrent systems often creates data races which can lead to bugs that are challenging to discover. Techniques that use Satisfiability Modulo Theories (SMT) problems to symbolically model possible executions of concurrent software have recently been proposed for use in the formal verification of software. In this work we describe a new technique for modeling executions of concurrent software that use a message passing API called MCAPI. Our technique uses an execution trace to create an SMT problem that symbolically models all possible concurrent executions and follows the same sequence of conditional branch outcomes as the provided execution trace. We check if there exists a satisfying assignment to the SMT problem with respect to specific safety properties. If such an assignment exists, it provides the conditions that lead to the violation of the property. We show how our method models behaviors of MCAPI applications that are ignored in previously published techniques.

Fischer, Topher; Mercer, Eric; Rungta, Neha

2011-01-01

207

Safe software processing by concurrent execution in a real-time operating system  

Microsoft Academic Search

The requirements for safety-related soft- ware systems increases rapidly. To detect arbitrary hardware faults, there are applicable coding mechanism, that add redundancy to the software. In this way it is possible to replace conventional multi-channel hardware and so reduce costs. Arithmetic codes are one possibility of coded processing and are used in this approach. A further approach to increase fault

Peter Raab; Stefan Kramer; Jurgen Mottok; Hans Meier; Stanislav Racek

2011-01-01

208

The concurrent validity of the career decision-making system cross-culturally  

Microsoft Academic Search

This paper compares the occupational codes on the Career Decision-Making System for people performing similar jobs in two countries. Codes for students in different college majors and vocational training programs are presented and are available for comparison with worker codes.

T. F. Harrington

1992-01-01

209

System Reliability Evaluation Using Concurrent MultiLevel Simulation of Structural Faults  

Microsoft Academic Search

This paper provides a methodology that leverages state-of-the-art techniques for efficient fault simulation of structural faults together with transaction level modeling. This way it is possible to accurately evaluate the impact of the faults on the entire hardware\\/software system.

Michael A. Kochte; Christian G. Zoellin; Rafal Baranowski; Michael E. Imhof; Hans-Joachim Wunderlich; Nadereh Hatami; Stefano Di Carlo; Paolo Prinetto

2010-01-01

210

Performance study of optimistic concurrency control schemes for distributed database systems  

E-print Network

. If the transaction does not conflict with others, then it is allowed to reflect its effects on the database. Otherwise, the transaction is aborted. When the majority of the transactions are read-only (query transactions), the policies with an optimistic... are the main components of the database system. Each data item has a value associated with it. The software modules sup- port commands to access the database, called operations, such as Read, Write, Start, Commit and Abort. A transaction is an execution...

Kim Lee, Hyunsoon

2012-06-07

211

A dynamic exposure system: Concurrent toluene inhalation and fixed ratio performance in mice  

SciTech Connect

The potential for occupational exposure to acute high doses of solvents, coupled with the rising incidence of inhalant abuse, necessitates the need to better characterize the behavioral effects of solvents. Vapor exposure was accomplished with a computer-controlled mass flow system where exposure levels were monitored by infrared spectroscopy. Twelve food-deprived CFW male mice were shaped to lever press for milk reinforcement under a FR20 schedule. Within-session concentration-effect relationships for toluene were determined by successive 5-minute exposures to 5 successively increasing concentrations, preceded by 5 minutes of air exposure. These results were compared to concentration-effect relationships determined by single concentration test sessions, utilizing 20-minute exposures, preceded and followed by 5 minutes of air exposure. Under the within-session method, very similar concentration related decreases in response rates were produced, regardless of whether the concentration range examined was 500-6,000 ppm or 125-2,000 ppm. Effects of toluene based upon exposure to single concentrations yielded a less sensitive effect for the concentration range 125-2,000 ppm. Return to baseline response rates were rapid, correlating well with the rapid rate of clearance classically exhibited by solvents. These results indicate that this dynamic mass flow system provides a sensitive and consistent means by which to measure the behavioral effects of inhalants and allows for a great deal of flexibility for rapid alteration of exposure conditions.

Tegeris, J.S.; Knisely, J.S.; Balster, R.L. (Medical Coll. of Virginia, Richmond (United States))

1990-02-26

212

IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses.  

PubMed

Central nervous system (CNS) autoimmunity such as uveitis and multiple sclerosis is accompanied by Th1 and Th17 responses. In their corresponding animal models, experimental autoimmune uveitis (EAU) and experimental autoimmune encephalomyelitis (EAE), both responses are induced and can drive disease independently. Because immune responses have inherent plasticity, therapeutic targeting of only one pathway could promote the other, without reducing pathology. IL-27p28 antagonizes gp130, required for signaling by IL-27 and IL-6, which respectively promote Th1 and Th17 responses. We therefore examined its ability to protect the CNS by concurrently targeting both effector responses. Overexpression of IL-27p28 in vivo ameliorated EAU as well as EAE pathology and reduced tissue infiltration by Th1 and Th17 cells in a disease prevention, as well as in a disease reversal protocol. Mechanistic studies revealed inhibition of Th1 and Th17 commitment in vitro and decreased lineage stability of pre-formed effectors in vivo, with reduction in expression of gp130-dependent transcription factors and cytokines. Importantly, IL-27p28 inhibited polarization of human T cells to the Th1 and Th17 effector pathways. The ability of IL-27p28 to inhibit generation as well as function of pathogenic Th1 and Th17 effector cells has therapeutic implications for controlling immunologically complex autoimmune diseases. PMID:24021664

Chong, Wai Po; Horai, Reiko; Mattapallil, Mary J; Silver, Phyllis B; Chen, Jun; Zhou, Ru; Sergeev, Yuri; Villasmil, Rafael; Chan, Chi-Chao; Caspi, Rachel R

2014-05-01

213

Slicing Concurrent Java Programs  

Microsoft Academic Search

Although many slicing algorithms have been proposed for object-oriented programs, no slicing algorithm has been proposed which can be used to handle the problem of slicing concurrent Java programs correctly. In this paper, we propose a slicing algorithm for concurrent Java programs. To slice concurrent Java programs, we present a dependence-based representation called multithreaded dependence graph, which extends previous dependence

Jianjun Zhao

1999-01-01

214

Muscle Atrophy in Response to Cytotoxic Chemotherapy Is Dependent on Intact Glucocorticoid Signaling in Skeletal Muscle  

PubMed Central

Cancer cachexia is a syndrome of weight loss that results from the selective depletion of skeletal muscle mass and contributes significantly to cancer morbidity and mortality. The driver of skeletal muscle atrophy in cancer cachexia is systemic inflammation arising from both the cancer and cancer treatment. While the importance of tumor derived inflammation is well described, the mechanism by which cytotoxic chemotherapy contributes to cancer cachexia is relatively unexplored. We found that the administration of chemotherapy to mice produces a rapid inflammatory response. This drives activation of the hypothalamic-pituitary-adrenal axis, which increases the circulating level of corticosterone, the predominant endogenous glucocorticoid in rodents. Additionally, chemotherapy administration results in a significant loss of skeletal muscle mass 18 hours after administration with a concurrent induction of genes involved with the ubiquitin proteasome and autophagy lysosome systems. However, in mice lacking glucocorticoid receptor expression in skeletal muscle, chemotherapy-induced muscle atrophy is completely blocked. This demonstrates that cytotoxic chemotherapy elicits significant muscle atrophy driven by the production of endogenous glucocorticoids. Further, it argues that pharmacotherapy targeting the glucocorticoid receptor, given in concert with chemotherapy, is a viable therapeutic strategy in the treatment of cancer cachexia. PMID:25254959

Braun, Theodore P.; Szumowski, Marek; Levasseur, Peter R.; Grossberg, Aaron J.; Zhu, XinXia; Agarwal, Anupriya; Marks, Daniel L.

2014-01-01

215

Introduction Concurrency and Multi-Threading  

E-print Network

and Technology Virginia Tech Arlington Research CenterModels of Time for Safety Critical Systems 1/ 46 #12Models of Time for Safety Critical Systems 2/ 46 #12;Motivation Introduction Concurrency and Multi for Safety Critical Systems 4/ 46 #12;Motivation Introduction Concurrency and Multi-Threading Distribution

Shapiro, Benjamin

216

Concurrent Graph and Term Graph Rewriting  

Microsoft Academic Search

Graph Rewriting Systems are a powerful formalism for the specification of parallel and distributed systems, and the corresponding theory is rich of results concerning parallelism and concurrency. I will review the main results of the theory of concurrency for the algebraic approach to graph rewriting, emphasizing the relationship with the theory of Petri nets. In fact, graph rewriting systems can

Andrea Corradini

1996-01-01

217

Generating Fast Code from Concurrent Program Dependence Graphs  

E-print Network

,soviani,sedwards}@cs.columbia.edu ABSTRACT While concurrency in embedded systems is most often supplied by real-time operating systems of concurrently-running processes and implemented using a real-time operating system (RTOS). While

218

CONCURRENT CHEMORADIOTHERAPY IN RESECTED EXTRAHEPATIC CHOLANGIOCARCINOMA  

PubMed Central

Purpose Extrahepatic cholangiocarcinoma is a rare malignancy. Despite radical resection, survival remains poor, with high rates of local and distant failure. To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy. Methods and Materials A total of 45 patients (13 with proximal and 32 with distal disease) underwent resection plus radiotherapy (median dose, 50.4 Gy). All but 1 patient received concurrent fluoropyrimidine-based chemotherapy. The median follow-up was 30 months for all patients and 40 months for survivors. Results Of the 45 patients, 33 underwent adjuvant radiotherapy, and 12 were treated neoadjuvantly. The 5-year actuarial overall survival, disease-free survival, metastasis-free survival, and locoregional control rates were 33%, 37%, 42%, and 78%, respectively. The median survival was 34 months. No patient died perioperatively. Patient age ?60 years and perineural involvement adversely affected survival on univariate analysis. Patients undergoing R0 resection had a significantly improved rate of local control but no survival advantage. Despite having more advanced disease at presentation, patients treated neoadjuvantly had a longer survival (5-year survival 53% vs. 23%, p = 0.16) and similar rates of Grade 2–3 surgical morbidity (16% vs. 33%, p = 0.24) compared with those treated in the postoperative setting. Conclusion These study results suggest a possible local control benefit from chemoradiotherapy combined with surgery in patients with advanced, resected biliary cancer. Furthermore, our results suggest that a treatment strategy that includes preoperative chemoradiotherapy might result in improved tumor resectability with similar surgical morbidity compared with patients treated postoperatively, as well as potentially improved survival outcomes. Distant failure remains a significant failure pattern, suggesting the need for more effective systemic therapy. PMID:18805651

Nelson, John W.; Ghafoori, A. Paiman; Willett, Christopher G.; Tyler, Douglas S.; Pappas, Theodore N.; Clary, Bryan M.; Hurwitz, Herbert I.; Bendell, Johanna C.; Morse, Michael A.; Clough, Robert W.; Czito, Brian G.

2014-01-01

219

Understanding Chemotherapy  

MedlinePLUS

... you may get chemotherapy before a peripheral blood stem cell transplant. Fill this section in with your doctor or nurse. I am ... in these forms: An IV (intravenously) A shot (injection) into a muscle or other part of your body A pill ...

220

HIV chemotherapy  

Microsoft Academic Search

The use of chemotherapy to suppress replication of the human immunodeficiency virus (HIV) has transformed the face of AIDS in the developed world. Pronounced reductions in illness and death have been achieved and healthcare utilization has diminished. HIV therapy has also provided many new insights into the pathogenesis and the viral and cellular dynamics of HIV infection. But challenges remain.

Douglas D. Richman

2001-01-01

221

Recovery of CD8+ T-Cell Function During Systemic Chemotherapy in Advanced Ovarian Cancer  

Microsoft Academic Search

Immunologic approaches are emerging as new treatment options in several types of cancer. However, whereas the ability of patients to develop potent CD8+ T-cell responses is crucial for efficient antitumor responses, immunocompetence and T-cell function are not tested routinely in patients entering immunotherapy. The objective of our study was to monitor T-cell function in advanced cancer and during chemotherapy. CD8+

Sharon Coleman; Aled Clayton; Malcolm D. Mason; Bharat Jasani; Malcolm Adams; Zsuzsanna Tabi

222

Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer  

Microsoft Academic Search

Breast cancer cells can metastasize early in the devel- opment of primary tumors. Adjuvant chemotherapy improves disease-free survival and overall survival (OS) in patients with early-stage breast cancer, both in pre- menopausal and postmenopausal women. Tamoxifen improves OS in patients whose tumors are estrogen-recep- tor-positive, regardless of age. Although the relative risk reduction with these interventions is the same for

FRANCISCO J. ESTEVA; G ABRIEL N. HORTOBAGYI

223

Measuring and modelling concurrency  

PubMed Central

This article explores three critical topics discussed in the recent debate over concurrency (overlapping sexual partnerships): measurement of the prevalence of concurrency, mathematical modelling of concurrency and HIV epidemic dynamics, and measuring the correlation between HIV and concurrency. The focus of the article is the concurrency hypothesis – the proposition that presumed high prevalence of concurrency explains sub-Saharan Africa's exceptionally high HIV prevalence. Recent surveys using improved questionnaire design show reported concurrency ranging from 0.8% to 7.6% in the region. Even after adjusting for plausible levels of reporting errors, appropriately parameterized sexual network models of HIV epidemics do not generate sustainable epidemic trajectories (avoid epidemic extinction) at levels of concurrency found in recent surveys in sub-Saharan Africa. Efforts to support the concurrency hypothesis with a statistical correlation between HIV incidence and concurrency prevalence are not yet successful. Two decades of efforts to find evidence in support of the concurrency hypothesis have failed to build a convincing case. PMID:23406964

Sawers, Larry

2013-01-01

224

The programming language concurrent pascal  

Microsoft Academic Search

The paper describes a new programming language for structured program- ming of computer operating systems. It extends the sequential programming language Pascal with concurrent programming tools called processes and moni- tors. Part I explains these concepts informally by means of pictures illustrating a hierarchical design of a simple spooling system. Part II uses the same exam- ple to introduce the

Per Brinch Hansen

1975-01-01

225

Preoperative chemotherapy in esophageal carcinoma  

Microsoft Academic Search

Preoperative chemotherapy for localized esophageal cancer is an area of increasing interest because neither surgery nor radiation has had a major impact on disease-free or overall survival. This is probably because, as several autopsy series have demonstrated, esophageal cancer is a systemic disease. Preoperative chemotherapy thus, in theory, allows a simultaneous attack on both the primary and metastatic disease. A

D. P. Kelsen

1987-01-01

226

Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy  

PubMed Central

U.S. SEER (Surveillance Epidemiology and End Results) data for age-adjusted mortality rates for all cancers combined for all races show only a modest overall 13% decline over the past 35 years. Moreover, the greatest contributor to cancer mortality is treatment-resistant metastatic disease. The accepted therapeutic paradigm for the past half-century for the treatment of advanced cancers has involved the use of systemic chemotherapy drugs cytotoxic for cycling cells (both normal and malignant) during DNA synthesis and/or mitosis. The failure of this therapeutic modality to achieve high-level, consistent rates of disease-free survival for some of the most common cancers, including tumors of the lung, colon breast, brain, melanoma, and others is the focus of this paper. A retrospective assessment of critical milestones in cancer chemotherapy indicates that most successful therapeutic regimens use cytotoxic cell cycle inhibitors in combined, maximum tolerated, dose-dense acute treatment regimens originally developed to treat acute lymphoblastic leukemia and some lymphomas. Early clinical successes in this area led to their wholesale application to the treatment of solid tumor malignancies that, unfortunately, has not produced consistent, long-term high cure rates for many common cancers. Important differences in therapeutic sensitivity of leukemias/lymphomas versus solid tumors can be explained by key biological differences that define the treatment-resistant solid tumor phenotype. A review of these clinical outcome data in the context of recent developments in our understanding of drug resistance mechanisms characteristic of solid tumors suggests the need for a new paradigm for the treatment of chemotherapy-resistant cancers. In contrast to reductionist approaches, the systemic approach targets both microenvironmental and systemic factors that drive and sustain tumor progression. These systemic factors include dysregulated inflammatory and oxidation pathways shown to be directly implicated in the development and maintenance of the cancer phenotype. The paradigm stresses the importance of a combined preventive/therapeutic approach involving adjuvant chemotherapies that incorporate anti-inflammatory and anti-oxidant therapeutics. PMID:23805101

Crawford, Sarah

2013-01-01

227

Optimization of Concurrent Deployments of the Juvenile Salmon Acoustic Telemetry System and Other Hydroacoustic Equipment at John Day Dam  

SciTech Connect

The purpose of this report is to document the results of the acoustic optimization study conducted at John Day Dam during January and February 2008. The goal of the study was to optimize performance of the Juvenile Salmon Acoustic Telemetry System (JSATS) by determining deployment and data acquisition methods to minimize electrical and acoustic interference from various other acoustic sampling devices. Thereby, this would allow concurrent sampling by active and passive acoustic methods during the formal evaluations of the prototype surface flow outlets at the dam during spring and summer outmigration seasons for juvenile salmonids. The objectives for the optimization study at John Day Dam were to: 1. Design and test prototypes and provide a total needs list of pipes and trolleys to deploy JSATS hydrophones on the forebay face of the powerhouse and spillway. 2. Assess the effect on mean percentage decoded of JSATS transmissions from tags arrayed in the forebay and detected on the hydrophones by comparing: turbine unit OFF vs. ON; spill bay OPEN vs. CLOSED; dual frequency identification sonar (DIDSON) and acoustic Doppler current profiler (ADCP) both OFF vs. ON at a spill bay; and, fixed-aspect hydroacoustic system OFF vs. ON at a turbine unit and a spill bay. 3. Determine the relationship between fixed-aspect hydroacoustic transmit level and mean percentage of JSATS transmissions decoded. The general approach was to use hydrophones to listen for transmissions from JSATS tags deployed in vertical arrays in a series perpendicular to the face of the dam. We used acoustic telemetry equipment manufactured by Technologic and Sonic Concepts. In addition, we assessed old and new JSATS signal detectors and decoders and two different types of hydrophone baffling. The optimization study consisted of a suite of off/on tests. The primary response variable was mean percentage of tag transmissions decoded. We found that there was no appreciable adverse effect on mean percentage decoded for JSATS transmitters from: turbine operations; spillway operations; DIDSON/ADCP acoustic energy; and PAS hydroacoustic systems at transmit level of -12 dB, although there was a significant impact at all higher transmit levels (-11 to -6 dB). The main conclusion from this optimization study is that valid JSATS telemetry data can be collected simultaneously with a DIDSON/ADCP and a PAS hydroacoustic system at transmit level -12 dB. Multiple evaluation tools should be considered to increase the robustness and thoroughness of future fish passage evaluations at John Day and other dams.

Ploskey, Gene R.; Hughes, James S.; Khan, Fenton; Kim, Jina; Lamarche, Brian L.; Johnson, Gary E.; Choi, Eric Y.; Faber, Derrek M.; Wilberding, Matthew C.; Deng, Zhiqun; Weiland, Mark A.; Zimmerman, Shon A.; Fischer, Eric S.; Cushing, Aaron W.

2008-09-01

228

Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study.  

PubMed

From November 1990 to September 1991, 23 adults with high-risk, nonmetastatic sarcomas (20 soft-tissue sarcomas and 3 chondrosarcomas) were entered in a pilot protocol (RHT-91) involving regional hyperthermia combined with systemic chemotherapy followed by surgery. Of these patients, 12 had undergone previous surgery and/or radiation, 5 had received previous multidrug chemotherapy, and 6 were previously untreated. A tumor size of > 8 cm and/or an extracompartmental tumor location (11 patients) or local recurrence (12 patients) were defined as high-risk factors in addition to tumor grading (21 patients had grade 2 or 3 sarcomas). Regional hyperthermia was produced by an electromagnetic deep-regional-heating device. For systemic chemotherapy, all patients received etoposide/ifosfamide/doxorubicin (EIA) and mesna, with regional hyperthermia being given only on days 1 and 4 in repeated EIA/regional hyperthermia cycles every 3 weeks. Tumor temperatures (range, 40 degrees-44 degrees C) were measured by invasive thermometry in all patients during each regional hyperthermia treatment. A total of 181 regional hyperthermia treatments were applied within the pelvic region (11 patients) or extremities (12 patients) bearing relatively large tumors (mean volume, 848 cm3). By the cutoff date for this analysis (October 15, 1991), 13 patients had undergone surgery after receiving 2-6 (mean, 3.8) cycles of EIA chemotherapy combined with regional hyperthermia; all tumors except one were resected without disfiguration. In 22 evaluable patients (minimum, 2 EIA plus regional hyperthermia cycles), the clinical response rate was 27%, with 6 patients showing partial responses (PRs). In addition, a pathologic response to preoperative thermochemotherapy was evaluable in 13 patients, with 4 responders (31%) having > 50% histologic necrosis. In all, 3 of the responders (1 PR and 2 patients with > 50% histologic necrosis) relapsed within 3 months of surgical resection. The other 7 responding patients (5 PRs and 2 patients with > 50% histologic necrosis) showed stable disease with local tumor control. The study (RHT-91) is continuing as a multicenter phase II trial (opened on November 19, 1991) in patients with high-risk soft-tissue sarcomas to test the potential of preoperative thermochemotherapy in regard to local control and survival. PMID:8453705

Issels, R D; Bosse, D; Abdel-Rahman, S; Starck, M; Panzer, M; Jauch, K W; Stiegler, H; Berger, H; Sauer, H; Peter, K

1993-01-01

229

Clinical Benefits of Systemic Chemotherapy for Patients with Metastatic Pheochromocytomas or Sympathetic Extra-Adrenal Paragangliomas: Insights from the Largest Single Institutional Experience  

PubMed Central

Background The purpose of this study was to evaluate the clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic paragangliomas by assessing reduction in tumor size, blood pressure, and improvement in overall survival. Methods We retrospectively reviewed the medical records of patients with metastatic pheochromocytomas-sympathetic paragangliomas who had received chemotherapy at The University of Texas MD Anderson Cancer Center Results Clinical benefit and overall survival (OS) were assessed. Of fifty-four patients treated with chemotherapy, fifty-two were evaluable for response. Seventeen (33%) experienced a response, defined as decreased or normalized blood pressure/decreased number and dosage of antihypertensive medications and/or reduced tumor size after the first chemotherapy regimen. The median OS time was 6.4 years (95 confidence interval (CI): 5.2–16.4) for responders and 3.7 (95% CI: 3.0–7.5) years for non-responders. Of patients who had synchronous metastatic disease, a positive response at 1 year after the start of chemotherapy was associated with a trend toward a longer overall survival (log-rank test, P-value =0.095). In a multivariate Cox proportional hazards model, the effect of response to chemotherapy on overall survival was significant (hazard ratio=0.22, 95% confidence interval: 0.05–1.0; P-value = 0.05). All responders had been treated with dacarbazine and cyclophosphamide. Vincristine was included for 14 responders and doxorubicin was included for 12 responders. We could not identify clinical factors that predicted response to chemotherapy. Conclusion Chemotherapy may decrease tumor size and facilitate blood pressure control in about 33% of patients with metastatic pheochromocytoma-sympathetic paraganglioma. These patients exhibit a longer survival. PMID:22006217

Ayala-Ramirez, Montserrat; Feng, Lei; Habra, Mouhammed A.; Rich, Thereasa; Dickson, Paxton V.; Perrier, Nancy; Phan, Alexandria; Waguespack, Steven; Patel, Shreyaskumar; Jimenez, Camilo

2013-01-01

230

Emerging integrated nanohybrid drug delivery systems to facilitate the intravenous-to-oral switch in cancer chemotherapy.  

PubMed

Nanohybrid drug delivery systems have presented lots of characteristic advantages as an efficient strategy to facilitate oral drug delivery. Nonetheless, oral administration of chemotherapy agents by nanoparticulate delivery technology still faces great challenges owing to the multiple biobarriers ranging from poorly physicochemical properties of drugs, to complex gastrointestinal disposition and to presystemic metabolism. This review briefly analyzes a series of biobarriers hindering oral absorption and describes the multiple aspects for facilitating the intravenous-to-oral switch in cancer therapy. Moreover, the developed nanoparticulate drug delivery strategies to overcome the above obstacles are provided, including metabolic enzyme inhibition, enteric-coated nanocarriers, bioadhesive and mucus-penetrating strategies, P-gp inhibition and active targeting. On these foundations, the emerging trends of integrated hybrid nanosystems in response to the present low-efficiency drug delivery of any single approach are summarized, such as mixed polymeric micelles and nanocomposite particulate systems. Finally, the recent advances of high-efficiency hybrid nanoparticles in oral chemotherapy are highlighted, with special attention on integrated approach to design drug delivery nanosystems. PMID:24389337

Luo, Cong; Sun, Jin; Du, Yuqian; He, Zhonggui

2014-02-28

231

Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review  

PubMed Central

Until now only intravenous and oral formulations of 5HT3 receptor antagonists have been available. Recently a new formulation of a 5HT3 receptor antagonist, transdermal granisetron, has been developed, and approved by the FDA. Three phase I studies to evaluate its pharmacokinetic profile have shown that granisetron administered by a transdermal delivery system is absorbed by passive diffusion and maximal concentration is reached 48 hours after patch application. The patch of 52 cm2, which contains 34.3 mg of granisetron, releases 3.3 mg of the drug every day and maintains a stable average plasma concentration of 2.2 ng/mL over 6 days, similar to levels obtained with 2 mg of oral granisetron, administered every day during the same period of time. Two randomized as yet unpublished clinical trials (phase II/III) have been conducted to evaluate the antiemetic efficacy of transdermal granisetron in chemotherapy-induced nausea and vomiting, in patients receiving moderately and highly emetogenic chemotherapy, compared with 2 mg of oral granisetron. More than 800 cancer patients were included in the trials. The rate of complete control of acute emesis was 49% for the phase II trial and 60% for the phase III trial. Neither trial showed a statistically significant difference between transdermal and oral granisetron. The control of delayed emesis was observed in 46% of patients, and there were no statistically significant differences between transdermal and oral granisetron. The most common adverse effects in both trials were constipation (<7%) and headache (<1%); there were no statistically significant differences between transdermal and oral granisetron. These data show that transdermal granisetron is effective and safe in controlling acute emesis induced by chemotherapy with both moderate and high emetogenic potential. Efficacy and safety of transdermal granisetron are fully comparable with that of oral granisetron. More clinical trials using regimens of 2 or 3 drugs, including dexamethasone and/or aprepitant, are needed to confirm the place of transdermal granisetron in the control of chemotherapy-induced nausea and vomiting. PMID:21188092

Tuca, Albert

2010-01-01

232

Integrating Action Definitions into Concurrent Declarative Programming  

Microsoft Academic Search

The semantics of a process defines the actions it can execute. Thus actions constitute an essential notion for concurrent systems. In this paper, we tackle the problem of integrating the definition of actions within the context of concurrent constraint functional logic program- ming. We propose to define actions in a meta-language, where abstract data types of programs are available, as

Rachid Echahed; Wendelin Serwe

2001-01-01

233

Hierarchical Concurrent Finite State Machines in Ptolemy  

Microsoft Academic Search

We implement a finite state machine (FSM) domain for specifying and simulating control functionality of a system within the Ptolemy software environment. The FSM domain is successfully integrated with synchronous data- flow (SDF) and discrete-event (DE) concurrency domains in Ptolemy. In this heterogeneous combination, the seman- tics of FSM, concurrency and hierarchy are naturally sup- ported in a manner similar

Bilung Lee; Edward A. Lee

1998-01-01

234

HIV chemotherapy  

NASA Astrophysics Data System (ADS)

The use of chemotherapy to suppress replication of the human immunodeficiency virus (HIV) has transformed the face of AIDS in the developed world. Pronounced reductions in illness and death have been achieved and healthcare utilization has diminished. HIV therapy has also provided many new insights into the pathogenesis and the viral and cellular dynamics of HIV infection. But challenges remain. Treatment does not suppress HIV replication in all patients, and the emergence of drug-resistant virus hinders subsequent treatment. Chronic therapy can also result in toxicity. These challenges prompt the search for new drugs and new therapeutic strategies to control chronic viral replication.

Richman, Douglas D.

2001-04-01

235

Concurrency Theory Alban Ponse  

E-print Network

(PGA) and Thread Algebra (TA), a systematic approach to sequential-imperative and object based, UvA) Concurrency Theory - Lecture 1 2013 - 2014 3 / 25 #12;Overview of Lecture 1 Contents PGA://staff.science.uva.nl/~alban/CT.html Alban Ponse (TCS, UvA) Concurrency Theory - Lecture 1 2013 - 2014 4 / 25 #12;Program algebra, or PGA

Ponse, Alban

236

Risk Factors for Severe Neutropenia following Intra-Arterial Chemotherapy for Intra-Ocular Retinoblastoma  

PubMed Central

Purpose Intra-arterial chemotherapy is a promising strategy for intra-ocular retinoblastoma. Neutropenia is the most commonly encountered systemic toxicity and in this study we aimed to determine the risk factors associated with the development of severe (?grade 3) neutropenia. Methods Retrospective review of 187 evaluable cycles of melphalan-containing intra-arterial chemotherapy from the first three cycles administered to 106 patients with intra-ocular retinoblastoma from May 2006 to June 2011. Cycles were considered to be evaluable if (1) blood count results were available in the 7 to 14 days post-treatment interval and (2) concurrent intravenous chemotherapy was not administered. Toxicity was assessed via the Common Terminology Criteria for Adverse Events version 4.0. Results 54 cycles (29%) were associated with grade 3 (n?=?43) or grade 4 (n?=?11) neutropenia. Multivariate stepwise logistic regression revealed that a higher melphalan dose (>0.40 mg/kg) was significantly associated with severe neutropenia during all 3 cycles (odds ratio during cycle one 4.11, 95% confidence interval 1.33–12.73, p?=?0.01), but the addition of topotecan and/or carboplatin were not. Prior treatment with systemic chemotherapy was not associated with severe neutropenia risk in any analysis. Conclusions Intra-arterial melphalan-based chemotherapy can cause severe neutropenia, especially when a dose of greater than 0.40 mg/kg is administered. Further study with a larger sample may be warranted. PMID:25303673

Dunkel, Ira J.; Shi, Weiji; Salvaggio, Kim; Marr, Brian P.; Brodie, Scott E.; Gobin, Y. Pierre; Abramson, David H.

2014-01-01

237

36 CFR 14.56 - Concurrence by Federal Highway Administration.  

Code of Federal Regulations, 2013 CFR

...2013-07-01 false Concurrence by Federal Highway Administration. 14.56 Section 14...23, U.S.C. (Interstate and Defense Highway System) § 14.56 Concurrence by Federal Highway Administration. The appropriate...

2013-07-01

238

36 CFR 14.56 - Concurrence by Federal Highway Administration.  

Code of Federal Regulations, 2010 CFR

...2010-07-01 false Concurrence by Federal Highway Administration. 14.56 Section 14...23, U.S.C. (Interstate and Defense Highway System) § 14.56 Concurrence by Federal Highway Administration. The appropriate...

2010-07-01

239

36 CFR 14.56 - Concurrence by Federal Highway Administration.  

Code of Federal Regulations, 2012 CFR

...2012-07-01 false Concurrence by Federal Highway Administration. 14.56 Section 14...23, U.S.C. (Interstate and Defense Highway System) § 14.56 Concurrence by Federal Highway Administration. The appropriate...

2012-07-01

240

36 CFR 14.56 - Concurrence by Federal Highway Administration.  

Code of Federal Regulations, 2011 CFR

...2011-07-01 false Concurrence by Federal Highway Administration. 14.56 Section 14...23, U.S.C. (Interstate and Defense Highway System) § 14.56 Concurrence by Federal Highway Administration. The appropriate...

2011-07-01

241

Evaluation of the Efficacy of Combined Continuous Arterial Infusion and Systemic Chemotherapy for the Treatment of Advanced Pancreatic Carcinoma  

SciTech Connect

Purpose. To evaluate the effects of combined continuous transcatheter arterial infusion (CTAI) and systemic chemotherapy in patients with advanced pancreatic carcinoma. Methods. CTAI was performed in 17 patients with stage IV pancreatic cancer with (n = 11) or without (n = 6) liver metastasis. The reservoir was transcutaneously implanted with the help of angiography. The inferior pancreatic artery (IPA) was embolized to achieve delivery of the pancreatic blood supply through only the celiac artery. The systemic administration of gemcitabine was combined with the infusion of 5-fluorouracil via the reservoir. Treatment effects were evaluated based on the primary tumor size, liver metastasis, and survival time and factors such as tumor size, tumor location, and stage of pancreatic carcinoma; the embolized arteries were analyzed with respect to treatment effects and prognosis. Results. A catheter was fixed in the gastroduodenal artery and splenic artery in 10 and 7 patients, respectively. Complete peripancreatic arterial occlusion was successful in 10 patients. CT showed a decrease in tumor size in 6 of 17 (35%) patients and a decrease in liver metastases in 6 of 11 (55%) patients. The survival time ranged from 4 to 18 months (mean {+-} SD, 8.8 {+-} 1.5 months). Complete embolization of arteries surrounding the pancreas was achieved in 10 patients; they manifested superior treatment effects and prognoses (p < 0.05). Conclusion. In patients with advanced pancreatic cancer, long-term CTAI with systemic chemotherapy appeared to be effective not only against the primary tumor but also against liver metastases. Patients with successfully occluded peripancreatic arteries tended to survive longer.

Ikeda, O., E-mail: osamu-3643ik@do9.enjoy.ne.jp; Kusunoki, S.; Kudoh, K. [Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, Department of Diagnostic Radiology (Japan); Takamori, H.; Tsuji, T.; Kanemitsu, K. [Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, Department of Gastroenterological Surgery (Japan); Yamashita, Y. [Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, Department of Diagnostic Radiology (Japan)

2006-06-15

242

Successful Concurrent Chemoradiotherapy with Cisplatin plus Vinorelbine for Locally Advanced Thymic Carcinoma  

PubMed Central

Little information is available about the usefulness of concurrent chemoradiotherapy for locally advanced thymic carcinoma due to a rare anterior mediastinal tumor. We experienced a case of locally advanced thymic carcinoma that responded well to concurrent thoracic radiotherapy combined with cisplatin plus vinorelbine chemotherapy. The patient showed remarkable tumor regression and has remained disease free for over 4 years following combined therapy. Concurrent chemoradiotherapy seems to be effective for locally advanced thymic carcinoma, and cisplatin plus vinorelbine could be an alternative chemotherapy regimen in combination with thoracic radiotherapy in patients with thymic carcinoma. PMID:24575019

Fukushima, Toshirou; Tateishi, Kazunari; Hanaoka, Masayuki; Koiwai, Keiichirou; Sasaki, Shigeru; Koizumi, Tomonobu

2014-01-01

243

Microfluidic System Based High Throughput Drug Screening System for Curcumin/TRAIL Combinational Chemotherapy in Human Prostate Cancer PC3 Cells.  

PubMed

We have developed a fully automated high throughput drug screening (HTDS) system based on the microfluidic cell culture array to perform combinational chemotherapy. This system has 64 individually addressable cell culture chambers where the sequential combinatorial concentrations of two different drugs can be generated by two microfluidic diffusive mixers. Each diffusive mixer has two integrated micropumps connected to the media and the drug reservoirs respectively for generating the desired combination without the need for any extra equipment to perfuse the solution such as syringe pumps. The cell array is periodically exposed to the drug combination with the programmed LabVIEW system during a couple of days without extra handling after seeding the cells into the microfluidic device and also, this device does not require the continuous generation of solutions compared to the previous systems. Therefore, the total amount of drug being consumed per experiment is less than a few hundred micro liters in each reservoir. The utility of this system is demonstrated through investigating the viability of the prostate cancer PC3 cell line with the combinational treatments of curcumin and tumor necrosis factor-alpha related apoptosis inducing ligand (TRAIL). Our results suggest that the system can be used for screening and optimizing drug combination with a small amount of reagent for combinatorial chemotherapy against cancer cells. PMID:25143816

An, Dami; Kim, Kwangmi; Kim, Jeongyun

2014-07-01

244

Towards concrete concurrency: occam-pi on the LEGO mindstorms  

Microsoft Academic Search

In a world of ad-hoc networks, highly interconnected mobile devices and increasingly large supercomputer clusters, students need models of computation that help them think about dynamic and concurrent systems. Many of the tools currently available for introducing students to concurrency are difficult to use and are not intrinsically motivating. To provide an authentic, hands-on, and enjoyable introduction to concurrency, we

Christian L. Jacobsen; Matthew C. Jadud

2005-01-01

245

The Tipping Point for Combination Therapy: Cancer Vaccines with Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors  

PubMed Central

Therapeutic cancer vaccines are a unique treatment modality in that they initiate a dynamic process of activating the host immune system, which can then be exploited by concurrent or subsequent therapies. The addition of immunotherapy to standard-of-care cancer therapies has shown evidence of efficacy in preclinical models and in the clinical setting. This review examines the preclinical and clinical interactions between vaccine-mediated tumor-specific immune responses and local radiation, systemic chemotherapy, or select small-molecule inhibitors, as well as the potential synergy between these modalities. PMID:22595055

Hodge, James W.; Ardiani, Andressa; Farsaci, Benedetto; Kwilas, Anna R.; Gameiro, Sofia

2012-01-01

246

The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer  

PubMed Central

Anaplastic thyroid cancer represents 1%–2% of thyroid cancers. For its aggressiveness, it is considered a systemic disease at the time of diagnosis. Surgery remains the cornerstone of therapy in resectable tumor. Traditional chemotherapy has little effect on metastatic disease. A multimodality approach, incorporating cytoreductive surgical resection, chemoradiation, either concurrently or sequentially, and new promising target therapies is advisable. Doxorubicin is the most commonly used agent, with a response rate of 22%. Recently, other chemotherapy agents have been used, such as paclitaxel and gemcitabine, with superimposable activity and response rates of 10%–20%. However, survival of patients with anaplastic thyroid cancer has changed little in the past 50 years, despite more aggressive systemic and radiotherapies. Several new agents are currently under investigation. Some of them, such as sorafenib, imatinib, and axitinib have been tested in small clinical trials, showing promising disease control rates ranging from 35%–75%. Referral of patients for participation in clinical trials is needed. PMID:24092989

Denaro, Nerina; Nigro, Cristiana Lo; Russi, Elvio G; Merlano, Marco C

2013-01-01

247

DOSIMETRIC PREDICTORS OF ACUTE HEMATOLOGIC TOXICITY IN CERVICAL CANCER PATIENTS TREATED WITH CONCURRENT CISPLATIN AND INTENSITY-MODULATED PELVIC RADIOTHERAPY  

Microsoft Academic Search

Purpose: To identify dosimetric parameters associated with acute hematologic toxicity (HT) and chemotherapy delivery in cervical cancer patients undergoing concurrent chemotherapy and intensity-modulated pelvic radio- therapy. Methods and Materials: We analyzed 37 cervical cancer patients receiving concurrent cisplatin (40 mg\\/m2\\/wk) and intensity-modulated pelvic radiotherapy. Pelvic bone marrow (BM) was contoured for each patient and divided into three subsites: lumbosacral spine,

LOREN K. MELL; JOEL D. KOCHANSKI; JOHN C. ROESKE; JOSH J. HASLAM; NEIL MEHTA; S. DIANE YAMADA; JEAN A. HURTEAU; YVONNE C. COLLINS; ERNST LENGYEL; ARNO J. MUNDT

2006-01-01

248

Heterogeneous concurrent computing with exportable services  

NASA Technical Reports Server (NTRS)

Heterogeneous concurrent computing, based on the traditional process-oriented model, is approaching its functionality and performance limits. An alternative paradigm, based on the concept of services, supporting data driven computation, and built on a lightweight process infrastructure, is proposed to enhance the functional capabilities and the operational efficiency of heterogeneous network-based concurrent computing. TPVM is an experimental prototype system supporting exportable services, thread-based computation, and remote memory operations that is built as an extension of and an enhancement to the PVM concurrent computing system. TPVM offers a significantly different computing paradigm for network-based computing, while maintaining a close resemblance to the conventional PVM model in the interest of compatibility and ease of transition Preliminary experiences have demonstrated that the TPVM framework presents a natural yet powerful concurrent programming interface, while being capable of delivering performance improvements of upto thirty percent.

Sunderam, Vaidy

1995-01-01

249

Central Nervous System Injury, Neurocognitive and Quality of Life Outcomes in Children with Brain Tumors Treated with Chemotherapy.  

E-print Network

??Two-thirds of children diagnosed with brain tumors achieve long-term survival, and increasingly, children younger than 5-6 years at diagnosis are treated with high-dose chemotherapy protocols,… (more)

Baron Nelson, Mary Christine

2012-01-01

250

Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.  

PubMed

Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis with chemotherapy alone. We therefore investigated in children and adolescents with bone marrow (?25% blasts) and/or CNS-positive Burkitt lymphoma the chemoimmunotherapy combination of rituximab (375 mg/m(2) ) and the standard chemotherapy arm of our previously reported French-American-British (FAB) Lymphome Malins de Burkitt (LMB) 96 trial. Central pathological and cytogenetic characterization was also performed. There were 40 evaluable patients with Burkitt histology (25 with leukaemia and 15 with CNS disease ± leukaemia). The chemoimmunotherapy regimen was well tolerated. The incidence of grade III/IV mucositis during induction cycles with combined chemotherapy and rituximab was 31% and 26%, respectively. The 3-year event-free survival (EFS)/overall survival (OS) was 90% (95% confidence interval [CI], 76-96%) in the entire cohort and 93% (95% CI, 61-99%) in patients with CNS disease. Based on the results of this trial, an international randomized study of FAB/LMB 96 chemotherapy ± rituximab for high-risk patients is currently under investigation. PMID:25066629

Goldman, Stanton; Smith, Lynette; Galardy, Paul; Perkins, Sherrie L; Frazer, John Kimble; Sanger, Warren; Anderson, James R; Gross, Thomas G; Weinstein, Howard; Harrison, Lauren; Shiramizu, Bruce; Barth, Matthew; Cairo, Mitchell S

2014-11-01

251

How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?  

PubMed

Latest evidence sets a clear mandate for concurrent chemoradiotherapy as the current standard of care for inoperable stage III non small cell lung cancer patients with good performance status and minimal co-morbidities. However, a survival plateau has been reached, with disappointing results from dose escalation studies using conventional fractionation and studies investigating the addition of systemic doses of chemotherapy delivered before or after concurrent chemoradiotherapy. A review was carried out to address three questions considered fundamental to improving outcome in patients with stage III non-small cell lung cancer: (1) Can radiotherapy regimens be optimised using advanced radiotherapy techniques to improve local control rate and overall survival? (2) Can systemic therapy regimens be optimised to reduce the risk of distant metastases? (3) Should concurrent chemoradiotherapy be considered standard of care for locally advanced non-small cell lung cancer in the elderly? It is clear that further improvement in outcome for these patients will be determined by better local control and by reducing the risk of distant recurrence. Given the technological advances in radiotherapy planning and delivery in recent years plus the abundance of novel targeted therapies exploiting critical oncogenic pathways, further advances in combined drug-radiation treatment for lung cancer seem highly possible. PMID:24373738

Bayman, Neil; Blackhall, Fiona; McCloskey, Paula; Taylor, Paul; Faivre-Finn, Corinne

2014-02-01

252

C formal verification with unix communication and concurrency  

NASA Technical Reports Server (NTRS)

The results of a NASA SBIR project are presented in which CSP-Ariel, a verification system for C programs which use Unix system calls for concurrent programming, interprocess communication, and file input and output, was developed. This project builds on ORA's Ariel C verification system by using the system of Hoare's book, Communicating Sequential Processes, to model concurrency and communication. The system runs in ORA's Clio theorem proving environment. The use of CSP to model Unix concurrency and sketch the CSP semantics of a simple concurrent program is outlined. Plans for further development of CSP-Ariel are discussed. This paper is presented in viewgraph form.

Hoover, Doug N.

1990-01-01

253

Concurrent reading and writing  

Microsoft Academic Search

The problem of sharing data among asynchronous processes is considered. It is assumed that only one process at a time can modify the data, but concurrent reading and writing is permitted. Two general theorems are proved, and some algorithms are presented to illustrate their use. These include a solution to the general problem in which a read is repeated if

Leslie Lamport

1977-01-01

254

Concurrent Reading While Writing  

Microsoft Academic Search

The problem of asynchronous processes reading shared data while the data are being modified by another process is considered. This problem differs from the standard readers\\/writers problem in that concurrent reading while writing is allowed. The model used here strongly limits the use and size of the shared variables. If multiple copies of the shared data are allowed, then simple,

Gary L. Peterson

1983-01-01

255

Specifying Concurrent Program Modules  

Microsoft Academic Search

A method for specifying program modules in a concurrent program is described. It is based upon temporal logic, but uses new kinds of temporal assertions to make the specifications simpler and easier to understand. The semantics of the specifications is described informally, and a sequence of examples are given culminating in a specification of three modules comprising the alternating-bit communication

Leslie Lamport

1983-01-01

256

Concurrency Theory Checkpoint 1  

E-print Network

on PGA-based syntax Consider Appendix B.2 in the Bergstra/Loots paper (JLAP51(2):125­156). Observe and discuss an appropriate projection function to PGA (max 3 pages). Literature. A paper on PGA with unit instruction that defines a projection function to PGA. Alban Ponse (TCS, UvA) Concurrency Theory - Checkpoint

Ponse, Alban

257

Solving finite element equations on concurrent computers  

NASA Technical Reports Server (NTRS)

This paper discusses the development of a concurrent algorithm for the solution of systems of equations arising in finite element applications. The approach is based on a hybrid of direct elimination method and preconditioned conjugate iteration. Two different preconditioners are used; diagonal scaling and a concurrent implementation of incomplete LU factorization. First, an automatic procedure is used to partition the finite element mesh into sub-structures. The particular mesh partition is chosen to minimize an estimate of the cost for evaluating the solution using this algorithm on a concurrent computer. These procedures are implemented in a finite element program on the JPL/CalTech MARK III hypercube computer. An overview of the structure of this program is presented. The performance of the solution method is demonstrated with the aid of a number of numerical test runs, and its advantages for concurrent implementations are discussed. Efficiency and speed-up factors over sequential machines for the numerical examples are highlighted.

Nour-Omid, B.; Raefsky, A.; Lyzenga, G.

1987-01-01

258

Intraperitoneal chemotherapy: rationale, applications, and limitations.  

PubMed

Intraperitoneal chemotherapy, involving the administration of certain chemotherapeutic agents directly to the intraperitoneal cavity, was developed as a novel therapeutic strategy early in the 1950s. Intraperitoneal administration of chemotherapy results in higher intraperitoneal concentration of the cytotoxic medications and minimal systemic exposure than observed with intravenous administration, which in turn may increase the efficacy of these agents with substantial reduction in systemic toxicity. Intraperitoneal chemotherapy was used successfully in peritoneal surface malignancies, including malignant peritoneal mesothelioma, pseudomyxoma peritonei, malignant ascites, sarcomatosis, and peritoneal carcinomatosis from gastrointestinal and ovarian cancers. Pharmacists may play a major role in optimizing intraperitoneal chemotherapy through verification of chemotherapy order for proper doses, dilution, preparation, and administration. Moreover, pharmacists are medication experts who can provide other health care professionals with the necessary drug information. Despite the local application of chemotherapy, intraperitoneal chemotherapy is not free of systemic side effects and can be associated with serious complications. The benefits of intraperitoneal chemotherapy should be weighed against its potential harm to maximize efficacy and to minimize morbidity and mortality as much as possible. The aim of this article is to review the current available literature regarding the safety and efficacy of intraperitoneal chemotherapy in cancer treatment. PMID:24166789

Al-Quteimat, Osama M; Al-Badaineh, Mariam A

2014-10-01

259

3D Radiotherapy Can Be Safely Combined With Sandwich Systemic Gemcitabine Chemotherapy in the Management of Pancreatic Cancer: Factors Influencing Outcome  

SciTech Connect

Purpose: The aim of this Phase II study was to examine whether concurrent continuous infusion 5-fluorouracil (CI 5FU) plus three-dimensional conformal planning radiotherapy sandwiched between gemcitabine chemotherapy is effective, tolerable, and safe in the management of pancreatic cancer. Methods and Materials: Patients were enrolled in two strata: (1) resected pancreatic cancer at high risk of local relapse (postsurgery arm, n = 22) or (2) inoperable pancreatic cancer in head or body without metastases (locally advanced arm, n = 41). Gemcitabine was given at 1,000 mg/m{sup 2} weekly for 3 weeks followed by 1 week rest then 5-6 weeks of radiotherapy and concurrent CI 5FU (200 mg/m{sup 2}/day). After 4 weeks' rest, gemcitabine treatment was reinitiated for 12 weeks. Results: For the two arms combined, treatment-related Grade 3 and 4 toxicities were reported by 25 (39.7%) and 7 (11.1%) patients, respectively. No significant late renal or hepatic toxicity was observed. In the postsurgery arm (R1 54.5%), median time to progressive disease from surgery was 11.0 months, median time to failure of local control was 32.9 months, and median survival time was 15.6 months. The 1- and 2-year survival rates were 63.6% and 31.8%. No significant associations between outcome and mutations in K-ras or TP53 or microsatellite instability were identified. Post hoc investigation of cancer antigen 19-9 levels found baseline levels and increases postbaseline were associated with shorter survival (p = 0.0061 and p < 0.0001, respectively). Conclusions: This three-dimensional chemoradiotherapy regimen is safe and promising, with encouraging local control for a substantial proportion of patients, and merits testing in a randomized trial.

Spry, Nigel [Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA (Australia)], E-mail: Nigel.Spry@health.wa.gov.au; Harvey, Jennifer [Department of Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland (Australia); MacLeod, Craig [Department of Radiation Oncology, Murray Valley Private Hospital, Wodonga, Victoria (Australia); Borg, Martin [Adelaide Radiotherapy Centre, Adelaide, SA (Australia); Ngan, Samuel Y. [Division of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria (Australia); Millar, Jeremy L. [Department of Radiation Oncology, The Alfred, Prahran, Victoria (Australia); Graham, Peter [Department of Radiation Oncology, St. George Hospital, Kogarah, NSW (Australia); Zissiadis, Yvonne [Department of Radiation Oncology, Royal Perth Hospital, Perth, WA (Australia); Kneebone, Andrew [Cancer Therapy Centre, Liverpool Hospital, Liverpool, NSW (Australia); Carroll, Susan [Department of Radiation Oncology, Prince of Wales Hospital, Randwick, NSW (Australia); Davies, Terri; Reece, William H.H. [Eli Lilly Australia, West Ryde, NSW (Australia); Iacopetta, Barry [School of Surgery and Pathology, University of Western Australia, Nedlands, WA (Australia); Goldstein, David [Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW (Australia)

2008-04-01

260

Modular Verification of Concurrent Thread , Xinyu Feng1  

E-print Network

; on the other hand, the thread management code in many real-world systems is concurrent, which might be executed system [15]. On the other hand, in many real-world systems such as Linux-2.6.10 [12] and FreeBSD-5.2 [13 to concurrent separation logic. 1 Introduction Thread scheduling in modern operating systems provides

261

A Case of the Cauda Equina Syndrome Associated With the Intrathecal Chemotherapy in a Patient With Primary Central Nervous System Lymphoma  

PubMed Central

The intrathecal chemotherapy with methotrexate and cytarabine arabinoside is used for the treatment and prophylaxis of the primary central nervous system lymphoma. The therapy may induce neurotoxicity including the cauda equina syndrome. We report a case of a 58-year-old man with the diffuse large B-cell lymphoma, who developed the cauda equina syndrome after the administration of intrathecal methotrexate and cytarabine arabinoside, as diagnosed by the electrodiagnostic, urodynamic, and radiologic approaches. PMID:23869341

Park, Seunglee; Kang, Jung-Il; Bang, Hyun; Kim, Bo-Ram

2013-01-01

262

Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy  

Microsoft Academic Search

Purpose  To identify and mathematically model molecular predictors of response to the enediyne chemotherapeutic agent, neocarzinostatin,\\u000a in nervous system cancer cell lines.\\u000a \\u000a \\u000a \\u000a Methods  Human neuroblastoma, breast cancer, glioma, and medulloblastoma cell lines were maintained in culture. Content of caspase-3\\u000a and Bcl-2, respectively, was determined relative to actin content for each cell line by Western blotting and optical densitometry.\\u000a For each cell line,

Danny Rogers; Karen D. Nylander; Zhiping Mi; Tong Hu; Nina F. Schor

2008-01-01

263

Controlling Chemotherapy Side Effects  

Microsoft Academic Search

Severe nausea and vomiting are commonly experienced by cancer patients after receiving chemotherapy treatments. Moreover, approximately 25% of these patients develop conditioned aversions to treatment and become nauseated before they receive their chemotherapy injections. The use of deep muscle relaxation hypnosis in conjunction with guided imagery to control pre- and post-chemotherapy nausea and emesis is discussed. Theoretical and clinical issues

William H. Redd; Patricia H. Rosenberger; Cobie S. Hendler

1982-01-01

264

Harnessing system models of cell death signalling for cytotoxic chemotherapy: towards personalised medicine approaches?  

PubMed

Most cytotoxic chemotherapeutics are believed to kill cancer cells by inducing apoptosis. Understanding the factors that contribute to impairment of apoptosis in cancer cells is therefore critical for the development of novel therapies that circumvent the widespread chemoresistance. Apoptosis, however, is a complex and tightly controlled process that can be induced by different classes of chemotherapeutics targeting different signalling nodes and pathways. Moreover, apoptosis initiation and apoptosis execution strongly depend on patient-specific, genomic and proteomic signatures. Here, we will review recent translational studies that suggest a critical link between the sensitivity of cancer cells to initiate apoptosis and clinical outcome. Next we will discuss recent advances in the field of system modelling of apoptosis pathways for the prediction of treatment responses. We propose that initiation of mitochondrial apoptosis, defined as the process of mitochondrial outer membrane permeabilisation (MOMP), is a dose-dependent decision process that allows for a prediction of individual therapy responses and therapeutic windows. We provide evidence in contrast that apoptosis execution post-MOMP may be a binary decision that dictates whether apoptosis is executed or not. We will discuss the implications of this concept for the future use of novel adjuvant therapeutics that specifically target apoptosis signalling pathways or which may be used to reduce the impact of cell-to-cell heterogeneity on therapy responses. Finally, we will discuss the technical and regulatory requirements surrounding the use and implications of system-based patient stratification tools for the future of personalised oncology. PMID:24477766

Huber, Heinrich J; McKiernan, Ross G; Prehn, Jochen H M

2014-03-01

265

Concurrent engineering: success stories in instrumentation, communications  

Microsoft Academic Search

Four case histories of the successful use of concurrent engineering (CE) to develop instrumentation and communications products are presented. They are the development of an oscilloscope at Hewlett-Packard, the development of internetworking products by Cisco Systems, large-scale systems development at Raytheon, and making one-of-a-kind products at ITEK optical systems.

R. Wheeler; R. W. Burnett; A. Rosenblatt

1991-01-01

266

Long-Term Follow-Up of Dose-Adapted and Reduced-Field Radiotherapy With or Without Chemotherapy for Central Nervous System Germinoma  

SciTech Connect

Purpose: To update our institutional experience with neoadjuvant chemotherapy and minimized radiotherapy vs. radiation monotherapy for intracranial germinoma. Methods and Materials: We retrospectively reviewed records of 59 patients with diagnosis of primary intracranial germinoma between 1977 and 2007. Treatment was irradiation alone or neoadjuvant platinum-based chemotherapy and local irradiation (initial tumor plus margin) for patients with localized complete response and reduced-dose craniospinal irradiation for others. Results: For the chemoradiotherapy group (n = 28), median follow-up was 7 years. No patient died. The freedom from progression (FFP) rate was 88% at 5 years and 80% at 10 years. In 4 patients, disease recurred 1.1 to 6.8 years after diagnosis. All were young male patients who received 30.6 Gy to local fields after complete response to chemotherapy. The FFP rate was 88% for local irradiation vs. 100% for more extensive fields (p = .06). For the radiotherapy-alone group (n = 31), median follow-up was 15 years. Overall and disease-free survival rates were 93% and 93% at 5 years and 90% and 87% at 15 years. In 5 patients, disease recurred 1.1 to 4.9 years after diagnosis. Most patients in this group were young men 18 to 23 years of age with suprasellar primary disease treated with about 50 Gy to local fields. The FFP rate was 44% for local irradiation vs. 100% for more extensive fields (p < .01). Conclusions: The addition of neoadjuvant chemotherapy to local-field radiotherapy reduced central nervous system cancer recurrence when high-risk patients were excluded by thorough pretreatment staging. There was trend toward improved central nervous system tumor control when larger fields (whole brain, whole ventricle, or craniospinal axis) were used.

Jensen, Ashley W. [Department of Radiation Oncology, Mayo Clinic, Rochester, MN (United States); Issa Laack, Nadia N., E-mail: laack.nadia@mayo.ed [Department of Radiation Oncology, Mayo Clinic, Rochester, MN (United States); Buckner, Jan C. [Department of Oncology, Mayo Clinic, Rochester, MN (United States); Schomberg, Paula J. [Department of Radiation Oncology, Mayo Clinic, Rochester, MN (United States); Wetmore, Cynthia J. [Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN (United States); Brown, Paul D. [Department of Radiation Oncology, Mayo Clinic, Rochester, MN (United States)

2010-08-01

267

From computational modelling of the intrinsic apoptosis pathway to a systems-based analysis of chemotherapy resistance: achievements, perspectives and challenges in systems medicine  

PubMed Central

Our understanding of the mitochondrial or intrinsic apoptosis pathway and its role in chemotherapy resistance has increased significantly in recent years by a combination of experimental studies and mathematical modelling. This combined approach enhanced the quantitative and kinetic understanding of apoptosis signal transduction, but also provided new insights that systems-emanating functions (i.e., functions that cannot be attributed to individual network components but that are instead established by multi-component interplay) are crucial determinants of cell fate decisions. Among these features are molecular thresholds, cooperative protein functions, feedback loops and functional redundancies that provide systems robustness, and signalling topologies that allow ultrasensitivity or switch-like responses. The successful development of kinetic systems models that recapitulate biological signal transduction observed in living cells have now led to the first translational studies, which have exploited and validated such models in a clinical context. Bottom-up strategies that use pathway models in combination with higher-level modelling at the tissue, organ and whole body-level therefore carry great potential to eventually deliver a new generation of systems-based diagnostic tools that may contribute to the development of personalised and predictive medicine approaches. Here we review major achievements in the systems biology of intrinsic apoptosis signalling, discuss challenges for further model development, perspectives for higher-level integration of apoptosis models and finally discuss requirements for the development of systems medical solutions in the coming years. PMID:24874730

Wurstle, M L; Zink, E; Prehn, J H M; Rehm, M

2014-01-01

268

Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy  

SciTech Connect

Purpose: To identify dosimetric parameters associated with acute hematologic toxicity (HT) and chemotherapy delivery in cervical cancer patients undergoing concurrent chemotherapy and intensity-modulated pelvic radiotherapy. Methods and Materials: We analyzed 37 cervical cancer patients receiving concurrent cisplatin (40 mg/m{sup 2}/wk) and intensity-modulated pelvic radiotherapy. Pelvic bone marrow (BM) was contoured for each patient and divided into three subsites: lumbosacral spine, ilium, and lower pelvis. The volume of each region receiving 10, 20, 30, and {>=}40 Gy (V{sub 1}, V{sub 2}, V{sub 3}, and V{sub 4}, respectively) was calculated. HT was graded according to Radiation Therapy Oncology Group system. Multivariate regression models were used to test associations between dosimetric parameters and HT and chemotherapy delivery. Results: Increased pelvic BM V{sub 1} (BM-V{sub 1}) was associated with an increased Grade 2 or worse leukopenia and neutropenia (odds ratio [OR], 2.09; 95% confidence interval [CI], 1.24-3.53; p = 0.006; and OR, 1.41; 95% CI, 1.02-1.94; p = 0.037, respectively). Patients with BM-V{sub 1} {>=}90% had higher rates of Grade 2 or worse leukopenia and neutropenia than did patients with BM-V{sub 1} <90% (11.1% vs. 73.7%, p < 0.01; and 5.6% vs. 31.6%, p = 0.09) and were more likely to have chemotherapy held on univariate (16.7% vs. 47.4%, p = 0.08) and multivariate (OR, 32.2; 95% CI, 1.67-622; p = 0.02) analysis. No associations between HT and V{sub 3} and V{sub 4} were observed. Dosimetric parameters involving the lumbosacral spine and lower pelvis had stronger associations with HT than did those involving the ilium. Conclusion: The volume of pelvic BM receiving low-dose radiation is associated with HT and chemotherapy delivery in cervical cancer patients undergoing concurrent chemoradiotherapy.

Mell, Loren K. [Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States) and Department of Radiation and Cellular Oncology, University of Illinois at Chicago, Chicago, IL (United States)]. E-mail: lmell@radonc.uchicago.edu; Kochanski, Joel D. [Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Department of Radiation and Cellular Oncology, University of Illinois at Chicago, Chicago, IL (United States); Roeske, John C. [Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Department of Radiation and Cellular Oncology, University of Illinois at Chicago, Chicago, IL (United States); Haslam, Josh J. [Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Department of Radiation and Cellular Oncology, University of Illinois at Chicago, Chicago, IL (United States); Mehta, Neil [Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Department of Radiation and Cellular Oncology, University of Illinois at Chicago, Chicago, IL (United States); Yamada, S. Diane [Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Hurteau, Jean A.; Collins, Yvonne C. [Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Illinois at Chicago, Chicago, IL (United States); Lengyel, Ernst [Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL (United States); Mundt, Arno J. [Department of Radiation Oncology, University of California, San Diego, School of Medicine, La Jolla, CA (United States)

2006-12-01

269

A Semantic-Serializability Based Fully-Distributed Concurrency Control Mechanism for Mobile Multi-Database Systems  

Microsoft Academic Search

The nodes of a mobile ad hoc network (MANET) represent mobile computers in which database systems (DBSs) may reside. In such an environment, we may have a mobile multidatabase system (mobile MDBS), i.e., a collection of autonomous, distributed, heterogeneous and mobile DBSs, where each mobile computer can access multiple DBSs of that collection by means of global transactions. In this

Angelo Brayner; Frank Stefan Alencar

2005-01-01

270

Chemotherapy of squamous cell carcinoma of the skin.  

PubMed

The role of systemic chemotherapy with cytotoxic agents in squamous cell carcinoma of the skin remains uncertain. A number of agents in combination have been reported to induce high rates of remission, either alone or as a component of a multidisciplinary management plan. Fragmentary data suggest that the most benefit is achieved when chemotherapy is applied to patients with advanced local disease not easily treated with surgery either due to location (eg, on the face) or comorbidity. Concurrent chemoradiation has been recommended for the control of extensive lymph node involvement as a result of experience derived from similar studies in patients with squamous cell carcinomas of the head and neck, cervix, and anus. No standard treatment of metastatic disease has been formulated, although combinations of cisplatin with 5-fluorouracil (5-FU), doxorubicin, or bleomycin have demonstrated some degree of efficacy, achieving complete responses (CRs) in some cases. Clearly, the relative rarity of patients with high-risk, potentially fatal, squamous cell carcinoma of the skin has limited prospective efforts to define ideal management. As our awareness of the increasing numbers of such problem patients becomes clear, hopefully more efforts will be forthcoming. PMID:22484186

DeConti, Ronald C

2012-04-01

271

Improving Network Processing Concurrency using TCPServers  

Microsoft Academic Search

Exponentially growing bandwidth requirements and slowing gains in processor speeds have led to the popularity of multi- processor architectures. Network stack parallelism is increas- ingly important to support such architectures. In this paper, we present techniques to improve network stack concurrency using our previous work, TCPServers, a system architecture for offload- ing network processing within an SMP system. TCPServers dedi-

Aniruddha Bohra; Liviu Iftode

2007-01-01

272

A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial  

Microsoft Academic Search

Currently, no prognostic gene-expression signature (GES) established from node-positive breast cancer cohorts, able to predict\\u000a evolution after systemic adjuvant chemotherapy, exists. Gene-expression profiles of 252 node-positive breast cancer patients\\u000a (median follow-up: 7.7 years), mostly included in a randomized clinical trial (PACS01), receiving systemic adjuvant regimen,\\u000a were determined by means of cDNA custom array. In the training cohort, we established a GES

Pascal Jézéquel; Mario Campone; Henri Roché; Wilfried Gouraud; Catherine Charbonnel; Gabriel Ricolleau; Florence Magrangeas; Stéphane Minvielle; Jean Genève; Anne-Laure Martin; Régis Bataille; Loïc Campion

2009-01-01

273

Preparation of chemotherapy drugs: planning policy for reduced waiting times  

E-print Network

Preparation of chemotherapy drugs: planning policy for reduced waiting times I.H.J. Masselink1 , T policies on patient waiting time in the Chemotherapy Day Unit of the Netherland Cancer Institute - Antoni Modelling, Queueing Systems, Pharmacy, Chemotherapy 1 Introduction Netherlands Cancer Institute - Antoni van

Boucherie, Richard J.

274

Coupling climate models with earth system modeling framework and common component architecture. Concurrency and Computation: Practice and Experience  

E-print Network

Typical Earth system models involve coupled model components in high-performance computing (HPC) environments. In the last few years, several frameworks have been developed for HPC applications. Two of them are component-based frameworks: the Earth System Modeling Framework (ESMF) defining a component interface for Earth system models and the Common Component Architecture (CCA) defining a generic component model. The purpose of this work is to investigate the relationship between ESMF and CCA to deploy the best features of ESMF and CCA into a ESMF–CCA prototype and examine the prototype through a representative coupled climate model. Copyright c ? 2005 John Wiley & Sons, Ltd. KEY WORDS: framework; climate model; model coupling 1.

S. J. Zhou

2006-01-01

275

Data Flow Analysis for Checking Properties of Concurrent Java Programs  

Microsoft Academic Search

ABSTRACT In this paper we show how the FLAVERS data flow anal - ysis technique, originally formulated for systems using a rendezvous concurrency model, can be applied to the vari - ous concurrency models used in Java programs The gen - eral approach of FLAVERS is based on modeling a concur - rent system as a flow graph and, using

George S. Avrunin; Gleb Naumovich; Lori A. Clarke

1998-01-01

276

Concurrent calorimetric and interferometric studies of steady-state natural convection from miniaturized horizontal single plate-fin systems and plate-fin arrays  

E-print Network

Concurrent calorimetric and interferometric studies have been conducted to investigate the effect that reduction of the base-plate dimensions has on the steady-state performance of the rate of natural convection heat ...

Harahap, Filino

277

Optimization of Concurrent Deployments of the Juvenile Salmon Acoustic Telemetry System and Other Hydroacoustic Equipment at John Day Dam.  

National Technical Information Service (NTIS)

The purpose of this report is to document the results of the acoustic optimization study conducted at John Day Dam during January and February 2008. The goal of the study was to optimize performance of the Juvenile Salmon Acoustic Telemetry System (JSATS)...

A. W. Cushing, F. Khan, G. R. Ploskey, J. S. Hughes, Z. Deng

2008-01-01

278

Concurrency emulation and analysis of parallel applications for multi-processor system-on-chip co-design  

Microsoft Academic Search

This paper presents a novel technique for the modeling and the simulation of parallel applications for Multi-Processor Systems-on-Chip (MPSoCs). This technique consists of an application-transparent emulation of OS primitives, includ- ing task creation, scheduling, synchronization etc.; this emu- lation guarantees compatibility with any program compiled against the standard POSIX library, independently of the target OS. This methodology can be used

Giovanni Beltrame; Luca Fossati; Donatella Sciuto

2008-01-01

279

Chemotherapy induced Takotsubo cardiomyopathy  

PubMed Central

Chemotherapy has been linked with Takotsubo cardiomyopathy. Most of the literature on chemotherapy associated Takotsubo cardiomyopathy is on the drug 5-fluorouracil. In this report, we describe the case of a 55-year-old Asian male who developed Takotsubo cardiomyopathy while receiving dual chemotherapy with cytarabine and daunorubicin for acute myeloid leukemia. To our knowledge, it is the first case of Takotsubo cardiomyopathy associated with daunorubicin and/or cytarabine.

Goel, Sunny; Sharma, Abhishek; Garg, Aakash; Chandra, Abhinav; Shetty, Vijay

2014-01-01

280

Chemotherapy induced Takotsubo cardiomyopathy.  

PubMed

Chemotherapy has been linked with Takotsubo cardiomyopathy. Most of the literature on chemotherapy associated Takotsubo cardiomyopathy is on the drug 5-fluorouracil. In this report, we describe the case of a 55-year-old Asian male who developed Takotsubo cardiomyopathy while receiving dual chemotherapy with cytarabine and daunorubicin for acute myeloid leukemia. To our knowledge, it is the first case of Takotsubo cardiomyopathy associated with daunorubicin and/or cytarabine. PMID:25325068

Goel, Sunny; Sharma, Abhishek; Garg, Aakash; Chandra, Abhinav; Shetty, Vijay

2014-10-16

281

Update on Chemotherapy in the Treatment of Urothelial Carcinoma  

PubMed Central

Urothelial carcinoma is the fifth most common malignancy diagnosed each year in the United States. Neoadjuvant and adjuvant chemotherapy are given to decrease the risk of recurrent or metastatic disease with the more robust clinical data supporting the former. Bladder preservation utilizes a trimodality approach with maximal transurethral resection followed by concurrent chemotherapy and radiation and is appropriate for select patients. Gemcitabine and cisplatin is the current standard of care for first-line treatment in fit patients with metastatic disease. Optimal second-line therapy remains undefined, and targeted agents are under investigation. Clinical trial participation should be encouraged in patients with urothelial carcinoma of the bladder to help improve treatment regimens and outcomes. Synopsis. Chemotherapy is commonly used in the treatment of urothelial carcinoma of the bladder. This paper will review the role of chemotherapy in the neoadjuvant, adjuvant, bladder sparing, and metastatic settings. PMID:22125450

Costantini, Carrie; Millard, Frederick

2011-01-01

282

Multidisciplinary Concurrent Design Optimization via the Internet  

NASA Technical Reports Server (NTRS)

A methodology is presented which uses commercial design and analysis software and the Internet to perform concurrent multidisciplinary optimization. The methodology provides a means to develop multidisciplinary designs without requiring that all software be accessible from the same local network. The procedures are amenable to design and development teams whose members, expertise and respective software are not geographically located together. This methodology facilitates multidisciplinary teams working concurrently on a design problem of common interest. Partition of design software to different machines allows each constituent software to be used on the machine that provides the most economy and efficiency. The methodology is demonstrated on the concurrent design of a spacecraft structure and attitude control system. Results are compared to those derived from performing the design with an autonomous FORTRAN program.

Woodard, Stanley E.; Kelkar, Atul G.; Koganti, Gopichand

2001-01-01

283

Concurrent execution of timed Petri nets  

Microsoft Academic Search

The dynamics of discrete event systems can be effectivelydescribed and analyized using the timed Petrinet formalism. The aim of this paper is to comprehensivelypresent the achievements attained in acceleratingPetri net executions by using parallel ordistributed multiprocessing environments. The basicproblem is to generate concurrent Petri net executionsinsuring correctness in the sense that the partialordering of transition firings produced is consistentwith the

Alois Ferscha

1994-01-01

284

Photoswitchable nanoparticles for in vivo cancer chemotherapy  

E-print Network

There are many obstacles to effective cancer chemotherapy, including drug penetration and accumulation in tumors and drug systemic toxicity. The penetration of therapies into tumors is limited by the dense tumor matrix and ...

Tong, Rong

285

Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients.  

PubMed

We evaluated whether the sequence or regimen of systemic chemotherapy could be a risk factor for breast cancer-related lymphedema (LE). We retrospectively analyzed 848 patients with stage II/III breast cancer who underwent curative surgery with adequate systemic therapy from 2004 to 2009. Adjuvant chemotherapy (ACT) was performed in 552 patients (65.1 %) and neoadjuvant chemotherapy (NAC) in 296 (34.9 %). We evaluated the incidence of LE based on clinicopathological factors and treatments. At a median follow-up of 5.1 years, 358 patients (42.2 %) had experienced LE and 243 (28.7 %) had retained (persistent LE) [120/552 (21.7 %) with ACT vs. 123/296 (41.6 %) with NAC; P < 0.001]. The incidence of LE in patients with taxane was greater than in those without taxane [233/704 (33.1 %) vs. 10/144 (6.9 %); P < 0.001]. Multivariate analysis showed that NAC [hazard ratio (HR), 1.63 in LE event; P < 0.001; HR, 1.39 in persistent LE; P = 0.02] and RT including supraclavicular area (SCRT) (HR 1.55; P = 0.02; HR 1.93; P = 0.006), number of dissected axillary lymph nodes (N-ALNs) >10 (HR, 1.37; P = 0.01; HR, 1.71; P = 0.001), advanced stage (HR, 1.31; P = 0.03; HR, 1.60; P = 0.002), and taxane (HR, 1.69; P = 0.03; HR, 2.07; P = 0.04) were independent risk factors for the LE occurrence. In addition to advanced stage, N-ALNs and SCRT, NAC, and taxane were shown to increase the risk of LE, which could help clinicians identify patients at risk for LE. PMID:25253173

Jung, So-Youn; Shin, Kyung Hwan; Kim, Myungsoo; Chung, Seung Hyun; Lee, Seeyoun; Kang, Han-Sung; Lee, Eun Sook; Kwon, Youngmee; Lee, Keun Seok; Park, In Hae; Ro, Jungsil

2014-11-01

286

An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels.  

PubMed

The current study characterizes the impact of docetaxel (DTX) distribution on efficacy following sustained intraperitoneal (IP) chemotherapy in murine models of ovarian cancer. A polymer-lipid biodegradable depot (PoLigel) was used to deliver DTX in a sustained manner over 21-days following IP administration. Distribution and efficacy studies were carried out in SCID mice bearing SKOV3 IP solid tumors or C57BL/6 mice with ID8 IP ascites fluid. In addition, a subcutaneous (SC) SKOV3 model was used to determine whether systemic drug levels that result from IP administration of the PoLigel influence antitumor efficacy. Immunostained IP and SC SKOV3 tumor sections were used to study cell death, intratumoral drug distribution and tumor penetration. Sustained concentrations of DTX were observed in plasma, tissue, tumor and ascites over the entire study period. Drug accumulation was several fold greater in tumors and ascites when compared to plasma levels. Sustained chemotherapy resulted in significant reduction in tumor burden and ascites volume. IP tumors showed greater cell death compared to the SC tumors as seen by higher TUNEL and caspase-3 expression. At the intratumoral level, DTX distributed more towards the core of IP tumors compared to the SC tumors. Tumor penetration of drug from nearest blood vessel was 1.5 fold greater in the IP tumors than the SC tumors. Overall, favorable drug distribution at the whole-body, peritoneal and intratumoral levels in combination with local and systemic sustained drug exposure contribute to the high efficacy observed. These results encourage the clinical use of IP sustained chemotherapy for ovarian cancer. PMID:22154933

Zahedi, Payam; Stewart, James; De Souza, Raquel; Piquette-Miller, Micheline; Allen, Christine

2012-03-28

287

A Compiler Approach to Scalable Concurrent Program Design  

E-print Network

abstractions. The compiler techniques are based on a simple transformation system together with a setA Compiler Approach to Scalable Concurrent Program Design Ian Foster Stephen Taylor Computer Science Department California institute of Technology #12;A Compiler Approach to Scalable Concurrent

288

SiLCC Is Linear Concurrent Constraint Programming  

Microsoft Academic Search

Introduction. The Concurrent Constraint (CC) (8) languages allow to model a large number of constraint programming systems, form Prolog coroutinings to constraints propagation mechanisms such these implemented in the Finite Domain (FD) solver of GNU-Prolog (2). These languages are an extension of CLP obtained by an addition of a synchronization primitive based on constraint implication. The Linear Concurrent Constraint (LCC)

Remy Haemmerle

2005-01-01

289

JAMA Patient Page: Chemotherapy  

MedlinePLUS

... cells as well. As a result, people undergoing chemotherapy often have side effects, which can be uncomfortable. • Nausea and vomiting are ... purchase bulk reprints, call 312/464-0776. Common side effects of chemotherapy treatment Nausea and vomiting Hair Temporary loss of ...

290

What's New in Chemotherapy Research?  

MedlinePLUS

... about chemotherapy Next Topic To learn more What’s new in chemotherapy research? Over the years, many people ... control, and some will come back. Several exciting new uses of chemotherapy and other agents hold even ...

291

A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer  

PubMed Central

The role of neoadjuvant chemotherapy and/or radiation for localized or potentially resectable cholangiocarcinoma (CCA) has not been well established. We present here the case of a patient with an extrahepatic CCA who achieved a pathologic complete response after undergoing preoperative gemcitabine-based chemotherapy, without sequential or concurrent use of radiation. Further evaluation of neoadjuvant strategies in CCA, including not only combined-modality therapy but also the use of chemotherapy exclusively, is warranted in prospective study design.

Walker, Evan J.; Simko, Jeffry P.; Nakakura, Eric K.

2014-01-01

292

Concurrent Teacher Education Program Introduction  

E-print Network

Program (CTEP) is intended for students who wish to become school-teachers in selected areas of study upon schools. CTEP students can prepare for teaching careers at both the elementary (Primary/Junior or PJ1 Concurrent Teacher Education Program HANDBOOK Introduction The Concurrent Teacher Education

Wells, Mathew G. - Department of Physical and Environmental Sciences, University of Toronto

293

A Thesis for Bounded Concurrency  

Microsoft Academic Search

In recent work, we have investigated the power of bounded cooperative concurrency. The underlying notion involves enriching computational devices with a bounded number of concurrent components that communicate, synchronize, or otherwise cooperate. Comparisons involving succinctness and the time complexity of reasoning about programs have been undertaken. The results, which are extremely robust, show that in all the cases we have

David Harel

1989-01-01

294

[A case of peritonitis carcinomatosa from goblet cell carcinoid of the appendix treated by intraperitoneal paclitaxel and systemic S-1 chemotherapy].  

PubMed

Goblet cell carcinoid of the appendix is a rare neoplasm and clinically tends to take a malignant course. Most cases are young and early stage, and the surgical strategy is available. But appropriate chemotherapy for inoperable cases with peritoneal dissemination is not established. A 77-year-old woman with a past history of appendectomy was admitted to our hospital complaining of abdominal fullness. Abdominal computed tomography showed massive ascites and slight contrast enhancement of appendix. A tumor was found by colonoscopic examination at the orifice of vermiform and was diagnosed pathologically as goblet cell carcinoid of the appendix. Laparoscopy showed multiple peritoneal dissemination. We performed intraperitoneal paclitaxel(PTX)administration at 70 mg/m(2) week without any resection of the tumor. Ascites were reduced immediately, but drug-induced interstitial pneumonia occurred due to PTX. After steroid therapy, we switched to systemic S-1 therapy. For about one year, her tumor was controlled but became worse thirteen months after diagnosis and died. It is thought that intraabdominal paclitaxel administration and systemic S-1 therapy can be one of appropriate forms of chemotherapy for inoperable peritoneal carcinomatosis from goblet cell carcinoid of appendix. PMID:19098416

Nakamura, Shingen; Kimura, Shigeaki; Kashima, Masahiro; Shichijo, Kana; Yoshida, Sumiko; Harada, Eiji; Matsushita, Takaya; Oshima, Yasushi; Tamaki, Yasutami; Horiuchi, Noriaki; Takeichi, Toshiaki; Fujimoto, Hiroshi; Masuda, Kazuhiko; Iwasaka, Naohito; Shinomiya, Sadao

2008-12-01

295

Adult medulloblastoma: multiagent chemotherapy.  

PubMed

In this study, the records of 17 adult patients with medulloblastoma treated with craniospinal radiation and 1 of 2 multiagent chemotherapy protocols were reviewed for progression-free survival, overall survival, and toxicity, and the patients were compared with each other and with similarly treated children and adults. Records of patients treated at 3 institutions were reviewed. Seventeen medulloblastoma patients (11 female, 6 male) with a median age of 23 years (range, 18-47 years) were treated with surgery, craniospinal radiation (CSRT) plus local boost, and 1 of 2 adjuvant chemotherapy regimens. All tumors were infratentorial (10 in 4th ventricle and 7 in left or right hemisphere). Ten patients presented with hydrocephalus, and 7 of them were shunted. Eight patients had gross total resection, 7 had subtotal resection (>50% removed), and 2 had partial resection (<50% removed). Postoperatively, 3 patients had positive cytology and 3 had positive spinal MRI. Five patients were classified as good risk and 12 were classified as poor risk (Chang staging system). Ten patients were treated with the "Packer protocol," consisting of CSRT plus weekly vincristine followed by 8 cycles of cisplatin, lomustine, and vincristine. Seven patients were treated with the Pediatric Oncology Group (POG) protocol, consisting of alternating courses of cisplatin/etoposide and cyclophosphamide/vincristine, followed by CSRT. Eight of 17 patients relapsed, with all 8 relapsing at the primary site. Other relapse sites included the leptomeninges (5), bone (1), and brain (1). The estimated median relapse-free survival (Kaplan-Meier) for all patients was 48 months (95% confidence interval, >26 months to infinity). Median relapse-free survival for patients on the Packer protocol was 26 months, and for those on the POG regimen was 48 months (P = 0.410). Five of 10 on the Packer protocol were relapse-free, while 4 of 7 were relapse-free on the POG regimen. Two patients relapsed during chemotherapy and 6 relapsed after completing all therapy at 18, 18, 26, 30, 40, and 48 months. The estimated median survival of all patients was 56 months (95% confidence interval, 27 to infinity) with 11 patients alive; for the Packer protocol, median survival was 36 months, and for the POG protocol, it was 57 months (P = 0.058). The hazard ratio was 0 (95% confidence interval, 0 to infinity). Toxicity during the Packer protocol was moderately severe, with only 1 of 10 patients able to complete all therapy. Two patients had severe abdominal pain during CSRT + vincristine, and 5 had peripheral neuropathy during vincristine therapy. Hearing loss (>20 dB) occurred in 7, neutropenia (<500 microl) in 6, thrombocytopenia (<50,000 microl) in 6, nephrotoxicity (>25% decrease by creatinine clearance) in 2, and decreased pulmonary function (diffusing capacity for carbon monoxide decrease >40%) in 1. On the POG protocol, only 1 patient had persistent nausea and vomiting, 2 had peripheral neuropathy, and 3 had hearing deficit (>20 dB) or tinnitus. The POG and Packer protocols did not have a statistically significant difference in relapse-free or overall survival because of the small sample size. The POG protocol seemed to have less nonhematologic toxicity. Adults on the Packer protocol appeared to have shorter median survival and greater toxicity than did children. To know whether adding adjuvant chemotherapy to craniospinal radiation in adult therapy increases relapse-free and overall survival, we must await the results of a larger randomized controlled clinical trial. PMID:11305414

Greenberg, H S; Chamberlain, M C; Glantz, M J; Wang, S

2001-01-01

296

Chemotherapy-related Changes in Central Nervous System Phospholipids and Neurocognitive Function in Childhood Acute Lymphoblastic Leukemia  

PubMed Central

Long-term survivors of childhood leukemia are at risk for neurocognitive impairment, though the neurophysiological basis is not well understood. The purpose of this study was to explore associations between changes in cerebrospinal fluid (CSF) phospholipids and neurocognitive function in children undergoing chemotherapy for acute lymphoblastic leukemia. 76 children were followed prospectively from diagnosis. CSF samples were collected during scheduled lumbar punctures and phospholipids were extracted. Neurocognitive evaluations were conducted annually beginning shortly after diagnosis. Concentrations of sphingomyelin (SM) increased following induction (p=0.03) and consolidation (p=0.04), while lysophosphatidylcholine (LPC) increased following induction (p=0.003). Multivariable analyses demonstrated associations between post-induction SM and motor speed at one (p<0.001), two (p=0.001), and three (p=0.02) years following diagnosis. Post-induction LPC was associated with verbal working memory (p=0.007). Results indicate early changes in phospholipids are related to neurocognitive decline and suggest a chemotherapy impact on white matter integrity. PMID:22856670

Krull, Kevin R.; Hockenberry, Marilyn J.; Miketova, Petra; Carey, Marissa; Moore, Ida M.

2013-01-01

297

Supervisory Control and Deadlock Avoidance Control Problem for Concurrent Discrete Event  

E-print Network

Supervisory Control and Deadlock Avoidance Control Problem for Concurrent Discrete Event Systems.Gaudin,Herve.Marchand}@irisa.fr Abstract-- We tackle the Non-Blocking Supervisory Control Problem control for Concurrent Discrete Event first outline the method allowing to solve the state avoidance control problem on concurrent systems. We

Paris-Sud XI, Université de

298

Integrated concurrent utilization quality review, Part one.  

PubMed

This article is the first of a two-part series which argues for the concurrent management of the appropriateness, necessity, and quality of patient care. Intensifying scrutiny by the credentialing groups, the PROs and all third-party payors underscores the vital need to implement cost-effective information systems which integrate the departmentalized functions of patient-physician profiling, DRG case-mix analyses, length of stay monitoring, pre-admission/admission and continued stay review, discharge planning, risk management, incident reporting and quality review. In the domain of physician performance regarding admitting and practice patterns, the ability to exercise concurrent utilization-quality review means early detection and prevention of events which would otherwise result in denials of payment and/or compromised patient care. Concurrent utilization-quality review must, by definition, be managerially invasive and focused; hence, it is integral to maintaining the integrity of the services and product lines offered by the provider. In fact, if PPO status is a marketing agenda, then the institutional objectives of cost-effectiveness, productivity, value, and competitiveness can only be achieved through concurrent utilization-quality review. PMID:10291443

Caterinicchio, R P

1987-01-01

299

On optimal chemotherapy with a strongly targeted agent for a model of tumor-immune system interactions with generalized logistic growth.  

PubMed

In this paper, a mathematical model for chemotherapy that takes tumor immune-system interactions into account is considered for a strongly targeted agent. We use a classical model originally formulated by Stepanova, but replace exponential tumor growth with a generalised logistic growth model function depending on a parameter v. This growth function interpolates between a Gompertzian model (in the limit v ? 0) and an exponential model (in the limit v ? ?). The dynamics is multi-stable and equilibria and their stability will be investigated depending on the parameter v. Except for small values of v, the system has both an asymptotically stable microscopic (benign) equilibrium point and an asymptotically stable macroscopic (malignant) equilibrium point. The corresponding regions of attraction are separated by the stable manifold of a saddle. The optimal control problem of moving an initial condition that lies in the malignant region into the benign region is formulated and the structure of optimal singular controls is determined. PMID:23906150

Ledzewicz, Urszula; Olumoye, Omeiza; Schättler, Heinz

2013-06-01

300

A Logic for True Concurrency  

NASA Astrophysics Data System (ADS)

We propose a logic for true concurrency whose formulae predicate about events in computations and their causal dependencies. The induced logical equivalence is hereditary history preserving bisimilarity, and fragments of the logic can be identified which correspond to other true concurrent behavioural equivalences in the literature: step, pomset and history preserving bisimilarity. Standard Hennessy-Milner logic, thus (interleaving) bisimilarity, is also recovered as a fragment. We believe that this contributes to a rational presentation of the true concurrent spectrum and to a deeper understanding of the relations between the involved behavioural equivalences.

Baldan, Paolo; Crafa, Silvia

301

Side Effects of Chemotherapy  

MedlinePLUS

... PCF Spotlight Glossary African American Men Living with Prostate Cancer Side Effects of Chemotherapy Side Effects Urinary Dysfunction ... side effects of docetaxel as used to treat prostate cancer are VERY different and less severe than the ...

302

Chemotherapy (For Parents)  

MedlinePLUS

... through a needle inserted into a fluid-filled space in the lower spine (below the spinal cord) Chemotherapy is sometimes used along with other cancer treatments, such as radiation therapy, surgery, or biological therapy (the use of substances ...

303

Chemotherapy induced peripheral neuropathic pain.  

PubMed

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most serious complications associated with anticancer drugs. CIPN leads to a lower quality of life and dysfunction of the sensory, motor, and autonomic systems, and often causes patients to discontinue chemotherapy. It is usually misdiagnosed and undertreated due to a lack of consensus and unclear pathophysiology, for which many mechanisms have been suggested, including mitochondrial dysfunction, various pain mediators, abnormal spontaneous discharge in A and C fibers, and others. To date, no agents have been shown to effectively prevent CIPN, leading to debate as to the standard protocol. Duloxetine has demonstrated a moderate therapeutic effect against CIPN. Although tricyclic antidepressants (such as nortriptyline or desipramine), gabapentin, and a topical gel containing baclofen (10 mg), amitriptyline HCL (40 mg), and ketamine (20 mg) showed inconclusive results in CIPN trials, these agents are currently considered the best options for CIPN treatment. Therefore, further studies on the pathophysiology and treatment of CIPN are needed. PMID:25097731

Park, Hue Jung

2014-07-01

304

Intraperitoneal Chemotherapy in Patients with Advanced Ovarian Cancer: The Con View  

Microsoft Academic Search

Objectives. In this paper we wish to present the reasons why i.p. chemotherapy cannot be accepted as standard of care for first-line systemic treatment of advanced ovarian carcinoma. Methods. The recent literature on i.p. chemotherapy iscriticallyreviewed.Allpossibleargumentsagainsti.p. chemotherapy are reviewed. Conclusions. Intraperitoneal chemotherapy is associ- ated with a higher toxicity rate than i.v. chemotherapy. For this reason, none of the regimens

IGNACE VERGOTE; F. Amant; K. Leunen; I. Cadron; T. Van Gorp; P. Neven; P. Berteloot

2008-01-01

305

29 CFR 541.106 - Concurrent duties.  

...DEPARTMENT OF LABOR REGULATIONS DEFINING AND DELIMITING THE EXEMPTIONS FOR EXECUTIVE, ADMINISTRATIVE, PROFESSIONAL, COMPUTER AND OUTSIDE SALES EMPLOYEES Executive Employees § 541.106 Concurrent duties. (a) Concurrent...

2014-07-01

306

Intel Concurrent Collections for Haskell  

E-print Network

Intel Concurrent Collections (CnC) is a parallel programming model in which a network of steps (functions) communicate through message-passing as well as a limited form of shared memory. This paper describes a new ...

Newton, Ryan

2011-03-22

307

Chemotherapy for upper gastrointestinal tumours  

PubMed Central

The aim of this review is to identify current chemotherapy treatment for tumours of the oesophagus, stomach, pancreas, and liver. The role of both neoadjuvant, adjuvant, and palliative chemotherapy regimens will be discussed. This review will be of interest to oncologists in clarifying current issues regarding chemotherapy, and to physicians in other medical specialties, to increase their general understanding of benefits and drawbacks of chemotherapy in this patient group.???Keywords: cancer; oesophagus; stomach; pancreas; chemotherapy PMID:10824043

Thomas, A; O'Byrne, K; Steward, W

2000-01-01

308

Concurrent Stereotactic Radiosurgery and Bevacizumab in Recurrent Malignant Gliomas: A Prospective Trial  

SciTech Connect

Purpose: Virtually all patients with malignant glioma (MG) eventually recur. This study evaluates the safety of concurrent stereotactic radiosurgery (SRS) and bevacizumab (BVZ), an antiangiogenic agent, in treatment of recurrent MG. Methods and Materials: Fifteen patients with recurrent MG, treated at initial diagnosis with surgery and adjuvant radiation therapy/temozolomide and then at least 1 salvage chemotherapy regimen, were enrolled in this prospective trial. Lesions <3 cm in diameter were treated in a single fraction, whereas those 3 to 5 cm in diameter received 5 5-Gy fractions. BVZ was administered immediately before SRS and 2 weeks later. Neurocognitive testing (Mini-Mental Status Exam, Trail Making Test A/B), Functional Assessment of Cancer Therapy-Brain (FACT-Br) quality-of-life assessment, physical exam, and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) were performed immediately before SRS and 1 week and 2 months following completion of SRS. The primary endpoint was central nervous system (CNS) toxicity. Secondary endpoints included survival, quality of life, microvascular properties as measured by DCE-MRI, steroid usage, and performance status. Results: One grade 3 (severe headache) and 2 grade 2 CNS toxicities were observed. No patients experienced grade 4 to 5 toxicity or intracranial hemorrhage. Neurocognition, quality of life, and Karnofsky performance status did not change significantly with treatment. DCE-MRI results suggest a significant decline in tumor perfusion and permeability 1 week after SRS and further decline by 2 months. Conclusions: Treatment of recurrent MG with concurrent SRS and BVZ was not associated with excessive toxicity in this prospective trial. A randomized trial of concurrent SRS/BVZ versus conventional salvage therapy is needed to establish the efficacy of this approach.

Cabrera, Alvin R. [Department of Radiation Oncology, Duke University, Durham, North Carolina (United States); Cuneo, Kyle C. [Department of Radiation Oncology, Duke University, Durham, North Carolina (United States); Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan (United States); Desjardins, Annick [Department of Surgery, Duke University, Durham, North Carolina (United States); Sampson, John H. [Department of Radiation Oncology, Duke University, Durham, North Carolina (United States); Department of Surgery, Duke University, Durham, North Carolina (United States); McSherry, Frances; Herndon, James E. [Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina (United States); Peters, Katherine B. [Department of Surgery, Duke University, Durham, North Carolina (United States); Allen, Karen [Department of Radiation Oncology, Duke University, Durham, North Carolina (United States); Hoang, Jenny K. [Department of Radiology, Duke University, Durham, North Carolina (United States); Chang, Zheng; Craciunescu, Oana [Department of Radiation Oncology, Duke University, Durham, North Carolina (United States); Vredenburgh, James J.; Friedman, Henry S. [Department of Surgery, Duke University, Durham, North Carolina (United States); Kirkpatrick, John P., E-mail: john.kirkpatrick@dm.duke.edu [Department of Radiation Oncology, Duke University, Durham, North Carolina (United States); Department of Surgery, Duke University, Durham, North Carolina (United States)

2013-08-01

309

Corporate ontologies and concurrent engineering  

Microsoft Academic Search

Concurrent engineering is based on the co-operation and collaboration of multi-disciplinary people who need to communicate and exchange information. Communication, as well as knowledge sharing and exchanging, are the corner stones of concurrent engineering. But each enterprise’s actor speaks his own language, with his own terms and meanings: the enterprise, and especially the virtual enterprise, is a Tower of Babel.

Christophe Roche

2000-01-01

310

Why Events Are a Bad Idea (for High-Concurrency Servers)  

Microsoft Academic Search

Event-based programming has been highly touted in recent years as the best way to write highly concurrent applications. Having worked on several of these systems, we now believe this approach to be a mistake. Specifically, we believe that threads can achieve all of the strengths of events, including support for high concurrency, low overhead, and a simple concurrency model. Moreover,

J. Robert Von Behren; Jeremy Condit; Eric A. Brewer

2003-01-01

311

Software For Drawing Design Details Concurrently  

NASA Technical Reports Server (NTRS)

Software system containing five computer-aided-design programs enables more than one designer to work on same part or assembly at same time. Reduces time necessary to produce design by implementing concept of parallel or concurrent detailing, in which all detail drawings documenting three-dimensional model of part or assembly produced simultaneously, rather than sequentially. Keeps various detail drawings consistent with each other and with overall design by distributing changes in each detail to all other affected details.

Crosby, Dewey C., III

1990-01-01

312

Small-cell lung cancer: initial treatment with sequential hemi-body irradiation VS 3-drug systemic chemotherapy.  

PubMed Central

The therapeutic value of sequential hemi-body irradiation (HBI) as a primary treatment for small-cell lung cancer (SCLC) was compared to 3-drug cyclic chemotherapy (CC) in a group of 64 patients with early and advanced disease. Thirty patients were randomized to receive sequential HBI and 34 to receive CC. All patients received a local radiation boost to the primary lesion. An overall response rate of 87% was obtained in patients treated with sequential HBI and 88% in patients treated with CC. In patients with early disease, the estimated median survival was 43 weeks when treated with HBI and 42 weeks when treated with CC, but in advanced disease the estimated median survival was 15 weeks and 44 weeks respectively. Of the patients with an initial complete response, the estimated median survival was 51 weeks for HBI and 62 weeks for CC. From these observations we suggest that sequential HBI treatment technique with local radiation boost is an efficient method of tumour control in patients with early small-cell lung cancer. PMID:6295422

Urtasun, R. C.; Belch, A. R.; McKinnon, S.; Higgins, E.; Saunders, W.; Feldstein, M.

1982-01-01

313

Is concurrent chemoradiation the standard of care for locally advanced non-small cell lung cancer? A review of guidelines and evidence.  

PubMed

In the past 15 years, the treatment of locally advanced non-small cell lung cancer (NSCLC) has shifted from radiotherapy alone. There are now schedules using induction chemotherapy, concurrent chemoradiation using either radiosensitising doses of chemotherapy or full-dose chemotherapy, consolidation chemotherapy after radiation or combinations of these options. There is no consensus on the optimal chemotherapy regimen and its scheduling and the issue of radiation dose and optimal fractionation equally remains unresolved. This overview is in two sections. First, we have evaluated a selection of international guidelines on the management of locally advanced NSCLC. We assessed the methodology by which individual guidelines were produced and the levels of evidence quoted in support of the recommendations. Second, we have updated the literature search of the 2004 Cochrane review on concurrent chemoradiation. Trials were identified that compared sequential with concurrent chemoradiation using median survival as the primary outcome measure. Two-year survival and toxicity were evaluated as secondary outcome measures. Eleven trials were identified, of which six fulfilled criteria for inclusion. The median survival for concurrent treatment was 16-17 months compared with 13-15 months with sequential treatment. Treatment-related mortality was 3% for concurrent treatment and 1.7% for sequential treatment. The rate of grade 3 or worse oesophagitis was 19% in concurrent treatment compared with 3% for sequential treatment. In conclusion, chemotherapy adds benefit to radiotherapy treatment of locally advanced NSCLC. Concurrent chemoradiation is associated with significant toxicity. The evidence to support concurrent chemoradiation as the standard of care is not robust, in spite of its recommendation within a number of guidelines. Further trials should be supported. PMID:20427167

O'Rourke, N; Macbeth, F

2010-06-01

314

Inhaled chemotherapy in lung cancer: future concept of nanomedicine  

PubMed Central

Regional chemotherapy was first used for lung cancer 30 years ago. Since then, new methods of drug delivery and pharmaceuticals have been investigated in vitro, and in animals and humans. An extensive review of drug delivery systems, pharmaceuticals, patient monitoring, methods of enhancing inhaled drug deposition, safety and efficacy, and also additional applications of inhaled chemotherapy and its advantages and disadvantages are presented. Regional chemotherapy to the lung parenchyma for lung cancer is feasible and efficient. Safety depends on the chemotherapy agent delivered to the lungs and is dose-dependent and time-dependent. Further evaluation is needed to provide data regarding early lung cancer stages, and whether regional chemotherapy can be used as neoadjuvant or adjuvant treatment. Finally, inhaled chemotherapy could one day be administered at home with fewer systemic adverse effects. PMID:22619512

Zarogoulidis, Paul; Chatzaki, Ekaterini; Porpodis, Konstantinos; Domvri, Kalliopi; Hohenforst-Schmidt, Wolfgang; Goldberg, Eugene P; Karamanos, Nikos; Zarogoulidis, Konstantinos

2012-01-01

315

Neoadjuvant Concurrent Chemoradiation for Curative Treatment of Penile Squamous Cell Carcinoma  

PubMed Central

Introduction. Penile cancer is a rare malignancy often treated with neoadjuvant chemotherapy followed by surgery. However, the utility of neoadjuvant chemoradiation, particularly when the tumor is resistant to chemotherapy alone, has not been established. In this study, we report a case of pT3cN3M0 penile squamous cell carcinoma with progression of nodal disease on chemotherapy, which was cured with use of neoadjuvant concurrent chemoradiation. Case Report. A 65-year-old male presented with a fixed left inguinal lymph node with associated firmness of the penile glans. Biopsies of both sites revealed evidence of squamous cell carcinoma. The patient underwent partial penectomy for the primary lesion and began neoadjuvant chemotherapy to reduce the size of the unresectable left inguinal node. However, he displayed disease progression in the left inguinal node. As such, we attempted concurrent chemoradiation therapy with regression of his nodal disease. The patient was able to undergo left inguinal node dissection and has no evidence of disease 18 months since his initial surgery. Conclusion. The use of neoadjuvant chemoradiation for bulky cN2-3 disease seems appropriate in the setting of progressive disease. Further studies are necessary to assess the utility of concurrent chemoradiation both in the neoadjuvant and salvage setting.

Schwartz, David; Leaf, Andrea; Karanikolas, Nikolaos; Weiss, Jeffrey P.; Schreiber, David

2014-01-01

316

Imperfect Information in Logic and Concurrent Games  

E-print Network

Imperfect Information in Logic and Concurrent Games Pierre Clairambault1 , Julian Gutierrez2 of Oxford Abstract. This paper builds on a recent definition of concurrent games as event structures and an application giving a concurrent-game model for predicate calculus. An extension to concurrent games

Winskel, Glynn

317

Chemotherapy and signaling  

PubMed Central

In recent years, oncologists have begun to conclude that chemotherapy has reached a plateau of efficacy as a primary treatment modality, even if toxicity can be effectively controlled. Emerging specific inhibitors of signaling and metabolic pathways (i.e., targeted agents) contrast with traditional chemotherapy drugs in that the latter primarily interfere with the DNA biosynthesis and the cell replication machinery. In an attempt to improve on the efficacy, combination of targeted drugs with conventional chemotherapeutics has become a routine way of testing multiple new agents in early phase clinical trials. This review discusses the recent advances including integrative systematic biology and RNAi approaches to counteract the chemotherapy resistance and to buttress the selectivity, efficacy and personalization of anticancer drug therapy. PMID:20935499

Bagnyukova, Tetyana; Serebriiskii, Ilya G; Zhou, Yan; Hopper-Borge, Elizabeth A; Golemis, Erica A

2010-01-01

318

Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination  

Microsoft Academic Search

Paclitaxel and docetaxel are currently the two clinically available taxanes. The combination of a taxane and a platinum compound has become the systemic chemotherapy of choice for primary ovarian cancer. Despite the high activity of these drugs in systemic chemotherapy, the majority of patients with advanced ovarian cancer will develop recurrent disease and ultimately decease of this disease. Therefore, more

E. de Bree; H. Rosing; J. Michalakis; J. Romanos; K. Relakis; P. A. Theodoropoulos; J. H. Beijnen; V. Georgoulias; D. D. Tsiftsis

2006-01-01

319

Learning from Mistakes --- A Comprehensive Study on Real World Concurrency Bug Characteristics. In the proceedings of the 13th International Conference on Architecture Support for Programming Languages and Operating Systems (ASPLOS'08), March 2008  

SciTech Connect

The reality of multi-core hardware has made concurrent programs pervasive. Unfortunately, writing correct concurrent programs is dif#2;cult. Addressing this challenge requires advances in multiple directions, including concurrency bug detection, concurrent program testing, concurrent programming model design, etc. Designing effective techniques in all these directions will signi#2;cantly bene#2;t from a deep understanding of real world concurrency bug characteristics. This paper provides the #2;rst (to the best of our knowledge) comprehensive real world concurrency bug characteristic study. Specifically, we have carefully examined concurrency bug patterns, manifestation, and #2;x strategies of 105 randomly selected real world concurrency bugs from 4 representative server and client opensource applications (MySQL, Apache, Mozilla and OpenOf#2;ce). Our study reveals several interesting #2;ndings and provides useful guidance for concurrency bug detection, testing, and concurrent programming language design. Some of our #2;ndings are as follows: (1) Around one third of the examined non-deadlock concurrency bugs are caused by violation to programmers' order intentions, which may not be easily expressed via synchronization primitives like locks and transactional memories; (2) Around 34% of the examined non-deadlock concurrency bugs involve multiple variables, which are not well addressed by existing bug detection tools; (3) About 92% of the examined concurrency bugs can be reliably triggered by enforcing certain orders among no more than 4 memory accesses. This indicates that testing concurrent programs can target at exploring possible orders among every small groups of memory accesses, instead of among all memory accesses; (4) About 73% of the examined non-deadlock concurrency bugs were not #2;xed by simply adding or changing locks, and many of the #2;xes were not correct at the #2;rst try, indicating the dif#2;culty of reasoning concurrent execution by programmers.

Yuanyuan Zhou

2008-03-01

320

Update on Adjuvant Chemotherapy for Early Breast Cancer  

PubMed Central

Breast cancer is the second most common cancer in women worldwide. Although most women are diagnosed with early breast cancer, a substantial number recur due to persistent micro-metastatic disease. Systemic adjuvant chemotherapy improves outcomes and has advanced from first-generation regimens to modern dose-dense combinations. Although chemotherapy is the cornerstone of adjuvant therapy, new biomarkers are identifying patients who can forego such treatment. Neo-adjuvant therapy is a promising platform for drug development, but investigators should recognize the limitations of surrogate endpoints and clinical trials. Previous decades have focused on discovering, developing, and intensifying adjuvant chemotherapy. Future efforts should focus on customizing therapy and reducing chemotherapy for patients unlikely to benefit. In some cases, it may be possible to replace chemotherapy with treatments directed at specific genetic or molecular breast cancer subtypes. Yet, we anticipate that chemotherapy will remain a critical component of adjuvant therapy for years to come. PMID:25336961

Rampurwala, Murtuza M; Rocque, Gabrielle B; Burkard, Mark E

2014-01-01

321

High-level language debugging for concurrent programs  

Microsoft Academic Search

An integrated system design for debugging distributed programs written in concurrent high-level languages is described. A variety of user-interface, monitoring, and analysis tools integrated around a uniform process model are provided. Because the tools are language-based, the user does not have to deal with low-level implementation details of distribution and concurrency, and instead can focus on the logic of the

German S. Goldszmidt; Shaula Yemini; Shmuel Katz

1990-01-01

322

Managing Chemotherapy Side Effects: Pain  

MedlinePLUS

... services national institutes of health Managing Chemotherapy Side Effects Pain “I was worried about getting addicted to ... to pay for pain medicine. Managing Chemotherapy Side Effects: Pain Keep track of the pain. Each day, ...

323

Surgical or percutaneous hepatic artery cannulation for chemotherapy.  

PubMed

The principle underlying administration of hepatic arterial chemotherapy (HACT) is to increase the local concentration of cytotoxic chemotherapy while limiting systemic toxicity. The chemotherapy agent is infused into the hepatic artery distal to branches that serve the stomach, duodenum, and pancreas. The intra-arterial catheter is connected to a subcutaneously implanted reservoir to allow repeated sessions of chemotherapy. Percutaneous placement is now a reliable and reproducible technique in the hands of well-trained interventional radiologists. Hepatic arterial cannulation by an open surgical approach is currently reserved for cases where the decision for HACT is made in the course of an hepatic surgical procedure. PMID:24582544

De Baere, T; Mariani, P

2014-04-01

324

Chemotherapy and Your Mouth  

MedlinePLUS

... problems. Check your mouth every day. Back to Top Why Should I See a Dentist? You may be surprised that your dentist is important ... 1 month, if possible, before chemotherapy begins. If you have already started ... Back to Top What Will the Dentist and Dental Hygienist Do? ...

325

Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer  

PubMed Central

Background Concurrent chemoradiotherapy (EBRT + cisplatin) plus intracavitary brachytherapy is the standard of care in patients with advanced cervical cancer. However, a number of patients could not undergone brachytherapy due to massive residual tumor or anatomical distortion. In this study, we have evaluated the treatment outcome in patients with locally advanced cervical cancer, undergone conventional EBRT plus cisplatin based chemotherapy. Methods In this study, we have selected patients with locally advanced cervical carcinoma (stage: IIB to IIIB) undergone external beam radiotherapy and chemotherapy without brachytherapy at our institute between October of 2007 and October of 2009. The patients have received 50 Gy within 5 weeks to whole pelvic that has followed by a localized boost dose on tumor to 70 Gy concurrently with cisplatin 35 mg/m2 weekly. The treatment has related toxicities, and survival (overall and disease free) have evaluated. Results 30 cases with a median age of 55 (range; 40 to 73) have been studied. According to FIGO classification, the clinical stages were as follows: stage: IIB 23, IIIA 4, and IIIB 3 cases. Three months after treatment, 19 patients (63.3%) have achieved complete response. With a median follow up time of 18 months (range; 10-33 months), 8/23 cases (34.7%) with stage IIB and 2/7 (28.5%) among stage IIIA-IIIB remained disease free at the end of follow up. Data have shown a 2-year overall survival rate of 58.7% ± 9% and 2- year disease free survival of 37.7% ± 9% . Most toxicities were grade I and II. 2 (6.6%) grade III diarrhea and 4 (13.3%) grade III neutropenia have recorded. Conclusion Although a considerable number of patients have achieved complete response using concurrent chemoradiotherapy without brachytherapy, the overall treatment outcomes especially for stage IIIA-IIIB were unsatisfactory. Using modern radiation therapy techniques with increased delivered boost dose could improve treatment results. PMID:25250134

Kadkhodayan, Sima; Homaei Shandiz, Fatemeh; Seilanian Toussi, Mehdi; Afzal Aghaee, Monavar; Farshidi, Farnoosh; Dehghan, Parvane

2013-01-01

326

Adjuvant chemotherapy following radical cystectomy  

Microsoft Academic Search

The optimal management of invasive bladder cancer remains controversial. Combination chemotherapy regimens have been increasingly advocated in association with definitive local therapy in an attempt at eradicating micrometastases and reducing the risk of recurrence. Chemotherapy used after radical cystectomy is referred to as “adjuvant” therapy. The term adjuvant is occasionally used for chemotherapy following an aggressive transurethral resection (TUR). Decisions

C. N. Sternberg

1993-01-01

327

Chemotherapy Operations Planning and Scheduling  

Microsoft Academic Search

Chemotherapy Operations Planning and Scheduling Turkcan et al. Chemotherapy operations planning and scheduling in oncology clinics is a complex problem due to several factors such as the cyclic nature of chemotherapy treatment plans, the high variability in resource requirements (treatment time, nurse time, pharmacy time) and the multiple clinic resources involved. Treatment plans are made by oncologists for each patient

Ayten Turkcan; Bo Zeng; Mark Lawley

2012-01-01

328

A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy  

E-print Network

the systemic side effects of chemotherapy drugs and otherreduce the toxic side effects of chemotherapy agents is tochemotherapy agents known, its clinical application is limited by its harmful side effects,

Ibsen, Stuart; Zahavy, Eran; Wrasdilo, Wolf; Berns, Michael; Chan, Michael; Esener, Sadik

2010-01-01

329

Using Diffuse Optical Tomography to Monitor Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients  

E-print Network

Using Diffuse Optical Tomography to Monitor Tumor Response to Neoadjuvant Chemotherapy in Breast ABSTRACT Breast cancer patients often undergo neoadjuvant chemotherapy to reduce the size of the tumor of breast cancer patients to neoadjuvant chemotherapy. Our breast imaging system is a continuous wave system

Hielscher, Andreas

330

Concurrent Games and Full Completeness  

Microsoft Academic Search

Abstract A new concurrent form of game semantics is introduced This overcomes the problems which had arisen with previ - ous, sequential forms of game semantics in modelling Lin - ear Logic It also admits an elegant and robust formal - ization A Full Completeness Theorem for Multiplicative - Additive Linear Logic is proved for this semantics

Samson Abramsky; Paul-andré Melliès

1999-01-01

331

Graphics techniques in concurrent simulation  

Microsoft Academic Search

This paper discusses work occurring in the hypercube simulation laboratory and visualization schemes for concurrent simulation. The principle contribution of this work is that of a cost effective technical approach to simulation visualization. This approach is being replicated and applied to contemporary large scale simulation problems of interest around the country.Since the hypercube graphics interface is a working prototype there

Van Warren; Pasadena California

1988-01-01

332

Visualization of Concurrent Program Executions  

NASA Technical Reports Server (NTRS)

Various program analysis techniques are efficient at discovering failures and properties. However, it is often difficult to evaluate results, such as program traces. This calls for abstraction and visualization tools. We propose an approach based on UML sequence diagrams, addressing shortcomings of such diagrams for concurrency. The resulting visualization is expressive and provides all the necessary information at a glance.

Artho, Cyrille; Havelund, Klaus; Honiden, Shinichi

2007-01-01

333

Transactional Monitors for Concurrent Objects  

Microsoft Academic Search

Transactional monitors are proposed as an alternative to monitors based on mutual-exclusion synchronization for object-oriented programming languages. Transactional monitors have execution semantics similar to mutual- exclusion monitors but implement monitors as lightweight transactions that can be executed concurrently (or in parallel on multiprocessors). They alleviate many of the constraints that inhibit construction of transparently scalable and robust applications. We undertake

Adam Welc; Suresh Jagannathan; Antony L. Hosking

2004-01-01

334

Solving problems on concurrent processors  

Microsoft Academic Search

This book explains how many major scientific algorithms can be used on large parallel machines. Based on five years of research on hypercubes, the book concentrates on practically motivated model problems, that serve to illustrate generic algorithmic and decomposition techniques. The authors include results for hypercube-class concurrent computers with up to 128 nodes, and the principles behind the extrapolation to

G Fox

1988-01-01

335

Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Cervical Cancer Patients Undergoing Concurrent Chemoradiotherapy  

PubMed Central

Objective We compare different dosimetric parameters in cervical cancer patients receiving concurrent chemotherapy and three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT) and explore the incidence of hematological toxicity (HT) in these patients. Methods Twenty patients receiving 3DCRT or IMRT and 4 weekly doses of cisplatin (25 mg/m2/w) were studied. The volumes of bone marrow receiving 10, 20, 30, 40 and 50 Gy or greater (V10, V20, V30, V40, and V50, respectively) were calculated. The HT was graded according to the guidelines of the Radiation Therapy Oncology Group system. The associations between dosimetric parameters and HT and chemotherapy delivery were analyzed. Results The bone marrows V30, V40, and V50 were lower in the IMRT group than in the 3DCRT group (62.93% vs 76.91%, 31.36% vs 39.60%, and 9.79% vs 15.44%, respectively). No statistical difference was observed for both V10 and V20. Acute hematologic toxicity occurred in both groups but was more frequent in the 3DCRT group. The percentage of patients with grade 2 and worse leukopenia and neutropenia was 90% and 80% in the 3DCRT group, whereas it was 80% and 40% in the IMRT group. The median nadir of white blood cells and the absolute neutrophil count were significantly lower in the 3DCRT group than in the IMRT group (1.96 × 109 vs 2.72 × 109 and 1.09 × 109 vs 1.86 × 109, respectively). Conclusion The IMRT reduced the volume of bone marrow irradiated at the higher doses and the incidence and severity of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy. PMID:25275663

Hui, Beina; Zhang, Yingbing; Shi, Fan; Wang, Juan; Wang, Tao; Wang, Jiquan; Yuan, Wei; Li, Yi; Liu, Zi

2014-01-01

336

Primary Tumor Necrosis Predicts Distant Control in Locally Advanced Soft-Tissue Sarcomas After Preoperative Concurrent Chemoradiotherapy  

SciTech Connect

Purpose: Various neoadjuvant approaches have been evaluated for the treatment of locally advanced soft-tissue sarcomas. This retrospective study describes a uniquely modified version of the Eilber regimen developed at the University of Chicago. Methods and Materials: We treated 34 patients (28 Stage III and 6 Stage IV) with locally advanced soft-tissue sarcomas of an extremity between 1995 and 2008. All patients received preoperative therapy including ifosfamide (2.5 g/m2 per day for 5 days) with concurrent radiation (28 Gy in 3.5-Gy daily fractions), sandwiched between various chemotherapy regimens. Postoperatively, 47% received further adjuvant chemotherapy. Results: Most tumors (94%) were Grade 3, and all were T2b, with a median size of 10.3 cm. Wide excision was performed in 29 patients (85%), and 5 required amputation. Of the resected tumor specimens, 50% exhibited high (>=90%) treatment-induced necrosis and 11.8% had a complete pathologic response. Surgical margins were negative in all patients. The 5-year survival rate was 42.3% for all patients and 45.2% for Stage III patients. For limb-preservation patients, the 5-year local control rate was 89.0% and reoperation was required for wound complications in 17.2%. The 5-year freedom-from-distant metastasis rate was 53.4% (Stage IV patients excluded), and freedom from distant metastasis was superior if treatment-induced tumor necrosis was 90% or greater (84.6% vs. 19.9%, p = 0.02). Conclusions: This well-tolerated concurrent chemoradiotherapy approach yields excellent rates of limb preservation and local control. The resulting treatment-induced necrosis rates are predictive of subsequent metastatic risk, and this information may provide an opportunity to guide postoperative systemic therapies.

MacDermed, Dhara M. [Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL (United States); Miller, Luke L. [Pritzker School of Medicine, University of Chicago, Chicago, IL (United States); Peabody, Terrance D.; Simon, Michael A.; Luu, Hue H.; Haydon, Rex C. [Section of Orthopaedic Surgery and Rehabilitation, Department of Surgery, University of Chicago, Chicago, IL (United States); Montag, Anthony G. [Department of Pathology, University of Chicago, Chicago, IL (United States); Undevia, Samir D. [Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL (United States); Connell, Philip P., E-mail: pconnell@radonc.uchicago.ed [Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL (United States)

2010-03-15

337

Chemotherapy of tuberculosis  

Microsoft Academic Search

Summary  In order to fit the sulphonamides and sulphones out better for use in the chemotherapy of tuberculosis and leprosy, synthesis\\u000a has been effected of a series ofo-phthalic ando-toluic acid derivatives of well-known sulphonamides and disubstituted diphenyl sulphones as possible mycobacterial antagonists.\\u000a \\u000a Phthalic ando-toluic acid derivatives were chosen for synthesis in view of the recent theory advanced by Shemiakin that the

C. V. Deliwala; S. Rajagopalan

1950-01-01

338

Intensity-Modulated Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer: Toxicities and Efficacy  

PubMed Central

Background. Intensity-modulated radiation therapy (IMRT) and alternative chemotherapy regimens strive to maintain efficacy while minimizing toxicity in locally advanced head and neck cancer (LAHNC) treatment. Our experience with concurrent IMRT and taxane-based chemotherapy is presented. Methods. A retrospective review of 150 consecutive patients with LAHNC treated with IMRT and concurrent taxane-based chemotherapy with curative intent was performed. The IMRT fractionation regimen consisted of 69.3 Gy to gross disease (2.1 Gy/fraction) and 56.1 Gy to prophylactic nodal sites (1.7 Gy/fraction). Weekly paclitaxel (30 mg/m2) and carboplatin (area under the concentration–time curve [AUC], 1) were given concurrently to all patients, and 69% received weekly induction with paclitaxel (60 mg/m2) and carboplatin (AUC, 2). Results. Over 90% of patients received the prescribed radiation dose. Ninety-six percent completed five or more cycles of concurrent chemotherapy, with similar tolerability for induction chemotherapy. A percutaneous endoscopic gastrostomy (PEG) tube was required in 80 patients, with 10 maintaining PEG use >18 months. Acute grade 4 mucositis and dermatitis developed in 2.0% and 4.0% of patients, respectively. No patient experienced nadir sepsis, grade ?3 late xerostomia, or significant nephropathy or gastrointestinal toxicity. Median follow-up was 30 months. The 3-year locoregional control rate was 83.2% with disease-free survival and overall survival rates of 78.8% and 76.5%, respectively. Conclusion. Rates of acute and late toxicities were low, with excellent radiation dose delivery and impressive tumor control at 3 years, suggesting that concurrent carboplatin and paclitaxel with IMRT is a reasonable therapeutic option for the curative treatment of LAHNC. PMID:22550060

Vlacich, Gregory; Diaz, Roberto; Thorpe, Steven W.; Murphy, Barbara A.; Kirby, Wyndee; Sinard, Robert J.; Shakhtour, Bashar; Shyr, Yu; Murphy, Patrick; Netterville, James L.; Yarbrough, Wendell G.

2012-01-01

339

A quantitative and qualitative evaluation of LISA, a decision support system for chemotherapy dosing in childhood Acute Lymphoblastic Leukaemia  

Microsoft Academic Search

Objectives: To assess the acceptability to clinicians of a web- based decision support system designed to assist with dosage adjustments during maintenance therapy for childhood Acute Lymphoblastic Leukaemia (ALL), and to evaluate the potential impact of the system on decision-making and dosage calcula- tions. Design: Balanced-block crossover experiment with simulated cases; questionnaire study and semi-structured in- terviews. Participants: 36 clinicians

Jonathan Bury; Chris Hurt; Anindita Roy; Mike Bradburn; Simon Cross; John Fox; Vaskar Saha

340

Chemotherapy with cisplatin or carboplatin in combination with etoposide for small-cell esophageal cancer: a systemic analysis of case series.  

PubMed

Chemotherapy has been the first-choice treatment for small-cell esophageal cancer (SCEC), etoposide plus cisplatin or carboplatin (EP/CP) is the most commonly recommended chemotherapeutical strategy. However, the choice of chemotherapy in treating SCEC has not been validated by studies of large cohorts of cases because of the rarity of the malignancy, and the efficacy superiority of EP/CP over other chemotherapy combinations has not been confirmed. The present case series analysis was conducted to address the above issues. Reported studies of SCEC patients were retrieved. Case series with more than five patients were enrolled. Eight patients treated in our institute were also included as another case series. Data pertaining to clinical stages, treatment regimens, and survival time were collected and analyzed. Altogether, 19 SCEC case series were enrolled, including 164 male and 61 female patients with a median age of 63.5?years. The follow-up time ranged from 0.1 to 221 months (median 12.3 months). The median survival time (MST) was 19 months for limited disease (LD) patients (124 cases) and 9 months for extensive disease (ED) patients (88 cases) (P < 0.001). For LD patients, MST was obviously prolonged by chemotherapeutical regimens (20 vs. 10 months, P < 0.01), whereas this superiority was not proved in ED patients (10 vs. 10 months, P > 0.05). EP/CP did not result in significantly longer MST, compared with that of the cases treated by other chemotherapy combinations (P > 0.05, for either LD or ED cases). Chemotherapy prolongs the survival time of the LD SCEC patients, which indicates that chemotherapeutical treatment is effective for SCEC. EP/CP, as commonly recommended multidrug chemotherapy regimen, is not superior to other chemotherapy combinations. PMID:24118373

Gao, R; Zhang, Y; Wen, X P; Fu, J; Zhang, G J

2014-11-01

341

Altered Cerebral Blood Flow One Month after Systemic Chemotherapy for Breast Cancer: A Prospective Study Using Pulsed Arterial Spin Labeling MRI Perfusion  

PubMed Central

Cerebral structural and functional alterations have been reported after chemotherapy for non-CNS cancers, yet the causative mechanism behind these changes remains unclear. This study employed a novel, non-invasive, MRI-based neuroimaging measure to provide the first direct longitudinal measurement of resting cerebral perfusion in breast cancer patients, which was tested for association with changes in cognitive function and gray matter density. Perfusion was measured using pulsed arterial spin labeling MRI in women with breast cancer treated with (N?=?27) or without (N?=?26) chemotherapy and matched healthy controls (N?=?26) after surgery before other treatments (baseline), and one month after chemotherapy completion or yoked intervals. Voxel-based analysis was employed to assess perfusion in gray matter; changes were examined in relation to overall neuropsychological test performance and frontal gray matter density changes measured by structural MRI. Baseline perfusion was not significantly different across groups. Unlike control groups, chemotherapy-treated patients demonstrated significantly increased perfusion post-treatment relative to baseline, which was statistically significant relative to controls in the right precentral gyrus. This perfusion increase was negatively correlated with baseline overall neuropsychological performance, but was not associated with frontal gray matter density reduction. However, decreased frontal gray matter density was associated with decreased perfusion in bilateral frontal and parietal lobes in the chemotherapy-treated group. These findings indicate that chemotherapy is associated with alterations in cerebral perfusion which are both related to and independent of gray matter changes. This pattern of results suggests the involvement of multiple mechanisms of chemotherapy-induced cognitive dysfunction. Additionally, lower baseline cognitive function may be a risk factor for treatment-associated perfusion dysregulation. Future research is needed to clarify these mechanisms, identify individual differences in susceptibility to treatment-associated changes, and further examine perfusion change over time in survivors. PMID:24816641

McDonald, Brenna C.; Conroy, Susan K.; Smith, Dori J.; West, John D.; O'Neill, Darren P.; Schneider, Bryan P.; Saykin, Andrew J.

2014-01-01

342

Intraperitoneal chemotherapy against peritoneal carcinomatosis: current status and future perspective.  

PubMed

Peritoneal carcinomatosis (PC), caused by advanced abdominal malignancies, such as those of the ovarian and gastrointestinal tracts, has an extremely poor prognosis. Intraperitoneal (IP) chemotherapy has been clinically applied for several decades, but its clinical efficacy has not been fully determined. An accumulating body of evidence suggests that cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is the optimal treatment for selected patients with ovarian and colorectal cancers with PC. Recent studies suggest that IP administration of taxane with systemic chemotherapy in a neoadjuvant setting improves patient survival in gastric cancer with PC. The pharmacokinetics of IP-administered drugs should be primarily considered in order to optimize IP chemotherapy. Therefore, the development of specific IP drugs using newly emerging molecular targeted reagents or new drug delivery systems, such as nanomedicine or controlled absorption/release methods, is essential to improve the efficacy of IP chemotherapy. PMID:24721661

Kitayama, Joji

2014-06-01

343

Toxicity of concurrent radiochemotherapy for locally advanced non--small-cell lung cancer: a systematic review of the literature.  

PubMed

Concurrent radiochemotherapy (RCT) is the treatment of choice for patients with locally advanced non-small-cell lung cancer (NSCLC). Two meta-analyses were inconclusive in an attempt to define the optimal concurrent RCT scheme. Besides efficacy, treatment toxicity will influence the appointed treatment of choice. A systematic review of the literature was performed to record the early and late toxicities, as well as overall survival, of concurrent RCT regimens in patients with NSCLC. The databases of PubMed, Ovid, Medline, and the Cochrane Library were searched for articles on concurrent RCT published between January 1992 and December 2009. Publications of phase II and phase III trials with ? 50 patients per treatment arm were selected. Patient characteristics, chemotherapy regimen (mono- or polychemotherapy, high or low dose) and radiotherapy scheme, acute and late toxicity, and overall survival data were compared. Seventeen articles were selected: 12 studies with cisplatin-containing regimens and 5 studies using carboplatin. A total of 13 series with mono- or polychemotherapy schedules--as single dose or double or triple high-dose or daily cisplatin-containing (? 30 mg/m(2)/wk) chemotherapy were found. Acute esophagitis ? grade 3 was observed in up to 18% of the patients. High-dose cisplatin regimens resulted in more frequent and severe hematologic toxicity, nausea, and vomiting than did other schemes. The toxicity profile was more favorable in low-dose chemotherapy schedules. From phase II and III trials published between 1992 and 2010, it can be concluded that concurrent RCT with monochemotherapy consisting of daily cisplatin results in favorable acute and late toxicity compared with concurrent RCT with single high-dose chemotherapy, doublets, or triplets. PMID:23751283

Koning, Caro C; Wouterse, Sanne J; Daams, Joost G; Uitterhoeve, Lon L; van den Heuvel, Michel M; Belderbos, José S

2013-09-01

344

A Multimode Optical Imaging System for Preclinical Applications In Vivo: Technology Development, Multiscale Imaging, and Chemotherapy Assessment  

PubMed Central

Purpose Several established optical imaging approaches have been applied, usually in isolation, to preclinical studies; however, truly useful in vivo imaging may require a simultaneous combination of imaging modalities to examine dynamic characteristics of cells and tissues. We developed a new multimode optical imaging system designed to be application-versatile, yielding high sensitivity, and specificity molecular imaging. Procedures We integrated several optical imaging technologies, including fluorescence intensity, spectral, lifetime, intravital confocal, two-photon excitation, and bioluminescence, into a single system that enables functional multiscale imaging in animal models. Results The approach offers a comprehensive imaging platform for kinetic, quantitative, and environmental analysis of highly relevant information, with micro-to-macroscopic resolution. Applied to small animals in vivo, this provides superior monitoring of processes of interest, represented here by chemo-/nanoconstruct therapy assessment. Conclusions This new system is versatile and can be optimized for various applications, of which cancer detection and targeted treatment are emphasized here. PMID:21874388

Hwang, Jae Youn; Wachsmann-Hogiu, Sebastian; Ramanujan, V. Krishnan; Ljubimova, Julia; Gross, Zeev; Gray, Harry B.; Medina-Kauwe, Lali K.; Farkas, Daniel L.

2012-01-01

345

[Antitumoral immunization during cancer chemotherapy].  

PubMed

Most anticancer agents are thought to act through direct induction of tumoral, stromal and endothelial cell death by apoptosis or necrosis. In a 2008 issue of Bulletin de l'Académie Nationale de Médecine, we described an alternative (or complementary) theory whereby the immune system participates in the antitumoral effects of some chemotherapy or radiotherapy regimens by promoting an immunogenic cell death pathway. In particular, we showed the critical importance of two pre-mortem stressors that determine the immunogenicity of dying tumor cells. The first, an ER stress response culminating in calreticuline exposure at the tumor cell surface, is mandatory for the uptake and efficient phagocytosis of apoptotic bodies by dendritic cells. In the second, autophagy leads to the release of ATP by dying tumor cells, resulting in the recruitment of inflammatory phagocytes and antigen-presenting cells, and also triggering the inflammasome that causes IL-1beta release and CD8+ T cell polarization. The tumor microenvironment changes following chemotherapy, favoring sequential accumulation of a series of innate and cognate effectors that act in a coordinated fashion to promote tumor eradication. These findings will help to identify immune predictors of the response to conventional anticancer treatments and to design innovative combinatorial immunochemotherapy regimens. PMID:23596856

Zitvogel, Laurence; Hannani, Dalil; Aymeric, Laetitia; Kepp, Oliver; Martins, Isabelle; Kroemer, Guido

2012-06-01

346

Chemotherapy and Dietary Phytochemical Agents  

PubMed Central

Chemotherapy has been used for cancer treatment already for almost 70 years by targeting the proliferation potential and metastasising ability of tumour cells. Despite the progress made in the development of potent chemotherapy drugs, their toxicity to normal tissues and adverse side effects in multiple organ systems as well as drug resistance have remained the major obstacles for the successful clinical use. Cytotoxic agents decrease considerably the quality of life of cancer patients manifesting as acute complaints and impacting the life of survivors also for years after the treatment. Toxicity often limits the usefulness of anticancer agents being also the reason why many patients discontinue the treatment. The nutritional approach may be the means of helping to raise cancer therapy to a new level of success as supplementing or supporting the body with natural phytochemicals cannot only reduce adverse side effects but improve also the effectiveness of chemotherapeutics. Various plant-derived compounds improve the efficiency of cytotoxic agents, decrease their resistance, lower and alleviate toxic side effects, reduce the risk of tumour lysis syndrome, and detoxify the body of chemotherapeutics. The personalised approach using various phytochemicals provides thus a new dimension to the standard cancer therapy for improving its outcome in a complex and complementary way. PMID:23320169

Sak, Katrin

2012-01-01

347

Concurrent processing simulation of the space station  

NASA Technical Reports Server (NTRS)

The development of a new capability for the time-domain simulation of multibody dynamic systems and its application to the study of a large angle rotational maneuvers of the Space Station is described. The effort was divided into three sequential tasks, which required significant advancements of the state-of-the art to accomplish. These were: (1) the development of an explicit mathematical model via symbol manipulation of a flexible, multibody dynamic system; (2) the development of a methodology for balancing the computational load of an explicit mathematical model for concurrent processing; and (3) the implementation and successful simulation of the above on a prototype Custom Architectured Parallel Processing System (CAPPS) containing eight processors. The throughput rate achieved by the CAPPS operating at only 70 percent efficiency, was 3.9 times greater than that obtained sequentially by the IBM 3090 supercomputer simulating the same problem. More significantly, analysis of the results leads to the conclusion that the relative cost effectiveness of concurrent vs. sequential digital computation will grow substantially as the computational load is increased. This is a welcomed development in an era when very complex and cumbersome mathematical models of large space vehicles must be used as substitutes for full scale testing which has become impractical.

Gluck, R.; Hale, A. L.; Sunkel, John W.

1989-01-01

348

Concurrent initialization for Bearing-Only SLAM.  

PubMed

Simultaneous Localization and Mapping (SLAM) is perhaps the most fundamental problem to solve in robotics in order to build truly autonomous mobile robots. The sensors have a large impact on the algorithm used for SLAM. Early SLAM approaches focused on the use of range sensors as sonar rings or lasers. However, cameras have become more and more used, because they yield a lot of information and are well adapted for embedded systems: they are light, cheap and power saving. Unlike range sensors which provide range and angular information, a camera is a projective sensor which measures the bearing of images features. Therefore depth information (range) cannot be obtained in a single step. This fact has propitiated the emergence of a new family of SLAM algorithms: the Bearing-Only SLAM methods, which mainly rely in especial techniques for features system-initialization in order to enable the use of bearing sensors (as cameras) in SLAM systems. In this work a novel and robust method, called Concurrent Initialization, is presented which is inspired by having the complementary advantages of the Undelayed and Delayed methods that represent the most common approaches for addressing the problem. The key is to use concurrently two kinds of feature representations for both undelayed and delayed stages of the estimation. The simulations results show that the proposed method surpasses the performance of previous schemes. PMID:22294884

Munguía, Rodrigo; Grau, Antoni

2010-01-01

349

A Geometric Analysis of Bang-Bang Extremals in Optimal Control Problems for Combination Cancer Chemotherapy*  

E-print Network

Chemotherapy* Heinz Sch¨attler Dept. of Electrical and Systems Engineering, Washington University, St. Louis of cancer cells under combination chemotherapies are considered as multi-input optimal control problems over for chemotherapy over a fixed therapy interval. For these problems, and consistent with medical practice, optimal

Ledzewicz, Urszula

350

Optimal Control for a Bilinear Model with Recruiting Agent in Cancer Chemotherapy Urszula Ledzewicz  

E-print Network

Optimal Control for a Bilinear Model with Recruiting Agent in Cancer Chemotherapy Urszula Ledzewicz chemotherapy as optimal control problem for a bilinear system and give necessary and sufficient conditions in mathematical models for cancer chemotherapy when treatment protocols over a fixed therapy interval

Ledzewicz, Urszula

351

Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy  

Microsoft Academic Search

Objective: Despite many trials of systemic chemotherapy in advanced gastric cancer, treatment after failure with first-line chemotherapy\\u000a remains controversial. We prospectively assessed quality of life (QL) in gastric cancer patients treated with second-line\\u000a chemotherapy. Methods: Forty-three patients who received second-line chemotherapy for advanced gastric cancer completed the European Organization\\u000a for Research and Treatment of Cancer (EORTC) QLQ-C30 and hospital anxiety

Se Hoon Park; Woon Ki Lee; Min Chung; Soo-Mee Bang; Eun Kyung Cho; Jae Hoon Lee; Dong Bok Shin

2006-01-01

352

Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.  

PubMed

Ovarian cancer remains the fourth leading cause of cancer death in women in France. It is all too often diagnosed at an advanced stage with peritoneal carcinomatosis (PC), but remains confined to the peritoneal cavity throughout much of its natural history. Because of cellular selection pressure over time, most tumor recurrences eventually develop resistance to systemic platinum. Options for salvage therapy include alternative systemic chemotherapies and further cytoreductive surgery (CRS), but the prognosis remains poor. Over the past two decades, a new therapeutic approach to PC has been developed that combines CRS with hyperthermic intraperitoneal chemotherapy (HIPEC). This treatment strategy has already been shown to be effective in non-gynecologic carcinomatosis in numerous reports. There is a strong rationale for the use of HIPEC for PC of ovarian origin. On the one hand, three prospective randomized trials have demonstrated the superiority of intraperitoneal chemotherapy (without hyperthermia) in selected patients compared to systemic chemotherapy. Moreover, retrospective studies and case-control studies of HIPEC have reported encouraging survival data, especially when used to treat chemoresistant recurrence. However, HIPEC has specific morbidity and mortality; this calls for very careful selection of eligible patients by a multidisciplinary team in specialized centers. HIPEC needs to be evaluated by means of randomized trials for ovarian cancer at different developmental stages: as first line therapy, as consolidation, and for chemoresistant recurrence. Several European phase III studies are currently ongoing. PMID:25168575

Bakrin, N; Classe, J M; Pomel, C; Gouy, S; Chene, G; Glehen, O

2014-10-01

353

A Nanoparticle-Based Combination Chemotherapy Delivery System for Enhanced Tumor Killing by Dynamic Rewiring of Signaling Pathways  

PubMed Central

Exposure to the EGFR (epidermal growth factor receptor) inhibitor erlotinib promotes the dynamic rewiring of apoptotic pathways, which sensitizes cells within a specific period to subsequent exposure to the DNA-damaging agent doxorubicin. A critical challenge for translating this therapeutic network rewiring into clinical practice is the design of optimal drug delivery systems. We report the generation of a nanoparticle delivery vehicle that contained more than one therapeutic agent and produced a controlled sequence of drug release. Liposomes, representing the first clinically approved nanomedicine systems, are well-characterized, simple, and versatile platforms for the manufacture of functional and tunable drug carriers. Using the hydrophobic and hydrophilic compartments of liposomes, we effectively incorporated both hydrophobic (erlotinib) and hydrophilic (doxorubicin) small molecules, through which we achieved the desired time sequence of drug release. We also coated the liposomes with folate to facilitate targeting to cancer cells. When compared to the time-staggered application of individual drugs, staggered release from tumor-targeted single liposomal particles enhanced dynamic rewiring of apoptotic signaling pathways, resulting in improved tumor cell killing in culture and tumor shrinkage in animal models. PMID:24825919

Morton, Stephen W.; Lee, Michael J.; Deng, Zhou J.; Dreaden, Erik C.; Siouve, Elise; Shopsowitz, Kevin E.; Shah, Nisarg J.; Yaffe, Michael B.; Hammond, Paula T.

2014-01-01

354

ASSOCIATION BETWEEN BONE MARROW DOSIMETRIC PARAMETERS ANDACUTE HEMATOLOGIC TOXICITY IN ANAL CANCER PATIENTS TREATED WITH CONCURRENT CHEMOTHERAPYAND INTENSITY-MODULATED RADIOTHERAPY  

Microsoft Academic Search

Purpose: To test the hypothesis that the volume of pelvic bone marrow (PBM) receiving 10 and 20 Gy or more (PBM-V10 and PBM-V20) is associated with acute hematologic toxicity (HT) in anal cancer patients treated with concurrent chemoradiotherapy. Methods and Materials: We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy. The median radiation dose

LOREN K. MELL; DAVID A. SCHOMAS; JOSEPH K. SALAMA; HEDY L. KINDLER; ARNO J. MUNDT; JOHN C. ROESKE; STEVEN J. CHMURA

2008-01-01

355

Concurrent engineering teams. Volume 2: Annotated bibliography  

NASA Astrophysics Data System (ADS)

Specific concurrent engineering practices vary among organizations. There are, however, various management practices that appear to work well for most organizations. This paper presents the reader with specific, useful examples from several defense contractors illustrating how multifunctional concurrent engineering teams are being organized and managed and how concurrent engineering team meetings are conducted and supported. The types of computer support that could be used to enhance the efficiency and effectiveness of concurrent engineering team meetings are identified. The general findings are that there exists a direct relationship between total quality management (TQM) and concurrent engineering, and that many applications of computer-aided group problem solving are possible and practical today for the concurrent engineering team meetings. Areas identified for additional research are the documentation of the decision process and rationale during the product and process definition, the capturing of lessons learned during the implementation of concurrent engineering, and the performance evaluation and training of team members.

Richter, Karen J.; Dierolf, David A.

1990-11-01

356

[Questionnaire survey in Japan for sperm cryopreservation before chemotherapy ].  

PubMed

Questionnaires were mailed to 104 urological departments in universities, colleges, and cancer centers in February 2008. Ninety institutions returned answers to the questionnaire. Sperm cryopreservation before chemotherapy was performed in 24 institutions (26.7%) mainly in the gynecological department, whereas the others introduced the candidates to other institutions including private hospitals and clinics. Fifty-eight institutes gave information about fertility preservation routinely to young patients with testicular cancer before chemotherapy. Urological doctors in 57 institutions (63%) had no experience in consultation of patients with hematological/pediatric malignancies for fertility-preservation. Among 24 institutions performing sperm cryopreservation before chemotherapy, 18 preserved motile sperm even if during chemotherapy, as well as before chemotherapy but 2 institutions replied that patients during chemotherapy were contra-indication for sperm cryopreservation. For the patients with azoospermia, 2 institutions replied they tried to preserve testicular sperm before chemotherapy. The fee for sperm cryopreservation was free in 10 institutions. This nation-wide questionnaire survey clarified that the systems and indications for sperm cryopreservation before chemotherapy were different among institutions. PMID:18975572

Nishiyama, Hiroyuki; Soda, Takeshi; Ichioka, Kentaro; Okubo, Kazutoshi; Ogawa, Osamu

2008-09-01

357

Chemotherapy-induced takotsubo cardiomyopathy.  

PubMed

Two patients presented with takotsubo cardiomyopathy after chemotherapy. Neither of the patients had any known cardiac history until the initiation of chemotherapy. These patients were treated with different chemotherapy regimens appropriate to their malignancies. After chemotherapy initiation, they presented with symptoms ranging from exertional dyspnea to cardiogenic shock requiring intra-aortic balloon pump and pressor support. Cardiac catheterization demonstrated characteristic apical ballooning with nonobstructive coronary artery disease. Both of the patients demonstrated a transient reduction in left ventricular function which resolved on follow-up echocardiography. These cases suggest a potential novel etiology for takotsubo cardiomyopathy. PMID:19057042

Kim, Luke; Karas, Maria; Wong, S Chiu

2008-12-01

358

BlobSeer: Bringing High Throughput under Heavy Concurrency  

E-print Network

versions of Hadoop or other Map/Reduce frameworks. II. SPECIALIZED FILE SYSTEMS FOR DATA-INTENSIVE MAP is a software framework supporting the Map/Reduce programming model. It relies on the Hadoop Dis- tributed File-intensive; Map/Reduce-based applications; Distributed file system; High Throughput; Heavy access concurrency

Paris-Sud XI, Université de

359

Temporal Coding of Concurrent Acoustic Signals in Auditory Midbrain  

Microsoft Academic Search

A fundamental problem faced by the auditory system of hu- mans and other vertebrates is the segregation of concurrent vocal signals. To discriminate between individual vocalizations, the auditory system must extract information about each signal from the single temporal waveform that results from the sum- mation of the simultaneous acoustic signals. Here, we present the first report of midbrain coding

Deana A. Bodnar; Andrew H. Bass

1997-01-01

360

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.  

PubMed

The kidney is involved in 70% of patients with immunoglobulin light-chain (AL) amyloidosis, but little is known on progression or reversibility of renal involvement, and criteria for renal response have never been validated. Newly diagnosed patients from the Pavia (n = 461, testing cohort) and Heidelberg (n = 271, validation cohort) centers were included. Proteinuria >5 g/24 h and estimated glomerular filtration rate (eGFR) <50 mL/min predicted progression to dialysis best. Proteinuria below and eGFR above the thresholds indicated low risk (0 and 4% at 3 years in the testing and validation cohorts, respectively). High proteinuria and low eGFR indicated high risk (60% and 85% at 3 years). At 6 months, a ?25% eGFR decrease predicted poor renal survival in both cohorts and was adopted as criterion for renal progression. A decrease in proteinuria by ?30% or below 0.5 g/24 h without renal progression was the criterion for renal response, being associated with longer renal survival in the testing and validation populations. Hematologic very good partial or complete remission at 6 months improved renal outcome in both populations. We identified and validated a staging system for renal involvement and criteria for early assessment of renal response and progression in AL amyloidosis that should be used in clinical practice and trial design. PMID:25115890

Palladini, Giovanni; Hegenbart, Ute; Milani, Paolo; Kimmich, Christoph; Foli, Andrea; Ho, Anthony D; Rosin, Marta Vidus; Albertini, Riccardo; Moratti, Remigio; Merlini, Giampaolo; Schönland, Stefan

2014-10-01

361

Evaluation of Intrahepatic Perfusion on Fusion Imaging Using a Combined CT/SPECT System: Influence of Anatomic Variations on Hemodynamic Modification Before Installation of Implantable Port Systems for Hepatic Arterial Infusion Chemotherapy  

SciTech Connect

Background. In some patients with hepatic tumors, anatomic variations in the hepatic arteries may require hemodynamic modification to render effective hepatic arterial infusion chemotherapy delivered via implantable port systems. We used a combined CT/SPECT system to obtain fused images of the intrahepatic perfusion patterns in patients with such anatomic variations and assessed their effects on the treatment response of hepatic tumors. Methods. Using a combined SPECT/CT system, we obtained fused images in 110 patients with malignant liver tumors (n = 75) or liver metastasis from unresectable pancreatic cancer (n = 35). Patients with anatomic hepatic arteries variations underwent hemodynamic modification before the placement of implantable port systems for hepatic arterial infusion chemotherapy. We evaluated their intrahepatic perfusion patterns and the initial treatment response of their liver tumors. The perfusion patterns on the fused images were classified as homogeneous, local hypoperfusion, and/or perfusion defect. Using the WHO criteria of complete response (CR), partial response (PR), no change (NC), and progressive disease (PD), we evaluated the patients' tumor responses after 3 months on multislice helical CT scans. The treatment was regarded as effective in patients who achieved a complete response or partial response. Results. Anatomic hepatic artery variations were present in 15 of the 110 patients (13.6%); 5 manifested replacement of the left hepatic artery (LHA), 8 of the right hepatic artery (RHA), and 1 each had replacement of the RHA and LHA, and replacement of the LHA plus an accessory RHA. In 13 of these 15 patients (87%), occlusion with metallic coils was successful. On fusion imaging, the perfusion patterns were recorded as homogeneous in 6 patients (43%), as hypoperfusion in 7 (50%), and 1 patient had a perfusion defect (7.1%) in the embolized arterial region. Of the 8 patients with RHA replacement, 4 manifested a homogeneous distribution and 3 hypoperfusion. In 2 of 5 patients with LHA replacement, the distribution was homogeneous. In 1 patient with RHA and LHA replacement, and in 1 patient with LHA replacement and an accessory RHA, we noted hypoperfusion in the RHA territory. All 6 patients with homogeneous distribution were classified as PR or NC on follow-up multidetector CT. Of the 7 patients manifesting hypoperfusion, 3 were classified as PD (43%), 3 as NC (43%), and 1 as PR (14%) on follow-up CT. Conclusion. Hemodynamic modification of anatomic hepatic artery variations resulted in hypoperfusion on fusion images. Differences in the intrahepatic perfusion patterns may affect the response to hepatic arterial infusion chemotherapy.

Ikeda, Osamu, E-mail: osamu-3643ik@do9.enjoy.ne.jp; Tamura, Yoshitaka; Nakasone, Yutaka; Shiraishi, Shinya; Kawanaka, Kouichi; Tomiguchi, Seiji [Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, Department of Diagnostic Radiology (Japan); Takamori, Hiroshi; Chikamoto, Akira; Kanemitsu, Keiichirou [Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, Department of Gastroenterology Surgery (Japan); Yamashita, Yasuyuki [Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, Department of Diagnostic Radiology (Japan)

2007-06-15

362

Flow Analysis for Verifying Properties of Concurrent Software Matthew B. Dwyer Lori A. Clarke Gleb Naumovich  

E-print Network

Flow Analysis for Verifying Properties of Concurrent Software Systems # Matthew B. Dwyer Lori A@cis.ksu.edu {clarke, jcobleig}@cs.umass.edu gleb@poly.edu Classification D.2.4 Software/Program Verification, D.1 that analyzes whether concurrent systems satisfy user�defined, behavioral properties. FLAVERS automatically

Naumovich, Gleb

363

Flow Analysis for Verifying Properties of Concurrent Software Matthew B. Dwyer Lori A. Clarke Gleb Naumovich  

E-print Network

Flow Analysis for Verifying Properties of Concurrent Software Systems Matthew B. Dwyer Lori A@cis.ksu.edu {clarke, jcobleig}@cs.umass.edu gleb@poly.edu Classification D.2.4 Software/Program Verification, D.1 that analyzes whether concurrent systems satisfy user-defined, behavioral properties. FLAVERS automatically

Naumovich, Gleb

364

The role of chemotherapy and prophylactic bilateral oophorectomy in a case of colorectal adenocarcinoma with ovarian metastases.  

PubMed Central

A 66-year-old female presented with a large abdominal mass and accompanying systemic complaints of abdominal pain, constipation. and fever. On exploratory laparotomy, the mass was found to be a moderately differentiated adenocarcinoma of the sigmoid colon with metastasis to the left ovary. A primary colorectal carcinoma that has metastasized to the ovaries can be difficult to distinguish clinically from an advanced primary ovarian tumor. Histology and tumor markers are currently the most useful tools available in making an accurate diagnosis. If the nature of the primary tumor is uncertain and the initial response to chemotherapy is poor, the patient's prognosis will also he poor. Though controversy exists regarding the role of prophylactic bilateral oophorectomy during resection for primary colorectal cancer, later confusion can be avoided by performing this procedure when the colorectal carcinoma is first diagnosed. However the possibility of a concurrent primary ovarian tumor must not be overlooked. Images Figure 1 PMID:11393261

Shin, E. K.; Takizawa, B. T.; Masters, L.; Shahabi, S.

2001-01-01

365

Thalidomide Combined with Neoadjuvant Chemotherapy in Angiosarcoma of the Breast with Complete Pathologic Response: Case Report and Review of Literature  

PubMed Central

Summary Background Primary angiosarcoma of the breast is a rare malignancy. Case Report We report on a 41-year-old female patient who initially presented with locally advanced disease. Core biopsy showed angiosarcoma of the breast, grade 1, CD31-positive. The patient was treated with neoadjuvant systemic chemotherapy based on cisplatin, doxorubicin, and paclitaxel, given concurrently with thalidomide. After treatment completion, the patient underwent radical mastectomy. Pathologic complete response in the breast and axillary lymph nodes was achieved. The patient has no evidence of disease recurrence 6 months after her initial diagnosis. Conclusion Anti-angiogenic therapy may be considered as part of the management of primary angiosarcoma of the breast. PMID:24715848

Alvarado-Miranda, Alberto; Bacon-Fonseca, Ludwing; Ulises Lara-Medina, Fernando; Maldonado-Martinez, Hector; Arce-Salinas, Claudia

2013-01-01

366

Preparing HEP software for concurrency  

NASA Astrophysics Data System (ADS)

The necessity for thread-safe experiment software has recently become very evident, largely driven by the evolution of CPU architectures towards exploiting increasing levels of parallelism. For high-energy physics this represents a real paradigm shift, as concurrent programming was previously only limited to special, well-defined domains like control software or software framework internals. This paradigm shift, however, falls into the middle of the successful LHC programme and many million lines of code have already been written without the need for parallel execution in mind. In this paper we have a closer look at the offline processing applications of the LHC experiments and their readiness for the many-core era. We review how previous design choices impact the move to concurrent programming. We present our findings on transforming parts of the LHC experiment reconstruction software to thread-safe code, and the main design patterns that have emerged during the process. A plethora of parallel-programming patterns are well known outside the HEP community, but only a few have turned out to be straightforward enough to be suited for non-expert physics programmers. Finally, we propose a potential strategy for the migration of existing HEP experiment software to the many-core era.

Clemencic, M.; Hegner, B.; Mato, P.; Piparo, D.

2014-06-01

367

Cancer cell adaptation to chemotherapy  

Microsoft Academic Search

BACKGROUND: Tumor resistance to chemotherapy may be present at the beginning of treatment, develop during treatment, or become apparent on re-treatment of the patient. The mechanisms involved are usually inferred from experiments with cell lines, as studies in tumor-derived cells are difficult. Studies of human tumors show that cells adapt to chemotherapy, but it has been largely assumed that clonal

Federica Di Nicolantonio; Stuart J Mercer; Louise A Knight; Francis G Gabriel; Pauline A Whitehouse; Sanjay Sharma; Augusta Fernando; Sharon Glaysher; Silvana Di Palma; Penny Johnson; Shaw S Somers; Simon Toh; Bernie Higgins; Alan Lamont; Tim Gulliford; Jeremy Hurren; Constantinos Yiangou; Ian A Cree

2005-01-01

368

Oral Chemotherapy: What You Need to Know  

MedlinePLUS

Oral Chemotherapy: What You Need to Know Oral chemo is any drug you take by mouth to treat cancer. ... be ready for oral chemo. What is oral chemotherapy? There are many types of chemotherapy (chemo). Oral ...

369

Radiation and third-generation chemotherapy.  

PubMed

All of the third-generation chemotherapeutic agents reviewed in this article are independently active against NSCLC, although the agents differ significantly in their cellular and molecular mechanisms of cytotoxicity. All have also been shown to potentiate radiation effects, and thus are promising in exerting further cytotoxicity when used in combination chemoradiation therapy for locally advanced NSCLC. Although the toxicity to normal tissue varies among these agents when used alone, phase I/II clinical results consistently demonstrated higher risk and severity of esophagitis and pneumonitis when these agents were administered concurrently with thoracic radiation. These results were consistent with the radiosensitization properties of all these agents. Nonetheless, most chemoradiation combinations have been made feasible through careful phase I studies that establish safe doses of these agents given concurrently with radiation. Indeed, phase I outcomes consistently have demonstrated the need for dose reduction compared with doses applied in the stage IV, metastatic disease setting (see Tables 1 and 2). There have been many different dose schedules in phase I/II studies for stage III NSCLC, and most have yielded improved response rates with these agents. For all these agents discussed, multiagent chemoradiation increased toxicity when compared with single agent chemoradiation, particularly in the risk of neutropenia, and the tumor response rates were no better than single-agent chemoradiation. Most studies have not reached an adequate interval for survival endpoint to assess the impact on survival using multiagent chemoradiation. A few earlier studies using paclitaxel chemoradiation, in fact, showed that the significant improvement in tumor response rate resulted in only a small gain in survival outcome. Despite much preclinical research conducted with these agents, the optimal sequence and dose of drug and the optimal schedule for combining the two modalities remain unknown. Optimal sequencing of the chemoradiation regimens may improve distant disease control and primary tumor control, as was seen in studies that administered both full-dose induction chemotherapy and concurrent chemoradiation at reduced drug dose and in studies that administered consolidative, full-dose chemotherapy after chemoradiation. Strategically altering the treatment schedule may also enhance the radiosensitizing effects while keeping toxicity low, such as was seen in the pulsed low-dose paclitaxel chemoradiation reported by Chen et al . This pulsed low-dose schedule resulted in superior tumor response (100%) and durable primary tumor control while keeping the toxicity low. Other methods to minimize normal tissue injury and to deliver higher radiation doses, such as conformal three-dimensional radiotherapy that excludes nontarget tissues from the radiation field, are under investigation. Marks and colleagues were able to deliver radiation to 80 Gy using accelerated hyperfractionation radiation after induction chemotherapy. Intensity-modulated radiotherapy is expected to revolutionize the targeting of tumor and exclusion of normal tissues from the high-dose radiation volume in the future. Integrating biologic response modifiers, radioprotectors, and molecular targeting strategies also are being investigated. It remains unclear which agent among the third-generation drugs performs better for combination chemoradiation. The CALGB 9431 study reported by Vokes et al provided some preliminary information, in that it was a randomized phase II study of a three-arm comparison of cisplatin-containing, two-drug combination chemoradiation with one of the third-generation agents. Although direct statistical comparison between the treatment arms was not valid for a phase II setting, such an analysis did indeed reveal similar overall response rates for these three arms. Chemoradiation using third-generation chemotherapeutic agents has improved local tumor response rates, with enhanced radiation toxicity such as esophagitis and pneumonitis. The challenge of targ

Chen, Yuhchyau; Okunieff, Paul

2004-02-01

370

Concurrence of superpositions of many states  

SciTech Connect

In this paper, we use the concurrence vector as a measure of entanglement, and investigate lower and upper bounds on the concurrence of a superposition of bipartite states as a function of the concurrence of the superposed states. We show that the amount of entanglement quantified by the concurrence vector is exactly the same as that quantified by I concurrence, so that our results can be compared to those given in Phys. Rev. A 76, 042328 (2007). We obtain a tighter lower bound in the case in which the two superposed states are orthogonal. We also show that when the two superposed states are not necessarily orthogonal, both lower and upper bounds are, in general, tighter than the bounds given in terms of the I concurrence. An extension of the results to the case with more than two states in the superpositions is also given.

Akhtarshenas, Seyed Javad [Department of Physics, University of Isfahan, Isfahan, Iran and Quantum Optics Group, University of Isfahan, Isfahan (Iran, Islamic Republic of)

2011-04-15

371

Multipartite continuous-variable entanglement from concurrent nonlinearities  

SciTech Connect

We show theoretically that concurrent interactions in a second-order nonlinear medium placed inside an optical resonator can generate multipartite entanglement between the resonator modes. We show that there is a mathematical connection between this system and van Loock and Braunstein's proposal for entangling N continuous quantum optical variables by interfering with the outputs of N degenerate optical parametric amplifiers (OPA) at a N-port beam splitter. Our configuration, however, requires only one nondegenerate OPA and no interferometer. In a preliminary experimental study, we observe the concurrence of the appropriate interactions in periodically poled RbTiOAsO{sub 4}.

Pfister, Olivier; Feng Sheng; Jennings, Gregory; Pooser, Raphael; Xie Daruo [Department of Physics, University of Virginia, 382 McCormick Road, Charlottesville, Virginia 22904-4714 (United States)

2004-08-01

372

How Formal Dynamic Verification Tools Facilitate Novel Concurrency Visualizations  

NASA Astrophysics Data System (ADS)

With the exploding scale of concurrency, presenting valuable pieces of information collected by formal verification tools intuitively and graphically can greatly enhance concurrent system debugging. Traditional MPI program debuggers present trace views of MPI program executions. Such views are redundant, often containing equivalent traces that permute independent MPI calls. In our ISP formal dynamic verifier for MPI programs, we present a collection of alternate views made possible by the use of formal dynamic verification. Some of ISP’s views help pinpoint errors, some facilitate discerning errors by eliminating redundancy, while others help understand the program better by displaying concurrent even orderings that must be respected by all MPI implementations, in the form of completes-before graphs. In this paper, we describe ISP’s graphical user interface (GUI) capabilities in all these areas which are currently supported by a portable Java based GUI, a Microsoft Visual Studio GUI, and an Eclipse based GUI whose development is in progress.

Aananthakrishnan, Sriram; Delisi, Michael; Vakkalanka, Sarvani; Vo, Anh; Gopalakrishnan, Ganesh; Kirby, Robert M.; Thakur, Rajeev

373

Concurrent design and manufacturing process of automotive composite components  

Microsoft Academic Search

Purpose – To present the findings of the research on the use of concurrent engineering in the development of polymeric based composite automotive clutch pedal. It covers the use of various IT such as expert system, FEA, CAD, mould flow and rapid prototyping in order to carry out various activities such as material selection, total design, design analysis and mould

S. M. Sapuan

2005-01-01

374

Concurrent Operation Scheduling and Unit Allocation with an Evolutionary Technique  

E-print Network

Concurrent Operation Scheduling and Unit Allocation with an Evolutionary Technique Gregor Papa, Jurij Silc Computer Systems Department, Jozef Stefan Institute Jamova c. 39, SI-1000 Ljubljana, Slovenia gregor.papa@ijs.si, jurij.silc@ijs.si Abstract This paper presents a method with an evolutionary approach

Silc, Jurij

375

Designing application specific circuits with concurrent C# programs  

Microsoft Academic Search

This paper presents an investigation into the possibility of using a regular concurrent programming language for modeling and implementing digital circuits. Some of the reasons for using an existing language include the ability to use existing compilers and analysis tools for circuit design and verification. Another important reason is the ever increasing need to model complete systems that comprise interacting

David J. Greaves; Satnam Singh

2010-01-01

376

The role of product safety and liability in concurrent engineering  

Microsoft Academic Search

This paper explores the role of product safety and liability in the early stages of product design in a concurrent engineering environment. The paper presents an overview of literature pertaining to the significance of product liability for manufacturers. Further, the paper presents a system approach to product safety, a conceptual framework for design for safety and liability, and a product

S Dowlatshahi

2001-01-01

377

Supraglottitis and concurrent Hemophilus meningitis.  

PubMed

Acute epiglottitis is a true pediatric emergency. The intense inflammation of the supraglottic larynx may completely obstruct the larynx within several hours. This infection is secondary to infiltration of Hemophilus influenzae type b (HIB), and 90% to 95% of patients have positive blood cultures. During this period of generalized septicemia HIB involvement of other soft tissue sites may occur. The goal of this article is to alert otolaryngologists to the possibility of extraepiglottitic HIB involvement. In particular, HIB meningitis, concurrent with supraglottitis, will be discussed. Although the overall incidence of multiple site involvement is relatively low, it is important to be aware of the possibility, since the outcome may be significantly altered. PMID:4051404

Friedman, E M; Damion, J; Healy, G B; McGill, T J

1985-01-01

378

Concurrent Engineering: A Partnership Approach  

NSDL National Science Digital Library

This paper describes the development of a new course in concurrent engineering. Teaching concepts in product development benefits greatly from a hands-on approach. The authors have attempted to establish this goal in three ways: by developing and using a number of laboratories and demonstrations, by inviting speakers from industry who can make classroom lessons concrete, and by using cases as the basis for class discussion. This paper includes a discussion of the curriculum, of existing teaching materials, and of specific methods and materials developed for the course. The course was developed jointly by faculty and research assistants at the University of Washington (UW), the University of Puerto Ricos Mayagez campus (UPRM), and at Penn State (PSU), as part of the Manufacturing Engineering Education Partnership (MEEP), funded through the ARPA Technology Reinvestment Program.

Barton, Russell R.; Nowack, Craig A.; Smith, Robert P.; Zayas-Castro, Jose L.

2011-03-10

379

Macrocell design for concurrent signal processing  

SciTech Connect

Macrocells serve as subsystems at the top level of the hardware design hierarchy. The authors present the macrocell design technique as applied to the implementation of real-time, sampled-data signal processing functions. The design of such circuits is particularly challenging due to the computationally intensive nature of signal-processing algorithms and the constraints of real-time operation. The most efficient designs make use of a high degree of concurrency-a property facilitated by the microcell approach. Two circuit projects whose development resulted largely from the macrocell methodology described are used as examples throughout the report: a linear-predictive vocoder circuit, and a front-end filter-bank chip for a speech recognition system. Both are monolithic multiprocessor implementations: the lpc vocoder circuit contains three processors, the filter-bank chip two processors. 10 references.

Pope, S.P.; Brodersen, R.W.

1983-01-01

380

Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V  

Microsoft Academic Search

Dasatinib has been reported to potently inhibit juxtamembrane domain mutant KITD816V autophosphorylation and KIT-dependent activation of down stream signaling important for cell growth and survival of neoplastic cells. Additionally, dasatinib induced apoptosis in mast cell and leukemia cell lines expressing KITD816V. Here, we present the first case report of long-term hematologic and molecular remission achieved with combined treatment with chemotherapy

Celalettin Ustun; Christopher L. Corless; Natasha Savage; Warren Fiskus; Elizabeth Manaloor; Michael C. Heinrich; Grant Lewis; Preetha Ramalingam; Ilana Kepten; Anand Jillella; Kapil Bhalla

2009-01-01

381

A Framework of Concurrent Task Scheduling and Dynamic Voltage and Frequency Scaling in Real-Time Embedded Systems with Energy Harvesting  

E-print Network

as a prospective method for overcoming the energy limitation in traditional battery-powered embedded systems and achieving energy autonomy. Available ambient energy sources for energy harvesting include sunlight, wind-Time Embedded Systems with Energy Harvesting Xue Lin1 , Yanzhi Wang1 , Siyu Yue1 , Naehyuck Chang2 and Massoud

Pedram, Massoud

382

An Algebraic Compositional Semantics of an Object Oriented Notation with Concurrency  

E-print Network

definition allows to model also concurrent features of the O­O language if any, by underlying an ap­ proach in a top­down way. Sect. 1 presents the syntax and semantics of class combinators, showing how the kind of dynamics of the system (sequential or concurrent). Sect. 2 shows how the treatment

Robbiano, Lorenzo

383

An efficient approach to pipeline scheme for concurrent testing of VLSI circuits  

Microsoft Academic Search

Presents a unifying procedure, called implicit tree search algorithm (ITSA), for automated allocation of test events in a pipeline scheme for concurrent testing of VLSI circuits. The procedure fully exploits the test parallelism where the test intervals of compatible test events are overlaid so that the system can test as many of them as possible concurrently. Moreover, the utilization of

Chien-In Henry Chen; Joel Yuen

1992-01-01

384

Orbital and Periorbital Side Effects of Chemotherapy  

Microsoft Academic Search

\\u000a In this chapter, the side effects of chemotherapeutic agents on the orbit and periorbital structures, such as the eyelids,\\u000a eyelashes, eyebrows, and conjunctiva, are discussed. Chemotherapy can affect these structures when it is administered topically\\u000a for local disease, via selective ophthalmic artery infusion for regional disease in the orbit, or systemically for more diffuse\\u000a metastatic disease or as adjuvant treatment.

John D. Ng

385

Concurrency revisited: increasing and compelling epidemiological evidence  

PubMed Central

Multiple sexual partnerships must necessarily lie at the root of a sexually transmitted epidemic. However, that overlapping or concurrent partnerships have played a pivotal role in the generalized epidemics of sub-Saharan Africa has been challenged. Much of the original proposition that concurrent partnerships play such a role focused on modelling, self-reported sexual behaviour data and ethnographic data. While each of these has definite merit, each also has had methodological limitations. Actually, more recent cross-national sexual behaviour data and improved modelling have strengthened these lines of evidence. However, heretofore the epidemiologic evidence has not been systematically brought to bear. Though assessing the epidemiologic evidence regarding concurrency has its challenges, a careful examination, especially of those studies that have assessed HIV incidence, clearly indicates a key role for concurrency. Such evidence includes: 1) the early and dramatic rise of HIV infection in generalized epidemics that can only arise from transmission through rapid sequential acute infections and thereby concurrency; 2) clear evidence from incidence studies that a major portion of transmission in the population occurs via concurrency both for concordant negative and discordant couples; 3) elevation in risk associated with partner's multiple partnering; 4) declines in HIV associated with declines in concurrency; 5) bursts and clustering of incident infections that indicate concurrency and acute infection play a key role in the propagation of epidemics; and 6) a lack of other plausible explanations, including serial monogamy and non-sexual transmission. While other factors, such as sexually transmitted infections, other infectious diseases, biological factors and HIV sub-type, likely play a role in enhancing transmission, it appears most plausible that these would amplify the role of concurrency rather than alter it. Additionally, critics of concurrency have not proposed plausible alternative explanations for why the explosive generalized epidemics occurred. Specific behaviour change messaging bringing the concepts of multiple partnering and concurrency together appears salient and valid in promoting safer individual behaviour and positive social norms. PMID:21689437

2011-01-01

386

Comparison of Intrahepatic and Pancreatic Perfusion on Fusion Images Using a Combined SPECT/CT System and Assessment of Efficacy of Combined Continuous Arterial Infusion and Systemic Chemotherapy in Advanced Pancreatic Carcinoma  

SciTech Connect

Purpose. The purpose of this study was to compare intrahepatic and pancreatic perfusion on fusion images using a combined single-photon emission computed tomography (SPECT)/CT system and to evaluate the efficacy of combined continuous transcatheter arterial infusion (CTAI) and systemic chemotherapy in the treatment of advanced pancreatic carcinoma. Materials and Methods. CTAI was performed in 33 patients (22 men, 11 women; age range, 35-77 years; mean age, 60 years) with stage IV pancreatic cancer with liver metastasis. The reservoir was transcutaneously implanted with the help of angiography. The systemic administration of gemcitabine was combined with the infusion of 5-fluorouracil via the reservoir. In all patients we obtained fusion images using a combined SPECT/CT system. Pancreatic perfusion on fusion images was classified as perfusion presence or as perfusion absent in the pancreatic cancer. Using WHO criteria we recorded the tumor response after 3 months on multislice helical CT scans. Treatment effects were evaluated based on the pancreatic cancer, liver metastasis, and factors such as intrahepatic and pancreatic perfusion on fusion images. For statistical analysis we used the chi-square test; survival was evaluated by the Kaplan Meier method (log-rank test). Results. On fusion images, pancreatic and intrahepatic perfusion was recorded as hot spot and as homogeneous distribution, respectively, in 18 patients (55%) and as cold spot and heterogeneous distribution, respectively, in 15 (45%). Patients with hot spot in the pancreatic tumor and homogeneous distribution in the liver manifested better treatment results (p < 0.05 and p < 0.01, respectively). Patients with hot spot both in the pancreatic cancer and in the liver survived longer than those with cold spot in the pancreatic cancer and heterogeneous distribution in the liver (median {+-} SD, 16.0 {+-} 3.7 vs. 8.0 {+-} 1.4 months; p < 0.05). Conclusions. We conclude that in patients with advanced pancreatic cancer, CTAI with systemic chemotherapy appeared to be effective and may prolong their survival. The development of a reservoir port system allowing for the homogeneous distribution of anticancer drugs is necessary to improve the prognosis of patients with advanced pancreatic cancer.

Ikeda, Osama, E-mail: osamu-3643ik@do9.enjoy.ne.jp; Tamura, Yoshitaka; Nakasone, Yutaka; Shiraishi, Shinya; Kawanaka, Kouichi; Tomiguchi, Seiji; Yamashita, Yasuyuki [Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, Department of Diagnostic Radiology (Japan); Takamori, Hiroshi; Kanemitsu, Keiichiro; Baba, Hideo [Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, Department of Gastroenterological Surgery (Japan)

2007-09-15

387

Concurrent partnerships and HIV: an inconvenient truth  

PubMed Central

The strength of the evidence linking concurrency to HIV epidemic severity in southern and eastern Africa led the Joint United Nations Programme on HIV/AIDS and the Southern African Development Community in 2006 to conclude that high rates of concurrent sexual partnerships, combined with low rates of male circumcision and infrequent condom use, are major drivers of the AIDS epidemic in southern Africa. In a recent article in the Journal of the International AIDS Society, Larry Sawers and Eileen Stillwaggon attempt to challenge the evidence for the importance of concurrency and call for an end to research on the topic. However, their "systematic review of the evidence" is not an accurate summary of the research on concurrent partnerships and HIV, and it contains factual errors concerning the measurement and mathematical modelling of concurrency. Practical prevention-oriented research on concurrency is only just beginning. Most interventions to raise awareness about the risks of concurrency are less than two years old; few evaluations and no randomized-controlled trials of these programmes have been conducted. Determining whether these interventions can help people better assess their own risks and take steps to reduce them remains an important task for research. This kind of research is indeed the only way to obtain conclusive evidence on the role of concurrency, the programmes needed for effective prevention, the willingness of people to change behaviour, and the obstacles to change. PMID:21406080

2011-01-01

388

Modelling Concurrent Cognitive Architectures using Process Calculi  

E-print Network

of the pivotal cognitive architecture SOAR: #15; natural language descriptions augmented with box and arrowModelling Concurrent Cognitive Architectures using Process Calculi Howard Bowman Computing disciplines in which concurrency arises. Further- more, a number of existing theories of cognitive science

Kent, University of

389

Concurrence control for transactions with priorities  

NASA Technical Reports Server (NTRS)

Priority inversion occurs when a process is delayed by the actions of another process with less priority. With atomic transactions, the concurrency control mechanism can cause delays, and without taking priorities into account can be a source of priority inversion. Three traditional concurrency control algorithms are extended so that they are free from unbounded priority inversion.

Marzullo, Keith

1989-01-01

390

Modelling Component Behaviour with Concurrent Automata  

Microsoft Academic Search

The effective (re)use of components requires languages for the precise description of observable behaviour, along with methods for checking the compatibility of component interfaces in a design. This is even more challenging in the presence of concurrency. In previous work we have considered a set-based model of components and their composition, in a concurrent setting. In this paper, we present

Sotiris Moschoyiannis; Michael W. Shields; Paul J. Krause

2005-01-01

391

Concurrent Engineering in the Construction Industry  

Microsoft Academic Search

The construction industry has been suffering from low productivity and poor performance In an attempt to improve its performance, industry practitioners and researchers have looked at the manufacturing industry as a point of reference and a source of innovation Conse quently, the industry has acquired and adapted the Concurrent Engineering (CE) approach to manufacturing, to construction Concurrent Con struction (CC)

Peter E. D. Love; A. Gunasekaran

1997-01-01

392

[Chemotherapy for prostate cancer].  

PubMed

For many years the benefit of chemotherapy in patients with prostate cancer was thought to be limited to palliation of late-stage disease, and thus this treatment option only became involved in patient care towards the end of the disease process, if at all. However, two landmark phase-III trials with docetaxel-based therapy (TAX 327 and Southwest Oncology Group, SWOG, 9916) have shown a survival benefit for patients with hormone refractory prostate cancer (HRPC) thus prompting a change in patterns of care. With raising interest for chemotherapeutic options and clinical trials for new drugs and new indications (neoadjuvant therapy, adjuvant therapy, increasing PSA levels after local treatment, and hormone sensitive cancer) under way our goal was to review within the context of a multidisciplinary team the available evidence and explore the standard for the medical treatment of prostate cancer outside of clinical trials. We are carefully evaluating the current treatment recommendations based on the available evidence and highlight potential future treatment options but also discuss important clinical topics (treatment until progression versus the advantage of chemo holidays, definition of particular patient subgroups and potential second line options) for which there are no clear cut answers to date. The role and importance of radiotherapy, biphosphonate treatment and the medical management of pain and side effects is also discussed. The multitude of treatment options for patients with advanced prostate cancer clearly asks for a close collaboration between urologists, medical oncologists and radiation therapists. PMID:18726672

Rauchenwald, Michael; De Santis, Maria; Fink, Eleonore; Höltl, Wolfgang; Kramer, Gero; Marei, Isabella-Carolina; Neumann, Hans-Jörg; Reissigl, Andreas; Schmeller, Nikolaus; Stackl, Walter; Hobisch, Alfred; Krainer, Michael

2008-01-01

393

Managing Chemotherapy Side Effects: Anemia  

MedlinePLUS

... National Institutes of Health Managing Chemotherapy Side Effects Anemia Call your doctor or nurse if you feel: ? ... tired ? Your heart beating very fast What is anemia? Anemia is when your body doesn’t have ...

394

Understanding resistance to combination chemotherapy  

E-print Network

The current clinical application of combination chemotherapy is guided by a historically successful set of practices that were developed by basic and clinical researchers 50–60 years ago. Thus, in order to understand how ...

Pritchard, Justin R.

395

ManagingandUnderstanding YourChemotherapy  

E-print Network

chemotherapy treatment How to manage side effects How to best prepare yourself, family, and friends StrategiesManagingandUnderstanding YourChemotherapy Your physician recommends this class before starting chemotherapy Being as prepared as possible for your chemotherapy helps ensure a positive and successful course

Bejerano, Gill

396

Neoadjuvant chemotherapy for bladder cancer  

Microsoft Academic Search

The 30–45% failure rate after radical cystoprostatectomy mandates that we explore and optimize multimodal therapy to achieve better disease control in these patients. Cisplatin-based multi-agent combination chemotherapy has been used with success in metastatic disease and has therefore also been introduced in patients with high-risk but non-metastatic bladder cancer. There is now convincing evidence that chemotherapy given pre-operatively can improve

Peter C. Black; Gordon A. Brown; H. Barton Grossman; Colin P. Dinney

2006-01-01

397

Clinical and histological resolution of a basal cell carcinoma in a patient undergoing concurrent treatment of B-cell lymphoma with systemic R-CHOP.  

PubMed

Surgical resection is the definitive treatment modality for basal cell carcinoma (BCC). However, not all patients may be suitable for surgery. We describe a patient with a BCC, which resolved clinically and histologically when he underwent systemic R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) for treatment of a high grade B-cell lymphoma. Although topical and intra-lesional 5-fluorouracil (5-FU) has been used as an adjunct to treatment, more recent reports have illustrated the treatment of BCC with systemic 5-FU in combination with bleomycin and cisplatin. We postulate that the combination of cyclophosphamide and doxorubicin with rituximab and prednisolone, which has not been previously reported in the literature, contributed to remission in this case. PMID:25052183

Rahman, Shakeel M; Bhat, W; Wiper, J D; Platt, A J

2014-09-01

398

Malaria Parasite Infection Compromises Control of Concurrent Systemic Non-typhoidal Salmonella Infection via IL-10-Mediated Alteration of Myeloid Cell Function  

PubMed Central

Non-typhoidal Salmonella serotypes (NTS) cause a self-limited gastroenteritis in immunocompetent individuals, while children with severe Plasmodium falciparum malaria can develop a life-threatening disseminated infection. This co-infection is a major source of child mortality in sub-Saharan Africa. However, the mechanisms by which malaria contributes to increased risk of NTS bacteremia are incompletely understood. Here, we report that in a mouse co-infection model, malaria parasite infection blunts inflammatory responses to NTS, leading to decreased inflammatory pathology and increased systemic bacterial colonization. Blunting of NTS-induced inflammatory responses required induction of IL-10 by the parasites. In the absence of malaria parasite infection, administration of recombinant IL-10 together with induction of anemia had an additive effect on systemic bacterial colonization. Mice that were conditionally deficient for either myeloid cell IL-10 production or myeloid cell expression of IL-10 receptor were better able to control systemic Salmonella infection, suggesting that phagocytic cells are both producers and targets of malaria parasite-induced IL-10. Thus, IL-10 produced during the immune response to malaria increases susceptibility to disseminated NTS infection by suppressing the ability of myeloid cells, most likely macrophages, to control bacterial infection. PMID:24787713

Butler, Brian P.; Xavier, Mariana N.; Chau, Jennifer Y.; Schaltenberg, Nicola; Begum, Ramie H.; Muller, Werner; Luckhart, Shirley; Tsolis, Renee M.

2014-01-01

399

Response of hemorrhagic bullous skin lesions of the breast secondary to primary systemic amyloidosis to a five-drug combination chemotherapy: a case report and review of the literature  

PubMed Central

Two major types of amyloidosis are primary amyloidosis or amyloid light chain amyloidosis and secondary amyloidosis. Although amyloidosis involves a variety of organ systems including skin, the occurrence of bullous skin lesions is rare. Little is known about the mechanism of blister formation. These blisters are often hemorrhagic and typically occur in the oral mucosa. Only a few case reports have described skin involvement in systemic amyloidosis. The manifestation of bullous lesions on the breast in association with primary amyloidosis has not been previously reported. Therefore, we report a case of cutaneous hemorrhagic bullous of the breast secondary to primary systemic amyloidosis, which may be important for medical oncologists to be aware of this uncommon presentation of plasma cell dysrasias. Furthermore, this case only partially responded to the commonly used multiple myeloma-type regimen, the skin lesions responded completely to a five-drug combination chemotherapy regimen, utilizing immunomodulators, liposomal doxorubicin, cyclophosphamide, bortezomib, and dexamethasone, suggesting that a more aggressive modality of chemotherapy may be necessary to treat such cases. PMID:23210921

2012-01-01

400

Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy  

PubMed Central

Malignant glioma, or glioblastoma, is the most common and lethal form of brain tumor with a median survival time of 15 months. The established therapeutic regimen includes a tripartite therapy of surgical resection followed by radiation and temozolomide (TMZ) chemotherapy, concurrently with radiation and then as an adjuvant. TMZ, a DNA alkylating agent, is the most successful antiglioma drug and has added several months to the life expectancy of malignant glioma patients. However, TMZ is also responsible for inducing lymphopenia and myelosuppression in malignant glioma patients undergoing chemotherapy. Although TMZ-induced lymphopenia has been attributed to facilitate antitumor vaccination studies by inducing passive immune response, in general lymphopenic conditions have been associated with poor immune surveillance leading to opportunistic infections in glioma patients, as well as disrupting active antiglioma immune response by depleting both T and NK cells. Deletion of O6-methylguanine-DNA-methyltransferase (MGMT) activity, a DNA repair enzyme, by temozolomide has been determined to be the cause of lymphopenia. Drug-resistant mutation of the MGMT protein has been shown to render chemoprotection against TMZ. The immune modulating role of TMZ during glioma chemotherapy and possible mechanisms to establish a strong TMZ-resistant immune response have been discussed. PMID:23133490

Sengupta, Sadhak; Marrinan, Jaclyn; Frishman, Caroline; Sampath, Prakash

2012-01-01

401

Concurrent Exposure to Heat Shock and H7 Synergizes to Trigger Breast Cancer Cell Apoptosis while Sparing Normal Cells  

Microsoft Academic Search

Most cancer therapies, including chemotherapy, kill tumor cells by inducing apoptosis. Consequently, the propensity of tumor cells to evade apoptotic signals contributes to therapeutic resistance. Here we show that breast cancer cells exhibiting a highly resistant phenotype undergo apoptosis when exposed to concurrent heat shock and H7, a potent serine\\/threonine kinase inhibitor. The anti-tumor effects of this combination are synergistic

Wenle Xia; Lys Hardy; Leihua Liu; Sumin Zhao; Mark Goodman; Richard Voellmy; Neil L. Spector

2003-01-01

402

Preoperative concurrent 5Fluorouracil infusion, Mitomycin C and pelvic radiation therapy in tethered and fixed rectal carcinoma  

Microsoft Academic Search

This is a Phase 1\\/2 study of preoperative concurrent radiation and chemotherapy in tethered and fixed rectal carcinoma. This study examined the curative resectability, the acute toxicities during chemo-radiation and the surgical complications. Between 1986 and 1990, 46 patients were treated with preoperative pelvic radiation (4,000 cGy in 20 fractions in 4 weeks), 5-Fluorouracil infusion (20 mg\\/m[sup 2], days 1--4

Alexander Chan; Alfred Wong; James Langevin; Robert Khoo

1993-01-01

403

Reducing Concurrency Bottlenecks in Parallel I/O Workloads  

SciTech Connect

To enable high performance parallel checkpointing we introduced the Parallel Log Structured File System (PLFS). PLFS is middleware interposed on the file system stack to transform concurrent writing of one application file into many non-concurrently written component files. The promising effectiveness of PLFS makes it important to examine its performance for workloads other than checkpoint capture, notably the different ways that state snapshots may be later read, to make the case for using PLFS in the Exascale I/O stack. Reading a PLFS file involved reading each of its component files. In this paper we identify performance limitations on broader workloads in an early version of PLFS, specifically the need to build and distribute an index for the overall file, and the pressure on the underlying parallel file system's metadata server, and show how PLFS's decomposed components architecture can be exploited to alleviate bottlenecks in the underlying parallel file system.

Manzanares, Adam C. [Los Alamos National Laboratory; Bent, John M. [Los Alamos National Laboratory; Wingate, Meghan [Los Alamos National Laboratory

2011-01-01

404

Fertility Preservation Options After Gonadotoxic Chemotherapy  

PubMed Central

Chemotherapy has the potential to deplete and destroy a woman’s reproductive potential. Although many oncologists are referring women for fertility preservation before chemotherapy, in many cases there is limited time for fertility preservation. This review provides an overview of the impact of cancer and chemotherapy on the ovarian reserve, a summary of methods of fertility preservation prior to chemotherapy, and current knowledge of fertility preservation techniques after gonadotoxic chemotherapy. PMID:24453520

Hyman, Jordana Hadassah; Tulandi, Togas

2013-01-01

405

Long-term results of concurrent chemoradiotherapy for T3/T4 locally advanced nasopharyngeal carcinoma  

PubMed Central

Nasopharyngeal carcinoma (NPC) is one of the most commonly diagnosed head and neck malignancies. This study investigated the outcome of locally advanced NPC patients on concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF). A total of 226 patients with locally advanced NPC received IMRT, with a total dose of 65–70 Gy and concurrent chemotherapy, with 2 cycles of TPF administered during radiotherapy, between March, 2005 and March, 2007. An additional 2 to 4 cycles of chemotherapy were administered every 21 days following radiotherapy. With a median follow-up time of 35 months (range, 7–60), the 5-year overall survival (OS) rate was 81.4%, with 93.6 and 75.0% for T3 and T4 lesions, respectively, (P=0.001). The 5-year progression-free survival (PFS) was 50.4%, with 66.7 and 46.9% for T3 and T4 lesions, respectively (P<0.001). T-classification was a significant prognostic factor for PFS and OS. The subgroup analysis revealed that pterygopalatine fossa invasion was associated with a significantly lower 5-year PFS (P=0.001) and OS (P=0.002), foramen rotundum invasion was associated with a significantly lower 5-year PFS (P<0.001) and OS (P=0.004), foramen ovale invasion was associated with a significantly lower 5-year PFS (P=0.013) and OS (P=0.024) and foramen lacerum and cavernous sinus invasion were associated with a significantly lower 5-year PFS (P<0.001 and P<0.001, respectively). Concurrent chemoradiotherapy is an advocated regimen for patients with locally advanced NPC, since it exhibits satisfactory 5-year PFS and OS rates. Our results suggest that the estimation of invasive range may identify a subgroup of patients with a higher risk of locoregional failure who may be better candidates for this treatment strategy. PMID:24649201

XIAO, CAN; WANG, LILI; JIAO, YANG; SUN, KEKANG; QIN, SONGBING; XU, XIAOTING; GUO, JIAN; ZHOU, JUYING

2013-01-01

406

Sexual concurrency among young African American women.  

PubMed

Young African-American women are disproportionately affected by human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) sexually transmitted infections (STI), and engage in greater sexual concurrency than other race/ethnicities. It is important to evaluate behaviors and characteristics associated with the risk of sexual concurrency, so that interventions can target factors most likely to affect positive change. An emphasis on correlates of concurrency beyond individual-level factors has been suggested. The purpose of this study, therefore, was to identify individual- and partner-level characteristics associated with sexual concurrency among high-risk, young African-American women. Data were collected from 570 African-American adolescent women (aged 15-21) recruited from a STI clinic, a family planning clinic, and a teen clinic located in Atlanta, GA from March 2002 through August 2004. Logistic regression analysis was conducted in 2012 to evaluate correlates of sexual concurrency. Results show that almost one-quarter of participants reported sexually concurrent partnerships and 28.4% suspected male partner concurrency. Logistic regression results indicated the number of lifetime sexual partners and relationship factors were the primary contributors to engaging in concurrency in this sample. These findings suggest relationship factors may be important contributors to the prevalence of sexual concurrency among young African-American women. Interventions targeted toward sexual health among young African-American women may need to specifically address partner/relationship factors. Through these findings, we hope to better understand sexual risk taking and develop strategies that would overcome barriers to existing interventions aimed at improving the sexual health outcomes of young African-American women. PMID:23363034

Waldrop-Valverde, Drenna G; Davis, Teaniese L; Sales, Jessica M; Rose, Eve S; Wingood, Gina M; DiClemente, Ralph J

2013-01-01

407

[Buccal manifestations in patients submitted to chemotherapy].  

PubMed

Several changes in the oral cavity due to chemotherapy can be observed and can lead to important systemic complications, increasing the time of the patient in hospital and the costs of the treatment as well as affect the quality of life of the patients. The aim of this study was to assess the oral manifestation in patients treated with chemotherapy according to sex, age and tumor type. Data was collected in an oncology hospital in Juiz de Fora, Minas Gerais State, from patients' records that were submitted to oncologic treatment. It was possible to verify that mucositis, associated or not to other type of lesions, was the most common lesion in both sex of all ages (15.5%). Xerostomia and other lesions, such as Candida infection and aphthous lesions, were also present. It is possible to improve the quality of life of the patient during and after anti-neoplastic therapies through a protocol of odontological assistance that includes changes of the oral environment previous to chemotherapy such as profilaxis, caries removal, treatment of periodontal and periapical lesions, oral hygiene instructions, diet orientation and laser therapy. It is very important the insertion of the dentist in the oncologic medical team for the early diagnosis of the oral manifestation and follow-up during treatment time. PMID:20640266

Hespanhol, Fernando Luiz; Tinoco, Eduardo Muniz Barretto; Teixeira, Henrique Guilherme de Castro; Falabella, Márcio Eduardo Vieira; Assis, Neuza Maria de Souza Picorelli

2010-06-01

408

Magnetic nanoparticle-based therapeutic agents for thermo-chemotherapy treatment of cancer.  

PubMed

Magnetic nanoparticles have been widely investigated for their great potential as mediators of heat for localised hyperthermia therapy. Nanocarriers have also attracted increasing attention due to the possibility of delivering drugs at specific locations, therefore limiting systematic effects. The enhancement of the anti-cancer effect of chemotherapy with application of concurrent hyperthermia was noticed more than thirty years ago. However, combining magnetic nanoparticles with molecules of drugs in the same nanoformulation has only recently emerged as a promising tool for the application of hyperthermia with combined chemotherapy in the treatment of cancer. The main feature of this review is to present the recent advances in the development of multifunctional therapeutic nanosystems incorporating both magnetic nanoparticles and drugs, and their superior efficacy in treating cancer compared to either hyperthermia or chemotherapy as standalone therapies. The principle of magnetic fluid hyperthermia is also presented. PMID:25212238

Hervault, Aziliz; Thanh, Nguyen Th Kim

2014-10-21

409

Superior vena cava replacement in thymic tumours treated with radio-chemotherapy.  

PubMed

From 1987 to 2000 108 patients were operated on for thymic tumours. Two of these underwent replacement of the superior vena cava with polytetrafluoroethylene prostheses because the tumours invaded the superior vena cava. One of these was affected by myasthenia gravis, and was treated preoperatively with concurrent radio-chemotherapy and lymphocytopheresis. The other received preoperative chemotherapy and post-operative radio-chemotherapy because of minimal residual disease. The clinical courses of the two patients are reported here and we conclude that eradication of thymic malignancies is suitable even when superior vena cava replacement is required, and that neither antimyasthenic therapy nor adjuvant and/or neoadjuvant treatment interfere with aggressive surgical management or vice versa. Moreover, the long-term survival of one of these patients despite relapse of disease shows that extended surgery is indicated in these cases. PMID:15916142

Muscolino, Giuseppe; Doria, Orietta; Vercellio, Gianni

2005-01-01

410

Magnetic nanoparticle-based therapeutic agents for thermo-chemotherapy treatment of cancer  

NASA Astrophysics Data System (ADS)

Magnetic nanoparticles have been widely investigated for their great potential as mediators of heat for localised hyperthermia therapy. Nanocarriers have also attracted increasing attention due to the possibility of delivering drugs at specific locations, therefore limiting systematic effects. The enhancement of the anti-cancer effect of chemotherapy with application of concurrent hyperthermia was noticed more than thirty years ago. However, combining magnetic nanoparticles with molecules of drugs in the same nanoformulation has only recently emerged as a promising tool for the application of hyperthermia with combined chemotherapy in the treatment of cancer. The main feature of this review is to present the recent advances in the development of multifunctional therapeutic nanosystems incorporating both magnetic nanoparticles and drugs, and their superior efficacy in treating cancer compared to either hyperthermia or chemotherapy as standalone therapies. The principle of magnetic fluid hyperthermia is also presented.

Hervault, Aziliz; Thanh, Nguy&Ecirtil; N. Thá»? Kim

2014-09-01

411

Metastatic Colorectal Cancer Treated with Herbal Pharmacopuncture during FOLFIRI Chemotherapy: A Case Report  

PubMed Central

According to the 2008 World Cancer Report by the World Health Organization (WHO), colorectal cancer is one of the leading cancers worldwide. This case study evaluates the effectiveness of Korean medicine treatment, including herbal pharmacopuncture (HP), as a complementary treatment during FOLFIRI chemotherapy. A 73-year-old male who was diagnosed with metastatic colorectal cancer (mCRC) in September 2012 was treated concurrently with HP and FOLFIRI chemotherapy for 4 months. The effectiveness of the combined therapy was evaluated by CT. Furthermore, quality of life was assessed using a visual analogue scale. The tumor mass sizes of lung and lymph node metastases decreased, and the side effects caused by chemotherapy were mitigated. Based on these results, this case report suggests that Korean medicine treatment including HP therapy could be a complementary therapy for mCRC. PMID:24987356

Lee, Jung-Woo; Han, Jae-bok; Kim, Sung-su; Seong, Shin

2014-01-01

412

Imaging enhancement of malignancy by cyclophosphamide: surprising chemotherapy opposite effects  

NASA Astrophysics Data System (ADS)

Although side effects of cancer chemotherapy are well known, "opposite effects" of chemotherapy which enhance the malignancy of the treated cancer are not well understood. We have observed a number of steps of malignancy that are enhanced by chemotherapy pre-treatment of mice before transplantation of human tumor cells. The induction of intravascular proliferation, extravasation, and colony formation by cancer cells, critical steps of metastasis was enhanced by pretreatment of host mice with the commonly-used chemotherapy drug cyclophosphamide. Cyclophosphamide appears to interfere with a host process that inhibits intravascular proliferation, extravasation, and extravascular colony formation by at least some tumor cells. Cyclophosphamide does not directly affect the cancer cells since cyclophosphamide has been cleared by the time the cancer cells were injected. Without cyclophosphamide pretreatment, human colon cancer cells died quickly after injection in the portal vein of nude mice. Extensive clasmocytosis (destruction of the cytoplasm) of the cancer cells occurred within 6 hours. The number of apoptotic cells rapidly increased within the portal vein within 12 hours of injection. However, when the host mice were pretreated with cyclophosphamide, the cancer cells survived and formed colonies in the liver after portal vein injection. These results suggest that a cyclophosphamide-sensitive host cellular system attacked the cancer cells. This review describes an important unexpected "opposite effects" of chemotherapy that enhances critical steps in malignancy rather than inhibiting them, suggesting that certain current approaches to cancer chemotherapy should be modified.

Yamauchi, Kensuke; Yang, Meng; Hayashi, Katsuhiro; Jiang, Ping; Xu, Mingxu; Yamamoto, Norio; Tsuchiya, Hiroyuki; Tomita, Katsuro; Moossa, A. R.; Bouvet, Michael; Hoffman, Robert M.

2008-02-01